



CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EV 272 143 344 US

Date of Deposit: February 23, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Box PATENT APPLICATION, Commissioner for Patents, Washington, D.C. 20231.


Rebecca McElkoy

**NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 101P3A11
USEFUL IN TREATMENT AND DETECTION OF CANCER**

RELATED APPLICATIONS

This application claims benefit of priority from U.S. Provisional Application Serial Number 60/291,118, filed May 15, 2001 and is a continuation-in-part of U.S. Application Serial Number 09/680,728, filed October 5, 2000, which claims benefit of priority from U.S. Provisional Application Serial Number 60/157,902, filed October 5, 1999. All three of these applications are hereby incorporated in their entireties as if fully set forth.

FIELD OF THE INVENTION

The invention described herein relates to a novel gene and its encoded protein, termed 101P3A11, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 101P3A11 (also referred to as PHOR-1).

BACKGROUND OF THE INVENTION

Cancer is the second leading cause of human death next to coronary disease. Worldwide, millions of people die from cancer every year. In the United States alone, as reported by the American Cancer Society, cancer causes the death of well over a half-million people annually, with over 1.2 million new cases diagnosed per year. While deaths from heart disease have been declining significantly, those resulting from cancer generally are on the rise. In the early part of the next century, cancer is predicted to become the leading cause of death.

Worldwide, several cancers stand out as the leading killers. In particular, carcinomas of the lung, prostate, breast, colon, pancreas, and ovary represent the primary causes of cancer death. These and virtually all other carcinomas share a common lethal feature. With very few exceptions, metastatic disease from a carcinoma is fatal. Moreover, even for those cancer patients who initially survive their primary cancers, common experience has shown that their lives are dramatically altered. Many cancer patients experience strong anxieties driven by the awareness of the potential for recurrence or treatment failure. Many cancer patients experience physical debilitations following treatment. Furthermore, many cancer patients experience a recurrence.

Worldwide, prostate cancer is the fourth most prevalent cancer in men. In North America and Northern Europe, it is by far the most common cancer in males and is the second leading cause of cancer death in men. In the United States alone, well over 30,000 men die annually of this disease - second only to lung cancer. Despite the magnitude of these figures, there is still no effective treatment for metastatic prostate cancer. Surgical prostatectomy, radiation therapy, hormone ablation therapy, surgical castration and chemotherapy continue to be the main treatment

modalities. Unfortunately, these treatments are ineffective for many and are often associated with undesirable consequences.

On the diagnostic front, the lack of a prostate tumor marker that can accurately detect early-stage, localized tumors remains a significant limitation in the diagnosis and management of this disease. Although the serum prostate specific antigen (PSA) assay has been a very useful tool, however its specificity and general utility is widely regarded as lacking in several important respects.

Progress in identifying additional specific markers for prostate cancer has been improved by the generation of prostate cancer xenografts that can recapitulate different stages of the disease in mice. The LAPC (Los Angeles Prostate Cancer) xenografts are prostate cancer xenografts that have survived passage in severe combined immune deficient (SCID) mice and have exhibited the capacity to mimic the transition from androgen dependence to androgen independence (Klein et al., 1997, Nat. Med. 3:402). More recently identified prostate cancer markers include PCTA-1 (Su et al., 1996, Proc. Natl. Acad. Sci. USA 93: 7252), prostate-specific membrane (PSM) antigen (Pinto et al., Clin Cancer Res 1996 Sep 2 (9): 1445-51), STEAP (Hubert, et al., Proc Natl Acad Sci U S A. 1999 Dec 7; 96(25): 14523-8) and prostate stem cell antigen (PSCA) (Reiter et al., 1998, Proc. Natl. Acad. Sci. USA 95: 1735).

While previously identified markers such as PSA, PSM, PCTA and PSCA have facilitated efforts to diagnose and treat prostate cancer, there is need for the identification of additional markers and therapeutic targets for prostate and related cancers in order to further improve diagnosis and therapy.

Renal cell carcinoma (RCC) accounts for approximately 3 percent of adult malignancies. Once adenomas reach a diameter of 2 to 3 cm, malignant potential exists. In the adult, the two principal malignant renal tumors are renal cell adenocarcinoma and transitional cell carcinoma of the renal pelvis or ureter. The incidence of renal cell adenocarcinoma is estimated at more than 29,000 cases in the United States, and more than 11,600 patients died of this disease in 1998. Transitional cell carcinoma is less frequent, with an incidence of approximately 500 cases per year in the United States.

Surgery has been the primary therapy for renal cell adenocarcinoma for many decades. Until recently, metastatic disease has been refractory to any systemic therapy. With recent developments in systemic therapies, particularly immunotherapies, metastatic renal cell carcinoma may be approached aggressively in appropriate patients with a possibility of durable responses. Nevertheless, there is a remaining need for effective therapies for these patients.

Of all new cases of cancer in the United States, bladder cancer represents approximately 5 percent in men (fifth most common neoplasm) and 3 percent in women (eighth most common neoplasm). The incidence is increasing slowly, concurrent with an increasing older population. In 1998, there was an estimated 54,500 cases, including 39,500 in men and 15,000 in women. The age-adjusted incidence in the United States is 32 per 100,000 for men and 8 per 100,000 in women. The historic male/female ratio of 3:1 may be decreasing related to smoking patterns in women. There were an estimated 11,000 deaths from bladder cancer in 1998 (7,800 in men and 3,900 in women). Bladder cancer incidence and mortality strongly increase with age and will be an increasing problem as the population becomes more elderly.

Most bladder cancers recur in the bladder. Bladder cancer is managed with a combination of transurethral resection of the bladder (TUR) and intravesical chemotherapy or immunotherapy. The multifocal and recurrent nature of bladder cancer points out the limitations of TUR. Most muscle-invasive cancers are not cured by TUR alone. Radical cystectomy and urinary diversion is the most effective means to eliminate the cancer but carry an undeniable

impact on urinary and sexual function. There continues to be a significant need for treatment modalities that are beneficial for bladder cancer patients.

An estimated 130,200 cases of colorectal cancer occurred in 2000 in the United States, including 93,800 cases of colon cancer and 36,400 of rectal cancer. Colorectal cancers are the third most common cancers in men and women. Incidence rates declined significantly during 1992-1996 (-2.1% per year). Research suggests that these declines have been due to increased screening and polyp removal, preventing progression of polyps to invasive cancers. There were an estimated 56,300 deaths (47,700 from colon cancer, 8,600 from rectal cancer) in 2000, accounting for about 11% of all U.S. cancer deaths.

At present, surgery is the most common form of therapy for colorectal cancer, and for cancers that have not spread, it is frequently curative. Chemotherapy, or chemotherapy plus radiation, is given before or after surgery to most patients whose cancer has deeply perforated the bowel wall or has spread to the lymph nodes. A permanent colostomy (creation of an abdominal opening for elimination of body wastes) is occasionally needed for colon cancer and is infrequently required for rectal cancer. There continues to be a need for effective diagnostic and treatment modalities for colorectal cancer.

There were an estimated 164,100 new cases of lung and bronchial cancer in 2000, accounting for 14% of all U.S. cancer diagnoses. The incidence rate of lung and bronchial cancer is declining significantly in men, from a high of 86.5 per 100,000 in 1984 to 70.0 in 1996. In the 1990s, the rate of increase among women began to slow. In 1996, the incidence rate in women was 42.3 per 100,000.

Lung and bronchial cancer caused an estimated 156,900 deaths in 2000, accounting for 28% of all cancer deaths. During 1992-1996, mortality from lung cancer declined significantly among men (-1.7% per year) while rates for women were still significantly increasing (0.9% per year). Since 1987, more women have died each year of lung cancer than breast cancer, which, for over 40 years, was the major cause of cancer death in women. Decreasing lung cancer incidence and mortality rates most likely resulted from decreased smoking rates over the previous 30 years; however, decreasing smoking patterns among women lag behind those of men. Of concern, although the declines in adult tobacco use have slowed, tobacco use in youth is increasing again.

Treatment options for lung and bronchial cancer are determined by the type and stage of the cancer and include surgery, radiation therapy, and chemotherapy. For many localized cancers, surgery is usually the treatment of choice. Because the disease has usually spread by the time it is discovered, radiation therapy and chemotherapy are often needed in combination with surgery. Chemotherapy alone or combined with radiation is the treatment of choice for small cell lung cancer; on this regimen, a large percentage of patients experience remission, which in some cases is long lasting. There is however, an ongoing need for effective treatment and diagnostic approaches for lung and bronchial cancers.

An estimated 182,800 new invasive cases of breast cancer were expected to occur among women in the United States during 2000. Additionally, about 1,400 new cases of breast cancer were expected to be diagnosed in men in 2000. After increasing about 4% per year in the 1980s, breast cancer incidence rates in women have leveled off in the 1990s to about 110.6 cases per 100,000.

In the U.S. alone, there were an estimated 41,200 deaths (40,800 women, 400 men) in 2000 due to breast cancer. Breast cancer ranks second among cancer deaths in women. According to the most recent data, mortality rates

declined significantly during 1992–1996 with the largest decreases in younger women, both white and black. These decreases were probably the result of earlier detection and improved treatment.

Taking into account the medical circumstances and the patient's preferences, treatment of breast cancer may involve lumpectomy (local removal of the tumor) and removal of the lymph nodes under the arm; mastectomy (surgical removal of the breast) and removal of the lymph nodes under the arm; radiation therapy; chemotherapy; or hormone therapy. Often, two or more methods are used in combination. Numerous studies have shown that, for early stage disease, long-term survival rates after lumpectomy plus radiotherapy are similar to survival rates after modified radical mastectomy. Significant advances in reconstruction techniques provide several options for breast reconstruction after mastectomy. Recently, such reconstruction has been done at the same time as the mastectomy.

Local excision of ductal carcinoma in situ (DCIS) with adequate amounts of surrounding normal breast tissue may prevent the local recurrence of the DCIS. Radiation to the breast and/or tamoxifen may reduce the chance of DCIS occurring in the remaining breast tissue. This is important because DCIS, if left untreated, may develop into invasive breast cancer. Nevertheless, there are serious side effects or sequelae to these treatments. There is, therefore, a need for efficacious breast cancer treatments.

There were an estimated 23,100 new cases of ovarian cancer in the United States in 2000. It accounts for 4% of all cancers among women and ranks second among gynecologic cancers. During 1992–1996, ovarian cancer incidence rates were significantly declining. Consequent to ovarian cancer, there were an estimated 14,000 deaths in 2000. Ovarian cancer causes more deaths than any other cancer of the female reproductive system.

Surgery, radiation therapy, and chemotherapy are treatment options for ovarian cancer. Surgery usually includes the removal of one or both ovaries, the fallopian tubes (salpingo-oophorectomy), and the uterus (hysterectomy). In some very early tumors, only the involved ovary will be removed, especially in young women who wish to have children. In advanced disease, an attempt is made to remove all intra-abdominal disease to enhance the effect of chemotherapy. There continues to be an important need for effective treatment options for ovarian cancer.

There were an estimated 28,300 new cases of pancreatic cancer in the United States in 2000. Over the past 20 years, rates of pancreatic cancer have declined in men. Rates among women have remained approximately constant but may be beginning to decline. Pancreatic cancer caused an estimated 28,200 deaths in 2000 in the United States. Over the past 20 years, there has been a slight but significant decrease in mortality rates among men (about –0.9% per year) while rates have increased slightly among women.

Surgery, radiation therapy, and chemotherapy are treatment options for pancreatic cancer. These treatment options can extend survival and/or relieve symptoms in many patients but are not likely to produce a cure for most. There is a significant need for additional therapeutic and diagnostic options for pancreatic cancer.

SUMMARY OF THE INVENTION

The present invention relates to a gene, designated 101P3A11, that is over-expressed in the normal tissues and cancers listed in Table I. Northern blot expression analysis of 101P3A11 gene expression in normal tissues shows a restricted expression pattern in adult tissues. The nucleotide (Figure 2) and amino acid (Figure 2, and Figure 3) sequences of 101P3A11 are provided. The tissue-related profile of 101P3A11 in normal adult tissues, combined with the over-expression observed in tumors of the tissues listed in Table I, shows that 101P3A11 is aberrantly over-

expressed in certain some cancers, and thus serves as a useful diagnostic, prophylactic, prognostic, and/or therapeutic target for cancers that express the protein, such as those listed in Table I.

The invention provides polynucleotides corresponding or complementary to all or part of the 101P3A11 genes, mRNAs, and/or coding sequences, preferably in isolated form, including polynucleotides encoding 101P3A11-related proteins and fragments of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more than 25 contiguous amino acids; at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95, 100 or more than 100 contiguous amino acids of a 101P3A11-related protein, as well as the peptides/proteins themselves; DNA, RNA, DNA/RNA hybrids, and related molecules, polynucleotides or oligonucleotides complementary or having at least a 90% homology to the 101P3A11 genes or mRNA sequences or parts thereof, and polynucleotides or oligonucleotides that hybridize to the 101P3A11 genes, mRNAs, or to 101P3A11-encoding polynucleotides. Also provided are means for isolating cDNAs and the genes encoding 101P3A11. Recombinant DNA molecules containing 101P3A11 polynucleotides, cells transformed or transduced with such molecules, and host-vector systems for the expression of 101P3A11 gene products are also provided. The invention further provides antibodies that bind to 101P3A11 proteins and polypeptide fragments thereof, including polyclonal and monoclonal antibodies, murine and other mammalian antibodies, chimeric antibodies, humanized and fully human antibodies, and antibodies labeled with a detectable marker. In certain embodiments there is a proviso that the entire nucleic acid sequence of Figure 2 is not encoded and/or the entire amino acid sequence of Figure 2 is not prepared. In certain embodiments, the entire nucleic acid sequence of Figure 2 is encoded and/or the entire amino acid sequence of Figure 2 is prepared, either of which are in respective human unit dose forms.

The invention further provides methods for detecting the presence and status of 101P3A11 polynucleotides and proteins in various biological samples, as well as methods for identifying cells that express 101P3A11. A typical embodiment of this invention provides methods for monitoring 101P3A11 gene products in a tissue or hematology sample having or suspected of having some form of growth dysregulation such as cancer.

The invention further provides various immunogenic or therapeutic compositions and strategies for treating cancers that express 101P3A11 such as cancers of tissues listed in Table I, including therapies aimed at inhibiting the transcription, translation, processing or function of 101P3A11 as well as cancer vaccines. In one aspect, the invention provides compositions, and methods comprising them, for treating a cancer that expresses 101P3A11 (PHOR-1) in a human subject wherein the composition comprises a carrier suitable for human use and a human unit dose of one or more than one agent that inhibits the production or function of 101P3A11 (PHOR-1). Preferably, the carrier is a uniquely human carrier. In another aspect of the invention, the agent is a moiety that is immunoreactive with 101P3A11 protein. Non-limiting examples of such moieties include, but are not limited to, antibodies (such as single chain, monoclonal, polyclonal, humanized, or human antibodies), functional equivalents thereof (whether naturally occurring or synthetic), and combinations thereof. In another aspect, the agent is a small molecule as defined herein.

In another aspect, the agent comprises one or more than one peptide which comprises a cytotoxic T lymphocyte (CTL) epitope that binds an HLA class I molecule in a human to elicit a CTL response to 101P3A11 and/or one or more than one peptide which comprises a helper T lymphocyte (HTL) epitope which binds an HLA class II molecule in a human to elicit an HTL response. In a further aspect of the invention, the agent comprises one or more than one nucleic acid molecule that expresses one or more than one of the CTL or HTL response stimulating peptides as described above. In yet another aspect of the invention, the one or more than one nucleic acid molecule may express a

moiety that is immunologically reactive with 101P3A11 as described above. The one or more than one nucleic acid molecule may also be, or encodes, a molecule that inhibits production of 101P3A11. Non-limiting examples of such molecules include, but are not limited to, those complementary to a nucleotide sequence essential for production of 101P3A11 (e.g. antisense sequences or molecules that form a triple helix with a nucleotide double helix essential for 101P3A11 production) or a ribozyme effective to lyse 101P3A11 mRNA.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1. 101P3A11 SSH sequence. The 101P3A11 SSH sequence is shown as SEQ ID NO: 2864.

Figures 2A-2D. The cDNA (SEQ ID. NO. ~~2865~~; 2865) and amino acid sequence (SEQ ID. NO. ~~2866~~; 2866) of 101P3A11. The start methionine is underlined. The open reading frame extends from nucleic acid 133 to 1086 including the stop codon (the codon for the initial M is omitted as the shorter peptide has a more favorable Kozak sequence).

Figure 3. Amino acid sequence of 101P3A11 (SEQ ID. NO. ~~2866~~; 2866). The 101P3A11 protein has 317 amino acids.

Figure 4. Alignment of 101P3A11 (Sbjct—SEQ ID NO: 2867) with mouse olfactory receptor S25 (Query—SEQ ID NO: 2868.) The transmembrane regions of 101P3A11 and mouse olfactory receptor S25 (ORS25) predicted using the TMHMM algorithm are highlighted in gray. The amino acids of ORS25 predicted (Floriano, W.B., et al, 2000, Proc. Natl. Acad. Sci., USA, 97:10712-10716) to be involved in binding of the ligand hexanol and/or involved in the formation of the ligand binding pocket are italicized and bolded in the Figure, and are: Leu 131, Val 134, Val 135, Gly 138, Thr139, Ser 193, Ser 197, Phe 225, Ala 230, Ile 231, Gly 234, Thr 284, Phe 287, Gln 300, Lys 302.

Figure 5. Hydrophilicity amino acid profile of 101P3A11 determined by computer algorithm sequence analysis using the method of Hopp and Woods (Hopp T.P., Woods K.R., 1981. Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828) accessed on the Protscale website (www.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biology server.

Figure 6. Hydropathicity amino acid profile of 101P3A11 determined by computer algorithm sequence analysis using the method of Kyte and Doolittle (Kyte J., Doolittle R.F., 1982. J. Mol. Biol. 157:105-132) accessed on the ProtScale website (www.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biology server.

Figure 7. Percent accessible residues amino acid profile of 101P3A11 determined by computer algorithm sequence analysis using the method of Janin (Janin J., 1979 Nature 277:491-492) accessed on the ProtScale website (www.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biology server.

Figure 8. Average flexibility amino acid profile of 101P3A11 determined by computer algorithm sequence analysis using the method of Bhaskaran and Ponnuswamy (Bhaskaran R., and Ponnuswamy P.K., 1988. Int. J. Pept. Protein Res. 32:242-255) accessed on the ProtScale website (www.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biology server.

Figure 9. Beta-turn amino acid profile of 101P3A11 determined by computer algorithm sequence analysis using the method of Deleage and Roux (Deleage, G., Roux B. 1987 Protein Engineering 1:289-294) accessed on the ProtScale website (www.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biology server.

Figure 10A. Expression of 101P3A11 by RT-PCR. First strand cDNA was prepared from vital pool 1 (VP1: liver, lung and kidney), vital pool 2 (VP2, pancreas, colon and stomach), prostate xenograft pool, prostate cancer pool, kidney cancer pool, colon cancer pool, breast cancer pool, and cancer metastasis pool. Normalization was performed by PCR using primers to actin and GAPDH. Semi-quantitative PCR, using primers to 101P3A11, was performed at 30 cycles of amplification. Expression of 101P3A11 was observed in prostate xenograft pool, prostate cancer pool, kidney cancer pool, colon cancer pool, breast cancer pool, and cancer metastasis pool, but not in VP1 and VP2.

Figure 10B. Expression of 101P3A11 in human cancers demonstrated by dot blot analysis of tumor RNA (T) and normal RNA (N) matched samples using patient-derived amplified cDNAs. Up-regulation of PHOR-1 expression was found in 3 of 3 prostate cancer patients, 6 of 14 kidney cancer patients, 2 of 8 uterine cancer patients, 3 of 8 stomach cancer patients and 7 of 7 rectal cancer patients.

Figure 11. Expression of 101P3A11 in human patient cancer specimens. RNA was extracted from a pool of three prostate cancer tumors, kidney cancer tumors, colon cancer tumors, breast cancer tumors, and a cancer metastasis pool derived from cancer patients, as well as from normal prostate (NP), normal bladder (NB), normal kidney (NK) and normal colon (NC). Northern blots with 10 µg of total RNA/lane were probed with a 101P3A11 fragment. Size standards in kilobases (kb) are indicated on the side. The results showed expression of 101P3A11 in prostate cancer tumors, kidney cancer tumors, colon cancer tumors, breast cancer tumors, cancer metastasis pool, bladder cancer pool, and in the normal prostate but not in the other normal tissues. A picture of the ethidium-bromide staining of the RNA gel is also presented.

Figure 12A. Expression of 101P3A11 in prostate cancer patient specimens. RNA was extracted from prostate tumors (T) and their normal adjacent tissues (Nat) derived from prostate cancer patients. Northern blots with 10 µg of total RNA/lane were probed with 101P3A11 sequences. Results show upregulated expression of 101P3A11 in 8 of 10 tumor specimens.

Figure 12B. Photomicrograph showing 101P3A11 expression in prostatic intraepithelial neoplasia (PIN) by in situ hybridization with an anti-sense 101P3A11 riboprobe.

Figure 12C. Photomicrograph showing 101P3A11 expression in prostate cancer tissue by in situ hybridization with an anti-sense 101P3A11 riboprobe.

Figure 12D. Photomicrograph showing 101P3A11 expression in prostate cancer by in situ hybridization with an anti-sense 101P3A11 riboprobe. Note up-regulation of expression relative to normal prostate, FIG. 12E.

Figure 12E. Photomicrograph showing 101P3A11 expression in normal prostate by in situ hybridization with an anti-sense 101P3A11 riboprobe.

Figure 13. Expression of 101P3A11 in colon cancer patient specimens. RNA was extracted from colon tumors (T) and their normal adjacent tissues (Nat) derived from colon cancer patients. Northern blots with 10 µg of total RNA/lane were probed with 101P3A11 sequences. Size standards in kilobases (kb) are indicated on the side. Results showed expression of 101P3A11 in colon tumors but not in normal tissues. Expression was also seen in the colon cancer cell line T84. A picture of the ethidium-bromide staining of the RNA gel is also presented.

Figure 14. Expression of 101P3A11 in kidney cancer patient specimens. RNA was extracted from kidney tumors (T) and their normal adjacent tissues (Nat) derived from kidney cancer patients. Northern blots with 10 µg of total RNA/lane were probed with 101P3A11 sequences. Size standards in kilobases (kb) are indicated on the side. The

results showed expression of 101P3A11 in five of six kidney tumor specimens. The expression detected in normal adjacent tissues (isolated from diseased tissues) but not in normal tissues (isolated from healthy donors) indicates that these tissues are not fully normal and that 101P3A11 is expressed in early stage tumors. A picture of the ethidium-bromide staining of the RNA gel is also presented.

Figures 15A-15C. Androgen regulation of 101P3A11 in tissue culture cells. LAPC-9 cells were grown in charcoal-stripped medium and stimulated with the synthetic androgen mibolerone, for either 14 or 24 hours. Northern blots with 10 µg of total RNA/lane were probed with 101P3A11 sequences (Figure 15A). A picture of the ethidium-bromide staining of the RNA gel is also presented (Figure 15C). Results showed expression of 101P3A11 was not regulated by androgen. The experimental samples were confirmed by testing for the expression of the androgen-regulated prostate cancer gene PSA (Figure 15B). This experiment showed that, as expected, PSA levels go down in presence of charcoal-stripped serum, and expression is induced at 14 and 24 hours in presence of mibolerone.

Figure 16. Androgen regulation of 101P3A11 *in vivo*. Male mice were injected with LAPC-9AD tumor cells. When tumors reached a palpable size (0.3-0.5cm in diameter), mice were castrated and tumors harvested at different time points following the castration. RNA was isolated from the xenograft tissues. Northern blots with 10 µg of total RNA/lane were probed with 101P3A11 sequences. Size standards in kilobases (kb) are indicated on the side. A picture of the ethidium-bromide staining of the RNA gel is also presented. The results showed that expression of 101P3A11 is not androgen regulated.

Figure 17. Expression and detection of 101P3A11(159-202)-psecFc fusion protein. The 101P3A11(159-202)-psecFc vector was constructed. The recombinant expression vector DNA was transfected into either 293T cells or Cos-7 cells. Cells as well as culture supernatants (media) were harvested 24 hours later. The cells were lysed, and run on SDS-PAGE gel along with the media samples. The gel was transferred to nitrocellulose, stained with HRP-labeled anti-human IgG and developed using the ECL chemiluminescence detection kit. Results showed expression of the 101P3A11(159-202)-psecFc fusion protein in the lysates of both 293T and Cos-7 cells. The 101P3A11(159-202)-psecFc fusion protein was also secreted and detected in the culture supernatants of both cell types.

Figure 18. Expression of 101P3A11 in 300.19 cells following retroviral-mediated gene delivery. 300.19 cells were transduced with the pSRα retroviral vector encoding the 101P3A11 gene. Following selection with neomycin, the cells were expanded and RNA was extracted. A Northern blot with 10 µg of total RNA/lane was probed with the 101P3A11 sequence. Size standards in kilobases (kb) are indicated on the side. Results showed expression of the 101P3A11 transcript driven from the retroviral LTR. LAPC-4AD and LAPC-9AD showed expression of the endogenous 101P3A11 transcript. The figure shows results of a short exposure of the autoradiogram.

Figures 19A-19C. Secondary structure and transmembrane prediction for 101P3A11 (SEQ ID NO: 2866). Figure 19A: The secondary structure of 101P3A11 protein was predicted using the HNN - Hierarchical Neural Network method (Guermeur, 1997, http://pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_nn.html), accessed from the ExPasy molecular biology server (<http://www.expasy.ch/tools/>). This method predicts the presence and location of alpha helices, extended strands, and random coils from the primary protein sequence. The percent of the protein in a given secondary structure is also given. Figure 19B is a schematic representation of the probability of existence of transmembrane regions and orientation of 101P3A11 based on the TMPred algorithm of Hofmann and Stoffel which utilizes TMBASE (K. Hofmann, W. Stoffel. TMBASE - A database of membrane spanning protein segments Biol.

Chem. Hoppe-Seyler 374:166, 1993). Figure 19C is a schematic representation of the probability of the existence of transmembrane regions and the extracellular and intracellular orientation of 101P3A11 based on the TMHMM algorithm of Sonnhammer, von Heijne, and Krogh (Erik L.L. Sonnhammer, Gunnar von Heijne, and Anders Krogh: A hidden Markov model for predicting transmembrane helices in protein sequences. In Proc. of Sixth Int. Conf. on Intelligent Systems for Molecular Biology, p 175-182 Ed J. Glasgow, T. Littlejohn, F. Major, R. Lathrop, D. Sankoff, and C. Sensen Menlo Park, CA: AAAI Press, 1998). The TMpred and TMHMM algorithms are accessed from the ExPasy molecular biology server (<http://www.expasy.ch/tools/>). The results of the transmembrane prediction programs presented in Figure 19B and 19C depict 101P3A11 as containing 7 transmembrane domains consistent with that of a G-protein coupled receptor.

Figure 20. Expression of 101P3A11 in NIH-3T3 Tumors. Mice were injected subcutaneously with control 3T3-neo or NIH3T3 cells expressing 101P3A11. Tumors were allowed to grow, the mice were then sacrificed and tumors harvested. RNA was isolated from LAPC-4AD and LAPC-4AI xenografts, 3T3-neo and 3T3-101P3A11 cells grown in culture were used as controls. RNA isolated from six different tumors derived from 3T3-101P3A11 cells (Tumor #1-3) were compared by Northern blotting. Northern blots with 10 µg of total RNA/lane were probed with 101P3A11 sequence. A picture of the ethidium-bromide staining of the RNA gel is also presented. Results showed expression of 101P3A11 in all 3T3-101P3A11 tumors as well as in 3T3/101P3A11 cells used to derive the tumors, but not in the negative control cells 3T3/neo cells.

Figure 21. 101P3A11 Induces Tumor Formation of 3T3 Cells. Injection of 106 3T3-neo, 3T3-Ras or 3T3-101P3A11 cells (106 of the indicated cells mixed with Matrigel) subcutaneously into 6 male SCID mice (right flank) revealed that 6/6 3T3-v12Ras-injected mice formed tumors, 6/6 3T3-101P3A11-injected mice formed tumors, and 0/6 3T3-neo-injected mice formed tumors. Each data point represents the mean tumor volume (n = 6) in each group.

Figure 22. PTX reduces the in vivo growth of 3T3-101P3A11 Tumors. Pertussis toxin was found to inhibit the sub-cutaneous growth of 3T3-101P3A11 tumors in SCID mice in a dose dependent manner.

Figure 23. Alignment of 101P3A11-PHOR-1 (Phor-SEQ ID NO: 2869) with the rat GPCR RA1C -SEQ ID NO: 2870 (gi|3420759). Identities = 179/299 (59%), Positives = 231/299 (76%), Gaps = 1/299 (0%).

Figure 24. Alignment of 101P3A11-PHOR-1 (Phor-SEQ ID NO: 2871) with the human prostate specific GPCR-SEQ ID NO: 2872 (gi|13540539). Identities = 179/299 (59%), Positives = 233/299 (77%), Gaps = 1/299 (0%).

Figure 25. Alignment of 101P3A11-PHOR-1 (Phor-SEQ ID NO: 2873) with human olfactory receptor 5II12, HOR5-SEQ ID NO: 2874, (gi|14423836). Identities = 163/304 (53%), Positives = 214/304 (69%), Gaps = 1/304 (0%).

Figure 26. 101P3A11 Modulated Tyrosine Phosphorylation in NIH-3T3 Cells. 101P3A11 mediated the de-phosphorylation of proteins at 200, 120-140, 85-90 and 55 kDa. 101P3A11 induced the phosphorylation of proteins at 80 and 29 kDa in NIH-3T3 cells.

Figure 27. ERK Phosphorylation by PCR ligands in 101P3A11 Expressing Cells. FBS, lipophosphatidic acid, gastrin releasing peptide, leukotriene and platelet activating factor induced the phosphorylation of ERK in 101P3A11 expressing cells.

Figure 28. Inhibition of 101P3A11-Mediated ERK Activation by PD98059. ERK phosphorylation was inhibited by a MEK specific(PD98059) but not a p38 specific (SB203580) inhibitor in PC3-101P3A11 cells.

Figure 29. Enhanced ERK Phosphorylation in Sodium Orthovanadate Treated PC3-101P3A11 Cells. Sodium orthovanadate induced increased ERK phosphorylation in PC3-101P3A11 cells relative to PC3-neo cells.

Figure 30. Inhibition of 101P3A11-Mediated ERK Phosphorylation by AG1517. The EGFR inhibitor, AG1517, inhibits EGF-mediated ERK phosphorylation in control and 101P3A11-expressing PC3 cells. AG1517 partially inhibits 101P3A11 mediated ERK phosphorylation in PC3 cells.

Figures 31A-31B. Activation of p38 in PC3-101P3A11 Cells. Expression of 101P3A11 mediates p38 phosphorylation in cells treated with 10% FBS as shown by blotting with antibodies to phospho-p38 (Figure 31A) compared to p38 (Figure 31B).

Figure 32. 101P3A11 Induced Accumulation of cAMP in PC3 Cells. Expression of 101P3A11 increased the accumulation of cAMP in cells treated with 0.1% and 10% FBS. FBS-induced cAMP accumulation in 101P3A11 cells was inhibited by pertussis toxin.

Figure 33. Pertussis Toxin Inhibits 101P3A11 Mediated ERK Phosphorylation. Pertussis toxin inhibited FBS- mediated ERK phosphorylation in 101P3A11 expressing cells.

Figure 34. Pertussis Toxin Inhibited ERK Phosphorylation in PC3-101P3A11 Cells. Pertussis toxin inhibited FBS- mediated ERK phosphorylation in 101P3A11 expressing cells. The inhibitory activity of pertussis toxin on ERK phosphorylation was more dramatic in FBS-treated than EGF or GRP-treated PC3-101P3A11 cells

Figure 35. Inhibition of 101P3A11-mediated signaling by Suranim, a G protein inhibitor. Control NIH 3T3 and 3T3-101P3A11 cells were grown in the presence of absence of G protein inhibitors Suranim and NF449. Proliferation was analyzed by Alamar blue after 72 hours. Suranim and NF449 inhibited the proliferation of 101P3A11 expressing but not control cells.

Figures 36A-36B. 101P3A11 Mediated ERK Phosphorylation By Conditioned Media. Figure 36A: blotting with anti-phospho ERK antibodies; Figure 36B: blotting with anti-ERK antibodies. Supernatants from PC3, PC3-101P3A11, PrEC and LAPC42 cells induce ERK phosphorylation in PC3 101P3A11 but not PC3 cells. Supernatants from 3T3 and 293T cells had little specific effect on ERK phosphorylation.

Figure 37. 101P3A11 Enhances the Proliferation of 3T3 Cells. Control NIH 3T3 and 3T3-101P3A11 cells were grown in the presence of absence 0.5 or 10% FBS. Proliferation was analyzed by Alamar blue after 48 hours. Expression of 101P3A11 induced a 6 fold increase in the proliferation of 3T3 cells grown in 0.5% FBS.

Figure 38. Inhibition of 101P3A11 Mediated ERK Phosphorylation by 101P3A11 Specific Antibodies. Expression of 101P3A11 induced ERK phosphorylation in 293T cells. Anti-101P3A11 pAb inhibited ERK Phosphorylation in 293T-101P3A11 cells.

Figure 39. Anti-101P3A11 Ab Mediated cAMP Accumulation in PC3-101P3A11 Cells. Control PC3 cells and cells expressing 101P3A11 were treated with anti-101P3A11 pAb for 2 min and evaluated for intracellular cAMP content. The assay was performed in duplicate.

Figures 40A-40F. Photomicrographs showing immunohistochemical analysis using anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded prostate cancer tissues (Figure 40A); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded prostate

cancer cell line, LNCaP (Figure 40B); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded prostate cancer tissues (Figure 40C); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded normal prostate (Figure 40D); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded prostate cancer tissues (Figure 40E); and anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded normal prostate (Figure 40F).

Figures 41A-41F. Photomicrographs showing immunohistochemical analysis using anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded prostate cancer tissues (Figure 41A); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded bladder cancer tissues (Figure 41B); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded kidney cancer tissues (Figure 41C); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded colon cancer tissues (Figure 41D); anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded lung cancer tissues (Figure 41E); and anti-101P3A11 (peptide 1; amino acids 1-14) rabbit polyclonal antibody on formalin fixed and paraffin embedded breast cancer tissues (Figure 41F).

Figure 42 shows demonstrates that 101P3A11 induces orthotopic growth of tumors. 5×10^5 cells were injected orthotopically into SCID mice, 7 mice per group; tumor weight was evaluated 24-25 days post cell injection.

Figure 43 shows that 101P3A11 induces colony formation in a soft agar assay.

DETAILED DESCRIPTION OF THE INVENTION

Outline of Sections

I.) Definitions

II.) 101P3A11 Polynucleotides

II.A.) Uses of 101P3A11 Polynucleotides

II.A.1.) Monitoring of Genetic Abnormalities

II.A.2.) Antisense Embodiments

II.A.3.) Primers and Primer Pairs

II.A.4.) Isolation of 101P3A11-Encoding Nucleic Acid Molecules

II.A.5.) Recombinant Nucleic Acid Molecules and Host-Vector Systems

III.) 101P3A11-related Proteins

III.A.) Motif-bearing Protein Embodiments

III.B.) Expression of 101P3A11-related Proteins

III.C.) Modifications of 101P3A11-related Proteins

III.D.) Uses of 101P3A11-related Proteins

IV.) 101P3A11 Antibodies

V.) 101P3A11 Cellular Immune Responses

VI.) 101P3A11 Transgenic Animals

VII.) Methods for the Detection of 101P3A11

VIII.) Methods for Monitoring the Status of 101P3A11-related Genes and Their Products

IX.) Identification of Molecules That Interact With 101P3A11

X.) Therapeutic Methods and Compositions

X.A.) Anti-Cancer Vaccines

X.B.) 101P3A11 as a Target for Antibody-Based Therapy

X.C.) 101P3A11 as a Target for Cellular Immune Responses

X.C.1. Minigene Vaccines

X.C.2. Combinations of CTL Peptides with Helper Peptides

X.C.3. Combinations of CTL Peptides with T Cell Priming Agents

X.C.4. Vaccine Compositions Comprising DC Pulsed with CTL and/or HTL Peptides

X.D.) Adoptive Immunotherapy

X.E.) Administration of Vaccines for Therapeutic or Prophylactic Purposes

XI.) Diagnostic and Prognostic Embodiments of 101P3A11.

XII.) Inhibition of 101P3A11 Protein Function

XII.A.) Inhibition of 101P3A11 With Intracellular Antibodies

XII.B.) Inhibition of 101P3A11 with Recombinant Proteins

XII.C.) Inhibition of 101P3A11 Transcription or Translation

XII.D.) General Considerations for Therapeutic Strategies

XIII.) KITS

I.) Definitions:

Unless otherwise defined, all terms of art, notations and other scientific terms or terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. Many of the techniques and procedures described or referenced herein are well understood and commonly employed using conventional methodology by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd. edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer defined protocols and/or parameters unless otherwise noted.

The terms "advanced prostate cancer", "locally advanced prostate cancer", "advanced disease" and "locally advanced disease" mean prostate cancers that have extended through the prostate capsule, and are meant to include stage C disease under the American Urological Association (AUA) system, stage C1 - C2 disease under the Whitmore-Jewett system, and stage T3 - T4 and N+ disease under the TNM (tumor, node, metastasis) system. In general, surgery is not recommended for patients with locally advanced disease, and these patients have substantially less favorable outcomes compared to patients having clinically localized (organ-confined) prostate cancer. Locally advanced disease is clinically identified by palpable evidence of induration beyond the lateral border of the prostate, or asymmetry or

induration above the prostate base. Locally advanced prostate cancer is presently diagnosed pathologically following radical prostatectomy if the tumor invades or penetrates the prostatic capsule, extends into the surgical margin, or invades the seminal vesicles.

"Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence 101P3A11 (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence 101P3A11. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.

The term "analog" refers to a molecule which is structurally similar or shares similar or corresponding attributes with another molecule (e.g. a 101P3A11-related protein). For example an analog of the 101P3A11 protein can be specifically bound by an antibody or T cell that specifically binds to 101P3A11.

The term "antibody" is used in the broadest sense. Therefore an "antibody" can be naturally occurring or man-made such as monoclonal antibodies produced by conventional hybridoma technology. Anti-101P3A11 antibodies comprise monoclonal and polyclonal antibodies as well as fragments containing the antigen-binding domain and/or one or more complementarity determining regions of these antibodies.

An "antibody fragment" is defined as at least a portion of the variable region of the immunoglobulin molecule that binds to its target, i.e., the antigen-binding region. In one embodiment it specifically covers single anti-101P3A11 antibodies and clones thereof (including agonist, antagonist and neutralizing antibodies) and anti-101P3A11 antibody compositions with polypeptidic specificity.

The term "codon optimized sequences" refers to nucleotide sequences that have been optimized for a particular host species by replacing any codons having a usage frequency of less than about 20%. Nucleotide sequences that have been optimized for expression in a given host species by elimination of spurious polyadenylation sequences, elimination of exon/intron splicing signals, elimination of transposon-like repeats and/or optimization of GC content in addition to codon optimization are referred to herein as an "expression enhanced sequences."

The term "cytotoxic agent" refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes chemotherapeutic agents, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof. Examples of cytotoxic agents include, but are not limited to maytansinoids, yttrium, bismuth, ricin, ricin A-chain, doxorubicin, daunorubicin, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crocin, calicheamicin, sapaonaria officinalis inhibitor, and glucocorticoid and other chemotherapeutic agents, as well as radioisotopes such as At²¹¹, I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³² and radioactive isotopes of Lu. Antibodies may also be conjugated to an anti-cancer pro-drug activating enzyme capable of converting the pro-drug to its active form.

The term "homolog" refers to a molecule which exhibits homology to another molecule, by for example, having sequences of chemical residues that are the same or similar at corresponding positions.

"Human Leukocyte Antigen" or "HLA" is a human class I or class II Major Histocompatibility Complex (MHC) protein (*see, e.g., Stites, et al., IMMUNOLOGY*, 8TH ED., Lange Publishing, Los Altos, CA (1994).

The terms "hybridize", "hybridizing", "hybridizes" and the like, used in the context of polynucleotides, are meant to refer to conventional hybridization conditions, preferably such as hybridization in 50% formamide/6XSSC/0.1% SDS/100 µg/ml ssDNA, in which temperatures for hybridization are above 37 degrees C and temperatures for washing in 0.1XSSC/0.1% SDS are above 55 degrees C.

5 The phrases "isolated" or "biologically pure" refer to material which is substantially or essentially free from components which normally accompany the material as it is found in its native state. Thus, isolated peptides in accordance with the invention preferably do not contain materials normally associated with the peptides in their *in situ* environment. For example, a polynucleotide is said to be "isolated" when it is substantially separated from contaminant polynucleotides that correspond or are complementary to genes other than the 101P3A11 gene or that encode polypeptides other than 101P3A11 gene product or fragments thereof. A skilled artisan can readily employ nucleic acid isolation
10 procedures to obtain an isolated 101P3A11 polynucleotide. A protein is said to be "isolated," for example, when physical, mechanical or chemical methods are employed to remove the 101P3A11 protein from cellular constituents that are normally associated with the protein. A skilled artisan can readily employ standard purification methods to obtain an isolated 101P3A11 protein. Alternatively, an isolated protein can be prepared by chemical means.

15 The term "mammal" refers to any organism classified as a mammal, including mice, rats, rabbits, dogs, cats, cows, horses and humans. In one embodiment of the invention, the mammal is a mouse. In another embodiment of the invention, the mammal is a human.

The terms "metastatic prostate cancer" and "metastatic disease" mean prostate cancers that have spread to regional lymph nodes or to distant sites, and are meant to include stage D disease under the AUA system and stage
20 TxNxM+ under the TNM system. As is the case with locally advanced prostate cancer, surgery is generally not indicated for patients with metastatic disease, and hormonal (androgen ablation) therapy is a preferred treatment modality. Patients with metastatic prostate cancer eventually develop an androgen-refractory state within 12 to 18 months of treatment initiation. Approximately half of these androgen-refractory patients die within 6 months after developing that status. The most common site for prostate cancer metastasis is bone. Prostate cancer bone metastases
25 are often osteoblastic rather than osteolytic (i.e., resulting in net bone formation). Bone metastases are found most frequently in the spine, followed by the femur, pelvis, rib cage, skull and humerus. Other common sites for metastasis include lymph nodes, lung, liver and brain. Metastatic prostate cancer is typically diagnosed by open or laparoscopic pelvic lymphadenectomy, whole body radionuclide scans, skeletal radiography, and/or bone lesion biopsy.

30 The term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the antibodies comprising the population are identical except for possible naturally occurring mutations that are present in minor amounts.

A "motif", as in biological motif of an 101P3A11-related protein, refers to any pattern of amino acids forming part of the primary sequence of a protein, that is associated with a particular function (e.g. protein-protein interaction, protein-DNA interaction, etc) or modification (e.g. that is phosphorylated, glycosylated or amidated), or localization
35 (e.g. secretory sequence, nuclear localization sequence, etc.) or a sequence that is correlated with being immunogenic, either humorally or cellularly. A motif can be either contiguous or capable of being aligned to certain positions that are generally correlated with a certain function or property. In the context of HLA motifs, "motif" refers to the pattern of residues in a peptide of defined length, usually a peptide of from about 8 to about 13 amino acids for a class I HLA

motif and from about 6 to about 25 amino acids for a class II HLA motif, which is recognized by a particular HLA molecule. Peptide motifs for HLA binding are typically different for each protein encoded by each human HLA allele and differ in the pattern of the primary and secondary anchor residues.

A "pharmaceutical excipient" comprises a material such as an adjuvant, a carrier, pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservative, and the like.

"Pharmaceutically acceptable" refers to a non-toxic, inert, and/or composition that is physiologically compatible with humans or other mammals.

The term "polynucleotide" means a polymeric form of nucleotides of at least 10 bases or base pairs in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide, and is meant to include single and double stranded forms of DNA and/or RNA. In the art, this term is often used interchangeably with "oligonucleotide". A polynucleotide can comprise a nucleotide sequence disclosed herein wherein thymidine (T) (as shown for example in SEQ ID NO: 702) can also be uracil (U); this definition pertains to the differences between the chemical structures of DNA and RNA, in particular the observation that one of the four major bases in RNA is uracil (U) instead of thymidine (T).

The term "polypeptide" means a polymer of at least about 4, 5, 6, 7, or 8 amino acids. Throughout the specification, standard three letter or single letter designations for amino acids are used. In the art, this term is often used interchangeably with "peptide" or "protein".

An HLA "primary anchor residue" is an amino acid at a specific position along a peptide sequence which is understood to provide a contact point between the immunogenic peptide and the HLA molecule. One to three, usually two, primary anchor residues within a peptide of defined length generally defines a "motif" for an immunogenic peptide. These residues are understood to fit in close contact with peptide binding groove of an HLA molecule, with their side chains buried in specific pockets of the binding groove. In one embodiment, for example, the primary anchor residues for an HLA class I molecule are located at position 2 (from the amino terminal position) and at the carboxyl terminal position of a 8, 9, 10, 11, or 12 residue peptide epitope in accordance with the invention. In another embodiment, for example, the primary anchor residues of a peptide that will bind an HLA class II molecule are spaced relative to each other, rather than to the termini of a peptide, where the peptide is generally of at least 9 amino acids in length. The primary anchor positions for each motif and supermotif are set forth in Table IV. For example, analog peptides can be created by altering the presence or absence of particular residues in the primary and/or secondary anchor positions shown in Table IV. Such analogs are used to modulate the binding affinity and/or population coverage of a peptide comprising a particular HLA motif or supermotif.

A "recombinant" DNA or RNA molecule is a DNA or RNA molecule that has been subjected to molecular manipulation *in vitro*.

"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured nucleic acid sequences to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature that can be used. As a result, it

follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).

"Stringent conditions" or "high stringency conditions", as defined herein, are identified by, but not limited to, those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42 °C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42 °C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55 °C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55 °C.

"Moderately stringent conditions" are described by, but not limited to, those in Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

An HLA "supermotif" is a peptide binding specificity shared by HLA molecules encoded by two or more HLA alleles.

As used herein "to treat" or "therapeutic" and grammatically related terms, refer to any improvement of any consequence of disease, such as prolonged survival, less morbidity, and/or a lessening of side effects which are the byproducts of an alternative therapeutic modality; full eradication of disease is not required.

A "transgenic animal" (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A "transgene" is a DNA that is integrated into the genome of a cell from which a transgenic animal develops.

As used herein, an HLA or cellular immune response "vaccine" is a composition that contains or encodes one or more peptides of the invention. There are numerous embodiments of such vaccines, such as a cocktail of one or more individual peptides; one or more peptides of the invention comprised by a polyepitopic peptide; or nucleic acids that encode such individual peptides or polypeptides, e.g., a minigene that encodes a polyepitopic peptide. The "one or more peptides" can include any whole unit integer from 1-150 or more, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 or more peptides of the invention. The peptides or polypeptides can optionally be modified, such as by lipidation, addition of targeting or other sequences. HLA class I peptides of the invention can be admixed with, or linked to, HLA class II

peptides, to facilitate activation of both cytotoxic T lymphocytes and helper T lymphocytes. HLA vaccines can also comprise peptide-pulsed antigen presenting cells, *e.g.*, dendritic cells.

The term "variant" refers to a molecule that exhibits a variation from a described type or norm, such as a protein that has one or more different amino acid residues in the corresponding position(s) of a specifically described protein (*e.g.* the 101P3A11 protein shown in Figure 2 or Figure 3). An analog is an example of a variant protein.

The 101P3A11-related proteins of the invention include those specifically identified herein, as well as allelic variants, conservative substitution variants, analogs and homologs that can be isolated/generated and characterized without undue experimentation following the methods outlined herein or readily available in the art. Fusion proteins that combine parts of different 101P3A11 proteins or fragments thereof, as well as fusion proteins of a 101P3A11 protein and a heterologous polypeptide are also included. Such 101P3A11 proteins are collectively referred to as the 101P3A11-related proteins, the proteins of the invention, or 101P3A11. The term "101P3A11-related protein" refers to a polypeptide fragment or an 101P3A11 protein sequence of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more than 25 amino acids; or, at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95, 100 or more than 100 amino acids.

II.) 101P3A11 Polynucleotides

One aspect of the invention provides polynucleotides corresponding or complementary to all or part of an 101P3A11 gene, mRNA, and/or coding sequence, preferably in isolated form, including polynucleotides encoding an 101P3A11-related protein and fragments thereof, DNA, RNA, DNA/RNA hybrid, and related molecules, polynucleotides or oligonucleotides complementary to an 101P3A11 gene or mRNA sequence or a part thereof, and polynucleotides or oligonucleotides that hybridize to an 101P3A11 gene, mRNA, or to an 101P3A11 encoding polynucleotide (collectively, "101P3A11 polynucleotides"). In all instances when referred to in this section, T can also be U in Figure 2.

Embodiments of a 101P3A11 polynucleotide include: a 101P3A11 polynucleotide having the sequence shown in Figure 2, the nucleotide sequence of 101P3A11 as shown in Figure 2, wherein T is U; at least 10 contiguous nucleotides of a polynucleotide having the sequence as shown in Figure 2; or, at least 10 contiguous nucleotides of a polynucleotide having the sequence as shown in Figure 2 where T is U. For example, embodiments of 101P3A11 nucleotides comprise, without limitation:

(a) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in Figure 2 (SEQ ID NO.: 2865), wherein T can also be U;

(b) a polynucleotide comprising, consisting essentially of, or consisting of the sequence as shown in Figure 2 (SEQ ID NO.: 2865), from nucleotide residue number 133 through nucleotide residue number 1086, wherein T can also be U;

(c) a polynucleotide that encodes a 101P3A11-related protein whose sequence is encoded by the cDNAs contained in the plasmid designated p101P3A11, clone GTH10 deposited with American Type Culture Collection as Accession No. PTA-312 on July 2, 1999;

(d) a polynucleotide that encodes an 101P3A11-related protein that is at least 90% homologous to the entire amino acid sequence shown in Figure 2 (SEQ ID NO.: 2866);

- (e) a polynucleotide that encodes an 101P3A11-related protein that is at least 90% identical to the entire amino acid sequence shown in Figure 2 (SEQ ID NO: 2866);
- (f) a polynucleotide that encodes at least one peptide set forth in Tables V-XVIII or XXVI-XXVIII;
- (g) a polynucleotide that encodes a peptide region of at least 5 amino acids of Figure 3 in any whole number increment up to 317 that includes an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of Figure 5;
- (h) a polynucleotide that encodes a peptide region of at least 5 amino acids of Figure 3 in any whole number increment up to 317 that includes an amino acid position having a value less than 0.5 in the Hydropathicity profile of Figure 6;
- (i) a polynucleotide that encodes a peptide region of at least 5 amino acids of Figure 3 in any whole number increment up to 317 that includes an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profile of Figure 7;
- (j) a polynucleotide that encodes a peptide region of at least 5 amino acids of Figure 3 in any whole number increment up to 317 that includes an amino acid position having a value greater than 0.5 in the Average Flexibility profile on Figure 8;
- (k) a polynucleotide that encodes a peptide region of at least 5 amino acids of Figure 3 in any whole number increment up to 317 that includes an amino acid position having a value greater than 0.5 in the Beta-turn profile of Figure 9;
- (l) a polynucleotide that is fully complementary to a polynucleotide of any one of (a)-(k);
- (m) a polynucleotide that selectively hybridizes under stringent conditions to a polynucleotide of (a)-(l);
- (n) a peptide that is encoded by any of (a)-(k); and,
- (o) a polynucleotide of any of (a)-(m) or peptide of (n) together with a pharmaceutical excipient and/or in a human unit dose form.

As used herein, a range is understood to specifically disclose all whole unit positions thereof.

Typical embodiments of the invention disclosed herein include 101P3A11 polynucleotides that encode specific portions of the 101P3A11 mRNA sequence (and those which are complementary to such sequences) such as those that encode the protein and fragments thereof, for example of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 250, 275, 300, or 317 contiguous amino acids.

For example, representative embodiments of the invention disclosed herein include: polynucleotides and their encoded peptides themselves encoding about amino acid 1 to about amino acid 10 of the 101P3A11 protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 10 to about amino acid 20 of the 101P3A11 protein shown in Figure 2, or Figure 3, polynucleotides encoding about amino acid 20 to about amino acid 30 of the 101P3A11 protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 30 to about amino acid 40 of the 101P3A11 protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 40 to about amino acid 50 of the 101P3A11 protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 50 to about amino acid 60 of the 101P3A11 protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 60 to about amino acid 70 of the 101P3A11 protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 70 to about amino acid 80 of the 101P3A11 protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 80 to about amino acid 90 of the 101P3A11 protein shown in Figure 2 or Figure 3, polynucleotides encoding about amino acid 90 to about amino acid 100 of the 101P3A11 protein shown in Figure 2 or Figure 3, in increments of about 10 amino acids, ending at the carboxyl terminal amino acid set forth in Figure 2 or Figure 3. Accordingly polynucleotides encoding portions of the amino acid sequence (of about 10 amino acids), of amino acids 100 through the carboxyl terminal amino acid of the 101P3A11 protein are embodiments of the invention. Wherein it is understood that each particular amino acid position discloses that position plus or minus five amino acid residues.

Polynucleotides encoding relatively long portions of the 101P3A11 protein are also within the scope of the invention. For example, polynucleotides encoding from about amino acid 1 (or 20 or 30 or 40 etc.) to about amino acid 20, (or 30, or 40 or 50 etc.) of the 101P3A11 protein shown in Figure 2 or Figure 3 can be generated by a variety of techniques well known in the art. These polynucleotide fragments can include any portion of the 101P3A11 sequence as shown in Figure 2 or Figure 3.

Additional illustrative embodiments of the invention disclosed herein include 101P3A11 polynucleotide fragments encoding one or more of the biological motifs contained within the 101P3A11 protein sequence, including one or more of the subsequences of the 101P3A11 protein set forth in Tables V-XVIII or XXVI-XXVIII. In another embodiment, typical polynucleotide fragments of the invention encode one or more of the regions of 101P3A11 that exhibit homology to a known molecule. In another embodiment of the invention, typical polynucleotide fragments can encode one or more of the 101P3A11 N-glycosylation sites, cAMP and cGMP-dependent protein kinase phosphorylation sites, casein kinase II phosphorylation sites or N-myristoylation site and amidation sites.

II.A.) Uses of 101P3A11 Polynucleotides

II.A.1.) Monitoring of Genetic Abnormalities

The polynucleotides of the preceding paragraphs have a number of different specific uses. The human 101P3A11 gene maps to the chromosomal location set forth in Table XXV. For example, because the 101P3A11 gene maps to this chromosome, polynucleotides that encode different regions of the 101P3A11 protein are used to characterize cytogenetic abnormalities of this chromosomal locale, such as abnormalities that are identified as being associated with various cancers. In certain genes, a variety of chromosomal abnormalities including rearrangements have been identified as frequent cytogenetic abnormalities in a number of different cancers (see e.g. Krajinovic et al., Mutat. Res. 382(3-4): 81-83 (1998); Johansson et al., Blood 86(10): 3905-3914 (1995) and Finger et al., P.N.A.S.

85(23): 9158-9162 (1988)). Thus, polynucleotides encoding specific regions of the 101P3A11 protein provide new tools that can be used to delineate, with greater precision than previously possible, cytogenetic abnormalities in the chromosomal region that encodes 101P3A11 that may contribute to the malignant phenotype. In this context, these polynucleotides satisfy a need in the art for expanding the sensitivity of chromosomal screening in order to identify more subtle and less common chromosomal abnormalities (see e.g. Evans et al., Am. J. Obstet. Gynecol 171(4): 1055-1057 (1994)).

Furthermore, as 101P3A11 was shown to be highly expressed in prostate and other cancers, 101P3A11 polynucleotides are used in methods assessing the status of 101P3A11 gene products in normal versus cancerous tissues. Typically, polynucleotides that encode specific regions of the 101P3A11 protein are used to assess the presence of perturbations (such as deletions, insertions, point mutations, or alterations resulting in a loss of an antigen etc.) in specific regions of the 101P3A11 gene, such as such regions containing one or more motifs. Exemplary assays include both RT-PCR assays as well as single-strand conformation polymorphism (SSCP) analysis (see, e.g., Marrogi et al., J. Cutan. Pathol. 26(8): 369-378 (1999), both of which utilize polynucleotides encoding specific regions of a protein to examine these regions within the protein.

II.A.2.) Antisense Embodiments

Other specifically contemplated nucleic acid related embodiments of the invention disclosed herein are genomic DNA, cDNAs, ribozymes, and antisense molecules, as well as nucleic acid molecules based on an alternative backbone, or including alternative bases, whether derived from natural sources or synthesized, and include molecules capable of inhibiting the RNA or protein expression of 101P3A11. For example, antisense molecules can be RNAs or other molecules, including peptide nucleic acids (PNAs) or non-nucleic acid molecules such as phosphorothioate derivatives, that specifically bind DNA or RNA in a base pair-dependent manner. A skilled artisan can readily obtain these classes of nucleic acid molecules using the 101P3A11 polynucleotides and polynucleotide sequences disclosed herein.

Antisense technology entails the administration of exogenous oligonucleotides that bind to a target polynucleotide located within the cells. The term "antisense" refers to the fact that such oligonucleotides are complementary to their intracellular targets, e.g., 101P3A11. See for example, Jack Cohen, Oligodeoxynucleotides, Antisense Inhibitors of Gene Expression, CRC Press, 1989; and Synthesis 1:1-5 (1988). The 101P3A11 antisense oligonucleotides of the present invention include derivatives such as S-oligonucleotides (phosphorothioate derivatives or S-oligos, see, Jack Cohen, supra), which exhibit enhanced cancer cell growth inhibitory action. S-oligos (nucleoside phosphorothioates) are isoelectronic analogs of an oligonucleotide (O-oligo) in which a nonbridging oxygen atom of the phosphate group is replaced by a sulfur atom. The S-oligos of the present invention can be prepared by treatment of the corresponding O-oligos with 3H-1,2-benzodithiol-3-one-1,1-dioxide, which is a sulfur transfer reagent. See Iyer, R. P. et al, J. Org. Chem. 55:4693-4698 (1990); and Iyer, R. P. et al., J. Am. Chem. Soc. 112:1253-1254 (1990). Additional 101P3A11 antisense oligonucleotides of the present invention include morpholino antisense oligonucleotides known in the art (see, e.g., Partridge et al., 1996, Antisense & Nucleic Acid Drug Development 6: 169-175).

The 101P3A11 antisense oligonucleotides of the present invention typically can be RNA or DNA that is complementary to and stably hybridizes with the first 100 5' codons or last 100 3' codons of the 101P3A11 genomic sequence or the corresponding mRNA. Absolute complementarity is not required, although high degrees of complementarity are preferred. Use of an oligonucleotide complementary to this region allows for the selective

hybridization to 101P3A11 mRNA and not to mRNA specifying other regulatory subunits of protein kinase. In one embodiment, 101P3A11 antisense oligonucleotides of the present invention are 15 to 30-mer fragments of the antisense DNA molecule that have a sequence that hybridizes to 101P3A11 mRNA. Optionally, 101P3A11 antisense oligonucleotide is a 30-mer oligonucleotide that is complementary to a region in the first 10 5' codons or last 10 3' codons of 101P3A11. Alternatively, the antisense molecules are modified to employ ribozymes in the inhibition of 101P3A11 expression, see, e.g., L. A. Couture & D. T. Stinchcomb; *Trends Genet* 12: 510-515 (1996).

II.A.3.) Primers and Primer Pairs

Further specific embodiments of this nucleotides of the invention include primers and primer pairs, which allow the specific amplification of polynucleotides of the invention or of any specific parts thereof, and probes that selectively or specifically hybridize to nucleic acid molecules of the invention or to any part thereof. Probes can be labeled with a detectable marker, such as, for example, a radioisotope, fluorescent compound, bioluminescent compound, a chemiluminescent compound, metal chelator or enzyme. Such probes and primers are used to detect the presence of a 101P3A11 polynucleotide in a sample and as a means for detecting a cell expressing a 101P3A11 protein.

Examples of such probes include polypeptides comprising all or part of the human 101P3A11 cDNA sequence shown in Figure 2. Examples of primer pairs capable of specifically amplifying 101P3A11 mRNAs are also described in the Examples. As will be understood by the skilled artisan, a great many different primers and probes can be prepared based on the sequences provided herein and used effectively to amplify and/or detect a 101P3A11 mRNA.

The 101P3A11 polynucleotides of the invention are useful for a variety of purposes, including but not limited to their use as probes and primers for the amplification and/or detection of the 101P3A11 gene(s), mRNA(s), or fragments thereof; as reagents for the diagnosis and/or prognosis of prostate cancer and other cancers; as coding sequences capable of directing the expression of 101P3A11 polypeptides; as tools for modulating or inhibiting the expression of the 101P3A11 gene(s) and/or translation of the 101P3A11 transcript(s); and as therapeutic agents.

The present invention includes the use of any probe as described herein to identify and isolate a 101P3A11 or 101P3A11 related nucleic acid sequence from a naturally occurring source, such as humans or other mammals, as well as the isolated nucleic acid sequence *per se*, which would comprise all or most of the sequences found in the probe used.

II.A.4.) Isolation of 101P3A11-Encoding Nucleic Acid Molecules

The 101P3A11 cDNA sequences described herein enable the isolation of other polynucleotides encoding 101P3A11 gene product(s), as well as the isolation of polynucleotides encoding 101P3A11 gene product homologs, alternatively spliced isoforms, allelic variants, and mutant forms of the 101P3A11 gene product as well as polynucleotides that encode analogs of 101P3A11-related proteins. Various molecular cloning methods that can be employed to isolate full length cDNAs encoding an 101P3A11 gene are well known (see, for example, Sambrook, J. et al., *Molecular Cloning: A Laboratory Manual*, 2d edition, Cold Spring Harbor Press, New York, 1989; *Current Protocols in Molecular Biology*. Ausubel et al., Eds., Wiley and Sons, 1995). For example, lambda phage cloning methodologies can be conveniently employed, using commercially available cloning systems (e.g., Lambda ZAP Express, Stratagene). Phage clones containing 101P3A11 gene cDNAs can be identified by probing with a labeled 101P3A11 cDNA or a fragment thereof. For example, in one embodiment, the 101P3A11 cDNA (Figure 2) or a portion thereof can be synthesized and used as a probe to retrieve overlapping and full-length cDNAs corresponding to a 101P3A11 gene. The 101P3A11 gene itself can be isolated by

screening genomic DNA libraries, bacterial artificial chromosome libraries (BACs), yeast artificial chromosome libraries (YACs), and the like, with 101P3A11 DNA probes or primers.

II.A.5.) Recombinant Nucleic Acid Molecules and Host-Vector Systems

The invention also provides recombinant DNA or RNA molecules containing an 101P3A11 polynucleotide, a fragment, analog or homologue thereof, including but not limited to phages, plasmids, phagemids, cosmids, YACs, BACs, as well as various viral and non-viral vectors well known in the art, and cells transformed or transfected with such recombinant DNA or RNA molecules. Methods for generating such molecules are well known (see, for example, Sambrook et al, 1989, supra).

The invention further provides a host-vector system comprising a recombinant DNA molecule containing a 101P3A11 polynucleotide, fragment, analog or homologue thereof within a suitable prokaryotic or eukaryotic host cell. Examples of suitable eukaryotic host cells include a yeast cell, a plant cell, or an animal cell, such as a mammalian cell or an insect cell (e.g., a baculovirus-infectible cell such as an Sf9 or HighFive cell). Examples of suitable mammalian cells include various prostate cancer cell lines such as DU145 and TsuPr1, other transfectable or transducible prostate cancer cell lines, primary cells (PrEC), as well as a number of mammalian cells routinely used for the expression of recombinant proteins (e.g., COS, CHO, 293, 293T cells). More particularly, a polynucleotide comprising the coding sequence of 101P3A11 or a fragment, analog or homolog thereof can be used to generate 101P3A11 proteins or fragments thereof using any number of host-vector systems routinely used and widely known in the art.

A wide range of host-vector systems suitable for the expression of 101P3A11 proteins or fragments thereof are available, see for example, Sambrook et al., 1989, supra; Current Protocols in Molecular Biology, 1995, supra). Preferred vectors for mammalian expression include but are not limited to pcDNA 3.1 myc-His-tag (Invitrogen) and the retroviral vector pSR α tkneo (Muller et al., 1991, MCB 11:1785). Using these expression vectors, 101P3A11 can be expressed in several prostate cancer and non-prostate cell lines, including for example 293, 293T, rat-1, NIH 3T3 and TsuPr1. The host-vector systems of the invention are useful for the production of a 101P3A11 protein or fragment thereof. Such host-vector systems can be employed to study the functional properties of 101P3A11 and 101P3A11 mutations or analogs.

Recombinant human 101P3A11 protein or an analog or homolog or fragment thereof can be produced by mammalian cells transfected with a construct encoding a 101P3A11-related nucleotide. For example, 293T cells can be transfected with an expression plasmid encoding 101P3A11 or fragment, analog or homolog thereof, the 101P3A11 or related protein is expressed in the 293T cells, and the recombinant 101P3A11 protein is isolated using standard purification methods (e.g., affinity purification using anti-101P3A11 antibodies). In another embodiment, a 101P3A11 coding sequence is subcloned into the retroviral vector pSR α MSVtkneo and used to infect various mammalian cell lines, such as NIH 3T3, TsuPr1, 293 and rat-1 in order to establish 101P3A11 expressing cell lines. Various other expression systems well known in the art can also be employed. Expression constructs encoding a leader peptide joined in frame to the 101P3A11 coding sequence can be used for the generation of a secreted form of recombinant 101P3A11 protein.

As discussed herein, redundancy in the genetic code permits variation in 101P3A11 gene sequences. In particular, it is known in the art that specific host species often have specific codon preferences, and thus one can adapt the disclosed sequence as preferred for a desired host. For example, preferred analog codon sequences typically have

rare codons (i.e., codons having a usage frequency of less than about 20% in known sequences of the desired host) replaced with higher frequency codons. Codon preferences for a specific species are calculated, for example, by utilizing codon usage tables available on the INTERNET such as at URL www.dna.affrc.go.jp/~nakamura/codon.html.

Additional sequence modifications are known to enhance protein expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon/intron splice site signals, transposon-like repeats, and/or other such well-characterized sequences that are deleterious to gene expression. The GC content of the sequence is adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. Where possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures. Other useful modifications include the addition of a translational initiation consensus sequence at the start of the open reading frame, as described in Kozak, *Mol. Cell Biol.*, 9:5073-5080 (1989). Skilled artisans understand that the general rule that eukaryotic ribosomes initiate translation exclusively at the 5' proximal AUG codon is abrogated only under rare conditions (see, e.g., Kozak PNAS 92(7): 2662-2666, (1995) and Kozak NAR 15(20): 8125-8148 (1987)).

III.) 101P3A11-related Proteins

Another aspect of the present invention provides 101P3A11-related proteins. Specific embodiments of 101P3A11 proteins comprise a polypeptide having all or part of the amino acid sequence of human 101P3A11 as shown in Figure 2 or Figure 3. Alternatively, embodiments of 101P3A11 proteins comprise variant, homolog or analog polypeptides that have alterations in the amino acid sequence of 101P3A11 shown in Figure 2 or Figure 3.

In general, naturally occurring allelic variants of human 101P3A11 share a high degree of structural identity and homology (e.g., 90% or more homology). Typically, allelic variants of the 101P3A11 protein contain conservative amino acid substitutions within the 101P3A11 sequences described herein or contain a substitution of an amino acid from a corresponding position in a homologue of 101P3A11. One class of 101P3A11 allelic variants are proteins that share a high degree of homology with at least a small region of a particular 101P3A11 amino acid sequence, but further contain a radical departure from the sequence, such as a non-conservative substitution, truncation, insertion or frame shift. In comparisons of protein sequences, the terms, similarity, identity, and homology each have a distinct meaning as appreciated in the field of genetics. Moreover, orthology and paralogy can be important concepts describing the relationship of members of a given protein family in one organism to the members of the same family in other organisms.

Amino acid abbreviations are provided in Table II. Conservative amino acid substitutions can frequently be made in a protein without altering either the conformation or the function of the protein. Proteins of the invention can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 conservative substitutions. Such changes include substituting any of isoleucine (I), valine (V), and leucine (L) for any other of these hydrophobic amino acids; aspartic acid (D) for glutamic acid (E) and vice versa; glutamine (Q) for asparagine (N) and vice versa; and serine (S) for threonine (T) and vice versa. Other substitutions can also be considered conservative, depending on the environment of the particular amino acid and its role in the three-dimensional structure of the protein. For example, glycine (G) and alanine (A) can frequently be interchangeable, as can alanine (A) and valine (V). Methionine (M), which is relatively hydrophobic, can frequently be interchanged with leucine and isoleucine, and sometimes with valine. Lysine (K) and arginine (R) are frequently interchangeable in locations in which the significant feature of the amino acid residue is its charge and the differing pK's of these two amino acid residues are not significant. Still other changes can be considered "conservative"

in particular environments (see, e.g. Table III herein; pages 13-15 "Biochemistry" 2nd ED. Lubert Stryer ed (Stanford University); Henikoff et al., PNAS 1992 Vol 89 10915-10919; Lei et al., J Biol Chem 1995 May 19; 270(20):11882-6).

Embodiments of the invention disclosed herein include a wide variety of art-accepted variants or analogs of 101P3A11 proteins such as polypeptides having amino acid insertions, deletions and substitutions. 101P3A11 variants can be made using methods known in the art such as site-directed mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis (Carter et al., *Nucl. Acids Res.*, 13:4331 (1986); Zoller et al., *Nucl. Acids Res.*, 10:6487 (1987)), cassette mutagenesis (Wells et al., *Gene*, 34:315 (1985)), restriction selection mutagenesis (Wells et al., *Philos. Trans. R. Soc. London SerA*, 317:415 (1986)) or other known techniques can be performed on the cloned DNA to produce the 101P3A11 variant DNA.

Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence that is involved in a specific biological activity such as a protein-protein interaction. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions (Creighton, *The Proteins*, (W.H. Freeman & Co., N.Y.); Chothia, *J. Mol. Biol.*, 150:1 (1976)). If alanine substitution does not yield adequate amounts of variant, an isosteric amino acid can be used.

As defined herein, 101P3A11 variants, analogs or homologs, have the distinguishing attribute of having at least one epitope that is "cross reactive" with a 101P3A11 protein having the amino acid sequence of SEQ ID NO: 703. As used in this sentence, "cross reactive" means that an antibody or T cell that specifically binds to an 101P3A11 variant also specifically binds to the 101P3A11 protein having the amino acid sequence of SEQ ID NO: 703. A polypeptide ceases to be a variant of the protein shown in SEQ ID NO: 703 when it no longer contains any epitope capable of being recognized by an antibody or T cell that specifically binds to the 101P3A11 protein. Those skilled in the art understand that antibodies that recognize proteins bind to epitopes of varying size, and a grouping of the order of about four or five amino acids, contiguous or not, is regarded as a typical number of amino acids in a minimal epitope. See, e.g., Nair et al., *J. Immunol* 2000 165(12): 6949-6955; Hebbes et al., *Mol Immunol* (1989) 26(9):865-73; Schwartz et al., *J Immunol* (1985) 135(4):2598-608.

Another class of 101P3A11-related protein variants share 70%, 75%, 80%, 85% or 90% or more similarity with the amino acid sequence of SEQ ID NO: 703 or a fragment thereof. Another specific class of 101P3A11 protein variants or analogs comprise one or more of the 101P3A11 biological motifs described herein or presently known in the art. Thus, encompassed by the present invention are analogs of 101P3A11 fragments (nucleic or amino acid) that have altered functional (e.g. immunogenic) properties relative to the starting fragment. It is to be appreciated that motifs now or which become part of the art are to be applied to the nucleic or amino acid sequences of Figure 2 or Figure 3.

As discussed herein, embodiments of the claimed invention include polypeptides containing less than the full amino acid sequence of the 101P3A11 protein shown in Figure 2 or Figure 3. For example, representative embodiments of the invention comprise peptides/proteins having any 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more contiguous amino acids of the 101P3A11 protein shown in Figure 2 or Figure 3. With respect to any aspect or embodiment of the

invention, a peptide or peptides may be on one or more than one molecule and may include “pseudopeptides” made of amino acid -like residues that are linked by non-peptide bonds such as, but not limited to, -CH₂-NH-.

Moreover, representative embodiments of the invention disclosed herein include polypeptides consisting of about amino acid 1 to about amino acid 10 of the 101P3A11 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 10 to about amino acid 20 of the 101P3A11 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 20 to about amino acid 30 of the 101P3A11 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 30 to about amino acid 40 of the 101P3A11 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 40 to about amino acid 50 of the 101P3A11 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 50 to about amino acid 60 of the 101P3A11 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 60 to about amino acid 70 of the 101P3A11 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 70 to about amino acid 80 of the 101P3A11 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 80 to about amino acid 90 of the 101P3A11 protein shown in Figure 2 or Figure 3, polypeptides consisting of about amino acid 90 to about amino acid 100 of the 101P3A11 protein shown in Figure 2 or Figure 3, etc. throughout the entirety of the 101P3A11 amino acid sequence. Moreover, polypeptides consisting of about amino acid 1 (or 20 or 30 or 40 etc.) to about amino acid 20, (or 130, or 140 or 150 etc.) of the 101P3A11 protein shown in Figure 2 or Figure 3 are embodiments of the invention. It is to be appreciated that the starting and stopping positions in this paragraph refer to the specified position as well as that position plus or minus 5 residues.

101P3A11-related proteins are generated using standard peptide synthesis technology or using chemical cleavage methods well known in the art. Alternatively, recombinant methods can be used to generate nucleic acid molecules that encode a 101P3A11-related protein. In one embodiment, nucleic acid molecules provide a means to generate defined fragments of the 101P3A11 protein (or variants, homologs or analogs thereof).

III.A.) Motif-bearing Protein Embodiments

Additional illustrative embodiments of the invention disclosed herein include 101P3A11 polypeptides comprising the amino acid residues of one or more of the biological motifs contained within the 101P3A11 polypeptide sequence set forth in Figure 2 or Figure 3. Various motifs are known in the art, and a protein can be evaluated for the presence of such motifs by a number of publicly available Internet sites (see, e.g., URL addresses: pfam.wustl.edu/; searchlauncher.bcm.tmc.edu/seq-search/struc-predict.html; psort.ims.u-tokyo.ac.jp/; www.cbs.dtu.dk; www.ebi.ac.uk/interpro/scan.html; www.expasy.ch/tools/scnpsit1.html; Epimatrix™ and Epimer™, Brown University, www.brown.edu/Research/TB-HIV_Lab/epimatrix/epimatrix.html; and BIMAS, bimas.dcrf.nih.gov/).

Motif bearing subsequences of the 101P3A11 protein are set forth and identified in Table XIX.

Table XX sets forth several frequently occurring motifs based on pfam searches (see URL address pfam.wustl.edu/). The columns of Table XX list (1) motif name abbreviation, (2) percent identity found amongst the different member of the motif family, (3) motif name or description and (4) most common function; location information is included if the motif is relevant for location.

Polypeptides comprising one or more of the 101P3A11 motifs discussed above are useful in elucidating the specific characteristics of a malignant phenotype in view of the observation that the 101P3A11 motifs discussed above are associated with growth dysregulation and because 101P3A11 is expressed or overexpressed in certain cancers (See,

e.g., Table I). Casein kinase II, cAMP and camp-dependent protein kinase, and Protein Kinase C, for example, are enzymes known to be associated with the development of the malignant phenotype (see e.g. Chen et al., Lab Invest., 78(2): 165-174 (1998); Gaiddon et al., Endocrinology 136(10): 4331-4338 (1995); Hall et al., Nucleic Acids Research 24(6): 1119-1126 (1996); Peterziel et al., Oncogene 18(46): 6322-6329 (1999) and O'Brian, Oncol. Rep. 5(2): 305-309 (1998)). Moreover, both glycosylation and myristoylation are protein modifications also associated with cancer and cancer progression (see e.g. Dennis et al., Biochem. Biophys. Acta 1473(1):21-34 (1999); Raju et al., Exp. Cell Res. 235(1): 145-154 (1997)). Amidation is another protein modification also associated with cancer and cancer progression (see e.g. Treston et al., J. Natl. Cancer Inst. Monogr. (13): 169-175 (1992)).

In another embodiment, proteins of the invention comprise one or more of the immunoreactive epitopes identified in accordance with art-accepted methods, such as the peptides set forth in Tables V-XVIII or XXVI-XXVIII. CTL epitopes can be determined using specific algorithms to identify peptides within an I01P3A11 protein that are capable of optimally binding to specified HLA alleles (e.g., Table IV; Epimatrix™ and Epimer™, Brown University, URL brown.edu/Research/TB-HIV_Lab/epimatrix/epimatrix.html; and BIMAS, URL bimas.dcrn.nih.gov/.) Moreover, processes for identifying peptides that have sufficient binding affinity for HLA molecules and which are correlated with being immunogenic epitopes, are well known in the art, and are carried out without undue experimentation. In addition, processes for identifying peptides that are immunogenic epitopes, are well known in the art, and are carried out without undue experimentation either *in vitro* or *in vivo*.

Also known in the art are principles for creating analogs of such epitopes in order to modulate immunogenicity. For example, one begins with an epitope that bears a CTL or HTL motif (see, e.g., the HLA Class I and HLA Class II motifs/supermotifs of Table IV). The epitope is analoged by substituting out an amino acid at one of the specified positions, and replacing it with another amino acid specified for that position. For example, one can substitute out a deleterious residue in favor of any other residue, such as a preferred residue as defined in Table IV; substitute a less-preferred residue with a preferred residue as defined in Table IV; or substitute an originally-occurring preferred residue with another preferred residue as defined in Table IV. Substitutions can occur at primary anchor positions or at other positions in a peptide; see, e.g., Table IV.

A variety of references reflect the art regarding the identification and generation of epitopes in a protein of interest as well as analogs thereof. See, for example, WO 9733602 to Chesnut et al.; Sette, Immunogenetics 1999 50(3-4): 201-212; Sette et al., J. Immunol. 2001 166(2): 1389-1397; Sidney et al., Hum. Immunol. 1997 58(1): 12-20; Kondo et al., Immunogenetics 1997 45(4): 249-258; Sidney et al., J. Immunol. 1996 157(8): 3480-90; and Falk et al., Nature 351: 290-6 (1991); Hunt et al., Science 255:1261-3 (1992); Parker et al., J. Immunol. 149:3580-7 (1992); Parker et al., J. Immunol. 152:163-75 (1994)); Kast et al., 1994 152(8): 3904-12; Borrás-Cuesta et al., Hum. Immunol. 2000 61(3): 266-278; Alexander et al., J. Immunol. 2000 164(3): 1625-1633; Alexander et al., PMID: 7895164, UI: 95202582; O'Sullivan et al., J. Immunol. 1991 147(8): 2663-2669; Alexander et al., Immunity 1994 1(9): 751-761 and Alexander et al., Immunol. Res. 1998 18(2): 79-92.

Related embodiments of the inventions include polypeptides comprising combinations of the different motifs set forth in Table XIX, and/or, one or more of the predicted CTL epitopes of Table V through Table XVIII, and/or, one or more of the T cell binding motifs known in the art. Preferred embodiments contain no insertions, deletions or substitutions either within the motifs or the intervening sequences of the polypeptides. In addition, embodiments which

include a number of either N-terminal and/or C-terminal amino acid residues on either side of these motifs may be desirable (to, for example, include a greater portion of the polypeptide architecture in which the motif is located). Typically the number of N-terminal and/or C-terminal amino acid residues on either side of a motif is between about 1 to about 100 amino acid residues, preferably 5 to about 50 amino acid residues.

101P3A11-related proteins are embodied in many forms, preferably in isolated form. A purified 101P3A11 protein molecule will be substantially free of other proteins or molecules that impair the binding of 101P3A11 to antibody, T cell or other ligand. The nature and degree of isolation and purification will depend on the intended use. Embodiments of a 101P3A11-related proteins include purified 101P3A11-related proteins and functional, soluble 101P3A11-related proteins. In one embodiment, a functional, soluble 101P3A11 protein or fragment thereof retains the ability to be bound by antibody, T cell or other ligand.

The invention also provides 101P3A11 proteins comprising biologically active fragments of the 101P3A11 amino acid sequence shown in Figure 2 or Figure 3. Such proteins exhibit properties of the 101P3A11 protein, such as the ability to elicit the generation of antibodies that specifically bind an epitope associated with the 101P3A11 protein; to be bound by such antibodies; to elicit the activation of HTL or CTL; and/or, to be recognized by HTL or CTL.

101P3A11-related polypeptides that contain particularly interesting structures can be predicted and/or identified using various analytical techniques well known in the art, including, for example, the methods of Chou-Fasman, Garnier-Robson, Eisenberg, Karplus-Schultz or Jameson-Wolf analysis, Hopp T.P. and Woods K.R., Kyte J. and Doolittle R.F., Janin J., Bhaskaran R., and Ponnuswamy P.K., Deleage, G. and Roux B., or on the basis of immunogenicity. Fragments that contain such structures are particularly useful in generating subunit-specific anti-101P3A11 antibodies, or T cells or in identifying cellular factors that bind to 101P3A11.

CTL epitopes can be determined using specific algorithms to identify peptides within an 101P3A11 protein that are capable of optimally binding to specified HLA alleles (e.g., by using the SYFPEITHI site at World Wide Web URL syfpeithi.bmi-heidelberg.com/; the listings in Table IV(A)-(E); Epimatrix™ and Epimer™, Brown University, URL (www.brown.edu/Research/TB-HIV_I.ab/epimatrix/epimatrix.html); and BIMAS, URL bimas.dcrt.nih.gov/). Illustrating this, peptide epitopes from 101P3A11 that are presented in the context of human MHC class I molecules HLA-A1, A2, A3, A11, A24, B7 and B35 were predicted (Tables V-XVIII). Specifically, the complete amino acid sequence of the 101P3A11 protein was entered into the HLA Peptide Motif Search algorithm found in the Bioinformatics and Molecular Analysis Section (BIMAS) web site listed above. The HLA peptide motif search algorithm was developed by Dr. Ken Parker based on binding of specific peptide sequences in the groove of HLA Class I molecules, in particular HLA-A2 (see, e.g., Falk et al., Nature 351: 290-6 (1991); Hunt et al., Science 255:1261-3 (1992); Parker et al., J. Immunol. 149:3580-7 (1992); Parker et al., J. Immunol. 152:163-75 (1994)). This algorithm allows location and ranking of 8-mer, 9-mer, and 10-mer peptides from a complete protein sequence for predicted binding to HLA-A2 as well as numerous other HLA Class I molecules. Many HLA class I binding peptides are 8-, 9-, 10 or 11-mers. For example, for class I HLA-A2, the epitopes preferably contain a leucine (L) or methionine (M) at position 2 and a valine (V) or leucine (L) at the C-terminus (see, e.g., Parker et al., J. Immunol. 149:3580-7 (1992)). Selected results of 101P3A11 predicted binding peptides are shown in Tables V-XVIII or XXVI-XXVIII herein. In Tables V-XVIII, the top 50 ranking candidates, 9-mers and 10-mers, for each family member are shown along with their location, the amino acid sequence of each specific peptide, and an estimated binding score. The binding score corresponds to the estimated half

time of dissociation of complexes containing the peptide at 37°C at pH 6.5. Peptides with the highest binding score are predicted to be the most tightly bound to HLA Class I on the cell surface for the greatest period of time and thus represent the best immunogenic targets for T-cell recognition.

In the BIMAS site, the algorithm used to score each 8-mer, 9-mer, or 10-mer peptide subsequence is as follows: The initial (running) score is set to 1.0. For each residue position, the program examines which amino acid appears at that position. The running score is then multiplied by the coefficient for that amino acid type, at that position, for the chosen HLA molecule. These coefficients were pre-calculated and were stored for use by the scoring algorithm in a separate directory as a collection of HLA coefficient files. Using 9-mers, nine multiplications are performed. Using 10-mers, nine multiplications are again performed, because the residue lying at the fifth position in the subsequence is skipped. The resulting running score is multiplied by a final constant to yield an estimate of the half time of disassociation. (This constant is stored at the end of the coefficient file for the HLA molecule. It can have a different value for each HLA molecule.) The final multiplication yields the score reported in the output table. Using 8-mers, eight multiplications are performed instead of nine, with a different coefficient matrix employed (20-by-8 rather than 20-by-9). For each HLA molecule evaluated by the BIMAS site, the coefficient values discussed above are stored in a file in a separate directory of coefficient files. When the user selects the HLA molecule type (or, on the restricted Web page for advanced users, selects the actual filename from the coefficient filename menu) and selects "9-mer" or "10-mer" as the length of the subsequence, the "standard" file containing the 20-by-9 coefficient matrix for the HLA molecule is read on-the-fly, with the 181 values (180 coefficient values plus one final constant) being read into an internal array for use by the scoring program. If the user selected "8-mer" as the subsequence length, then the program proceeds in the same fashion, but reads in a different coefficient file appropriate for 8-mer searches on that selected HLA molecule type.

In addition epitopes were identified from the SYFPEITHI site (SEQ ID NO: 2875) listed above. The scoring system for the SYFPEITHI site evaluates every amino acid within a given peptide. Individual amino acids may be given the arbitrary value 1 for amino acids that are only slightly preferred in the respective position, optimal anchor residues are given the value 15; any value between these two is possible. Negative values are also possible for amino acids which are disadvantageous for the peptide's binding capacity at a certain sequence position. The allocation of values is based on the frequency of the respective amino acid in natural ligands, T-cell epitopes, or binding peptides. Further explanations on the algorithm can be found in Rammensee, HG, et al. (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213-219. In order to have an extremely reliable SYFPEITHI epitope prediction algorithm, only those MHC class I alleles for which a large amount of data is available are included in the "epitope prediction" section of SYFPEITHI. A reliability of at least 80% in retrieving the most apt epitope can be expected. Thus the naturally presented epitope should be among the top-scoring 2 % of all peptides predicted in 80 % of all predictions. For example, if a protein sequence is as long as 400 amino acids, it can be split into 392 possible nonameric peptides. Therefore, the correct epitope should then be among the 8 top-scoring peptides. For epitope predictions using MHC class II motifs high reliabilities usually cannot be achieved because of the more variable pocket binding behavior. A reliability of approximately 50% only is expected for HLA class II epitopes.

Also, different MHC class I molecules prefer a different length of ligands. For example, SYFPEITHI offers predictions for H2-Kb octamers, HLA-A*0201 nonamers and decamers, or HLA-B8 octamers and nonamers. The

maximal scores vary between different MHC alleles. Therefore, one can include known ligands/epitopes in order to have an approximation of the scoring. For example, the maximal score for HLA-A*0201 peptides is 36. The well-known epitope GILGFVFTL derived from the influenza A matrix protein scores 30. All predicted MHC class II ligands are 15mers, consisting of three N-terminal flanking residues, the nonamer core sequence located within the binding groove, and three C-terminal flanking residues. Thus, anchor residue P1 appears in position 4 of the peptides predicted with "SYFPEITHI".

Accordingly, identification of HLA Class I and Class II immunogenic peptides for 101P3A11 was carried out using the SYFPEITHI database for MHC ligands and the accompanying prediction algorithm (Hans-Georg Rammensee, Jutta Bachmann, Niels Nikolaus Emmerich, Oskar Alexander Bachor, Stefan Stevanovic: SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50: 213-219) accessed through the website with a URL: syfpeithi.bmi-heidelberg.com/scripts/MHCServer.dll/home.htm. (Tables XXVI-XXVIII) For HLA Class I alleles nonameric (Table XXVI) and decameric peptides (Table XXVII) were identified. Given the nature of the HLA Class II binding pocket, for HLA Class II alleles sample 15-mer peptides were identified (Table XXVIII). It is appreciated by those in the art that additional amino acids can be present on the termini of the 15-mer epitopes, or that less than 15 amino acids can be present, and that the epitope will still be bound in the open-ended HLA Class II binding pocket.

For each given HLA allele, listed in Tables XXVI-XXVIII are the peptides whose score ranks within the top 50% of the highest scoring peptide(s) predicted for that allele. For example, if the highest scoring value for nonamers of the HLA-A1 allele is 30, all peptides that are given a score of 15 or higher are listed. Listed in the tables is the amino acid position within the 101P3A11 protein sequence for the first amino acid of each listed peptide (Pos), the peptide sequence, and the relative ranked score (Score).

Actual binding of peptides to an HLA allele can be evaluated by stabilization of HLA expression on the antigen-processing defective cell line T2 (see, e.g., Xue et al., Prostate 30:73-8 (1997) and Peshwa et al., Prostate 36:129-38 (1998)). Immunogenicity of specific peptides can be evaluated *in vitro* by stimulation of CD8+ cytotoxic T lymphocytes (CTL) in the presence of antigen presenting cells such as dendritic cells.

It is to be appreciated that every epitope predicted by the BIMAS site, Epimer™ and Epimatrix™ sites, or specified by the HLA class I or class II motifs available in the art or which become part of the art such as set forth in Table IV (or determined using World Wide Web site URL syfpeithi.bmi-heidelberg.com/) are to be "applied" to the 101P3A11 protein. As used in this context "applied" means that the 101P3A11 protein is evaluated, e.g., visually or by computer-based patterns finding methods, as appreciated by those of skill in the relevant art. Every subsequence of the 101P3A11 of 8, 9, 10, or 11 amino acid residues that bears an HLA Class I motif, or a subsequence of 9 or more amino acid residues that bear an HLA Class II motif are within the scope of the invention.

III.B.) Expression of 101P3A11-related Proteins

In an embodiment described in the examples that follow, 101P3A11 can be conveniently expressed in cells (such as 293T cells) transfected with a commercially available expression vector such as a CMV-driven expression vector encoding 101P3A11 with a C-terminal 6XHis and MYC tag (pcDNA3.1/mycHIS, Invitrogen or Tag5, GenHunter Corporation, Nashville TN). The Tag5 vector provides an IgGK secretion signal that can be used to facilitate the production of a secreted 101P3A11 protein in transfected cells. The secreted HIS-tagged 101P3A11 in the culture media can be purified, e.g., using a nickel column using standard techniques.

III.C.) Modifications of 101P3A11-related Proteins

Modifications of 101P3A11-related proteins such as covalent modifications are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a 101P3A11 polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues of the 101P3A11. Another type of covalent modification of the 101P3A11 polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of a protein of the invention. Another type of covalent modification of 101P3A11 comprises linking the 101P3A11 polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

The 101P3A11-related proteins of the present invention can also be modified to form a chimeric molecule comprising 101P3A11 fused to another, heterologous polypeptide or amino acid sequence. Such a chimeric molecule can be synthesized chemically or recombinantly. A chimeric molecule can have a protein of the invention fused to another tumor-associated antigen or fragment thereof. Alternatively, a protein in accordance with the invention can comprise a fusion of fragments of the 101P3A11 sequence (amino or nucleic acid) such that a molecule is created that is not, through its length, directly homologous to the amino or nucleic acid sequences shown in Figure 2 or Figure 3. Such a chimeric molecule can comprise multiples of the same subsequence of 101P3A11. A chimeric molecule can comprise a fusion of a 101P3A11-related protein with a polyhistidine epitope tag, which provides an epitope to which immobilized nickel can selectively bind, with cytokines or with growth factors. The epitope tag is generally placed at the amino- or carboxyl- terminus of the 101P3A11. In an alternative embodiment, the chimeric molecule can comprise a fusion of a 101P3A11-related protein with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule (also referred to as an "immunoadhesin"), such a fusion could be to the Fc region of an IgG molecule. The Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a 101P3A11 polypeptide in place of at least one variable region within an Ig molecule. In a preferred embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3 regions of an IgG1 molecule. For the production of immunoglobulin fusions see, e.g., U.S. Patent No. 5,428,130 issued June 27, 1995.

III.D.) Uses of 101P3A11-related Proteins

The proteins of the invention have a number of different specific uses. As 101P3A11 is highly expressed in prostate and other cancers, 101P3A11-related proteins are used in methods that assess the status of 101P3A11 gene products in normal versus cancerous tissues, thereby elucidating the malignant phenotype. Typically, polypeptides from specific regions of the 101P3A11 protein are used to assess the presence of perturbations (such as deletions, insertions, point mutations etc.) in those regions (such as regions containing one or more motifs). Exemplary assays utilize antibodies or T cells targeting 101P3A11-related proteins comprising the amino acid residues of one or more of the biological motifs contained within the 101P3A11 polypeptide sequence in order to evaluate the characteristics of this region in normal versus cancerous tissues or to elicit an immune response to the epitope. Alternatively, 101P3A11-related proteins that contain the amino acid residues of one or more of the biological motifs in the 101P3A11 protein are used to screen for factors that interact with that region of 101P3A11.

101P3A11 protein fragments/subsequences are particularly useful in generating and characterizing domain-specific antibodies (e.g., antibodies recognizing an extracellular or intracellular epitope of an 101P3A11 protein), for identifying agents or cellular factors that bind to 101P3A11 or a particular structural domain thereof, and in various therapeutic and diagnostic contexts, including but not limited to diagnostic assays, cancer vaccines and methods of preparing such vaccines.

5 Proteins encoded by the 101P3A11 genes, or by analogs, homologs or fragments thereof, have a variety of uses, including but not limited to generating antibodies and in methods for identifying ligands and other agents and cellular constituents that bind to an 101P3A11 gene product. Antibodies raised against an 101P3A11 protein or fragment thereof are useful in diagnostic and prognostic assays, and imaging methodologies in the management of human cancers characterized by expression of 101P3A11 protein, such as those listed in Table I. Such antibodies can be expressed
10 intracellularly and used in methods of treating patients with such cancers. 101P3A11-related nucleic acids or proteins are also used in generating HTL or CTL responses.

Various immunological assays useful for the detection of 101P3A11 proteins are used, including but not limited to various types of radioimmunoassays, enzyme-linked immunosorbent assays (ELISA), enzyme-linked immunofluorescent assays (ELIFA), immunocytochemical methods, and the like. Antibodies can be labeled and used as immunological
15 imaging reagents capable of detecting 101P3A11-expressing cells (e.g., in radioscintigraphic imaging methods). 101P3A11 proteins are also particularly useful in generating cancer vaccines, as further described herein.

IV.) 101P3A11 Antibodies

Another aspect of the invention provides antibodies that bind to 101P3A11-related proteins. Preferred antibodies specifically bind to a 101P3A11-related protein and do not bind (or bind weakly) to peptides or proteins that are not
20 101P3A11-related proteins. For example, antibodies bind 101P3A11 can bind 101P3A11-related proteins such as the homologs or analogs thereof.

101P3A11 antibodies of the invention are particularly useful in cancer diagnostic, diagnostic and prognostic assays, and imaging methodologies. Similarly, such antibodies are useful in the treatment, diagnosis, and/or prognosis of other cancers, to the extent 101P3A11 is also expressed or overexpressed in these other cancers. Moreover,
25 intracellularly expressed antibodies (e.g., single chain antibodies) are therapeutically useful in treating cancers in which the expression of 101P3A11 is involved, such as advanced or metastatic prostate cancers.

The invention also provides various immunological assays useful for the detection and quantification of 101P3A11 and mutant 101P3A11-related proteins. Such assays can comprise one or more 101P3A11 antibodies capable of recognizing and binding a 101P3A11-related protein, as appropriate. These assays are performed within various immunological assay
30 formats well known in the art, including but not limited to various types of radioimmunoassays, enzyme-linked immunosorbent assays (ELISA), enzyme-linked immunofluorescent assays (ELIFA), and the like.

Immunological non-antibody assays of the invention also comprise T cell immunogenicity assays (inhibitory or stimulatory) as well as major histocompatibility complex (MHC) binding assays.

In addition, immunological imaging methods capable of detecting prostate cancer and other cancers expressing
35 101P3A11 are also provided by the invention, including but not limited to radioscintigraphic imaging methods using labeled 101P3A11 antibodies. Such assays are clinically useful in the detection, monitoring, and prognosis of 101P3A11 expressing cancers such as prostate cancer.

101P3A11 antibodies are also used in methods for purifying a 101P3A11-related protein and for isolating 101P3A11 homologues and related molecules. For example, a method of purifying a 101P3A11-related protein comprises incubating an 101P3A11 antibody, which has been coupled to a solid matrix, with a lysate or other solution containing a 101P3A11-related protein under conditions that permit the 101P3A11 antibody to bind to the 101P3A11-related protein; washing the solid matrix to eliminate impurities; and eluting the 101P3A11-related protein from the coupled antibody. Other uses of the 101P3A11 antibodies of the invention include generating anti-idiotypic antibodies that mimic the 101P3A11 protein.

Various methods for the preparation of antibodies are well known in the art. For example, antibodies can be prepared by immunizing a suitable mammalian host using a 101P3A11-related protein, peptide, or fragment, in isolated or immunoconjugated form (Antibodies: A Laboratory Manual, CSH Press, Eds., Harlow, and Lane (1988); Harlow, Antibodies, Cold Spring Harbor Press, NY (1989)). In addition, fusion proteins of 101P3A11 can also be used, such as a 101P3A11 GST-fusion protein. In a particular embodiment, a GST fusion protein comprising all or most of the amino acid sequence of Figure 2 or Figure 3 is produced, then used as an immunogen to generate appropriate antibodies. In another embodiment, a 101P3A11-related protein is synthesized and used as an immunogen.

In addition, naked DNA immunization techniques known in the art are used (with or without purified 101P3A11-related protein or 101P3A11 expressing cells) to generate an immune response to the encoded immunogen (for review, see Donnelly et al., 1997, Ann. Rev. Immunol. 15: 617-648).

The amino acid sequence of 101P3A11 as shown in Figure 2 or Figure 3 can be analyzed to select specific regions of the 101P3A11 protein for generating antibodies. For example, hydrophobicity and hydrophilicity analyses of the 101P3A11 amino acid sequence are used to identify hydrophilic regions in the 101P3A11 structure. Regions of the 101P3A11 protein that show immunogenic structure, as well as other regions and domains, can readily be identified using various other methods known in the art, such as Chou-Fasman, Garnier-Robson, Eisenberg, Karplus-Schultz or Jameson-Wolf analysis, Hopp T.P. and Woods K.R., Kyte J. and Doolittle R.F., Janin J., Bhaskaran R., and Ponnuswamy P.K., or, Deleage, G. and Roux B. Thus, each region identified by any of these programs or methods is within the scope of the present invention. Methods for the generation of 101P3A11 antibodies are further illustrated by way of the examples provided herein. Methods for preparing a protein or polypeptide for use as an immunogen are well known in the art. Also well known in the art are methods for preparing immunogenic conjugates of a protein with a carrier, such as BSA, KLH or other carrier protein. In some circumstances, direct conjugation using, for example, carbodiimide reagents are used; in other instances linking reagents such as those supplied by Pierce Chemical Co., Rockford, IL, are effective. Administration of a 101P3A11 immunogen is often conducted by injection over a suitable time period and with use of a suitable adjuvant, as is understood in the art. During the immunization schedule, titers of antibodies can be taken to determine adequacy of antibody formation.

101P3A11 monoclonal antibodies can be produced by various means well known in the art. For example, immortalized cell lines that secrete a desired monoclonal antibody are prepared using the standard hybridoma technology of Kohler and Milstein or modifications that immortalize antibody-producing B cells, as is generally known. Immortalized cell lines that secrete the desired antibodies are screened by immunoassay in which the antigen is a 101P3A11-related protein. When the appropriate immortalized cell culture is identified, the cells can be expanded and antibodies produced either from *in vitro* cultures or from ascites fluid.

The antibodies or fragments of the invention can also be produced, by recombinant means. Regions that bind specifically to the desired regions of the 101P3A11 protein can also be produced in the context of chimeric or complementarity determining region (CDR) grafted antibodies of multiple species origin. Humanized or human 101P3A11 antibodies can also be produced, and are preferred for use in therapeutic contexts. Methods for humanizing murine and other non-human antibodies, by substituting one or more of the non-human antibody CDRs for corresponding human antibody sequences, are well known (see for example, Jones et al., 1986, Nature 321: 522-525; Riechmann et al., 1988, Nature 332: 323-327; Verhoeyen et al., 1988, Science 239: 1534-1536). See also, Carter et al., 1993, Proc. Natl. Acad. Sci. USA 89: 4285 and Sims et al., 1993, J. Immunol. 151: 2296.

Methods for producing fully human monoclonal antibodies include phage display and transgenic methods (for review, see Vaughan et al., 1998, Nature Biotechnology 16: 535-539). Fully human 101P3A11 monoclonal antibodies can be generated using cloning technologies employing large human Ig gene combinatorial libraries (i.e., phage display) (Griffiths and Hoogenboom, Building an *in vitro* immune system: human antibodies from phage display libraries. In: Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, Clark, M. (Ed.), Nottingham Academic, pp 45-64 (1993); Burton and Barbas, Human Antibodies from combinatorial libraries. *Id.*, pp 65-82). Fully human 101P3A11 monoclonal antibodies can also be produced using transgenic mice engineered to contain human immunoglobulin gene loci as described in PCT Patent Application WO98/24893, Kucheralapati and Jakobovits et al., published December 3, 1997 (see also, Jakobovits, 1998, Exp. Opin. Invest. Drugs 7(4): 607-614; U.S. patents 6,162,963 issued 19 December 2000; 6,150,584 issued 12 November 2000; and, 6,114,598 issued 5 September 2000). This method avoids the *in vitro* manipulation required with phage display technology and efficiently produces high affinity authentic human antibodies.

Reactivity of 101P3A11 antibodies with an 101P3A11-related protein can be established by a number of well known means, including Western blot, immunoprecipitation, ELISA, and FACS analyses using, as appropriate, 101P3A11-related proteins, 101P3A11-expressing cells or extracts thereof. A 101P3A11 antibody or fragment thereof can be labeled with a detectable marker or conjugated to a second molecule. Suitable detectable markers include, but are not limited to, a radioisotope, a fluorescent compound, a bioluminescent compound, chemiluminescent compound, a metal chelator or an enzyme. Further, bi-specific antibodies specific for two or more 101P3A11 epitopes are generated using methods generally known in the art. Homodimeric antibodies can also be generated by cross-linking techniques known in the art (e.g., Wolff et al., Cancer Res. 53: 2560-2565).

V.) 101P3A11 Cellular Immune Responses

The mechanism by which T cells recognize antigens has been delineated. Efficacious peptide epitope vaccine compositions of the invention induce a therapeutic or prophylactic immune responses in very broad segments of the world-wide population. For an understanding of the value and efficacy of compositions of the invention that induce cellular immune responses, a brief review of immunology-related technology is provided.

A complex of an HLA molecule and a peptidic antigen acts as the ligand recognized by HLA-restricted T cells (Buus, S. *et al.*, Cell 47:1071, 1986; Babbitt, B. P. *et al.*, Nature 317:359, 1985; Townsend, A. and Bodmer, H., Annu. Rev. Immunol. 7:601, 1989; Germain, R. N., Annu. Rev. Immunol. 11:403, 1993). Through the study of single amino acid substituted antigen analogs and the sequencing of endogenously bound, naturally processed peptides, critical residues that correspond to motifs required for specific binding to HLA antigen molecules have been identified and are

set forth in Table IV (see also, e.g., Southwood, *et al.*, *J. Immunol.* 160:3363, 1998; Rammensee, *et al.*, *Immunogenetics* 41:178, 1995; Rammensee *et al.*, SYFPEITHI, access via World Wide Web at URL syfpeithi.bmi-heidelberg.com/; Sette, A. and Sidney, J. *Curr. Opin. Immunol.* 10:478, 1998; Engelhard, V. H., *Curr. Opin. Immunol.* 6:13, 1994; Sette, A. and Grey, H. M., *Curr. Opin. Immunol.* 4:79, 1992; Sinigaglia, F. and Hammer, J. *Curr. Biol.* 6:52, 1994; Ruppert *et al.*, *Cell* 74:929-937, 1993; Kondo *et al.*, *J. Immunol.* 155:4307-4312, 1995; Sidney *et al.*, *J. Immunol.* 157:3480-3490, 1996; Sidney *et al.*, *Human Immunol.* 45:79-93, 1996; Sette, A. and Sidney, J. *Immunogenetics* 1999 Nov; 50(3-4):201-12, Review).

Furthermore, x-ray crystallographic analyses of HLA-peptide complexes have revealed pockets within the peptide binding cleft/groove of HLA molecules which accommodate, in an allele-specific mode, residues borne by peptide ligands; these residues in turn determine the HLA binding capacity of the peptides in which they are present. (See, e.g., Madden, D.R. *Annu. Rev. Immunol.* 13:587, 1995; Smith, *et al.*, *Immunity* 4:203, 1996; Fremont *et al.*, *Immunity* 8:305, 1998; Stern *et al.*, *Structure* 2:245, 1994; Jones, E.Y. *Curr. Opin. Immunol.* 9:75, 1997; Brown, J. H. *et al.*, *Nature* 364:33, 1993; Guo, H. C. *et al.*, *Proc. Natl. Acad. Sci. USA* 90:8053, 1993; Guo, H. C. *et al.*, *Nature* 360:364, 1992; Silver, M. L. *et al.*, *Nature* 360:367, 1992; Matsumura, M. *et al.*, *Science* 257:927, 1992; Madden *et al.*, *Cell* 70:1035, 1992; Fremont, D. H. *et al.*, *Science* 257:919, 1992; Saper, M. A., Bjorkman, P. J. and Wiley, D. C., *J. Mol. Biol.* 219:277, 1991.)

Accordingly, the definition of class I and class II allele-specific HLA binding motifs, or class I or class II supermotifs allows identification of regions within a protein that are correlated with binding to particular HLA antigen(s).

Thus, by a process of HLA motif identification, candidates for epitope-based vaccines have been identified; such candidates can be further evaluated by HLA-peptide binding assays to determine binding affinity and/or the time period of association of the epitope and its corresponding HLA molecule. Additional confirmatory work can be performed to select, amongst these vaccine candidates, epitopes with preferred characteristics in terms of population coverage, and/or immunogenicity.

Various strategies can be utilized to evaluate cellular immunogenicity, including:

1) Evaluation of primary T cell cultures from normal individuals (see, e.g., Wentworth, P. A. *et al.*, *Mol. Immunol.* 32:603, 1995; Celis, E. *et al.*, *Proc. Natl. Acad. Sci. USA* 91:2105, 1994; Tsai, V. *et al.*, *J. Immunol.* 158:1796, 1997; Kawashima, I. *et al.*, *Human Immunol.* 59:1, 1998). This procedure involves the stimulation of peripheral blood lymphocytes (PBL) from normal subjects with a test peptide in the presence of antigen presenting cells *in vitro* over a period of several weeks. T cells specific for the peptide become activated during this time and are detected using, e.g., a lymphokine- or ⁵¹Cr-release assay involving peptide sensitized target cells.

2) Immunization of HLA transgenic mice (see, e.g., Wentworth, P. A. *et al.*, *J. Immunol.* 26:97, 1996; Wentworth, P. A. *et al.*, *Int. Immunol.* 8:651, 1996; Alexander, J. *et al.*, *J. Immunol.* 159:4753, 1997). For example, in such methods peptides in incomplete Freund's adjuvant are administered subcutaneously to HLA transgenic mice. Several weeks following immunization, splenocytes are removed and cultured *in vitro* in the presence of test peptide for approximately one week. Peptide-specific T cells are detected using, e.g., a ⁵¹Cr-release assay involving peptide sensitized target cells and target cells expressing endogenously generated antigen.

3) Demonstration of recall T cell responses from immune individuals who have been either effectively vaccinated and/or from chronically ill patients (*see, e.g.,* Rehmann, B. *et al., J. Exp. Med.* 181:1047, 1995; Doolan, D. L. *et al., Immunity* 7:97, 1997; Bertoni, R. *et al., J. Clin. Invest.* 100:503, 1997; Threlkeld, S. C. *et al., J. Immunol.* 159:1648, 1997; Diepolder, H. M. *et al., J. Virol.* 71:6011, 1997). Accordingly, recall responses are detected by culturing PBL from subjects that have been exposed to the antigen due to disease and thus have generated an immune response "naturally", or from patients who were vaccinated against the antigen. PBL from subjects are cultured *in vitro* for 1-2 weeks in the presence of test peptide plus antigen presenting cells (APC) to allow activation of "memory" T cells, as compared to "naive" T cells. At the end of the culture period, T cell activity is detected using assays including ⁵¹Cr release involving peptide-sensitized targets, T cell proliferation, or lymphokine release.

VI.) 101P3A11 Transgenic Animals

Nucleic acids that encode a 101P3A11-related protein can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. In accordance with established techniques, cDNA encoding 101P3A11 can be used to clone genomic DNA that encodes 101P3A11. The cloned genomic sequences can then be used to generate transgenic animals containing cells that express DNA that encode 101P3A11. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 issued 12 April 1988, and 4,870,009 issued 26 September 1989. Typically, particular cells would be targeted for 101P3A11 transgene incorporation with tissue-specific enhancers.

Transgenic animals that include a copy of a transgene encoding 101P3A11 can be used to examine the effect of increased expression of DNA that encodes 101P3A11. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this aspect of the invention, an animal is treated with a reagent and a reduced incidence of a pathological condition, compared to untreated animals that bear the transgene, would indicate a potential therapeutic intervention for the pathological condition.

Alternatively, non-human homologues of 101P3A11 can be used to construct a 101P3A11 "knock out" animal that has a defective or altered gene encoding 101P3A11 as a result of homologous recombination between the endogenous gene encoding 101P3A11 and altered genomic DNA encoding 101P3A11 introduced into an embryonic cell of the animal. For example, cDNA that encodes 101P3A11 can be used to clone genomic DNA encoding 101P3A11 in accordance with established techniques. A portion of the genomic DNA encoding 101P3A11 can be deleted or replaced with another gene, such as a gene encoding a selectable marker that can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector (*see, e.g.,* Thomas and Capecchi, *Cell*, 51:503 (1987) for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (*e.g.,* by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected (*see, e.g.,* Li *et al., Cell*, 69:915 (1992)). The selected cells are then injected into a blastocyst of an animal (*e.g.,* a mouse or rat) to form aggregation chimeras (*see, e.g.,* Bradley, in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal, and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously

recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knock out animals can be characterized, for example, for their ability to defend against certain pathological conditions or for their development of pathological conditions due to absence of the 101P3A11 polypeptide.

VII.) Methods for the Detection of 101P3A11

Another aspect of the present invention relates to methods for detecting 101P3A11 polynucleotides and 101P3A11-related proteins, as well as methods for identifying a cell that expresses 101P3A11. The expression profile of 101P3A11 makes it a diagnostic marker for metastasized disease. Accordingly, the status of 101P3A11 gene products provides information useful for predicting a variety of factors including susceptibility to advanced stage disease, rate of progression, and/or tumor aggressiveness. As discussed in detail herein, the status of 101P3A11 gene products in patient samples can be analyzed by a variety of protocols that are well known in the art including immunohistochemical analysis, the variety of Northern blotting techniques including *in situ* hybridization, RT-PCR analysis (for example on laser capture micro-dissected samples), Western blot analysis and tissue array analysis.

More particularly, the invention provides assays for the detection of 101P3A11 polynucleotides in a biological sample, such as serum, bone, prostate, and other tissues, urine, semen, cell preparations, and the like. Detectable 101P3A11 polynucleotides include, for example, a 101P3A11 gene or fragment thereof, 101P3A11 mRNA, alternative splice variant 101P3A11 mRNAs, and recombinant DNA or RNA molecules that contain a 101P3A11 polynucleotide. A number of methods for amplifying and/or detecting the presence of 101P3A11 polynucleotides are well known in the art and can be employed in the practice of this aspect of the invention.

In one embodiment, a method for detecting an 101P3A11 mRNA in a biological sample comprises producing cDNA from the sample by reverse transcription using at least one primer; amplifying the cDNA so produced using an 101P3A11 polynucleotides as sense and antisense primers to amplify 101P3A11 cDNAs therein; and detecting the presence of the amplified 101P3A11 cDNA. Optionally, the sequence of the amplified 101P3A11 cDNA can be determined.

In another embodiment, a method of detecting a 101P3A11 gene in a biological sample comprises first isolating genomic DNA from the sample; amplifying the isolated genomic DNA using 101P3A11 polynucleotides as sense and antisense primers; and detecting the presence of the amplified 101P3A11 gene. Any number of appropriate sense and antisense probe combinations can be designed from the nucleotide sequence provided for the 101P3A11 (Figure 2) and used for this purpose.

The invention also provides assays for detecting the presence of an 101P3A11 protein in a tissue or other biological sample such as serum, semen, bone, prostate, urine, cell preparations, and the like. Methods for detecting a 101P3A11-related protein are also well known and include, for example, immunoprecipitation, immunohistochemical analysis, Western blot analysis, molecular binding assays, ELISA, ELIFA and the like. For example, a method of detecting the presence of a 101P3A11-related protein in a biological sample comprises first contacting the sample with a 101P3A11 antibody, a 101P3A11-reactive fragment thereof, or a recombinant protein containing an antigen binding region of a 101P3A11 antibody; and then detecting the binding of 101P3A11-related protein in the sample.

Methods for identifying a cell that expresses 101P3A11 are also within the scope of the invention. In one embodiment, an assay for identifying a cell that expresses a 101P3A11 gene comprises detecting the presence of 101P3A11

mRNA in the cell. Methods for the detection of particular mRNAs in cells are well known and include, for example, hybridization assays using complementary DNA probes (such as *in situ* hybridization using labeled 101P3A11 riboprobes, Northern blot and related techniques) and various nucleic acid amplification assays (such as RT-PCR using complementary primers specific for 101P3A11, and other amplification type detection methods, such as, for example, branched DNA, SISBA, TMA and the like). Alternatively, an assay for identifying a cell that expresses a 101P3A11 gene comprises detecting the presence of 101P3A11-related protein in the cell or secreted by the cell. Various methods for the detection of proteins are well known in the art and are employed for the detection of 101P3A11-related proteins and cells that express 101P3A11-related proteins.

101P3A11 expression analysis is also useful as a tool for identifying and evaluating agents that modulate 101P3A11 gene expression. For example, 101P3A11 expression is significantly upregulated in prostate cancer, and is expressed in cancers of the tissues listed in Table I. Identification of a molecule or biological agent that inhibits 101P3A11 expression or over-expression in cancer cells is of therapeutic value. For example, such an agent can be identified by using a screen that quantifies 101P3A11 expression by RT-PCR, nucleic acid hybridization or antibody binding.

VIII.) Methods for Monitoring the Status of 101P3A11-related Genes and Their Products

Oncogenesis is known to be a multistep process where cellular growth becomes progressively dysregulated and cells progress from a normal physiological state to precancerous and then cancerous states (see, e.g., Alers et al., Lab Invest. 77(5): 437-438 (1997) and Isaacs et al., Cancer Surv. 23: 19-32 (1995)). In this context, examining a biological sample for evidence of dysregulated cell growth (such as aberrant 101P3A11 expression in cancers) allows for early detection of such aberrant physiology, before a pathologic state such as cancer has progressed to a stage that therapeutic options are more limited and or the prognosis is worse. In such examinations, the status of 101P3A11 in a biological sample of interest can be compared, for example, to the status of 101P3A11 in a corresponding normal sample (e.g. a sample from that individual or alternatively another individual that is not affected by a pathology). An alteration in the status of 101P3A11 in the biological sample (as compared to the normal sample) provides evidence of dysregulated cellular growth. In addition to using a biological sample that is not affected by a pathology as a normal sample, one can also use a predetermined normative value such as a predetermined normal level of mRNA expression (see, e.g., Grever et al., J. Comp. Neurol. 1996 Dec 9;376(2):306-14 and U.S. Patent No. 5,837,501) to compare 101P3A11 status in a sample.

The term "status" in this context is used according to its art accepted meaning and refers to the condition or state of a gene and its products. Typically, skilled artisans use a number of parameters to evaluate the condition or state of a gene and its products. These include, but are not limited to the location of expressed gene products (including the location of 101P3A11 expressing cells) as well as the level, and biological activity of expressed gene products (such as 101P3A11 mRNA, polynucleotides and polypeptides). Typically, an alteration in the status of 101P3A11 comprises a change in the location of 101P3A11 and/or 101P3A11 expressing cells and/or an increase in 101P3A11 mRNA and/or protein expression.

101P3A11 status in a sample can be analyzed by a number of means well known in the art, including without limitation, immunohistochemical analysis, *in situ* hybridization, RT-PCR analysis on laser capture micro-dissected samples, Western blot analysis, and tissue array analysis. Typical protocols for evaluating the status of the 101P3A11 gene and gene

products are found, for example in Ausubel et al. eds., 1995, Current Protocols In Molecular Biology, Units 2 (Northern Blotting), 4 (Southern Blotting), 15 (Immunoblotting) and 18 (PCR Analysis). Thus, the status of 101P3A11 in a biological sample is evaluated by various methods utilized by skilled artisans including, but not limited to genomic Southern analysis (to examine, for example perturbations in the 101P3A11 gene), Northern analysis and/or PCR analysis of 101P3A11 mRNA (to examine, for example alterations in the polynucleotide sequences or expression levels of 101P3A11 mRNAs), and, Western and/or immunohistochemical analysis (to examine, for example alterations in polypeptide sequences, alterations in polypeptide localization within a sample, alterations in expression levels of 101P3A11 proteins and/or associations of 101P3A11 proteins with polypeptide binding partners). Detectable 101P3A11 polynucleotides include, for example, a 101P3A11 gene or fragment thereof, 101P3A11 mRNA, alternative splice variants, 101P3A11 mRNAs, and recombinant DNA or RNA molecules containing a 101P3A11 polynucleotide.

The expression profile of 101P3A11 makes it a diagnostic marker for local and/or metastasized disease, and provides information on the growth or oncogenic potential of a biological sample. In particular, the status of 101P3A11 provides information useful for predicting susceptibility to particular disease stages, progression, and/or tumor aggressiveness. The invention provides methods and assays for determining 101P3A11 status and diagnosing cancers that express 101P3A11, such as cancers of the tissues listed in Table I. For example, because 101P3A11 mRNA is so highly expressed in prostate and other cancers relative to normal prostate tissue, assays that evaluate the levels of 101P3A11 mRNA transcripts or proteins in a biological sample can be used to diagnose a disease associated with 101P3A11 dysregulation, and can provide prognostic information useful in defining appropriate therapeutic options.

The expression status of 101P3A11 provides information including the presence, stage and location of dysplastic, precancerous and cancerous cells, predicting susceptibility to various stages of disease, and/or for gauging tumor aggressiveness. Moreover, the expression profile makes it useful as an imaging reagent for metastasized disease. Consequently, an aspect of the invention is directed to the various molecular prognostic and diagnostic methods for examining the status of 101P3A11 in biological samples such as those from individuals suffering from, or suspected of suffering from a pathology characterized by dysregulated cellular growth, such as cancer.

As described above, the status of 101P3A11 in a biological sample can be examined by a number of well-known procedures in the art. For example, the status of 101P3A11 in a biological sample taken from a specific location in the body can be examined by evaluating the sample for the presence or absence of 101P3A11 expressing cells (e.g. those that express 101P3A11 mRNAs or proteins). This examination can provide evidence of dysregulated cellular growth, for example, when 101P3A11-expressing cells are found in a biological sample that does not normally contain such cells (such as a lymph node), because such alterations in the status of 101P3A11 in a biological sample are often associated with dysregulated cellular growth. Specifically, one indicator of dysregulated cellular growth is the metastases of cancer cells from an organ of origin (such as the prostate) to a different area of the body (such as a lymph node). In this context, evidence of dysregulated cellular growth is important for example because occult lymph node metastases can be detected in a substantial proportion of patients with prostate cancer, and such metastases are associated with known predictors of disease progression (see, e.g., Murphy et al., Prostate 42(4): 315-317 (2000); Su et al., Semin. Surg. Oncol. 18(1): 17-28 (2000) and Freeman et al., J Urol 1995 Aug 154(2 Pt 1):474-8).

In one aspect, the invention provides methods for monitoring 101P3A11 gene products by determining the status of 101P3A11 gene products expressed by cells from an individual suspected of having a disease associated with

dysregulated cell growth (such as hyperplasia or cancer) and then comparing the status so determined to the status of 101P3A11 gene products in a corresponding normal sample. The presence of aberrant 101P3A11 gene products in the test sample relative to the normal sample provides an indication of the presence of dysregulated cell growth within the cells of the individual.

5 In another aspect, the invention provides assays useful in determining the presence of cancer in an individual, comprising detecting a significant increase in 101P3A11 mRNA or protein expression in a test cell or tissue sample relative to expression levels in the corresponding normal cell or tissue. The presence of 101P3A11 mRNA can, for example, be evaluated in tissue samples including but not limited to those listed in Table I. The presence of significant 101P3A11 expression in any of these tissues is useful to indicate the emergence, presence and/or severity of a cancer, 10 since the corresponding normal tissues do not express 101P3A11 mRNA or express it at lower levels.

In a related embodiment, 101P3A11 status is determined at the protein level rather than at the nucleic acid level. For example, such a method comprises determining the level of 101P3A11 protein expressed by cells in a test tissue sample and comparing the level so determined to the level of 101P3A11 expressed in a corresponding normal sample. In one embodiment, the presence of 101P3A11 protein is evaluated, for example, using immunohistochemical methods.

15 101P3A11 antibodies or binding partners capable of detecting 101P3A11 protein expression are used in a variety of assay formats well known in the art for this purpose.

In a further embodiment, one can evaluate the status of 101P3A11 nucleotide and amino acid sequences in a biological sample in order to identify perturbations in the structure of these molecules. These perturbations can include insertions, deletions, substitutions and the like. Such evaluations are useful because perturbations in the nucleotide and 20 amino acid sequences are observed in a large number of proteins associated with a growth dysregulated phenotype (see, e.g., Marrogi et al., 1999, J. Cutan. Pathol. 26(8):369-378). For example, a mutation in the sequence of 101P3A11 may be indicative of the presence or promotion of a tumor. Such assays therefore have diagnostic and predictive value where a mutation in 101P3A11 indicates a potential loss of function or increase in tumor growth.

A wide variety of assays for observing perturbations in nucleotide and amino acid sequences are well known in the 25 art. For example, the size and structure of nucleic acid or amino acid sequences of 101P3A11 gene products are observed by the Northern, Southern, Western, PCR and DNA sequencing protocols discussed herein. In addition, other methods for observing perturbations in nucleotide and amino acid sequences such as single strand conformation polymorphism analysis are well known in the art (see, e.g., U.S. Patent Nos. 5,382,510 issued 7 September 1999, and 5,952,170 issued 17 January 1995).

30 Additionally, one can examine the methylation status of the 101P3A11 gene in a biological sample. Aberrant demethylation and/or hypermethylation of CpG islands in gene 5' regulatory regions frequently occurs in immortalized and transformed cells, and can result in altered expression of various genes. For example, promoter hypermethylation of the pi-class glutathione S-transferase (a protein expressed in normal prostate but not expressed in >90% of prostate carcinomas) appears to permanently silence transcription of this gene and is the most frequently detected genomic 35 alteration in prostate carcinomas (De Marzo et al., Am. J. Pathol. 155(6): 1985-1992 (1999)). In addition, this alteration is present in at least 70% of cases of high-grade prostatic intraepithelial neoplasia (PIN) (Brooks et al, Cancer Epidemiol. Biomarkers Prev., 1998, 7:531-536). In another example, expression of the LAGE-I tumor specific gene (which is not expressed in normal prostate but is expressed in 25-50% of prostate cancers) is induced by deoxy-

azacytidine in lymphoblastoid cells, suggesting that tumoral expression is due to demethylation (Lethe et al., Int. J. Cancer 76(6): 903-908 (1998)). A variety of assays for examining methylation status of a gene are well known in the art. For example, one can utilize, in Southern hybridization approaches, methylation-sensitive restriction enzymes which cannot cleave sequences that contain methylated CpG sites to assess the methylation status of CpG islands. In addition, MSP (methylation specific PCR) can rapidly profile the methylation status of all the CpG sites present in a CpG island of a given gene. This procedure involves initial modification of DNA by sodium bisulfite (which will convert all unmethylated cytosines to uracil) followed by amplification using primers specific for methylated versus unmethylated DNA. Protocols involving methylation interference can also be found for example in Current Protocols In Molecular Biology, Unit 12, Frederick M. Ausubel et al. eds., 1995.

Gene amplification is an additional method for assessing the status of 101P3A11. Gene amplification is measured in a sample directly, for example, by conventional Southern blotting or Northern blotting to quantitate the transcription of mRNA (Thomas, 1980, Proc. Natl. Acad. Sci. USA, 77:5201-5205), dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies are employed that recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn are labeled and the assay carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Biopsied tissue or peripheral blood can be conveniently assayed for the presence of cancer cells using for example, Northern, dot blot or RT-PCR analysis to detect 101P3A11 expression. The presence of RT-PCR amplifiable 101P3A11 mRNA provides an indication of the presence of cancer. RT-PCR assays are well known in the art. RT-PCR detection assays for tumor cells in peripheral blood are currently being evaluated for use in the diagnosis and management of a number of human solid tumors. In the prostate cancer field, these include RT-PCR assays for the detection of cells expressing PSA and PSM (Verkaik et al., 1997, Urol. Res. 25:373-384; Ghossein et al., 1995, J. Clin. Oncol. 13:1195-2000; Heston et al., 1995, Clin. Chem. 41:1687-1688).

A further aspect of the invention is an assessment of the susceptibility that an individual has for developing cancer. In one embodiment, a method for predicting susceptibility to cancer comprises detecting 101P3A11 mRNA or 101P3A11 protein in a tissue sample, its presence indicating susceptibility to cancer, wherein the degree of 101P3A11 mRNA expression correlates to the degree of susceptibility. In a specific embodiment, the presence of 101P3A11 in prostate or other tissue is examined, with the presence of 101P3A11 in the sample providing an indication of prostate cancer susceptibility (or the emergence or existence of a prostate tumor). Similarly, one can evaluate the integrity 101P3A11 nucleotide and amino acid sequences in a biological sample, in order to identify perturbations in the structure of these molecules such as insertions, deletions, substitutions and the like. The presence of one or more perturbations in 101P3A11 gene products in the sample is an indication of cancer susceptibility (or the emergence or existence of a tumor).

The invention also comprises methods for gauging tumor aggressiveness. In one embodiment, a method for gauging aggressiveness of a tumor comprises determining the level of 101P3A11 mRNA or 101P3A11 protein expressed by tumor cells, comparing the level so determined to the level of 101P3A11 mRNA or 101P3A11 protein expressed in a corresponding normal tissue taken from the same individual or a normal tissue reference sample, wherein the degree of 101P3A11 mRNA or 101P3A11 protein expression in the tumor sample relative to the normal sample indicates the degree

of aggressiveness. In a specific embodiment, aggressiveness of a tumor is evaluated by determining the extent to which 101P3A11 is expressed in the tumor cells, with higher expression levels indicating more aggressive tumors. Another embodiment is the evaluation of the integrity of 101P3A11 nucleotide and amino acid sequences in a biological sample, in order to identify perturbations in the structure of these molecules such as insertions, deletions, substitutions and the like. The presence of one or more perturbations indicates more aggressive tumors.

Another embodiment of the invention is directed to methods for observing the progression of a malignancy in an individual over time. In one embodiment, methods for observing the progression of a malignancy in an individual over time comprise determining the level of 101P3A11 mRNA or 101P3A11 protein expressed by cells in a sample of the tumor, comparing the level so determined to the level of 101P3A11 mRNA or 101P3A11 protein expressed in an equivalent tissue sample taken from the same individual at a different time, wherein the degree of 101P3A11 mRNA or 101P3A11 protein expression in the tumor sample over time provides information on the progression of the cancer. In a specific embodiment, the progression of a cancer is evaluated by determining 101P3A11 expression in the tumor cells over time, where increased expression over time indicates a progression of the cancer. Also, one can evaluate the integrity 101P3A11 nucleotide and amino acid sequences in a biological sample in order to identify perturbations in the structure of these molecules such as insertions, deletions, substitutions and the like, where the presence of one or more perturbations indicates a progression of the cancer.

The above diagnostic approaches can be combined with any one of a wide variety of prognostic and diagnostic protocols known in the art. For example, another embodiment of the invention is directed to methods for observing a coincidence between the expression of 101P3A11 gene and 101P3A11 gene products (or perturbations in 101P3A11 gene and 101P3A11 gene products) and a factor that is associated with malignancy, as a means for diagnosing and prognosticating the status of a tissue sample. A wide variety of factors associated with malignancy can be utilized, such as the expression of genes associated with malignancy (e.g. PSA, PSCA and PSM expression for prostate cancer etc.) as well as gross cytological observations (see, e.g., Bocking et al., 1984, Anal. Quant. Cytol. 6(2):74-88; Epstein, 1995, Hum. Pathol. 26(2):223-9; Thorson et al., 1998, Mod. Pathol. 11(6):543-51; Baisden et al., 1999, Am. J. Surg. Pathol. 23(8):918-24). Methods for observing a coincidence between the expression of 101P3A11 gene and 101P3A11 gene products (or perturbations in 101P3A11 gene and 101P3A11 gene products) and another factor that is associated with malignancy are useful, for example, because the presence of a set of specific factors that coincide with disease provides information crucial for diagnosing and prognosticating the status of a tissue sample.

In one embodiment, methods for observing a coincidence between the expression of 101P3A11 gene and 101P3A11 gene products (or perturbations in 101P3A11 gene and 101P3A11 gene products) and another factor associated with malignancy entails detecting the overexpression of 101P3A11 mRNA or protein in a tissue sample, detecting the overexpression of PSA mRNA or protein in a tissue sample (or PSCA or PSM expression), and observing a coincidence of 101P3A11 mRNA or protein and PSA mRNA or protein overexpression (or PSCA or PSM expression). In a specific embodiment, the expression of 101P3A11 and PSA mRNA in prostate tissue is examined, where the coincidence of 101P3A11 and PSA mRNA overexpression in the sample indicates the existence of prostate cancer, prostate cancer susceptibility or the emergence or status of a prostate tumor.

Methods for detecting and quantifying the expression of 101P3A11 mRNA or protein are described herein, and standard nucleic acid and protein detection and quantification technologies are well known in the art. Standard methods for

the detection and quantification of 101P3A11 mRNA include *in situ* hybridization using labeled 101P3A11 riboprobes, Northern blot and related techniques using 101P3A11 polynucleotide probes, RT-PCR analysis using primers specific for 101P3A11, and other amplification type detection methods, such as, for example, branched DNA, SISBA, TMA and the like. In a specific embodiment, semi-quantitative RT-PCR is used to detect and quantify 101P3A11 mRNA expression.

Any number of primers capable of amplifying 101P3A11 can be used for this purpose, including but not limited to the various primer sets specifically described herein. In a specific embodiment, polyclonal or monoclonal antibodies specifically reactive with the wild-type 101P3A11 protein can be used in an immunohistochemical assay of biopsied tissue.

IX.) Identification of Molecules that Interact with 101P3A11

The 101P3A11 protein and nucleic acid sequences disclosed herein allow a skilled artisan to identify proteins, small molecules and other agents that interact with 101P3A11, as well as pathways activated by 101P3A11 via any one of a variety of art accepted protocols. For example, one can utilize one of the so-called interaction trap systems (also referred to as the "two-hybrid assay"). In such systems, molecules interact and reconstitute a transcription factor which directs expression of a reporter gene, whereupon the expression of the reporter gene is assayed. Other systems identify protein-protein interactions *in vivo* through reconstitution of a eukaryotic transcriptional activator, see, e.g., U.S. Patent Nos. 5,955,280 issued 21 September 1999, 5,925,523 issued 20 July 1999, 5,846,722 issued 8 December 1998 and 6,004,746 issued 21 December 1999. Algorithms are also available in the art for genome-based predictions of protein function (see, e.g., Marcotte, et al., Nature 402: 4 November 1999, 83-86).

Alternatively one can screen peptide libraries to identify molecules that interact with 101P3A11 protein sequences. In such methods, peptides that bind to 101P3A11 are identified by screening libraries that encode a random or controlled collection of amino acids. Peptides encoded by the libraries are expressed as fusion proteins of bacteriophage coat proteins, the bacteriophage particles are then screened against the 101P3A11 protein.

Accordingly, peptides having a wide variety of uses, such as therapeutic, prognostic or diagnostic reagents, are thus identified without any prior information on the structure of the expected ligand or receptor molecule. Typical peptide libraries and screening methods that can be used to identify molecules that interact with 101P3A11 protein sequences are disclosed for example in U.S. Patent Nos. 5,723,286 issued 3 March 1998 and 5,733,731 issued 31 March 1998.

Alternatively, cell lines that express 101P3A11 are used to identify protein-protein interactions mediated by 101P3A11. Such interactions can be examined using immunoprecipitation techniques (see, e.g., Hamilton B.J., et al. Biochem. Biophys. Res. Commun. 1999, 261:646-51). 101P3A11 protein can be immunoprecipitated from 101P3A11-expressing cell lines using anti-101P3A11 antibodies. Alternatively, antibodies against His-tag can be used in a cell line engineered to express fusions of 101P3A11 and a His-tag (vectors mentioned above). The immunoprecipitated complex can be examined for protein association by procedures such as Western blotting, ³⁵S-methionine labeling of proteins, protein microsequencing, silver staining and two-dimensional gel electrophoresis.

Small molecules and ligands that interact with 101P3A11 can be identified through related embodiments of such screening assays. For example, small molecules can be identified that interfere with protein function, including molecules that interfere with 101P3A11's ability to mediate phosphorylation and de-phosphorylation, interaction with DNA or RNA molecules as an indication of regulation of cell cycles, second messenger signaling or tumorigenesis. Similarly, small molecules that modulate 101P3A11-related ion channel, protein pump, or cell communication functions

are identified and used to treat patients that have a cancer that expresses 101P3A11 (see, e.g., Hille, B., *Ionic Channels of Excitable Membranes* 2nd Ed., Sinauer Assoc., Sunderland, MA, 1992). Moreover, ligands that regulate 101P3A11 function can be identified based on their ability to bind 101P3A11 and activate a reporter construct. Typical methods are discussed for example in U.S. Patent No. 5,928,868 issued 27 July 1999, and include methods for forming hybrid ligands in which at least one ligand is a small molecule. In an illustrative embodiment, cells engineered to express a fusion protein of 101P3A11 and a DNA-binding protein are used to co-express a fusion protein of a hybrid ligand/small molecule and a cDNA library transcriptional activator protein. The cells further contain a reporter gene, the expression of which is conditioned on the proximity of the first and second fusion proteins to each other, an event that occurs only if the hybrid ligand binds to target sites on both hybrid proteins. Those cells that express the reporter gene are selected and the unknown small molecule or the unknown ligand is identified. This method provides a means of identifying modulators which activate or inhibit 101P3A11.

An embodiment of this invention comprises a method of screening for a molecule that interacts with an 101P3A11 amino acid sequence shown in Figure 2 or Figure 3, comprising the steps of contacting a population of molecules with the 101P3A11 amino acid sequence, allowing the population of molecules and the 101P3A11 amino acid sequence to interact under conditions that facilitate an interaction, determining the presence of a molecule that interacts with the 101P3A11 amino acid sequence, and then separating molecules that do not interact with the 101P3A11 amino acid sequence from molecules that do. In a specific embodiment, the method further comprises purifying, characterizing and identifying a molecule that interacts with the 101P3A11 amino acid sequence. The identified molecule can be used to modulate a function performed by 101P3A11. In a preferred embodiment, the 101P3A11 amino acid sequence is contacted with a library of peptides.

Non-limiting examples of small molecules include compounds that bind members of the olfactory receptor family of GPCR., ligands including hormones, neuropeptides, chemokines, odorants, phospholipids, and functional equivalents thereof that bind and preferably inhibit 101P3A11 protein function. Such non-limiting small molecules preferably have a molecular weight of less than about 10 kDa, more preferably below about 9, about 8, about 7, about 6, about 5 or about 4 kDa; physically associates with, or binds, 101P3A11 protein; is not found in naturally occurring metabolic pathways; and/or are more soluble in aqueous than non-aqueous solutions.

X.) Therapeutic Methods and Compositions

The identification of 101P3A11 as a protein that is normally expressed in a restricted set of tissues, but which is also expressed in prostate and other cancers, opens a number of therapeutic approaches to the treatment of such cancers. As contemplated herein, 101P3A11 functions as a transcription factor involved in activating tumor-promoting genes or repressing genes that block tumorigenesis.

Accordingly, therapeutic approaches that inhibit the activity of the 101P3A11 protein are useful for patients suffering from a cancer that expresses 101P3A11. These therapeutic approaches generally fall into two classes. One class comprises various methods for inhibiting the binding or association of the 101P3A11 protein with its binding partner or with other proteins. Another class comprises a variety of methods for inhibiting the transcription of the 101P3A11 gene or translation of 101P3A11 mRNA.

X.A.) Anti-Cancer Vaccines

The invention provides cancer vaccines comprising a 101P3A11-related protein or 101P3A11-related nucleic acid. In view of the expression of 101P3A11, cancer vaccines prevent and/or treat 101P3A11-expressing cancers with minimal or no effects on non-target tissues. The use of a tumor antigen in a vaccine that generates humoral and/or cell-mediated immune responses as anti-cancer therapy is well known in the art and has been employed in prostate cancer using human PSMA and rodent PAP immunogens (Hodge et al., 1995, *Int. J. Cancer* 63:231-237; Fong et al., 1997, *J. Immunol.* 159:3113-3117).

Such methods can be readily practiced by employing a 101P3A11-related protein, or an 101P3A11-encoding nucleic acid molecule and recombinant vectors capable of expressing and presenting the 101P3A11 immunogen (which typically comprises a number of antibody or T cell epitopes). Skilled artisans understand that a wide variety of vaccine systems for delivery of immunoreactive epitopes are known in the art (see, e.g., Heryln et al., *Ann Med* 1999 Feb 31(1):66-78; Maruyama et al., *Cancer Immunol Immunother* 2000 Jun 49(3):123-32). Briefly, such methods of generating an immune response (e.g. humoral and/or cell-mediated) in a mammal, comprise the steps of: exposing the mammal's immune system to an immunoreactive epitope (e.g. an epitope present in the 101P3A11 protein shown in SEQ ID NO: 703 or analog or homolog thereof) so that the mammal generates an immune response that is specific for that epitope (e.g. generates antibodies that specifically recognize that epitope). In a preferred method, the 101P3A11 immunogen contains a biological motif, see e.g., Tables V-XVIII or XXVI-XXVIII, or a peptide of a size range from 101P3A11 indicated in Figure 5, Figure 6, Figure 7, Figure 8, and Figure 9.

The entire 101P3A11 protein, immunogenic regions or epitopes thereof can be combined and delivered by various means. Such vaccine compositions can include, for example, lipopeptides (e.g., Vitiello, A. et al., *J. Clin. Invest.* 95:341, 1995), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g., Eldridge, et al., *Molec. Immunol.* 28:287-294, 1991; Alonso et al., *Vaccine* 12:299-306, 1994; Jones et al., *Vaccine* 13:675-681, 1995), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al., *Nature* 344:873-875, 1990; Hu et al., *Clin Exp Immunol.* 113:235-243, 1998), multiple antigen peptide systems (MAPs) (see e.g., Tam, J. P., *Proc. Natl. Acad. Sci. U.S.A.* 85:5409-5413, 1988; Tam, J.P., *J. Immunol. Methods* 196:17-32, 1996), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, M. E. et al., In: *Concepts in vaccine development*, Kaufmann, S. H. E., ed., p. 379, 1996; Chakrabarti, S. et al., *Nature* 320:535, 1986; Hu, S. L. et al., *Nature* 320:537, 1986; Kieny, M.-P. et al., *AIDS Bio/Technology* 4:790, 1986; Top, F. H. et al., *J. Infect. Dis.* 124:148, 1971; Chanda, P. K. et al., *Virology* 175:535, 1990), particles of viral or synthetic origin (e.g., Kofler, N. et al., *J. Immunol. Methods.* 192:25, 1996; Eldridge, J. H. et al., *Sem. Hematol.* 30:16, 1993; Falo, L. D., Jr. et al., *Nature Med.* 7:649, 1995), adjuvants (Warren, H. S., Vogel, F. R., and Chedid, L. A. *Annu. Rev. Immunol.* 4:369, 1986; Gupta, R. K. et al., *Vaccine* 11:293, 1993), liposomes (Reddy, R. et al., *J. Immunol.* 148:1585, 1992; Rock, K. L., *Immunol. Today* 17:131, 1996), or, naked or particle absorbed cDNA (Ulmer, J. B. et al., *Science* 259:1745, 1993; Robinson, H. L., Hunt, L. A., and Webster, R. G., *Vaccine* 11:957, 1993; Shiver, J. W. et al., In: *Concepts in vaccine development*, Kaufmann, S. H. E., ed., p. 423, 1996; Cease, K. B., and Berzofsky, J. A., *Annu. Rev. Immunol.* 12:923, 1994 and Eldridge, J. H. et al., *Sem. Hematol.* 30:16, 1993). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.

In patients with 101P3A11-associated cancer, the vaccine compositions of the invention can also be used in conjunction with other treatments used for cancer, *e.g.*, surgery, chemotherapy, drug therapies, radiation therapies, *etc.* including use in combination with immune adjuvants such as IL-2, IL-12, GM-CSF, and the like.

Cellular Vaccines:

CTL epitopes can be determined using specific algorithms to identify peptides within 101P3A11 protein that bind corresponding HLA alleles (see *e.g.*, Table IV; Epimer™ and Epimatrix™, Brown University (URL www.brown.edu/Research/TB-HIV_Lab/epimatrix/epimatrix.html); and, BIMAS, (URL bimas.dcrt.nih.gov/; SYFPEITHI at URL syfpeithi.bmi-heidelberg.com/). In a preferred embodiment, the 101P3A11 immunogen contains one or more amino acid sequences identified using techniques well known in the art, such as the sequences shown in Tables V-XVIII or XXVI-XXVIII or a peptide of 8, 9, 10 or 11 amino acids specified by an HLA Class I motif/supermotif (*e.g.*, Table IV (A), Table IV (D), or Table IV (E)) and/or a peptide of at least 9 amino acids that comprises an HLA Class II motif/supermotif (*e.g.*, Table IV (B) or Table IV (C)). As is appreciated in the art, the HLA Class I binding groove is essentially closed ended so that peptides of only a particular size range can fit into the groove and be bound, generally HLA Class I epitopes are 8, 9, 10, or 11 amino acids long. In contrast, the HLA Class II binding groove is essentially open ended; therefore a peptide of about 9 or more amino acids can be bound by an HLA Class II molecule. Due to the binding groove differences between HLA Class I and II, HLA Class I motifs are length specific, *i.e.*, position two of a Class I motif is the second amino acid in an amino to carboxyl direction of the peptide. The amino acid positions in a Class II motif are relative only to each other, not the overall peptide, *i.e.*, additional amino acids can be attached to the amino and/or carboxyl termini of a motif-bearing sequence. HLA Class II epitopes are often 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids long, or longer than 25 amino acids.

Antibody-based Vaccines

A wide variety of methods for generating an immune response in a mammal are known in the art (for example as the first step in the generation of hybridomas). Methods of generating an immune response in a mammal comprise exposing the mammal's immune system to an immunogenic epitope on a protein (*e.g.* the 101P3A11 protein) so that an immune response is generated. In one embodiment the protein can be an anti idiotypic antibody. A typical embodiment consists of a method for generating an immune response to 101P3A11 in a host, by contacting the host with a sufficient amount of at least one 101P3A11 B cell or cytotoxic T-cell epitope or analog thereof; and at least one periodic interval thereafter re-contacting the host with the 101P3A11 B cell or cytotoxic T-cell epitope or analog thereof. A specific embodiment consists of a method of generating an immune response against a 101P3A11-related protein or a man-made multiepitopic peptide comprising: administering 101P3A11 immunogen (*e.g.* the 101P3A11 protein or a peptide fragment thereof, an 101P3A11 fusion protein or analog *etc.*) in a vaccine preparation to a human or another mammal. Typically, such vaccine preparations further contain a suitable adjuvant (see, *e.g.*, U.S. Patent No. 6,146,635) or a universal helper epitope such as a PADRE™ peptide (Epimmune Inc., San Diego, CA; see, *e.g.*, Alexander et al., *J. Immunol.* 2000 164(3): 1625-1633; Alexander et al., *Immunity* 1994 1(9): 751-761 and Alexander et al., *Immunol. Res.* 1998 18(2): 79-92). An alternative method comprises generating an immune response in an individual against a 101P3A11 immunogen by: administering *in vivo* to muscle or skin of the individual's body a DNA molecule that comprises a DNA sequence that encodes an 101P3A11 immunogen, the DNA sequence operatively linked to regulatory sequences which control the expression of the DNA sequence; wherein the DNA molecule is taken up by

cells, the DNA sequence is expressed in the cells and an immune response is generated against the immunogen (see, e.g., U.S. Patent No. 5,962,428). Optionally a genetic vaccine facilitator such as anionic lipids; saponins; lectins; estrogenic compounds; hydroxylated lower alkyls; dimethyl sulfoxide; and urea is also administered.

Nucleic Acid Vaccines:

Vaccine compositions of the invention include nucleic acid-mediated modalities. DNA or RNA that encode protein(s) of the invention can be administered to a patient. Genetic immunization methods can be employed to generate prophylactic or therapeutic humoral and cellular immune responses directed against cancer cells expressing 101P3A11. Constructs comprising DNA encoding a 101P3A11-related protein/immunogen and appropriate regulatory sequences can be injected directly into muscle or skin of an individual, such that the cells of the muscle or skin take-up the construct and express the encoded 101P3A11 protein/immunogen. Alternatively, a vaccine comprises a 101P3A11-related protein. Expression of the 101P3A11-related protein immunogen results in the generation of prophylactic or therapeutic humoral and cellular immunity against cells that bear 101P3A11 protein. Various prophylactic and therapeutic genetic immunization techniques known in the art can be used (for review, see information and references published at Internet address www.genweb.com). Nucleic acid-based delivery is described, for instance, in Wolff *et al.*, *Science* 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720. Examples of DNA-based delivery technologies include “naked DNA”, facilitated (bupivacaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated (“gene gun”) or pressure-mediated delivery (see, e.g., U.S. Patent No. 5,922,687).

For therapeutic or prophylactic immunization purposes, proteins of the invention can be expressed via viral or bacterial vectors. Various viral gene delivery systems that can be used in the practice of the invention include, but are not limited to, vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and sindbis virus (see, e.g., Restifo, 1996, *Curr. Opin. Immunol.* 8:658-663; Tsang *et al.* *J. Natl. Cancer Inst.* 87:982-990 (1995)). Non-viral delivery systems can also be employed by introducing naked DNA encoding a 101P3A11-related protein into the patient (e.g., intramuscularly or intradermally) to induce an anti-tumor response.

Vaccinia virus is used, for example, as a vector to express nucleotide sequences that encode the peptides of the invention. Upon introduction into a host, the recombinant vaccinia virus expresses the protein immunogenic peptide, and thereby elicits a host immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover *et al.*, *Nature* 351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, e.g. adeno and adeno-associated virus vectors, retroviral vectors, *Salmonella typhi* vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein.

Thus, gene delivery systems are used to deliver a 101P3A11-related nucleic acid molecule. In one embodiment, the full-length human 101P3A11 cDNA is employed. In another embodiment, 101P3A11 nucleic acid molecules encoding specific cytotoxic T lymphocyte (CTL) and/or antibody epitopes are employed.

Ex Vivo Vaccines

Various *ex vivo* strategies can also be employed to generate an immune response. One approach involves the use of antigen presenting cells (APCs) such as dendritic cells (DC) to present 101P3A11 antigen to a patient's immune system.

Dendritic cells express MHC class I and II molecules, B7 co-stimulator, and IL-12, and are thus highly specialized antigen presenting cells. In prostate cancer, autologous dendritic cells pulsed with peptides of the prostate-specific membrane antigen (PSMA) are being used in a Phase I clinical trial to stimulate prostate cancer patients' immune systems (Tjoa et al., 1996, Prostate 28:65-69; Murphy et al., 1996, Prostate 29:371-380). Thus, dendritic cells can be used to present 101P3A11 peptides to T cells in the context of MHC class I or II molecules. In one embodiment, autologous dendritic cells are pulsed with 101P3A11 peptides capable of binding to MHC class I and/or class II molecules. In another embodiment, dendritic cells are pulsed with the complete 101P3A11 protein. Yet another embodiment involves engineering the overexpression of the 101P3A11 gene in dendritic cells using various implementing vectors known in the art, such as adenovirus (Arthur et al., 1997, Cancer Gene Ther. 4:17-25), retrovirus (Henderson et al., 1996, Cancer Res. 56:3763-3770), lentivirus, adeno-associated virus, DNA transfection (Ribas et al., 1997, Cancer Res. 57:2865-2869), or tumor-derived RNA transfection (Ashley et al., 1997, J. Exp. Med. 186:1177-1182). Cells that express 101P3A11 can also be engineered to express immune modulators, such as GM-CSF, and used as immunizing agents.

X.B.) 101P3A11 as a Target for Antibody-based Therapy

101P3A11 is an attractive target for antibody-based therapeutic strategies. A number of antibody strategies are known in the art for targeting both extracellular and intracellular molecules (e.g., complement and ADCC mediated killing, the use of intrabodies, and conjugated antibodies) 101P3A11 is expressed by cancer cells of various lineages relative to corresponding normal cells, systemic administration of 101P3A11-immunoreactive compositions are prepared that exhibit excellent sensitivity without toxic, non-specific and/or non-target effects caused by binding of the immunoreactive composition to non-target organs and tissues. Antibodies specifically reactive with domains of 101P3A11 are useful to treat 101P3A11-expressing cancers systemically, either as conjugates with a toxin or therapeutic agent, or as naked antibodies capable of inhibiting cell proliferation or function.

101P3A11 antibodies can be introduced into a patient such that the antibody binds to 101P3A11 and modulates a function, such as an interaction with a binding partner, and consequently mediates destruction of the tumor cells and/or inhibits the growth of the tumor cells. Mechanisms by which such antibodies exert a therapeutic effect can include complement-mediated cytotoxicity, antibody-dependent cellular cytotoxicity, modulation of the physiological function of 101P3A11, inhibition of ligand binding or signal transduction pathways, modulation of tumor cell differentiation, alteration of tumor angiogenesis factor profiles, and/or apoptosis.

Those skilled in the art understand that antibodies can be used to specifically target and bind immunogenic molecules such as an immunogenic region of the 101P3A11 sequence shown in Figure 2 or Figure 3. In addition, skilled artisans understand that it is routine to conjugate antibodies to cytotoxic agents (see, e.g., Slevers et al. Blood 93:11 3678-3684 (June 1, 1999)). When cytotoxic and/or therapeutic agents are delivered directly to cells, such as by conjugating them to antibodies specific for a molecule expressed by that cell (e.g. 101P3A11), the cytotoxic agent will exert its known biological effect (i.e. cytotoxicity) on those cells.

A wide variety of compositions and methods for using antibody-cytotoxic agent conjugates to kill cells are known in the art. In the context of cancers, typical methods entail administering to an animal having a tumor a biologically effective amount of a conjugate comprising a selected cytotoxic and/or therapeutic agent linked to a targeting agent (e.g. an anti-101P3A11 antibody) that binds to a marker (e.g. 101P3A11) expressed, accessible to

binding or localized on the cell surfaces. A typical embodiment is a method of delivering a cytotoxic and/or therapeutic agent to a cell expressing 101P3A11, comprising conjugating the cytotoxic agent to an antibody that immunospecifically binds to a 101P3A11 epitope, and, exposing the cell to the antibody-agent conjugate. Another illustrative embodiment is a method of treating an individual suspected of suffering from metastasized cancer, comprising a step of administering parenterally to said individual a pharmaceutical composition comprising a therapeutically effective amount of an antibody conjugated to a cytotoxic and/or therapeutic agent.

Cancer immunotherapy using anti-101P3A11 antibodies can be done in accordance with various approaches that have been successfully employed in the treatment of other types of cancer, including but not limited to colon cancer (Arlen et al., 1998, Crit. Rev. Immunol. 18:133-138), multiple myeloma (Ozaki et al., 1997, Blood 90:3179-3186, Tsunenari et al., 1997, Blood 90:2437-2444), gastric cancer (Kasprzyk et al., 1992, Cancer Res. 52:2771-2776), B-cell lymphoma (Funakoshi et al., 1996, J. Immunother. Emphasis Tumor Immunol. 19:93-101), leukemia (Zhong et al., 1996, Leuk. Res. 20:581-589), colorectal cancer (Moun et al., 1994, Cancer Res. 54:6160-6166; Velders et al., 1995, Cancer Res. 55:4398-4403), and breast cancer (Shepard et al., 1991, J. Clin. Immunol. 11:117-127). Some therapeutic approaches involve conjugation of naked antibody to a toxin or radioisotope, such as the conjugation of Y⁹¹ or I¹³¹ to anti-CD20 antibodies (e.g., ZevalinTM, IDEC Pharmaceuticals Corp. or BexxarTM, Coulter Pharmaceuticals), while others involve co-administration of antibodies and other therapeutic agents, such as HerceptinTM (trastuzumab) with paclitaxel (Genentech, Inc.). To treat prostate cancer, for example, 101P3A11 antibodies can be administered in conjunction with radiation, chemotherapy or hormone ablation.

Although 101P3A11 antibody therapy is useful for all stages of cancer, antibody therapy can be particularly appropriate in advanced or metastatic cancers. Treatment with the antibody therapy of the invention is indicated for patients who have received one or more rounds of chemotherapy. Alternatively, antibody therapy of the invention is combined with a chemotherapeutic or radiation regimen for patients who have not received chemotherapeutic treatment. Additionally, antibody therapy can enable the use of reduced dosages of concomitant chemotherapy, particularly for patients who do not tolerate the toxicity of the chemotherapeutic agent very well. Fan et al. (Cancer Res. 53:4637-4642, 1993), Prewett et al. (International J. of Onco. 9:217-224, 1996), and Hancock et al. (Cancer Res. 51:4575-4580, 1991) describe the use of various antibodies and chemotherapeutic agents *in vitro*.

Cancer patients can be evaluated for the presence and level of 101P3A11 expression, preferably using immunohistochemical assessments of tumor tissue, quantitative 101P3A11 imaging, or other techniques that reliably indicate the presence and degree of 101P3A11 expression. Immunohistochemical analysis of tumor biopsies or surgical specimens is preferred for this purpose. Methods for immunohistochemical analysis of tumor tissues are well known in the art.

Anti-101P3A11 monoclonal antibodies that treat prostate and other cancers include those that initiate a potent immune response against the tumor or those that are directly cytotoxic. In this regard, anti-101P3A11 monoclonal antibodies (mAbs) can elicit tumor cell lysis by either complement-mediated or antibody-dependent cell cytotoxicity (ADCC) mechanisms, both of which require an intact Fc portion of the immunoglobulin molecule for interaction with effector cell Fc receptor sites on complement proteins. In addition, anti-101P3A11 mAbs that exert a direct biological effect on tumor growth are useful to treat cancers that express 101P3A11. Mechanisms by which directly cytotoxic mAbs act include: inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis

factor profiles, and the induction of apoptosis. The mechanism(s) by which a particular anti-101P3A11 mAb exerts an anti-tumor effect is evaluated using any number of *in vitro* assays that evaluate cell death such as ADCC, ADMMC, complement-mediated cell lysis, and so forth, as is generally known in the art.

In some patients, the use of murine or other non-human monoclonal antibodies, or human/mouse chimeric mAbs can induce moderate to strong immune responses against the non-human antibody. This can result in clearance of the antibody from circulation and reduced efficacy. In the most severe cases, such an immune response can lead to the extensive formation of immune complexes which, potentially, can cause renal failure. Accordingly, preferred monoclonal antibodies used in the therapeutic methods of the invention are those that are either fully human or humanized and that bind specifically to the target 101P3A11 antigen with high affinity but exhibit low or no antigenicity in the patient.

Therapeutic methods of the invention contemplate the administration of single anti-101P3A11 mAbs as well as combinations, or cocktails, of different mAbs. Such mAb cocktails can have certain advantages inasmuch as they contain mAbs that target different epitopes, exploit different effector mechanisms or combine directly cytotoxic mAbs with mAbs that rely on immune effector functionality. Such mAbs in combination can exhibit synergistic therapeutic effects. In addition, anti-101P3A11 mAbs can be administered concomitantly with other therapeutic modalities, including but not limited to various chemotherapeutic agents, androgen-blockers, immune modulators (e.g., IL-2, GM-CSF), surgery or radiation. The anti-101P3A11 mAbs are administered in their "naked" or unconjugated form, or can have a therapeutic agent(s) conjugated to them.

Anti-101P3A11 antibody formulations are administered via any route capable of delivering the antibodies to a tumor cell. Routes of administration include, but are not limited to, intravenous, intraperitoneal, intramuscular, intratumor, intradermal, and the like. Treatment generally involves repeated administration of the anti-101P3A11 antibody preparation, via an acceptable route of administration such as intravenous injection (IV), typically at a dose in the range of about 0.1, .2, .3, .4, .5, .6, .7, .8, .9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25 mg/kg body weight. In general, doses in the range of 10-1000 mg mAb per week are effective and well tolerated.

Based on clinical experience with the Herceptin mAb in the treatment of metastatic breast cancer, an initial loading dose of approximately 4 mg/kg patient body weight IV, followed by weekly doses of about 2 mg/kg IV of the anti- 101P3A11 mAb preparation represents an acceptable dosing regimen. Preferably, the initial loading dose is administered as a 90 minute or longer infusion. The periodic maintenance dose is administered as a 30 minute or longer infusion, provided the initial dose was well tolerated. As appreciated by those of skill in the art, various factors can influence the ideal dose regimen in a particular case. Such factors include, for example, the binding affinity and half life of the Ab or mAbs used, the degree of 101P3A11 expression in the patient, the extent of circulating shed 101P3A11 antigen, the desired steady-state antibody concentration level, frequency of treatment, and the influence of chemotherapeutic or other agents used in combination with the treatment method of the invention, as well as the health status of a particular patient.

Optionally, patients should be evaluated for the levels of 101P3A11 in a given sample (e.g. the levels of circulating 101P3A11 antigen and/or 101P3A11 expressing cells) in order to assist in the determination of the most effective dosing regimen, etc. Such evaluations are also used for monitoring purposes throughout therapy, and are

useful to gauge therapeutic success in combination with the evaluation of other parameters (for example, urine cytology and/or ImmunoCyt levels in bladder cancer therapy, or by analogy, serum PSA levels in prostate cancer therapy).

Anti-idiotypic anti-101P3A11 antibodies can also be used in anti-cancer therapy as a vaccine for inducing an immune response to cells expressing a 101P3A11-related protein. In particular, the generation of anti-idiotypic antibodies is well known in the art; this methodology can readily be adapted to generate anti-idiotypic anti-101P3A11 antibodies that mimic an epitope on a 101P3A11-related protein (see, for example, Wagner et al., 1997, Hybridoma 16: 33-40; Foon et al., 1995, J. Clin. Invest. 96:334-342; Herlyn et al., 1996, Cancer Immunol. Immunother. 43:65-76). Such an anti-idiotypic antibody can be used in cancer vaccine strategies.

X.C.) 101P3A11 as a Target for Cellular Immune Responses

Vaccines and methods of preparing vaccines that contain an immunogenically effective amount of one or more HLA-binding peptides as described herein are further embodiments of the invention. Furthermore, vaccines in accordance with the invention encompass compositions of one or more of the claimed peptides. A peptide can be present in a vaccine individually. Alternatively, the peptide can exist as a homopolymer comprising multiple copies of the same peptide, or as a heteropolymer of various peptides. Polymers have the advantage of increased immunological reaction and, where different peptide epitopes are used to make up the polymer, the additional ability to induce antibodies and/or CTLs that react with different antigenic determinants of the pathogenic organism or tumor-related peptide targeted for an immune response. The composition can be a naturally occurring region of an antigen or can be prepared, *e.g.*, recombinantly or by chemical synthesis.

Carriers that can be used with vaccines of the invention are well known in the art, and include, *e.g.*, thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly L-lysine, poly L-glutamic acid, influenza, hepatitis B virus core protein, and the like. The vaccines can contain a physiologically tolerable (*i.e.*, acceptable) diluent such as water, or saline, preferably phosphate buffered saline. The vaccines also typically include an adjuvant. Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum are examples of materials well known in the art. Additionally, as disclosed herein, CTL responses can be primed by conjugating peptides of the invention to lipids, such as tripalmitoyl-S-glycerylcysteinylserine (P₃CSS). Moreover, an adjuvant such as a synthetic cytosine-phosphorothiolated-guanine-containing (CpG) oligonucleotides has been found to increase CTL responses 10- to 100-fold. (see, *e.g.* Davila and Celis *J. Immunol.* 165:539-547 (2000))

Upon immunization with a peptide composition in accordance with the invention, via injection, aerosol, oral, transdermal, transmucosal, intrapleural, intrathecal, or other suitable routes, the immune system of the host responds to the vaccine by producing large amounts of CTLs and/or HTLs specific for the desired antigen. Consequently, the host becomes at least partially immune to later development of cells that express or overexpress 101P3A11 antigen, or derives at least some therapeutic benefit when the antigen was tumor-associated.

In some embodiments, it may be desirable to combine the class I peptide components with components that induce or facilitate neutralizing antibody and or helper T cell responses directed to the target antigen. A preferred embodiment of such a composition comprises class I and class II epitopes in accordance with the invention. An alternative embodiment of such a composition comprises a class I and/or class II epitope in accordance with the

invention, along with a cross reactive HTL epitope such as PADRE™ (Epimmune, San Diego, CA) molecule (described *e.g.*, in U.S. Patent Number 5,736,142).

A vaccine of the invention can also include antigen-presenting cells (APC), such as dendritic cells (DC), as a vehicle to present peptides of the invention. Vaccine compositions can be created *in vitro*, following dendritic cell mobilization and harvesting, whereby loading of dendritic cells occurs *in vitro*. For example, dendritic cells are transfected, *e.g.*, with a minigene in accordance with the invention, or are pulsed with peptides. The dendritic cell can then be administered to a patient to elicit immune responses *in vivo*. Vaccine compositions, either DNA- or peptide-based, can also be administered *in vivo* in combination with dendritic cell mobilization whereby loading of dendritic cells occurs *in vivo*.

Preferably, the following principles are utilized when selecting an array of epitopes for inclusion in a polypeptidic composition for use in a vaccine, or for selecting discrete epitopes to be included in a vaccine and/or to be encoded by nucleic acids such as a minigene. It is preferred that each of the following principles be balanced in order to make the selection. The multiple epitopes to be incorporated in a given vaccine composition may be, but need not be, contiguous in sequence in the native antigen from which the epitopes are derived.

1.) Epitopes are selected which, upon administration, mimic immune responses that have been observed to be correlated with tumor clearance. For HLA Class I this includes 3-4 epitopes that come from at least one tumor associated antigen (TAA). For HLA Class II a similar rationale is employed; again 3-4 epitopes are selected from at least one TAA (*see, e.g.*, Rosenberg *et al.*, *Science* 278:1447-1450). Epitopes from one TAA may be used in combination with epitopes from one or more additional TAAs to produce a vaccine that targets tumors with varying expression patterns of frequently-expressed TAAs.

2.) Epitopes are selected that have the requisite binding affinity established to be correlated with immunogenicity: for HLA Class I an IC₅₀ of 500 nM or less, often 200 nM or less; and for Class II an IC₅₀ of 1000 nM or less.

3.) Sufficient supermotif bearing-peptides, or a sufficient array of allele-specific motif-bearing peptides, are selected to give broad population coverage. For example, it is preferable to have at least 80% population coverage. A Monte Carlo analysis, a statistical evaluation known in the art, can be employed to assess the breadth, or redundancy of, population coverage.

4.) When selecting epitopes from cancer-related antigens it is often useful to select analogs because the patient may have developed tolerance to the native epitope.

5.) Of particular relevance are epitopes referred to as "nested epitopes." Nested epitopes occur where at least two epitopes overlap in a given peptide sequence. A nested peptide sequence can comprise B cell, HLA class I and/or HLA class II epitopes. When providing nested epitopes, a general objective is to provide the greatest number of epitopes per sequence. Thus, an aspect is to avoid providing a peptide that is any longer than the amino terminus of the amino terminal epitope and the carboxyl terminus of the carboxyl terminal epitope in the peptide. When providing a multi-epitopic sequence, such as a sequence comprising nested epitopes, it is generally important to screen the sequence in order to insure that it does not have pathological or other deleterious biological properties.

6.) If a polypeptidic protein is created, or when creating a minigene, an objective is to generate the smallest peptide that encompasses the epitopes of interest. This principle is similar, if not the same as that employed

when selecting a peptide comprising nested epitopes. However, with an artificial polyepitopic peptide, the size minimization objective is balanced against the need to integrate any spacer sequences between epitopes in the polyepitopic protein. Spacer amino acid residues can, for example, be introduced to avoid junctional epitopes (an epitope recognized by the immune system, not present in the target antigen, and only created by the man-made juxtaposition of epitopes), or to facilitate cleavage between epitopes and thereby enhance epitope presentation. Junctional epitopes are generally to be avoided because the recipient may generate an immune response to that non-native epitope. Of particular concern is a junctional epitope that is a "dominant epitope." A dominant epitope may lead to such a zealous response that immune responses to other epitopes are diminished or suppressed.

7.) Where the sequences of multiple variants of the same target protein are present, potential peptide epitopes can also be selected on the basis of their conservancy. For example, a criterion for conservancy may define that the entire sequence of an HLA class I binding peptide or the entire 9-mer core of a class II binding peptide be conserved in a designated percentage of the sequences evaluated for a specific protein antigen.

X.C.1. Minigene Vaccines

A number of different approaches are available which allow simultaneous delivery of multiple epitopes. Nucleic acids encoding the peptides of the invention are a particularly useful embodiment of the invention. Epitopes for inclusion in a minigene are preferably selected according to the guidelines set forth in the previous section. A preferred means of administering nucleic acids encoding the peptides of the invention uses minigene constructs encoding a peptide comprising one or multiple epitopes of the invention.

The use of multi-epitope minigenes is described below and in, Ishioka *et al.*, *J. Immunol.* 162:3915-3925, 1999; An, L. and Whitton, J. L., *J. Virol.* 71:2292, 1997; Thomson, S. A. *et al.*, *J. Immunol.* 157:822, 1996; Whitton, J. L. *et al.*, *J. Virol.* 67:348, 1993; Hanke, R. *et al.*, *Vaccine* 16:426, 1998. For example, a multi-epitope DNA plasmid encoding supermotif- and/or motif-bearing epitopes derived 101P3A11, the PADRE® universal helper T cell epitope (or multiple HTL epitopes from 101P3A11), and an endoplasmic reticulum-translocating signal sequence can be engineered. A vaccine may also comprise epitopes that are derived from other TAAs.

The immunogenicity of a multi-epitopic minigene can be confirmed in transgenic mice to evaluate the magnitude of CTL induction responses against the epitopes tested. Further, the immunogenicity of DNA-encoded epitopes *in vivo* can be correlated with the *in vitro* responses of specific CTL lines against target cells transfected with the DNA plasmid. Thus, these experiments can show that the minigene serves to both: 1.) generate a CTL response and 2.) that the induced CTLs recognized cells expressing the encoded epitopes.

For example, to create a DNA sequence encoding the selected epitopes (minigene) for expression in human cells, the amino acid sequences of the epitopes may be reverse translated. A human codon usage table can be used to guide the codon choice for each amino acid. These epitope-encoding DNA sequences may be directly adjoined, so that when translated, a continuous polypeptide sequence is created. To optimize expression and/or immunogenicity, additional elements can be incorporated into the minigene design. Examples of amino acid sequences that can be reverse translated and included in the minigene sequence include: HLA class I epitopes, HLA class II epitopes, antibody epitopes, a ubiquitination signal sequence, and/or an endoplasmic reticulum targeting signal. In addition, HLA presentation of CTL and HTL epitopes may be improved by including synthetic (*e.g.* poly-alanine) or naturally-

occurring flanking sequences adjacent to the CTL or HTL epitopes; these larger peptides comprising the epitope(s) are within the scope of the invention.

The minigene sequence may be converted to DNA by assembling oligonucleotides that encode the plus and minus strands of the minigene. Overlapping oligonucleotides (30-100 bases long) may be synthesized, phosphorylated, purified and annealed under appropriate conditions using well known techniques. The ends of the oligonucleotides can be joined, for example, using T4 DNA ligase. This synthetic minigene, encoding the epitope polypeptide, can then be cloned into a desired expression vector.

Standard regulatory sequences well known to those of skill in the art are preferably included in the vector to ensure expression in the target cells. Several vector elements are desirable: a promoter with a down-stream cloning site for minigene insertion; a polyadenylation signal for efficient transcription termination; an *E. coli* origin of replication; and an *E. coli* selectable marker (*e.g.* ampicillin or kanamycin resistance). Numerous promoters can be used for this purpose, *e.g.*, the human cytomegalovirus (hCMV) promoter. See, *e.g.*, U.S. Patent Nos. 5,580,859 and 5,589,466 for other suitable promoter sequences.

Additional vector modifications may be desired to optimize minigene expression and immunogenicity. In some cases, introns are required for efficient gene expression, and one or more synthetic or naturally-occurring introns could be incorporated into the transcribed region of the minigene. The inclusion of mRNA stabilization sequences and sequences for replication in mammalian cells may also be considered for increasing minigene expression.

Once an expression vector is selected, the minigene is cloned into the polylinker region downstream of the promoter. This plasmid is transformed into an appropriate *E. coli* strain, and DNA is prepared using standard techniques. The orientation and DNA sequence of the minigene, as well as all other elements included in the vector, are confirmed using restriction mapping and DNA sequence analysis. Bacterial cells harboring the correct plasmid can be stored as a master cell bank and a working cell bank.

In addition, immunostimulatory sequences (ISSs or CpGs) appear to play a role in the immunogenicity of DNA vaccines. These sequences may be included in the vector, outside the minigene coding sequence, if desired to enhance immunogenicity.

In some embodiments, a bi-cistronic expression vector which allows production of both the minigene-encoded epitopes and a second protein (included to enhance or decrease immunogenicity) can be used. Examples of proteins or polypeptides that could beneficially enhance the immune response if co-expressed include cytokines (*e.g.*, IL-2, IL-12, GM-CSF), cytokine-inducing molecules (*e.g.*, LeIF), costimulatory molecules, or for HTL responses, pan-DR binding proteins (PADRE™, Epimmune, San Diego, CA). Helper (HTL) epitopes can be joined to intracellular targeting signals and expressed separately from expressed CTL epitopes; this allows direction of the HTL epitopes to a cell compartment different than that of the CTL epitopes. If required, this could facilitate more efficient entry of HTL epitopes into the HLA class II pathway, thereby improving HTL induction. In contrast to HTL or CTL induction, specifically decreasing the immune response by co-expression of immunosuppressive molecules (*e.g.* TGF-β) may be beneficial in certain diseases.

Therapeutic quantities of plasmid DNA can be produced for example, by fermentation in *E. coli*, followed by purification. Aliquots from the working cell bank are used to inoculate growth medium, and grown to saturation in shaker flasks or a bioreactor according to well-known techniques. Plasmid DNA can be purified using standard

bioseparation technologies such as solid phase anion-exchange resins supplied by QIAGEN, Inc. (Valencia, California). If required, supercoiled DNA can be isolated from the open circular and linear forms using gel electrophoresis or other methods.

Purified plasmid DNA can be prepared for injection using a variety of formulations. The simplest of these is reconstitution of lyophilized DNA in sterile phosphate-buffer saline (PBS). This approach, known as "naked DNA," is currently being used for intramuscular (IM) administration in clinical trials. To maximize the immunotherapeutic effects of minigene DNA vaccines, an alternative method for formulating purified plasmid DNA may be desirable. A variety of methods have been described, and new techniques may become available. Cationic lipids, glycolipids, and fusogenic liposomes can also be used in the formulation (see, e.g., as described by WO 93/24640; Mannino & Gould-Fogerite, *BioTechniques* 6(7): 682 (1988); U.S. Pat No. 5,279,833; WO 91/06309; and Felgner, *et al.*, *Proc. Nat'l Acad. Sci. USA* 84:7413 (1987). In addition, peptides and compounds referred to collectively as protective, interactive, non-condensing compounds (PINC) could also be complexed to purified plasmid DNA to influence variables such as stability, intramuscular dispersion, or trafficking to specific organs or cell types.

Target cell sensitization can be used as a functional assay for expression and HLA class I presentation of minigene-encoded CTL epitopes. For example, the plasmid DNA is introduced into a mammalian cell line that is suitable as a target for standard CTL chromium release assays. The transfection method used will be dependent on the final formulation. Electroporation can be used for "naked" DNA, whereas cationic lipids allow direct *in vitro* transfection. A plasmid expressing green fluorescent protein (GFP) can be co-transfected to allow enrichment of transfected cells using fluorescence activated cell sorting (FACS). These cells are then chromium-51 (⁵¹Cr) labeled and used as target cells for epitope-specific CTL lines; cytolysis, detected by ⁵¹Cr release, indicates both production of, and HLA presentation of, minigene-encoded CTL epitopes. Expression of HTL epitopes may be evaluated in an analogous manner using assays to assess HTL activity.

In vivo immunogenicity is a second approach for functional testing of minigene DNA formulations. Transgenic mice expressing appropriate human HLA proteins are immunized with the DNA product. The dose and route of administration are formulation dependent (e.g., IM for DNA in PBS, intraperitoneal (i.p.) for lipid-complexed DNA). Twenty-one days after immunization, splenocytes are harvested and restimulated for one week in the presence of peptides encoding each epitope being tested. Thereafter, for CTL effector cells, assays are conducted for cytolysis of peptide-loaded, ⁵¹Cr-labeled target cells using standard techniques. Lysis of target cells that were sensitized by HLA loaded with peptide epitopes, corresponding to minigene-encoded epitopes, demonstrates DNA vaccine function for *in vivo* induction of CTLs. Immunogenicity of HTL epitopes is confirmed in transgenic mice in an analogous manner.

Alternatively, the nucleic acids can be administered using ballistic delivery as described, for instance, in U.S. Patent No. 5,204,253. Using this technique, particles comprised solely of DNA are administered. In a further alternative embodiment, DNA can be adhered to particles, such as gold particles.

Minigenes can also be delivered using other bacterial or viral delivery systems well known in the art, e.g., an expression construct encoding epitopes of the invention can be incorporated into a viral vector such as vaccinia.

X.C.2. Combinations of CTL Peptides with Helper Peptides

Vaccine compositions comprising CTL peptides of the invention can be modified, e.g., analoged, to provide desired attributes, such as improved serum half life, broadened population coverage or enhanced immunogenicity.

For instance, the ability of a peptide to induce CTL activity can be enhanced by linking the peptide to a sequence which contains at least one epitope that is capable of inducing a T helper cell response. Although a CTL peptide can be directly linked to a T helper peptide, often CTL epitope/HTL epitope conjugates are linked by a spacer molecule. The spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacers are typically selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optionally present spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer. When present, the spacer will usually be at least one or two residues, more usually three to six residues and sometimes 10 or more residues. The CTL peptide epitope can be linked to the T helper peptide epitope either directly or via a spacer either at the amino or carboxy terminus of the CTL peptide. The amino terminus of either the immunogenic peptide or the T helper peptide may be acylated.

In certain embodiments, the T helper peptide is one that is recognized by T helper cells present in a majority of a genetically diverse population. This can be accomplished by selecting peptides that bind to many, most, or all of the HLA class II molecules. Examples of such amino acid bind many HLA Class II molecules include sequences from antigens such as tetanus toxoid at positions 830-843 (QYIKANSKFIGITE; SEQ ID NO: ~~710~~2876), *Plasmodium falciparum* circumsporozoite (CS) protein at positions 378-398 (DIEKKIAKMEKASSVFNVVNS; SEQ ID NO: ~~711~~2877), and *Streptococcus* 18kD protein at positions 116-131 (GAVDSILGGVATYGAA; SEQ ID NO: ~~712~~2878). Other examples include peptides bearing a DR 1-4-7 supermotif, or either of the DR3 motifs.

Alternatively, it is possible to prepare synthetic peptides capable of stimulating T helper lymphocytes, in a loosely HLA-restricted fashion, using amino acid sequences not found in nature (see, e.g., PCT publication WO 95/07707). These synthetic compounds called Pan-DR-binding epitopes (e.g., PADRE™, Epimmune, Inc., San Diego, CA) are designed to most preferably bind most HLA-DR (human HLA class II) molecules. For instance, a pan-DR-binding epitope peptide having the formula: aKXVAAWTLKAAa (SEQ ID NO: ~~713~~2879), where "X" is either cyclohexylalanine, phenylalanine, or tyrosine, and a is either D-alanine or L-alanine, has been found to bind to most HLA-DR alleles, and to stimulate the response of T helper lymphocytes from most individuals, regardless of their HLA type. An alternative of a pan-DR binding epitope comprises all "L" natural amino acids and can be provided in the form of nucleic acids that encode the epitope.

HTL peptide epitopes can also be modified to alter their biological properties. For example, they can be modified to include D-amino acids to increase their resistance to proteases and thus extend their serum half life, or they can be conjugated to other molecules such as lipids, proteins, carbohydrates, and the like to increase their biological activity. For example, a T helper peptide can be conjugated to one or more palmitic acid chains at either the amino or carboxyl termini.

X.C.3. Combinations of CTL Peptides with T Cell Priming Agents

In some embodiments it may be desirable to include in the pharmaceutical compositions of the invention at least one component which primes B lymphocytes or T lymphocytes. Lipids have been identified as agents capable of priming CTL *in vivo*. For example, palmitic acid residues can be attached to the ϵ - and α - amino groups of a lysine residue and then linked, e.g., via one or more linking residues such as Gly, Gly-Gly-, Ser, Ser-Ser, or the like, to an immunogenic peptide. The lipidated peptide can then be administered either directly in a micelle or particle,

incorporated into a liposome, or emulsified in an adjuvant, *e.g.*, incomplete Freund's adjuvant. In a preferred embodiment, a particularly effective immunogenic composition comprises palmitic acid attached to ϵ - and α - amino groups of Lys, which is attached via linkage, *e.g.*, Ser-Ser, to the amino terminus of the immunogenic peptide.

As another example of lipid priming of CTL responses, *E. coli* lipoproteins, such as tripalmitoyl-S-glycerylcysteinylserine (P₃CSS) can be used to prime virus specific CTL when covalently attached to an appropriate peptide (*see, e.g.*, Deres, *et al.*, *Nature* 342:561, 1989). Peptides of the invention can be coupled to P₃CSS, for example, and the lipopeptide administered to an individual to specifically prime an immune response to the target antigen. Moreover, because the induction of neutralizing antibodies can also be primed with P₃CSS-conjugated epitopes, two such compositions can be combined to more effectively elicit both humoral and cell-mediated responses.

X.C.4. Vaccine Compositions Comprising DC Pulsed with CTL and/or HTL Peptides

An embodiment of a vaccine composition in accordance with the invention comprises *ex vivo* administration of a cocktail of epitope-bearing peptides to PBMC, or isolated DC therefrom, from the patient's blood. A pharmaceutical to facilitate harvesting of DC can be used, such as Progenipoin™ (Pharmacia-Monsanto, St. Louis, MO) or GM-CSF/IL-4. After pulsing the DC with peptides and prior to reinfusion into patients, the DC are washed to remove unbound peptides. In this embodiment, a vaccine comprises peptide-pulsed DCs which present the pulsed peptide epitopes complexed with HLA molecules on their surfaces.

The DC can be pulsed *ex vivo* with a cocktail of peptides, some of which stimulate CTL responses to 101P3A11. Optionally, a helper T cell (HTL) peptide, such as a natural or artificial loosely restricted HLA Class II peptide, can be included to facilitate the CTL response. Thus, a vaccine in accordance with the invention is used to treat a cancer which expresses or overexpresses 101P3A11.

X.D. Adoptive Immunotherapy

Antigenic 101P3A11-related peptides are used to elicit a CTL and/or HTL response *ex vivo*, as well. The resulting CTL or HTL cells, can be used to treat tumors in patients that do not respond to other conventional forms of therapy, or will not respond to a therapeutic vaccine peptide or nucleic acid in accordance with the invention. *Ex vivo* CTL or HTL responses to a particular antigen are induced by incubating in tissue culture the patient's, or genetically compatible, CTL or HTL precursor cells together with a source of antigen-presenting cells (APC), such as dendritic cells, and the appropriate immunogenic peptide. After an appropriate incubation time (typically about 7-28 days), in which the precursor cells are activated and expanded into effector cells, the cells are infused back into the patient, where they will destroy (CTL) or facilitate destruction (HTL) of their specific target cell (*e.g.*, a tumor cell). Transfected dendritic cells may also be used as antigen presenting cells.

X.E. Administration of Vaccines for Therapeutic or Prophylactic Purposes

Pharmaceutical and vaccine compositions of the invention are typically used to treat and/or prevent a cancer that expresses or overexpresses 101P3A11. In therapeutic applications, peptide and/or nucleic acid compositions are administered to a patient in an amount sufficient to elicit an effective B cell, CTL and/or HTL response to the antigen and to cure or at least partially arrest or slow symptoms and/or complications. An amount adequate to accomplish this is defined as "therapeutically effective dose." Amounts effective for this use will depend on, *e.g.*, the particular composition administered, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician.

For pharmaceutical compositions, the immunogenic peptides of the invention, or DNA encoding them, are generally administered to an individual already bearing a tumor that expresses 101P3A11. The peptides or DNA encoding them can be administered individually or as fusions of one or more peptide sequences. Patients can be treated with the immunogenic peptides separately or in conjunction with other treatments, such as surgery, as appropriate.

5 For therapeutic use, administration should generally begin at the first diagnosis of 101P3A11-associated cancer. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. The embodiment of the vaccine composition (*i.e.*, including, but not limited to embodiments such as peptide cocktails, polyepitopic polypeptides, minigenes, or TAA-specific CTLs or pulsed dendritic cells) delivered to the patient may vary according to the stage of the disease or the patient's health status. For example, in a patient with a tumor that expresses
10 101P3A11, a vaccine comprising 101P3A11-specific CTL may be more efficacious in killing tumor cells in patient with advanced disease than alternative embodiments.

It is generally important to provide an amount of the peptide epitope delivered by a mode of administration sufficient to effectively stimulate a cytotoxic T cell response; compositions which stimulate helper T cell responses can also be given in accordance with this embodiment of the invention.

15 The dosage for an initial therapeutic immunization generally occurs in a unit dosage range where the lower value is about 1, 5, 50, 500, or 1,000 μg and the higher value is about 10,000; 20,000; 30,000; or 50,000 μg . Dosage values for a human typically range from about 500 μg to about 50,000 μg per 70 kilogram patient. Boosting dosages of between about 1.0 μg to about 50,000 μg of peptide pursuant to a boosting regimen over weeks to months may be administered depending upon the patient's response and condition as determined by measuring the specific activity of
20 CTL and HTL obtained from the patient's blood. Administration should continue until at least clinical symptoms or laboratory tests indicate that the neoplasia, has been eliminated or reduced and for a period thereafter. The dosages, routes of administration, and dose schedules are adjusted in accordance with methodologies known in the art.

In certain embodiments, the peptides and compositions of the present invention are employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, as a result of the minimal
25 amounts of extraneous substances and the relative nontoxic nature of the peptides in preferred compositions of the invention, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions relative to these stated dosage amounts.

The vaccine compositions of the invention can also be used purely as prophylactic agents. Generally the dosage for an initial prophylactic immunization generally occurs in a unit dosage range where the lower value is about
30 1, 5, 50, 500, or 1000 μg and the higher value is about 10,000; 20,000; 30,000; or 50,000 μg . Dosage values for a human typically range from about 500 μg to about 50,000 μg per 70 kilogram patient. This is followed by boosting dosages of between about 1.0 μg to about 50,000 μg of peptide administered at defined intervals from about four weeks to six months after the initial administration of vaccine. The immunogenicity of the vaccine can be assessed by measuring the specific activity of CTL and HTL obtained from a sample of the patient's blood.

35 The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, oral, nasal, intrathecal, or local (*e.g.* as a cream or topical ointment) administration. Preferably, the pharmaceutical compositions are administered parentally, *e.g.*, intravenously, subcutaneously, intradermally, or intramuscularly. Thus, the invention

provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier.

A variety of aqueous carriers may be used, *e.g.*, water, buffered water, 0.8% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well-known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration.

The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservatives, and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, *etc.*

The concentration of peptides of the invention in the pharmaceutical formulations can vary widely, *i.e.*, from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, *etc.*, in accordance with the particular mode of administration selected.

A human unit dose form of a composition is typically included in a pharmaceutical composition that comprises a human unit dose of an acceptable carrier, in one embodiment an aqueous carrier, and is administered in a volume/quantity that is known by those of skill in the art to be used for administration of such compositions to humans (*see, e.g.*, Remington's Pharmaceutical Sciences, 17th Edition, A. Gennaro, Editor, Mack Publishing Co., Easton, Pennsylvania, 1985). For example a peptide dose for initial immunization can be from about 1 to about 50,000 μg , generally 100-5,000 μg , for a 70 kg patient. For example, for nucleic acids an initial immunization may be performed using an expression vector in the form of naked nucleic acid administered IM (or SC or ID) in the amounts of 0.5-5 mg at multiple sites. The nucleic acid (0.1 to 1000 μg) can also be administered using a gene gun (*i.e.*, ballistic delivery) in accordance with regimens known in the art. Following an incubation period of 3-4 weeks, a booster dose is then administered. The booster can be recombinant fowlpox virus administered at a dose of $5 \cdot 10^7$ to $5 \cdot 10^9$ pfu.

For antibodies, a treatment generally involves repeated administration of the anti-101P3A11 antibody preparation, via an acceptable route of administration such as intravenous injection (IV), typically at a dose in the range of about 0.1 to about 10 mg/kg body weight. In general, doses in the range of 10-500 mg mAb per week are effective and well tolerated. Moreover, an initial loading dose of approximately 4 mg/kg patient body weight IV, followed by weekly doses of about 2 mg/kg IV of the anti- 101P3A11 mAb preparation represents an acceptable dosing regimen. As appreciated by those of skill in the art, various factors can influence the ideal dose in a particular case. Such factors include, for example, half life of a composition, the binding affinity of an Ab, the immunogenicity of a substance, the degree of 101P3A11 expression in the patient, the extent of circulating shed 101P3A11 antigen, the desired steady-state concentration level, frequency of treatment, and the influence of chemotherapeutic or other agents used in combination with the treatment method of the invention, as well as the health status of a particular patient. Non-limiting preferred human unit doses are, for example, 500 μg - 1mg, 1mg - 50mg, 50mg-100mg, 100mg - 200 mg, 200mg - 300mg, 400mg - 500mg, 500mg - 600mg, 600mg - 700mg, or 1mg - 700mg. In certain embodiments, the dose is in a range of 2-5 mg/kg body weight, *e.g.*, with follow on weekly doses of 1-3 mg/kg; 0.5mg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10mg/kg body weight followed, *e.g.*, in two, three or four weeks by weekly doses; 0.5 - 10mg/kg body weight, *e.g.*, followed in two, three or four weeks by weekly doses; 225, 250, 275, 300, 325, 350, 375, 400mg m^2 of body area weekly; 1-600mg m^2 of

body area weekly; 225-400mg m² of body area weekly; these does can be followed by weekly doses for 2, 3, 4, 5, 6, 7, 8, 9, 19, 11, 12 or more weeks.

In one embodiment, human unit dose forms of polynucleotides comprise a suitable dosage range or effective amount that provides any therapeutic effect. As appreciated by one of ordinary skill in the art a therapeutic effect depends on a number of factors, including the sequence of the polynucleotide, molecular weight of the polynucleotide and route of administration. Dosages are generally selected by the physician or other health care professional in accordance with a variety of parameters known in the art, such as severity of symptoms, history of the patient and the like. Generally, for a polynucleotide of about 20 bases, a dosage range may be selected from, for example, an independently selected lower limit such as about 0.1, 0.25, 0.5, 1, 2, 5, 10, 20, 30, 40, 50, 60, 80, 100, 200, 300, 400 or 500 mg/kg up to an independently selected upper limit, greater than the lower limit, of about 60, 80, 100, 200, 300, 400, 500, 750, 1000, 1500, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000 or 10,000 mg/kg. For example, a dose may be about any of the following: 0.1 to 100 mg/kg, 0.1 to 50 mg/kg, 0.1 to 25 mg/kg, 0.1 to 10 mg/kg, 1 to 500 mg/kg, 100 to 400 mg/kg, 200 to 300 mg/kg, 1 to 100 mg/kg, 100 to 200 mg/kg, 300 to 400 mg/kg, 400 to 500 mg/kg, 500 to 1000 mg/kg, 500 to 5000 mg/kg, or 500 to 10,000 mg/kg. Generally, parenteral routes of administration may require higher doses of polynucleotide compared to more direct application to the nucleotide to diseased tissue, as do polynucleotides of increasing length.

In one embodiment, human unit dose forms of T-cells comprise a suitable dosage range or effective amount that provides any therapeutic effect. As appreciated by one of ordinary skill in the art, a therapeutic effect depends on a number of factors. Dosages are generally selected by the physician or other health care professional in accordance with a variety of parameters known in the art, such as severity of symptoms, history of the patient and the like. A dose may be about 10⁴ cells to about 10⁶ cells, about 10⁶ cells to about 10⁸ cells, about 10⁸ to about 10¹¹ cells, or about 10⁸ to about 5 x 10¹⁰ cells. A dose may also about 10⁶ cells/m² to about 10¹⁰ cells/m², or about 10⁶ cells/m² to about 10⁸ cells/m².

Proteins(s) of the invention, and/or nucleic acids encoding the protein(s), can also be administered via liposomes, which may also serve to: 1) target the proteins(s) to a particular tissue, such as lymphoid tissue; 2) to target selectively to diseases cells; or, 3) to increase the half-life of the peptide composition. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations, the peptide to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to a receptor prevalent among lymphoid cells, such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired peptide of the invention can be directed to the site of lymphoid cells, where the liposomes then deliver the peptide compositions. Liposomes for use in accordance with the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, *e.g.*, liposome size, acid lability and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, *e.g.*, Szoka, *et al.*, *Ann. Rev. Biophys. Bioeng.* 9:467 (1980), and U.S. Patent Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369.

For targeting cells of the immune system, a ligand to be incorporated into the liposome can include, *e.g.*, antibodies or fragments thereof specific for cell surface determinants of the desired immune system cells. A liposome

suspension containing a peptide may be administered intravenously, locally, topically, *etc.* in a dose which varies according to, *inter alia*, the manner of administration, the peptide being delivered, and the stage of the disease being treated.

For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the invention, and more preferably at a concentration of 25%-75%.

For aerosol administration, immunogenic peptides are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of peptides are about 0.01%-20% by weight, preferably about 1%-10%. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from about 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute about 0.1%-20% by weight of the composition, preferably about 0.25-5%. The balance of the composition is ordinarily propellant. A carrier can also be included, as desired, as with, *e.g.*, lecithin for intranasal delivery.

XI.) Diagnostic and Prognostic Embodiments of 101P3A11.

As disclosed herein, 101P3A11 polynucleotides, polypeptides, reactive cytotoxic T cells (CTL), reactive helper T cells (HTL) and anti-polypeptide antibodies are used in well known diagnostic, prognostic and therapeutic assays that examine conditions associated with dysregulated cell growth such as cancer, in particular the cancers listed in Table I (see, *e.g.*, both its specific pattern of tissue expression as well as its overexpression in certain cancers as described, *e.g.*, in the Example entitled "Expression analysis of 101P3A11 in normal tissues and patient specimens").

101P3A11 can be analogized to a prostate associated antigen PSA, the archetypal marker that has been used by medical practitioners for years to identify and monitor the presence of prostate cancer (see, *e.g.*, Merrill et al., J. Urol. 163(2): 503-5120 (2000); Polascik et al., J. Urol. Aug; 162(2):293-306 (1999) and Fortier et al., J. Nat. Cancer Inst. 91(19): 1635-1640(1999)). A variety of other diagnostic markers are also used in similar contexts including p53 and K-ras (see, *e.g.*, Tulchinsky et al., Int J Mol Med 1999 Jul 4(1):99-102 and Minimoto et al., Cancer Detect Prev 2000;24(1):1-12). Therefore, this disclosure of the 101P3A11 polynucleotides and polypeptides (as well as the 101P3A11 polynucleotide probes and anti-101P3A11 antibodies used to identify the presence of these molecules) and their properties allows skilled artisans to utilize these molecules in methods that are analogous to those used, for example, in a variety of diagnostic assays directed to examining conditions associated with cancer.

Typical embodiments of diagnostic methods which utilize the 101P3A11 polynucleotides, polypeptides, reactive T cells and antibodies are analogous to those methods from well-established diagnostic assays which employ, *e.g.*, PSA polynucleotides, polypeptides, reactive T cells and antibodies. For example, just as PSA polynucleotides are used as probes (for example in Northern analysis, see, *e.g.*, Sharief et al., Biochem. Mol. Biol. Int. 33(3):567-74(1994)) and primers (for example in PCR analysis, see, *e.g.*, Okegawa et al., J. Urol. 163(4): 1189-1190 (2000)) to observe the

presence and/or the level of PSA mRNAs in methods of monitoring PSA overexpression or the metastasis of prostate cancers, the 101P3A11 polynucleotides described herein can be utilized in the same way to detect 101P3A11 overexpression or the metastasis of prostate and other cancers expressing this gene. Alternatively, just as PSA polypeptides are used to generate antibodies specific for PSA which can then be used to observe the presence and/or the level of PSA proteins in methods to monitor PSA protein overexpression (see, e.g., Stephan et al., *Urology* 55(4):560-3 (2000)) or the metastasis of prostate cells (see, e.g., Alanen et al., *Pathol. Res. Pract.* 192(3):233-7 (1996)), the 101P3A11 polypeptides described herein can be utilized to generate antibodies for use in detecting 101P3A11 overexpression or the metastasis of prostate cells and cells of other cancers expressing this gene.

Specifically, because metastases involves the movement of cancer cells from an organ of origin (such as the lung or prostate gland etc.) to a different area of the body (such as a lymph node), assays which examine a biological sample for the presence of cells expressing 101P3A11 polynucleotides and/or polypeptides can be used to provide evidence of metastasis. For example, when a biological sample from tissue that does not normally contain 101P3A11-expressing cells (lymph node) is found to contain 101P3A11-expressing cells such as the 101P3A11 expression seen in LAPC4 and LAPC9, xenografts isolated from lymph node and bone metastasis, respectively, this finding is indicative of metastasis.

Alternatively 101P3A11 polynucleotides and/or polypeptides can be used to provide evidence of cancer, for example, when cells in a biological sample that do not normally express 101P3A11 or express 101P3A11 at a different level are found to express 101P3A11 or have an increased expression of 101P3A11 (see, e.g., the 101P3A11 expression in the cancers listed in Table I and in patient samples etc. shown in the accompanying Figures). In such assays, artisans may further wish to generate supplementary evidence of metastasis by testing the biological sample for the presence of a second tissue restricted marker (in addition to 101P3A11) such as PSA, PSCA etc. (see, e.g., Alanen et al., *Pathol. Res. Pract.* 192(3): 233-237 (1996)).

Just as PSA polynucleotide fragments and polynucleotide variants are employed by skilled artisans for use in methods of monitoring PSA, 101P3A11 polynucleotide fragments and polynucleotide variants are used in an analogous manner. In particular, typical PSA polynucleotides used in methods of monitoring PSA are probes or primers which consist of fragments of the PSA cDNA sequence. Illustrating this, primers used to PCR amplify a PSA polynucleotide must include less than the whole PSA sequence to function in the polymerase chain reaction. In the context of such PCR reactions, skilled artisans generally create a variety of different polynucleotide fragments that can be used as primers in order to amplify different portions of a polynucleotide of interest or to optimize amplification reactions (see, e.g., Caetano-Anolles, G. *Biotechniques* 25(3): 472-476, 478-480 (1998); Robertson et al., *Methods Mol. Biol.* 98:121-154 (1998)). An additional illustration of the use of such fragments is provided in the Example entitled "Expression analysis of 101P3A11 in normal tissues and patient specimens", where a 101P3A11 polynucleotide fragment is used as a probe to show the expression of 101P3A11 RNAs in cancer cells. In addition, variant polynucleotide sequences are typically used as primers and probes for the corresponding mRNAs in PCR and Northern analyses (see, e.g., Sawai et al., *Fetal Diagn. Ther.* 1996 Nov-Dec 11(6):407-13 and *Current Protocols In Molecular Biology*, Volume 2, Unit 2, Frederick M. Ausubel et al. eds., 1995)). Polynucleotide fragments and variants are useful in this context where they are capable of binding to a target polynucleotide sequence (e.g. the 101P3A11 polynucleotide shown in SEQ ID NO: 701) under conditions of high stringency.

Furthermore, PSA polypeptides which contain an epitope that can be recognized by an antibody or T cell that specifically binds to that epitope are used in methods of monitoring PSA. 101P3A11 polypeptide fragments and polypeptide analogs or variants can also be used in an analogous manner. This practice of using polypeptide fragments or polypeptide variants to generate antibodies (such as anti-PSA antibodies or T cells) is typical in the art with a wide variety of systems such as fusion proteins being used by practitioners (see, e.g., Current Protocols In Molecular Biology, Volume 2, Unit 16, Frederick M. Ausubel et al. eds., 1995). In this context, each epitope(s) functions to provide the architecture with which an antibody or T cell is reactive. Typically, skilled artisans create a variety of different polypeptide fragments that can be used in order to generate immune responses specific for different portions of a polypeptide of interest (see, e.g., U.S. Patent No. 5,840,501 and U.S. Patent No. 5,939,533). For example it may be preferable to utilize a polypeptide comprising one of the 101P3A11 biological motifs discussed herein or a motif-bearing subsequence which is readily identified by one of skill in the art based on motifs available in the art. Polypeptide fragments, variants or analogs are typically useful in this context as long as they comprise an epitope capable of generating an antibody or T cell specific for a target polypeptide sequence (e.g. the 101P3A11 polypeptide shown in SEQ ID NO: 703).

As shown herein, the 101P3A11 polynucleotides and polypeptides (as well as the 101P3A11 polynucleotide probes and anti-101P3A11 antibodies or T cells used to identify the presence of these molecules) exhibit specific properties that make them useful in diagnosing cancers such as those listed in Table I. Diagnostic assays that measure the presence of 101P3A11 gene products, in order to evaluate the presence or onset of a disease condition described herein, such as prostate cancer, are used to identify patients for preventive measures or further monitoring, as has been done so successfully with PSA. Moreover, these materials satisfy a need in the art for molecules having similar or complementary characteristics to PSA in situations where, for example, a definite diagnosis of metastasis of prostatic origin cannot be made on the basis of a test for PSA alone (see, e.g., Alanen et al., Pathol. Res. Pract. 192(3): 233-237 (1996)), and consequently, materials such as 101P3A11 polynucleotides and polypeptides (as well as the 101P3A11 polynucleotide probes and anti-101P3A11 antibodies used to identify the presence of these molecules) must be employed to confirm metastases of prostatic origin.

Finally, in addition to their use in diagnostic assays, the 101P3A11 polynucleotides disclosed herein have a number of other utilities such as their use in the identification of oncogenetic associated chromosomal abnormalities in the chromosomal region to which the 101P3A11 gene maps (see Table XXV). Moreover, in addition to their use in diagnostic assays, the 101P3A11-related proteins and polynucleotides disclosed herein have other utilities such as their use in the forensic analysis of tissues of unknown origin (see, e.g., Takahama K Forensic Sci Int 1996 Jun 28;80(1-2): 63-9).

Additionally, 101P3A11-related proteins or polynucleotides of the invention can be used to treat a pathologic condition characterized by the over-expression of 101P3A11. For example, the amino acid or nucleic acid sequence of Figure 2 or Figure 3, or fragments of either, can be used to generate an immune response to the 101P3A11 antigen. Antibodies or other molecules that react with 101P3A11 can be used to modulate the function of this molecule, and thereby provide a therapeutic benefit.

XII.) Inhibition of 101P3A11 Protein Function

The invention includes various methods and compositions for inhibiting the binding of 101P3A11 to its binding partner or its association with other protein(s) as well as methods for inhibiting 101P3A11 function.

XII.A.) Inhibition of 101P3A11 With Intracellular Antibodies

In one approach, a recombinant vector that encodes single chain antibodies that specifically bind to 101P3A11 are introduced into 101P3A11 expressing cells via gene transfer technologies. Accordingly, the encoded single chain anti-101P3A11 antibody is expressed intracellularly, binds to 101P3A11 protein, and thereby inhibits its function. Methods for engineering such intracellular single chain antibodies are well known. Such intracellular antibodies, also known as “intrabodies”, are specifically targeted to a particular compartment within the cell, providing control over where the inhibitory activity of the treatment is focused. This technology has been successfully applied in the art (for review, see Richardson and Marasco, 1995, TIBTECH vol. 13). Intrabodies have been shown to virtually eliminate the expression of otherwise abundant cell surface receptors (see, e.g., Richardson et al., 1995, Proc. Natl. Acad. Sci. USA 92: 3137-3141; Beerli et al., 1994, J. Biol. Chem. 269: 23931-23936; Deshane et al., 1994, Gene Ther. 1: 332-337).

Single chain antibodies comprise the variable domains of the heavy and light chain joined by a flexible linker polypeptide, and are expressed as a single polypeptide. Optionally, single chain antibodies are expressed as a single chain variable region fragment joined to the light chain constant region. Well-known intracellular trafficking signals are engineered into recombinant polynucleotide vectors encoding such single chain antibodies in order to precisely target the intrabody to the desired intracellular compartment. For example, intrabodies targeted to the endoplasmic reticulum (ER) are engineered to incorporate a leader peptide and, optionally, a C-terminal ER retention signal, such as the KDEL amino acid motif. Intrabodies intended to exert activity in the nucleus are engineered to include a nuclear localization signal. Lipid moieties are joined to intrabodies in order to tether the intrabody to the cytosolic side of the plasma membrane. Intrabodies can also be targeted to exert function in the cytosol. For example, cytosolic intrabodies are used to sequester factors within the cytosol, thereby preventing them from being transported to their natural cellular destination.

In one embodiment, intrabodies are used to capture 101P3A11 in the nucleus, thereby preventing its activity within the nucleus. Nuclear targeting signals are engineered into such 101P3A11 intrabodies in order to achieve the desired targeting. Such 101P3A11 intrabodies are designed to bind specifically to a particular 101P3A11 domain. In another embodiment, cytosolic intrabodies that specifically bind to the 101P3A11 protein are used to prevent 101P3A11 from gaining access to the nucleus, thereby preventing it from exerting any biological activity within the nucleus (e.g., preventing 101P3A11 from forming transcription complexes with other factors).

In order to specifically direct the expression of such intrabodies to particular cells, the transcription of the intrabody is placed under the regulatory control of an appropriate tumor-specific promoter and/or enhancer. In order to target intrabody expression specifically to prostate, for example, the PSA promoter and/or promoter/enhancer can be utilized (See, for example, U.S. Patent No. 5,919,652 issued 6 July 1999).

XII.B.) Inhibition of 101P3A11 with Recombinant Proteins

In another approach, recombinant molecules bind to 101P3A11 and thereby inhibit 101P3A11 function. For example, these recombinant molecules prevent or inhibit 101P3A11 from accessing/binding to its binding partner(s) or associating with other protein(s). Such recombinant molecules can, for example, contain the reactive part(s) of a 101P3A11 specific antibody molecule. In a particular embodiment, the 101P3A11 binding domain of a 101P3A11 binding

partner is engineered into a dimeric fusion protein, whereby the fusion protein comprises two 101P3A11 ligand binding domains linked to the Fc portion of a human IgG, such as human IgG1. Such IgG portion can contain, for example, the C_H2 and C_H3 domains and the hinge region, but not the C_H1 domain. Such dimeric fusion proteins are administered in soluble form to patients suffering from a cancer associated with the expression of 101P3A11, whereby the dimeric fusion protein specifically binds to 101P3A11 and blocks 101P3A11 interaction with a binding partner. Such dimeric fusion proteins are further combined into multimeric proteins using known antibody linking technologies.

XII.C.) Inhibition of 101P3A11 Transcription or Translation

The present invention also comprises various methods and compositions for inhibiting the transcription of the 101P3A11 gene. Similarly, the invention also provides methods and compositions for inhibiting the translation of 101P3A11 mRNA into protein.

In one approach, a method of inhibiting the transcription of the 101P3A11 gene comprises contacting the 101P3A11 gene with a 101P3A11 antisense polynucleotide. In another approach, a method of inhibiting 101P3A11 mRNA translation comprises contacting the 101P3A11 mRNA with an antisense polynucleotide. In another approach, a 101P3A11 specific ribozyme is used to cleave the 101P3A11 message, thereby inhibiting translation. Such antisense and ribozyme based methods can also be directed to the regulatory regions of the 101P3A11 gene, such as the 101P3A11 promoter and/or enhancer elements. Similarly, proteins capable of inhibiting a 101P3A11 gene transcription factor are used to inhibit 101P3A11 mRNA transcription. The various polynucleotides and compositions useful in the aforementioned methods have been described above. The use of antisense and ribozyme molecules to inhibit transcription and translation is well known in the art.

Other factors that inhibit the transcription of 101P3A11 by interfering with 101P3A11 transcriptional activation are also useful to treat cancers expressing 101P3A11. Similarly, factors that interfere with 101P3A11 processing are useful to treat cancers that express 101P3A11. Cancer treatment methods utilizing such factors are also within the scope of the invention.

XII.D.) General Considerations for Therapeutic Strategies

Gene transfer and gene therapy technologies can be used to deliver therapeutic polynucleotide molecules to tumor cells synthesizing 101P3A11 (i.e., antisense, ribozyme, polynucleotides encoding intrabodies and other 101P3A11 inhibitory molecules). A number of gene therapy approaches are known in the art. Recombinant vectors encoding 101P3A11 antisense polynucleotides, ribozymes, factors capable of interfering with 101P3A11 transcription, and so forth, can be delivered to target tumor cells using such gene therapy approaches.

The above therapeutic approaches can be combined with any one of a wide variety of surgical, chemotherapy or radiation therapy regimens. The therapeutic approaches of the invention can enable the use of reduced dosages of chemotherapy (or other therapies) and/or less frequent administration, an advantage for all patients and particularly for those that do not tolerate the toxicity of the chemotherapeutic agent well.

The anti-tumor activity of a particular composition (e.g., antisense, ribozyme, intrabody), or a combination of such compositions, can be evaluated using various *in vitro* and *in vivo* assay systems. *In vitro* assays that evaluate therapeutic activity include cell growth assays, soft agar assays and other assays indicative of tumor promoting activity, binding assays capable of determining the extent to which a therapeutic composition will inhibit the binding of 101P3A11 to a binding partner, etc.

In vivo, the effect of a 101P3A11 therapeutic composition can be evaluated in a suitable animal model. For example, xenogenic prostate cancer models can be used, wherein human prostate cancer explants or passaged xenograft tissues are introduced into immune compromised animals, such as nude or SCID mice (Klein et al., 1997, Nature Medicine 3: 402-408). For example, PCT Patent Application WO98/16628 and U.S. Patent 6,107,540, Sawyers et al., published April 23, 1998, describes various xenograft models of human prostate cancer capable of recapitulating the development of primary tumors, micrometastasis, and the formation of osteoblastic metastases characteristic of late stage disease. Efficacy can be predicted using assays that measure inhibition of tumor formation, tumor regression or metastasis, and the like.

In vivo assays that evaluate the promotion of apoptosis are useful in evaluating therapeutic compositions. In one embodiment, xenografts from tumor bearing mice treated with the therapeutic composition can be examined for the presence of apoptotic foci and compared to untreated control xenograft-bearing mice. The extent to which apoptotic foci are found in the tumors of the treated mice provides an indication of the therapeutic efficacy of the composition.

The therapeutic compositions used in the practice of the foregoing methods can be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method. Suitable carriers include any material that when combined with the therapeutic composition retains the anti-tumor function of the therapeutic composition and is generally non-reactive with the patient's immune system. Examples include, but are not limited to, any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like (see, generally, Remington's Pharmaceutical Sciences 16th Edition, A. Osal., Ed., 1980).

Therapeutic formulations can be solubilized and administered via any route capable of delivering the therapeutic composition to the tumor site. Potentially effective routes of administration include, but are not limited to, intravenous, parenteral, intraperitoneal, intramuscular, intratumor, intradermal, intraorgan, orthotopic, and the like. A preferred formulation for intravenous injection comprises the therapeutic composition in a solution of preserved bacteriostatic water, sterile unpreserved water, and/or diluted in polyvinylchloride or polyethylene bags containing 0.9% sterile Sodium Chloride for Injection, USP. Therapeutic protein preparations can be lyophilized and stored as sterile powders, preferably under vacuum, and then reconstituted in bacteriostatic water (containing for example, benzyl alcohol preservative) or in sterile water prior to injection.

Dosages and administration protocols for the treatment of cancers using the foregoing methods will vary with the method and the target cancer, and will generally depend on a number of other factors appreciated in the art.

XIII.) Kits

For use in the diagnostic and therapeutic applications described herein, kits are also within the scope of the invention. Such kits can comprise a carrier, package or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in the method. For example, the container(s) can comprise a probe that is or can be detectably labeled. Such probe can be an antibody or polynucleotide specific for a 101P3A11-related protein or a 101P3A11 gene or message, respectively. Where the method utilizes nucleic acid hybridization to detect the target nucleic acid, the kit can also have containers containing nucleotide(s) for amplification of the target nucleic acid sequence and/or a container comprising a reporter-means, such as a biotin-binding protein, such as avidin or streptavidin, bound to a reporter molecule, such as an

enzymatic, florescent, or radioisotope label. The kit can include all or part of the amino acid sequence of Figure 2 or Figure 3 or analogs thereof, or a nucleic acid molecules that encodes such amino acid sequences or which hybridize to such sequences.

The kit of the invention will typically comprise the container described above and one or more other containers comprising materials desirable from a commercial and user standpoint, including buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. Any physical object in a kit of the invention, e.g. syringe or vial, can have a label affixed thereto. A label or package insert can have instructions for use in human administration printed thereon. Thus, a label can be present on the container to indicate that the composition is used for a specific therapy or non-therapeutic application, and can also indicate directions for either *in vivo* or *in vitro* use, such as those described above. Directions and or other information can also be included on an insert that is included with the kit.

EXAMPLES

Various aspects of the invention are further described and illustrated by way of the several examples that follow, none of which are intended to limit the scope of the invention.

Example 1: Expression analysis of 101P3A11 in normal tissues and patient specimens

Analysis of 101P3A11 by RT-PCR is shown in Figure 10A. First strand cDNA was prepared from vital pool 1 (VP1: liver, lung and kidney), vital pool 2 (VP2, pancreas, colon and stomach), prostate xenograft pool, prostate cancer pool, kidney cancer pool, colon cancer pool, breast cancer pool, and cancer metastasis pool. Normalization was performed by PCR using primers to actin and GAPDH. Semi-quantitative PCR, using primers to 101P3A11, was performed at 30 cycles of amplification. Expression of 101P3A11 was observed in prostate xenograft pool, prostate cancer pool, kidney cancer pool, colon cancer pool, breast cancer pool, and cancer metastasis pool, but not in VP1 and VP2. Dot blots using patient-derived amplified cDNAs (Clontech, CA) show upregulation of PHOR-1 in 3/3 prostate cancer patients, 6/14 kidney cancer patients, 2/8 uterine cancer, 1/1 cervical cancer, 3/8 stomach cancer, and in 7/7 rectal cancer patients (Figure 10B). Expression of 101P3A11 was assayed in a panel of human patient cancer specimens (Figure 11). RNA was extracted from a pool of three prostate cancer tumors, kidney cancer tumors, colon cancer tumors, breast cancer tumors, and cancer metastasis pool derived from cancer patients, as well as from normal prostate (NP), normal bladder (NB), normal kidney (NK) and normal colon (NC). Northern blots with 10 µg of total RNA/lane were probed with a 101P3A11 sequence fragment. Size standards in kilobases (kb) are indicated on the side. The results show expression of 101P3A11 in prostate cancer tumors, kidney cancer tumors, colon cancer tumors, breast cancer tumors, cancer metastasis pool, bladder cancer pool, and in the normal prostate but not in the other normal tissues.

Northern blot analysis on individual prostate patient tumor specimens is shown in Figure 12A. RNA was extracted from prostate tumors (T) and their normal adjacent tissues (Nat) derived from prostate cancer patients. Northern blots with 10 µg of total RNA/lane were probed with 101P3A11 sequence. Results showed expression of 101P3A11 in all three patient specimens, and expression is especially upregulated in one of the three prostate tumor tissues.

RNA in situ analysis using anti-sense 101P3A11 riboprobe showed significant glandular epithelial and basal cell expression in normal prostate (4/4), PIN (1/1), and prostate cancer (6/6) patients. 101P3A11 sense riboprobe had little to no staining. The RNA in situ staining in PIN and prostate cancer is shown in Figure 12B and 12C. The staining intensity in the cancer cells was generally higher than that observed in normal glands (Figure 12D and 12E). The RNA in situ results also demonstrate that the expression observed in the prostate tissues is in the glandular epithelia, basal cells, and cancer cells.

Endogenous expression of the 101P3A11 protein is demonstrated in the immunohistochemistry analysis of the anti-101P3A11 (PEPTIDE 1: amino acids 1-14) rabbit polyclonal antibody (Figure 40A-40F). Staining in prostate cancer is greater than the staining observed in normal prostate. The staining is localized apically within the luminal epithelia of the normal prostate (Figures 40E and 40F). The staining observed in prostate cancer is also localized apically in low to intermediate grade cancer (Figures 40B and 40C) and throughout all cells of more advanced prostate cancer (Figure 40A). Staining was observed in 19/20 normal prostate patients and in all of the nineteen prostate cancer patients analyzed. The prostate cancer cell line, LNCaP also shows similar staining (Figures 40D and 40F) in almost all cells.

In addition, the present protocol was used to identify endogenous expression of the 101P3A11 protein in prostate cancer, bladder cancer, kidney cancer, colon cancer, lung cancer, and breast cancer. Immunohistochemical analysis was performed with the anti-101P3A11 (PEPTIDE 1: amino acids 1-14) rabbit polyclonal antibody (prostate cancer, Figure 41A; bladder cancer, Figure 41B; kidney cancer, Figure 41C; colon cancer, lung cancer, Figure 41E; and breast cancer, Figure 41F). Specific staining is observed in tumor cells of the six cancers analyzed.

Expression of 101P3A11 was also detected in the tumors of two colon cancer patients but not in normal colon tissues (Figure 13), and in five out of six kidney tumors isolated from kidney cancer patients (Figure 14). The expression detected in normal adjacent tissues (isolated from diseased tissues) but not in normal tissues of the kidney (isolated from healthy donors) indicates that these tissues are not fully normal and that 101P3A11 is expressed in early stage tumors. In order to assay for androgen regulation of 101P3A11 expression, LAPC-9 cells were grown in charcoal-stripped medium and stimulated with the synthetic androgen mibolerone, for either 14 or 24 hours (Figure 15A, Figure 15B, and Figure 15C). Northern blots with 10 µg of total RNA/lane were probed with the 101P3A11 sequences (Figure 15A). A picture of the ethidium-bromide staining of the RNA gel is also presented (Figure 15C). Results showed expression of 101P3A11 is not regulated by androgen. The experimental samples were confirmed by testing for the expression of the androgen-regulated prostate cancer gene PSA (Figure 15B). This experiment showed that, as expected, PSA levels go down in presence of charcoal-stripped serum, and expression is induced at 14 and 24 hours in presence of mibolerone.

Analysis of androgen regulation of 101P3A11 *in vivo* is shown in Figure 16. Male mice were injected with LAPC-9AD tumor cells. When tumors reached a palpable size, mice were castrated and tumors harvested at different time points following castration. RNA was isolated from the xenograft tissues. Northern blots with 10 µg of total RNA/lane were probed with 101P3A11 sequences. Size standards in kilobases (kb) are indicated on the side. A picture of the ethidium-bromide staining of the RNA gel is also presented in Figure 16. The results showed that expression of 101P3A11 was not affected by androgen deprivation, and therefore, is not androgen regulated.

Example 2: Production of Recombinant 101P3A11 in Prokaryotic and Yeast Systems

To express recombinant 101P3A11 in prokaryotic cells, the full or partial length 101P3A11 cDNA sequences can be cloned into any one of a variety of expression vectors known in the art. One or more of the following regions of 101P3A11 are expressed in these constructs, amino acids 1 to 317; or any 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids from 101P3A11, variants, or analogs thereof.

A. *In vitro* transcription and translation constructs:

pCRII: To generate 101P3A11 sense and anti-sense RNA probes for RNA *in situ* investigations, pCRII constructs (Invitrogen, Carlsbad, CA) are generated encoding either all or fragments of the 101P3A11 cDNA. The pCRII vector has Sp6 and T7 promoters flanking the insert to drive the transcription of 101P3A11 RNA for use as probes in RNA *in situ* hybridization experiments. These probes are used to analyze the cell and tissue expression of 101P3A11 at the RNA level. Transcribed 101P3A11 RNA representing the cDNA amino acid coding region of the 101P3A11 gene is used in *in vitro* translation systems such as the TnTTM Coupled Reticulolysate System (Promega, Corp., Madison, WI) to synthesize 101P3A11 protein.

B. Bacterial Constructs:

pGEX Constructs: To generate recombinant 101P3A11 proteins in bacteria that are fused to the Glutathione S-transferase (GST) protein, all or parts of the 101P3A11 cDNA protein coding sequence are fused to the GST gene by cloning into pGEX-6P-1 or any other GST- fusion vector of the pGEX family (Amersham Pharmacia Biotech, Piscataway, NJ). These constructs allow controlled expression of recombinant 101P3A11 protein sequences with GST fused at the amino-terminus and a six histidine epitope (6X His) at the carboxyl-terminus. The GST and 6X His tags permit purification of the recombinant fusion protein from induced bacteria with the appropriate affinity matrix and allow recognition of the fusion protein with anti-GST and anti-His antibodies. The 6X His tag is generated by adding 6 histidine codons to the cloning primer at the 3' end, e.g., of the open reading frame (ORF). A proteolytic cleavage site, such as the PreScissionTM recognition site in pGEX-6P-1, can be employed that permits cleavage of the GST tag from 101P3A11-related protein. The ampicillin resistance gene and pBR322 origin permit selection and maintenance of the pGEX plasmids in *E. coli*. In one embodiment, amino acids 86-317 are cloned into the pGEX-2T expression vector, the protein is expressed and purified.

pMAL Constructs: To generate, in bacteria, recombinant 101P3A11 proteins that are fused to maltose-binding protein (MBP), all or parts of the 101P3A11 cDNA protein coding sequence are fused to the MBP gene by cloning into the pMAL-c2X and pMAL-p2X vectors (New England Biolabs, Beverly, MA). These constructs allow controlled expression of recombinant 101P3A11 protein sequences with MBP fused at the amino-terminus and a 6X His epitope tag at the carboxyl-terminus. The MBP and 6X His tags permit purification of the recombinant protein from induced bacteria with the appropriate affinity matrix and allow recognition of the fusion protein with anti-MBP and anti-His antibodies. The 6X His epitope tag is generated by adding 6 histidine codons to the 3' cloning primer. A Factor Xa recognition site permits cleavage of the pMAL tag from 101P3A11. The pMAL-c2X and pMAL-p2X vectors are optimized to express the recombinant protein in the cytoplasm or periplasm respectively. Periplasm expression enhances folding of proteins with disulfide bonds. In one embodiment, amino acids 86-310 is cloned into the pMAL-c2X expression vector, the protein is expressed and purified.

pET Constructs: To express 101P3A11 in bacterial cells, all or parts of the 101P3A11 cDNA protein coding sequence are cloned into the pET family of vectors (Novagen, Madison, WI). These vectors allow tightly controlled expression of recombinant 101P3A11 protein in bacteria with and without fusion to proteins that enhance solubility, such as NusA and thioredoxin (Trx), and epitope tags, such as 6X His and S-Tag™ that aid purification and detection of the recombinant protein. For example, constructs are made utilizing pET NusA fusion system 43.1 such that regions of the 101P3A11 protein are expressed as amino-terminal fusions to NusA.

C. **Yeast Constructs:**

pESC Constructs: To express 101P3A11 in the yeast species *Saccharomyces cerevisiae* for generation of recombinant protein and functional studies, all or parts of the 101P3A11 cDNA protein coding sequence are cloned into the pESC family of vectors each of which contain 1 of 4 selectable markers, HIS3, TRP1, LEU2, and URA3 (Stratagene, La Jolla, CA). These vectors allow controlled expression from the same plasmid of up to 2 different genes or cloned sequences containing either Flag™ or Myc epitope tags in the same yeast cell. This system is used to confirm protein-protein interactions of 101P3A11. In addition, expression in yeast yields similar post-translational modifications, such as glycosylations and phosphorylations, that are found when expressed in eukaryotic cells.

pESP Constructs: To express 101P3A11 in the yeast species *Saccharomyces pombe*, all or parts of the 101P3A11 cDNA protein coding sequence are cloned into the pESP family of vectors. These vectors allow controlled high level expression of a 101P3A11 protein sequence that is fused at either the amino terminus or at the carboxyl terminus to GST which aids purification of the recombinant protein. A Flag™ epitope tag allows detection of the recombinant protein with anti-Flag™ antibody.

Example 3: Production of Recombinant 101P3A11 in Higher Eukaryotic Systems

A. Mammalian Constructs:

To express recombinant 101P3A11 in eukaryotic cells, full or partial length 101P3A11 cDNA sequences can be cloned into any one of a variety of expression vectors known in the art. One or more of the following regions of 101P3A11 are expressed in these constructs, amino acids 1 to 317; or any 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids from 101P3A11, variants, or analogs thereof.

The constructs can be transfected into any one of a wide variety of mammalian cells such as 293T cells. Transfected 293T cell lysates can be probed with the anti-101P3A11 polyclonal serum, described herein.

pcDNA4/HisMax Constructs: To express 101P3A11 in mammalian cells, the 101P3A11 ORF was cloned into pcDNA4/HisMax Version A (Invitrogen, Carlsbad, CA). Protein expression is driven from the cytomegalovirus (CMV) promoter and the SP16 translational enhancer. The recombinant protein has Xpress™ and six histidine (6X His) epitopes fused to the amino-terminus. The pcDNA4/HisMax vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large T antigen. The Zeocin resistance gene allows for selection of mammalian cells expressing the protein and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in *E. coli*.

pcDNA3.1/MycHis Constructs: To express 101P3A11 in mammalian cells, the 101P3A11 ORF, with a consensus Kozak translation initiation site, was cloned into pcDNA3.1/MycHis Version A (Invitrogen, Carlsbad, CA). Protein expression is driven from the cytomegalovirus (CMV) promoter. The recombinant proteins have the myc epitope and 6X His epitope fused to the carboxyl-terminus. The pcDNA3.1/MycHis vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability, along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large T antigen. The Neomycin resistance gene can be used, as it allows for selection of mammalian cells expressing the protein and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in *E. coli*.

pcDNA3.1/CT-GFP-TOPO Construct: To express 101P3A11 in mammalian cells and to allow detection of the recombinant proteins using fluorescence, the 101P3A11 ORF, with a consensus Kozak translation initiation site, was cloned into pcDNA3.1/CT-GFP-TOPO (Invitrogen, CA). Protein expression is driven from the cytomegalovirus (CMV) promoter. The recombinant proteins have the Green Fluorescent Protein (GFP) fused to the carboxyl-terminus facilitating non-invasive, *in vivo* detection and cell biology studies. The pcDNA3.1CT-GFP-TOPO vector also contains the bovine growth hormone (BGH) polyadenylation signal and transcription termination sequence to enhance mRNA stability along with the SV40 origin for episomal replication and simple vector rescue in cell lines expressing the large T antigen. The Neomycin resistance gene allows for selection of mammalian cells that express the protein, and the ampicillin resistance gene and ColE1 origin permits selection and maintenance of the plasmid in *E. coli*. Additional constructs with an amino-terminal GFP fusion are made in pcDNA3.1/NT-GFP-TOPO spanning the entire length of the 101P3A11 proteins.

PAPtag: The 101P3A11 ORF, or portions thereof, of 101P3A11 are cloned into pAPtag-5 (GenHunter Corp. Nashville, TN). This construct generates an alkaline phosphatase fusion at the carboxyl-terminus of the 101P3A11 proteins while fusing the IgGκ signal sequence to the amino-terminus. Constructs are also generated in which alkaline phosphatase with an amino-terminal IgGκ signal sequence is fused to the amino-terminus of 101P3A11 proteins. The resulting recombinant 101P3A11 proteins are optimized for secretion into the media of transfected mammalian cells and can be used to identify proteins such as ligands or receptors that interact with the 101P3A11 proteins. Protein expression is driven from the CMV promoter and the recombinant proteins also contain myc and 6X His epitopes fused at the carboxyl-terminus that facilitates detection and purification. The Zeocin resistance gene present in the vector allows for selection of mammalian cells expressing the recombinant protein and the ampicillin resistance gene permits selection of the plasmid in *E. coli*.

ptag5: The 101P3A11 ORF, or portions thereof, of 101P3A11 are cloned into pTag-5. This vector is similar to pAPtag but without the alkaline phosphatase fusion. This construct generated 101P3A11 protein with an amino-terminal IgGκ signal sequence and myc and 6X His epitope tags at the carboxyl-terminus that facilitate detection and affinity purification. The resulting recombinant 101P3A11 protein was optimized for secretion into the media of transfected mammalian cells, and was used as immunogen or ligand to identify proteins such as ligands or receptors that interact with the 101P3A11 proteins. Protein expression is driven from the CMV promoter. The Zeocin resistance gene present in the vector allows for selection of mammalian cells expressing the protein, and the ampicillin resistance gene permits selection of the plasmid in *E. coli*.

PsecFc: The 101P3A11 ORF, or portions thereof, of 101P3A11 are also cloned into psecFc. The psecFc vector was assembled by cloning the human immunoglobulin G1 (IgG) Fc (hinge, CH2, CH3 regions) into pSecTag2 (Invitrogen, California). This construct generates an IgG1 Fc fusion at the carboxyl-terminus of the 101P3A11 proteins, while fusing the IgGk signal sequence to N-terminus. 101P3A11 fusions utilizing the murine IgG1 Fc region are also used. The resulting recombinant 101P3A11 proteins are optimized for secretion into the media of transfected mammalian cells, and can be used as immunogens or to identify proteins such as ligands or receptors that interact with the 101P3A11 protein. Protein expression is driven from the CMV promoter. The hygromycin resistance gene present in the vector allows for selection of mammalian cells that express the recombinant protein, and the ampicillin resistance gene permits selection of the plasmid in *E. coli*.

The amino acid region 159-202 of the 101P3A11 ORF was cloned into psecFc. The resulting recombinant 101P3A11(159-202)-psecFc construct was transfected into 293T and Cos-7 cells, and the expression of recombinant 101P3A11(159-202)-psecFc protein assayed by Western blotting (Figure 17). Results show that 101P3A11(159-202)-psecFc fusion protein was expressed in the lysates of both 293T and Cos-7 cells. The 101P3A11(159-202)-psecFc fusion protein was also secreted and detected in the culture supernatants of both cell types.

pSR α Constructs: To generate mammalian cell lines that express 101P3A11, constitutively, the ORF of 101P3A11 was cloned into pSR α constructs. Amphotropic and ecotropic retroviruses were generated by transfection of pSR α constructs into the 293T-10A1 packaging line or co-transfection of pSR α and a helper plasmid (containing deleted packaging sequences) into the 293 cells, respectively. The retrovirus was used to infect a variety of mammalian cell lines, resulting in the integration of the cloned gene, 101P3A11, into the host cell lines. Protein expression is driven from a long terminal repeat (LTR). The Neomycin resistance gene present in the vector allows for selection of mammalian cells that express the protein, and the ampicillin resistance gene and ColE1 origin permit selection and maintenance of the plasmid in *E. coli*. Figure 18 shows that 101P3A11 was expressed using the pSR α retroviral vector in the cell line 300.19. The retroviral vectors can thereafter be used for infection and generation of various cell lines using, for example, PC3, NIH 3T3, TsuPr1, 293 or rat-1 cells.

Additional pSR α constructs are made that fuse an epitope tag such as the FLAGTM tag to the carboxyl-terminus of 101P3A11 sequences to allow detection using anti-Flag antibodies. For example, the FLAGTM sequence 5' gat tac aag gat gac gac gat aag 3' is added to cloning primer at the 3' end of the ORF. Additional pSR α constructs are made to produce both amino-terminal and carboxyl-terminal GFP and myc/6X His fusion proteins of the full-length 101P3A11 proteins.

Additional Viral Vectors: Additional constructs are made for viral-mediated delivery and expression of 101P3A11. High virus titer leading to high level expression of 101P3A11 is achieved in viral delivery systems such as adenoviral vectors and herpes amplicon vectors. The 101P3A11 coding sequences or fragments thereof are amplified by PCR and subcloned into the AdEasy shuttle vector (Stratagene). Recombination and virus packaging are performed according to the manufacturer's instructions to generate adenoviral vectors. Alternatively, 101P3A11 coding sequences or fragments thereof are cloned into the HSV-1 vector (Imgenex) to generate herpes viral vectors. The viral vectors are thereafter used for infection of various cell lines such as SCaBER, NIH 3T3, 293 or rat-1 cells.

Regulated Expression Systems: To control expression of 101P3A11 in mammalian cells, coding sequences of 101P3A11, or portions thereof, are cloned into regulated mammalian expression systems such as the T-Rex System

(Invitrogen), the GeneSwitch System (Invitrogen) and the tightly-regulated Ecdysone System (Sratagene). These systems allow the study of the temporal and concentration dependent effects of recombinant 101P3A11. These vectors are thereafter used to control expression of 101P3A11 in various cell lines such as SCaBER, NIH 3T3, 293 or rat-1 cells.

B. Baculovirus Expression Systems

To generate recombinant 101P3A11 proteins in a baculovirus expression system, 101P3A11 ORF, or portions thereof, are cloned into the baculovirus transfer vector pBlueBac 4.5 (Invitrogen), which provides a His-tag at the N-terminus. Specifically, pBlueBac-101P3A11 is co-transfected with helper plasmid pBac-N-Blue (Invitrogen) into SF9 (*Spodoptera frugiperda*) insect cells to generate recombinant baculovirus (see Invitrogen instruction manual for details).

Baculovirus is then collected from cell supernatant and purified by plaque assay.

Recombinant 101P3A11 protein is then generated by infection of HighFive insect cells (Invitrogen) with purified baculovirus. Recombinant 101P3A11 protein can be detected using anti-101P3A11 or anti-His-tag antibody. 101P3A11 protein can be purified and used in various cell-based assays or as immunogen to generate polyclonal and monoclonal antibodies specific for 101P3A11.

Example 4 Antigenicity Profiles and Secondary Structure

Figure 5, Figure 6, Figure 7, Figure 8, and Figure 9 depict graphically five amino acid profiles of the 101P3A11 amino acid sequence, each assessment available by accessing the ProtScale website (URL www.expasy.ch/cgi-bin/protscale.pl) on the ExPasy molecular biology server.

These profiles: Figure 5, Hydrophilicity, (Hopp T.P., Woods K.R., 1981. Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828); Figure 6, Hydropathicity, (Kyte J., Doolittle R.F., 1982. J. Mol. Biol. 157:105-132); Figure 7, Percentage Accessible Residues (Janin J., 1979 Nature 277:491-492); Figure 8, Average Flexibility, (Bhaskaran R., and Ponnuswamy P.K., 1988. Int. J. Pept. Protein Res. 32:242-255); Figure 9, Beta-turn (Deleage, G., Roux B. 1987 Protein Engineering 1:289-294); and optionally others available in the art, such as on the ProtScale website, were used to identify antigenic regions of the 101P3A11 protein. Each of the above amino acid profiles of 101P3A11 were generated using the following ProtScale parameters for analysis: 1) A window size of 9; 2) 100% weight of the window edges compared to the window center; and, 3) amino acid profile values normalized to lie between 0 and 1.

Hydrophilicity (Figure 5), Hydropathicity (Figure 6) and Percentage Accessible Residues (Figure 7) profiles were used to determine stretches of hydrophilic amino acids (i.e., values greater than 0.5 on the Hydrophilicity and Percentage Accessible Residues profile, and values less than 0.5 on the Hydropathicity profile). Such regions are likely to be exposed to the aqueous environment, be present on the surface of the protein, and thus are available for immune recognition, such as by antibodies.

Average Flexibility (Figure 8) and Beta-turn (Figure 9) profiles determine stretches of amino acids (i.e., values greater than 0.5 on the Beta-turn profile and the Average Flexibility profile) that are not constrained in secondary structures such as beta sheets and alpha helices. Such regions are also more likely to be exposed portions of the protein and thus are accessible to immune recognition, such as by antibodies.

Antigenic sequences of the 101P3A11 protein indicated, e.g., by the profiles set forth in Figure 5, Figure 6, Figure 7, Figure 8, and/or Figure 9 are used to prepare immunogens, either peptides or nucleic acids that encode them,

to generate anti-101P3A11 antibodies. The immunogen can be any 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50 or more than 50 contiguous amino acids, or the corresponding nucleic acids that encode them, from the 101P3A11 protein. In particular, peptide immunogens of the invention can comprise, a peptide region of at least 5 amino acids of Figure 2 in any whole number increment up to 317 that includes an amino acid position having a value greater than 0.5 in the Hydrophilicity profile of Figure 5; a peptide region of at least 5 amino acids of Figure 2 in any whole number increment up to 317 that includes an amino acid position having a value less than 0.5 in the Hydropathicity profile of Figure 6; a peptide region of at least 5 amino acids of Figure 2 in any whole number increment up to 317 that includes an amino acid position having a value greater than 0.5 in the Percent Accessible Residues profile of Figure 7; a peptide region of at least 5 amino acids of Figure 2 in any whole number increment up to 317 that includes an amino acid position having a value greater than 0.5 in the Average Flexibility profile on Figure 8; and, a peptide region of at least 5 amino acids of Figure 2 in any whole number increment up to 317 that includes an amino acid position having a value greater than 0.5 in the Beta-turn profile of Figure 9. Peptide immunogens of the invention can also comprise nucleic acids that encode any of the foregoing.

All immunogens of the invention, peptide or nucleic acid, can be embodied in human unit dose form, or comprised by a composition that includes a pharmaceutical excipient compatible with human physiology.

The secondary structure of 101P3A11, namely the predicted presence and location of alpha helices, extended strands, and random coils, is predicted from the primary amino acid sequence using the HNN - Hierarchical Neural Network method (Guermeur, 1997, http://pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_nn.html), accessed from the ExPasy molecular biology server <http://www.expasy.ch/tools/>. The analysis indicates that 101P3A11 is composed 47.95% alpha helix, 21.45% extended strand, and 30.60% random coil (Figure 19A).

Analysis for the potential presence of transmembrane domains in 101P3A11 was carried out using a variety of transmembrane prediction algorithms accessed from the ExPasy molecular biology server <http://www.expasy.ch/tools>. The programs predict the presence of 7 transmembrane domains in 101P3A11, consistent with the structure of a G-protein coupled receptor. Shown graphically in Figure 19A are the results of analysis using the TMpred (Figure 19B) and TMHMM (Figure 19C) prediction programs depicting the location of the 7 transmembrane domains. The results of each program, namely the amino acids encoding the transmembrane domains are summarized in Table XXV.

Example 5: Generation of 101P3A11 Polyclonal Antibodies

Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. In addition to immunizing with the full length 101P3A11 protein, computer algorithms are employed in design of immunogens that, based on amino acid sequence analysis are antigenic and available for recognition by the immune system of the immunized host (see the Example entitled "Antigenicity Profiles and Secondary Structure"). Such regions would generally be hydrophilic, flexible, in beta-turn conformations, and/or exposed on the surface of the protein (see, e.g., Figure 5, Figure 6, Figure 7, Figure 8, or Figure 9 for amino acid profiles that indicate such regions of 101P3A11).

For example, 101P3A11 recombinant bacterial fusion proteins or peptides containing hydrophilic, flexible, beta-turn regions of the 101P3A11 amino acid sequence, such as amino acids 1-23, plus or minus 1-10 amino acids at

available termini, and amino acids 159-202, plus or minus 1-10 amino acids at available termini, are used as antigens to generate polyclonal antibodies in New Zealand White rabbits. It is useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include, but are not limited to, keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. In one embodiment, a peptide encoding amino acids 1-23 of 101P3A11 is conjugated to KLH and used to immunize the rabbit. Alternatively the immunizing agent may include all or portions of the 101P3A11 protein, analogs or fusion proteins thereof. For example, the 101P3A11 amino acid sequence can be fused using recombinant DNA techniques to any one of a variety of fusion protein partners that are well known in the art, such as glutathione-S-transferase (GST) and HIS tagged fusion proteins. Such fusion proteins are purified from induced bacteria using the appropriate affinity matrix.

In one embodiment, a GST-fusion protein encoding amino acids 86-317, plus or minus 1-10 amino acids at available termini, is produced and purified and used as immunogen. Other recombinant bacterial fusion proteins that may be employed include maltose binding protein, LacZ, thioredoxin, NusA, or an immunoglobulin constant region (see the section entitled "Production of 101P3A11 in Prokaryotic Systems" and Current Protocols In Molecular Biology, Volume 2, Unit 16, Frederick M. Ausubul et al. eds., 1995; Linsley, P.S., Brady, W., Urnes, M., Grosmaire, L., Damle, N., and Ledbetter, L.(1991) J.Exp. Med. 174, 561-566).

In addition to bacterial derived fusion proteins, mammalian expressed protein antigens are also used. These antigens are expressed from mammalian expression vectors such as the Tag5 and Fc-fusion vectors (see the section entitled "Production of Recombinant 101P3A11 in Eukaryotic Systems"), and retain post-translational modifications such as glycosylations found in native protein. In one embodiment, amino acids 159-202 is cloned into the Tag5 mammalian secretion vector. The recombinant protein is purified by metal chelate chromatography from tissue culture supernatants of 293T cells stably expressing the recombinant vector. The purified Tag5 101P3A11 protein is then used as immunogen.

During the immunization protocol, it is useful to mix or emulsify the antigen in adjuvants that enhance the immune response of the host animal. Examples of adjuvants include, but are not limited to, complete Freund's adjuvant (CFA) and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

In a typical protocol, rabbits are initially immunized subcutaneously with up to 200 µg, typically 100-200 µg, of fusion protein or peptide conjugated to KLH mixed in complete Freund's adjuvant (CFA). Rabbits are then injected subcutaneously every two weeks with up to 200 µg, typically 100-200 µg, of the immunogen in incomplete Freund's adjuvant (IFA). Test bleeds are taken approximately 7-10 days following each immunization and used to monitor the titer of the antiserum by ELISA.

To test reactivity and specificity of immune serum, such as the rabbit serum derived from immunization with Tag5 101P3A11 encoding amino acids 159-202, the full-length 101P3A11 cDNA is cloned into pCDNA 3.1 myc-his expression vector (Invitrogen, see the Example entitled "Production of Recombinant 101P3A11 in Eukaryotic Systems"). After transfection of the constructs into 293T cells, cell lysates are probed with the anti-101P3A11 serum and with anti-His antibody (Santa Cruz Biotechnologies, Santa Cruz, CA) to determine specific reactivity to denatured 101P3A11 protein using the Western blot technique. Immunoprecipitation and flow cytometric analyses of 293T and other recombinant 101P3A11-expressing cells determine recognition of native protein by the antiserum. In addition,

Western blot, immunoprecipitation, fluorescent microscopy, and flow cytometric techniques using cells that endogenously express 101P3A11 are carried out to test specificity.

The anti-serum from the Tag5 101P3A11 immunized rabbit is affinity purified by passage over a column composed of the Tag5 antigen covalently coupled to Affigel matrix (BioRad, Hercules, Calif.). The serum is then further purified by protein G affinity chromatography to isolate the IgG fraction. Serum from rabbits immunized with fusion proteins, such as GST and MBP fusion proteins, are purified by depletion of antibodies reactive to the fusion partner sequence by passage over an affinity column containing the fusion partner either alone or in the context of an irrelevant fusion protein. Sera from other His-tagged antigens and peptide immunized rabbits as well as fusion partner depleted sera are affinity purified by passage over a column matrix composed of the original protein immunogen or free peptide.

Example 6: Generation of 101P3A11 Monoclonal Antibodies (mAbs)

In one embodiment, therapeutic mAbs to 101P3A11 comprise those that react with epitopes of the protein that would disrupt or modulate the biological function of 101P3A11, for example those that would disrupt its interaction with ligands or proteins that mediate or are involved in its biological activity. Therapeutic mAbs also comprise those that specifically bind epitopes of 101P3A11 exposed on the cell surface and thus are useful in targeting mAb-toxin conjugates. Immunogens for generation of such mAbs include those designed to encode or contain the entire 101P3A11 protein or regions of the 101P3A11 protein predicted to be exposed to the extracellular environment and/or antigenic from computer analysis of the amino acid sequence (see, e.g., Figure 5, Figure 6, Figure 7, Figure 8, or Figure 9, and the Example entitled "Antigenicity Profiles and Secondary Structure"). Immunogens include peptides, recombinant bacterial proteins, and mammalian expressed Tag 5 proteins and human and murine IgG FC fusion proteins. In addition, cells expressing high levels of 101P3A11, such as 293T-101P3A11 or 300.19-101P3A11 murine Pre-B cells, are used to immunize mice.

To generate mAbs to 101P3A11, mice are first immunized intraperitoneally (IP) with, typically, 10-50 µg of protein immunogen or 10^7 101P3A11-expressing cells mixed in complete Freund's adjuvant. Alternatively, mice are immunized intradermally. Mice are then subsequently immunized IP every 2-4 weeks with, typically, 10-50 µg of protein immunogen or 10^7 cells mixed in incomplete Freund's adjuvant. Alternatively, MPL-TDM adjuvant is used in immunizations. In addition to the above protein and cell-based immunization strategies, a DNA-based immunization protocol is employed in which a mammalian expression vector encoding 101P3A11 sequence is used to immunize mice by direct injection of the plasmid DNA. For example, the predicted first extracellular loop, amino acids 82-104, or second extracellular loop of 101P3A11, amino acids 159-202, or the third extracellular loop, amino acids 258 - 275 (in each instance plus or minus 10 amino acids) is cloned into the Tag5 mammalian secretion vector and the recombinant vector is used as immunogen. In another example the same amino acids are cloned into an Fc-fusion secretion vector in which the 101P3A11 sequence is fused at the amino-terminus to an IgK leader sequence and at the carboxyl-terminus to the coding sequence of the human IgG Fc region. This recombinant vector is then used as immunogen. The plasmid immunization protocols are used in combination with purified proteins expressed from the same vector and with cells expressing 101P3A11.

During the immunization protocol, test bleeds are taken 7-10 days following an injection to monitor titer and specificity of the immune response. Once appropriate reactivity and specificity is obtained as determined by ELISA, Western blotting, immunoprecipitation, fluorescence microscopy, and flow cytometric analyses, fusion and hybridoma generation is then carried out with established procedures well known in the art (see, e.g., Harlow and Lane, 1988).

In one embodiment for generating 101P3A11 monoclonal antibodies, a Tag5-101P3A11 antigen encoding amino acids 159-202 is expressed and purified from stably transfected 293T cells. Balb C mice are initially immunized intraperitoneally with 25 µg of the Tag5-101P3A11 protein mixed in complete Freund's adjuvant. Mice are subsequently immunized every two weeks with 25 µg of the antigen mixed in incomplete Freund's adjuvant for a total of three immunizations. ELISA using the Tag5 antigen determines the titer of serum from immunized mice. Reactivity and specificity of serum to full length 101P3A11 protein is monitored by Western blotting, immunoprecipitation and flow cytometry using 293T cells transfected with an expression vector encoding the 101P3A11 cDNA (see e.g., the Example entitled "Production of Recombinant 101P3A11 in Eukaryotic Systems"). Other recombinant 101P3A11-expressing cells or cells endogenously expressing 101P3A11 are also used. Mice showing the strongest reactivity are rested and given a final injection of Tag5 antigen in PBS and then sacrificed four days later. The spleens of the sacrificed mice are harvested and fused to SPO/2 myeloma cells using standard procedures (Harlow and Lane, 1988). Supernatants from HAT selected growth wells are screened by ELISA, Western blot, immunoprecipitation, fluorescent microscopy, and flow cytometry to identify 101P3A11 specific antibody-producing clones.

The binding affinity of a 101P3A11 monoclonal antibody is determined using standard technologies. Affinity measurements quantify the strength of antibody to epitope binding and are used to help define which 101P3A11 monoclonal antibodies preferred, e.g., for diagnostic or therapeutic use, as appreciated by one of skill in the art. The BIAcore system (Uppsala, Sweden) is a preferred method for determining binding affinity. The BIAcore system uses surface plasmon resonance (SPR, Welford K. 1991, Opt. Quant. Elect. 23:1; Morton and Myszk, 1998, Methods in Enzymology 295: 268) to monitor biomolecular interactions in real time. BIAcore analysis conveniently generates association rate constants, dissociation rate constants, equilibrium dissociation constants, and affinity constants.

Example 7: HLA Class I and Class II Binding Assays

HLA class I and class II binding assays using purified HLA molecules are performed in accordance with disclosed protocols (e.g., PCT publications WO 94/20127 and WO 94/03205; Sidney *et al.*, *Current Protocols in Immunology* 18.3.1 (1998); Sidney, *et al.*, *J. Immunol.* 154:247 (1995); Sette, *et al.*, *Mol. Immunol.* 31:813 (1994)). Briefly, purified MHC molecules (5 to 500 nM) are incubated with various unlabeled peptide inhibitors and 1-10 nM ¹²⁵I-radiolabeled probe peptides as described. Following incubation, MHC-peptide complexes are separated from free peptide by gel filtration and the fraction of peptide bound is determined. Typically, in preliminary experiments, each MHC preparation is titered in the presence of fixed amounts of radiolabeled peptides to determine the concentration of HLA molecules necessary to bind 10-20% of the total radioactivity. All subsequent inhibition and direct binding assays are performed using these HLA concentrations.

Since under these conditions [label]<[HLA] and IC₅₀≥[HLA], the measured IC₅₀ values are reasonable approximations of the true K_D values. Peptide inhibitors are typically tested at concentrations ranging from 120 µg/ml to 1.2 ng/ml, and are tested in two to four completely independent experiments. To allow comparison of the data

obtained in different experiments, a relative binding figure is calculated for each peptide by dividing the IC₅₀ of a positive control for inhibition by the IC₅₀ for each tested peptide (typically unlabeled versions of the radiolabeled probe peptide). For database purposes, and inter-experiment comparisons, relative binding values are compiled. These values can subsequently be converted back into IC₅₀ nM values by dividing the IC₅₀ nM of the positive controls for inhibition by the relative binding of the peptide of interest. This method of data compilation is accurate and consistent for comparing peptides that have been tested on different days, or with different lots of purified MHC.

Binding assays as outlined above may be used to analyze HLA supermotif and/or HLA motif-bearing peptides.

Example 8: Identification of HLA Supermotif- and Motif-Bearing CTL Candidate Epitopes

HLA vaccine compositions of the invention can include multiple epitopes. The multiple epitopes can comprise multiple HLA supermotifs or motifs to achieve broad population coverage. This example illustrates the identification and confirmation of supermotif- and motif-bearing epitopes for the inclusion in such a vaccine composition. Calculation of population coverage is performed using the strategy described below.

Computer searches and algorithms for identification of supermotif and/or motif-bearing epitopes

The searches performed to identify the motif-bearing peptide sequences in the Example entitled "Antigenicity Profiles" and Tables V-XVIII or XXVI-XXVIII employ the protein sequence data from the gene product of 101P3A11 set forth in Figures 2 and 3.

Computer searches for epitopes bearing HLA Class I or Class II supermotifs or motifs are performed as follows. All translated 101P3A11 protein sequences are analyzed using a text string search software program to identify potential peptide sequences containing appropriate HLA binding motifs; such programs are readily produced in accordance with information in the art in view of known motif/supermotif disclosures. Furthermore, such calculations can be made mentally.

Identified A2-, A3-, and DR-supermotif sequences are scored using polynomial algorithms to predict their capacity to bind to specific HLA-Class I or Class II molecules. These polynomial algorithms account for the impact of different amino acids at different positions, and are essentially based on the premise that the overall affinity (or ΔG) of peptide-HLA molecule interactions can be approximated as a linear polynomial function of the type:

$$"\Delta G" = a_{1i} \times a_{2i} \times a_{3i} \dots \times a_{ni}$$

where a_{ji} is a coefficient which represents the effect of the presence of a given amino acid (j) at a given position (i) along the sequence of a peptide of n amino acids. The crucial assumption of this method is that the effects at each position are essentially independent of each other (i.e., independent binding of individual side-chains). When residue j occurs at position i in the peptide, it is assumed to contribute a constant amount j_i to the free energy of binding of the peptide irrespective of the sequence of the rest of the peptide.

The method of derivation of specific algorithm coefficients has been described in Gulukota *et al.*, *J. Mol. Biol.* 267:1258-126, 1997; (see also Sidney *et al.*, *Human Immunol.* 45:79-93, 1996; and Southwood *et al.*, *J. Immunol.* 160:3363-3373, 1998). Briefly, for all i positions, anchor and non-anchor alike, the geometric mean of the average relative binding (ARB) of all peptides carrying j is calculated relative to the remainder of the group, and used as the estimate of j_i . For Class II peptides, if multiple alignments are possible, only the highest scoring alignment is utilized, following an iterative procedure. To calculate an algorithm score of a given peptide in a test set, the ARB values

corresponding to the sequence of the peptide are multiplied. If this product exceeds a chosen threshold, the peptide is predicted to bind. Appropriate thresholds are chosen as a function of the degree of stringency of prediction desired.

Selection of HLA-A2 supertype cross-reactive peptides

Complete protein sequences from I01P3A11 are scanned utilizing motif identification software, to identify 8-, 9- 10- and 11-mer sequences containing the HLA-A2-supermotif main anchor specificity. Typically, these sequences are then scored using the protocol described above and the peptides corresponding to the positive-scoring sequences are synthesized and tested for their capacity to bind purified HLA-A*0201 molecules *in vitro* (HLA-A*0201 is considered a prototype A2 supertype molecule).

These peptides are then tested for the capacity to bind to additional A2-supertype molecules (A*0202, A*0203, A*0206, and A*6802). Peptides that bind to at least three of the five A2-supertype alleles tested are typically deemed A2-supertype cross-reactive binders. Preferred peptides bind at an affinity equal to or less than 500 nM to three or more HLA-A2 supertype molecules.

Selection of HLA-A3 supermotif-bearing epitopes

The I01P3A11 protein sequence scanned above is also examined for the presence of peptides with the HLA-A3-supermotif primary anchors. Peptides corresponding to the HLA A3 supermotif-bearing sequences are then synthesized and tested for binding to HLA-A*0301 and HLA-A*1101 molecules, the molecules encoded by the two most prevalent A3-supertype alleles. The peptides that bind at least one of the two alleles with binding affinities of ≤ 500 nM, often ≤ 200 nM, are then tested for binding cross-reactivity to the other common A3-supertype alleles (e.g., A*3101, A*3301, and A*6801) to identify those that can bind at least three of the five HLA-A3-supertype molecules tested.

Selection of HLA-B7 supermotif bearing epitopes

The I01P3A11 protein is also analyzed for the presence of 8-, 9- 10-, or 11-mer peptides with the HLA-B7-supermotif. Corresponding peptides are synthesized and tested for binding to HLA-B*0702, the molecule encoded by the most common B7-supertype allele (*i.e.*, the prototype B7 supertype allele). Peptides binding B*0702 with IC_{50} of ≤ 500 nM are identified using standard methods. These peptides are then tested for binding to other common B7-supertype molecules (e.g., B*3501, B*5101, B*5301, and B*5401). Peptides capable of binding to three or more of the five B7-supertype alleles tested are thereby identified.

Selection of A1 and A24 motif-bearing epitopes

To further increase population coverage, HLA-A1 and -A24 epitopes can also be incorporated into vaccine compositions. An analysis of the I01P3A11 protein can also be performed to identify HLA-A1- and A24-motif-containing sequences.

High affinity and/or cross-reactive binding epitopes that bear other motif and/or supermotifs are identified using analogous methodology.

Example 9: Confirmation of Immunogenicity

Cross-reactive candidate CTL A2-supermotif-bearing peptides that are identified as described herein are selected to confirm *in vitro* immunogenicity. Confirmation is performed using the following methodology:

Target Cell Lines for Cellular Screening:

The .221A2.1 cell line, produced by transferring the HLA-A2.1 gene into the HLA-A, -B, -C null mutant human B-lymphoblastoid cell line 721.221, is used as the peptide-loaded target to measure activity of HLA-A2.1-restricted CTL. This cell line is grown in RPMI-1640 medium supplemented with antibiotics, sodium pyruvate, nonessential amino acids and 10% (v/v) heat inactivated FCS. Cells that express an antigen of interest, or transfectants comprising the gene encoding the antigen of interest, can be used as target cells to confirm the ability of peptide-specific CTLs to recognize endogenous antigen.

Primary CTL Induction Cultures:

Generation of Dendritic Cells (DC): PBMCs are thawed in RPMI with 30 µg/ml DNase, washed twice and resuspended in complete medium (RPMI-1640 plus 5% AB human serum, non-essential amino acids, sodium pyruvate, L-glutamine and penicillin/streptomycin). The monocytes are purified by plating 10×10^6 PBMC/well in a 6-well plate. After 2 hours at 37°C, the non-adherent cells are removed by gently shaking the plates and aspirating the supernatants. The wells are washed a total of three times with 3 ml RPMI to remove most of the non-adherent and loosely adherent cells. Three ml of complete medium containing 50 ng/ml of GM-CSF and 1,000 U/ml of IL-4 are then added to each well. TNFα is added to the DCs on day 6 at 75 ng/ml and the cells are used for CTL induction cultures on day 7.

Induction of CTL with DC and Peptide: CD8⁺ T-cells are isolated by positive selection with Dynal immunomagnetic beads (Dynabeads® M-450) and the detach-bead® reagent. Typically about $200\text{--}250 \times 10^6$ PBMC are processed to obtain 24×10^6 CD8⁺ T-cells (enough for a 48-well plate culture). Briefly, the PBMCs are thawed in RPMI with 30 µg/ml DNase, washed once with PBS containing 1% human AB serum and resuspended in PBS/1% AB serum at a concentration of 20×10^6 cells/ml. The magnetic beads are washed 3 times with PBS/AB serum, added to the cells (140 µl beads/ 20×10^6 cells) and incubated for 1 hour at 4°C with continuous mixing. The beads and cells are washed 4x with PBS/AB serum to remove the nonadherent cells and resuspended at 100×10^6 cells/ml (based on the original cell number) in PBS/AB serum containing 100 µl/ml detach-bead® reagent and 30 µg/ml DNase. The mixture is incubated for 1 hour at room temperature with continuous mixing. The beads are washed again with PBS/AB/DNase to collect the CD8⁺ T-cells. The DC are collected and centrifuged at 1300 rpm for 5-7 minutes, washed once with PBS with 1% BSA, counted and pulsed with 40 µg/ml of peptide at a cell concentration of $1\text{--}2 \times 10^6$ /ml in the presence of 3 µg/ml β₂-microglobulin for 4 hours at 20°C. The DC are then irradiated (4,200 rads), washed 1 time with medium and counted again.

Setting up induction cultures: 0.25 ml cytokine-generated DC (at 1×10^5 cells/ml) are co-cultured with 0.25 ml of CD8⁺ T-cells (at 2×10^6 cell/ml) in each well of a 48-well plate in the presence of 10 ng/ml of IL-7. Recombinant human IL-10 is added the next day at a final concentration of 10 ng/ml and rhuman IL-2 is added 48 hours later at 10 IU/ml.

Restimulation of the induction cultures with peptide-pulsed adherent cells: Seven and fourteen days after the primary induction, the cells are restimulated with peptide-pulsed adherent cells. The PBMCs are thawed and washed twice with RPMI and DNase. The cells are resuspended at 5×10^6 cells/ml and irradiated at ~4200 rads. The PBMCs are plated at 2×10^6 in 0.5 ml complete medium per well and incubated for 2 hours at 37°C. The plates are washed twice with RPMI by tapping the plate gently to remove the nonadherent cells and the adherent cells pulsed with 10 µg/ml of peptide in the presence of 3 µg/ml β₂ microglobulin in 0.25 ml RPMI/5% AB per well for 2 hours at 37°C. Peptide

solution from each well is aspirated and the wells are washed once with RPMI. Most of the media is aspirated from the induction cultures (CD8+ cells) and brought to 0.5 ml with fresh media. The cells are then transferred to the wells containing the peptide-pulsed adherent cells. Twenty four hours later recombinant human IL-10 is added at a final concentration of 10 ng/ml and recombinant human IL2 is added the next day and again 2-3 days later at 50IU/ml (Tsai *et al.*, *Critical Reviews in Immunology* 18(1-2):65-75, 1998). Seven days later, the cultures are assayed for CTL activity in a ^{51}Cr release assay. In some experiments the cultures are assayed for peptide-specific recognition in the *in situ* IFN γ ELISA at the time of the second restimulation followed by assay of endogenous recognition 7 days later. After expansion, activity is measured in both assays for a side-by-side comparison.

Measurement of CTL lytic activity by ^{51}Cr release.

Seven days after the second restimulation, cytotoxicity is determined in a standard (5 hr) ^{51}Cr release assay by assaying individual wells at a single E:T. Peptide-pulsed targets are prepared by incubating the cells with 10 $\mu\text{g}/\text{ml}$ peptide overnight at 37°C.

Adherent target cells are removed from culture flasks with trypsin-EDTA. Target cells are labeled with 200 μCi of ^{51}Cr sodium chromate (Dupont, Wilmington, DE) for 1 hour at 37°C. Labeled target cells are resuspended at 10 6 per ml and diluted 1:10 with K562 cells at a concentration of 3.3 $\times 10^6/\text{ml}$ (an NK-sensitive erythroblastoma cell line used to reduce non-specific lysis). Target cells (100 μl) and effectors (100 μl) are plated in 96 well round-bottom plates and incubated for 5 hours at 37°C. At that time, 100 μl of supernatant are collected from each well and percent lysis is determined according to the formula:

$$\frac{[(\text{cpm of the test sample} - \text{cpm of the spontaneous } ^{51}\text{Cr release sample}) / (\text{cpm of the maximal } ^{51}\text{Cr release sample} - \text{cpm of the spontaneous } ^{51}\text{Cr release sample})] \times 100.}$$

Maximum and spontaneous release are determined by incubating the labeled targets with 1% Triton X-100 and media alone, respectively. A positive culture is defined as one in which the specific lysis (sample- background) is 10% or higher in the case of individual wells and is 15% or more at the two highest E:T ratios when expanded cultures are assayed.

In situ Measurement of Human IFN γ Production as an Indicator of Peptide-specific and Endogenous Recognition

Immulon 2 plates are coated with mouse anti-human IFN γ monoclonal antibody (4 $\mu\text{g}/\text{ml}$ 0.1M NaHCO $_3$, pH8.2) overnight at 4°C. The plates are washed with Ca $^{2+}$, Mg $^{2+}$ -free PBS/0.05% Tween 20 and blocked with PBS/10% FCS for two hours, after which the CTLs (100 $\mu\text{l}/\text{well}$) and targets (100 $\mu\text{l}/\text{well}$) are added to each well, leaving empty wells for the standards and blanks (which received media only). The target cells, either peptide-pulsed or endogenous targets, are used at a concentration of 1 $\times 10^6$ cells/ml. The plates are incubated for 48 hours at 37°C with 5% CO $_2$.

Recombinant human IFN-gamma is added to the standard wells starting at 400 pg or 1200pg/100 microliter/well and the plate incubated for two hours at 37°C. The plates are washed and 100 μl of biotinylated mouse anti-human IFN-gamma monoclonal antibody (2 microgram/ml in PBS/3%FCS/0.05% Tween 20) are added and incubated for 2 hours at room temperature. After washing again, 100 microliter HRP-streptavidin (1:4000) are added and the plates incubated for one hour at room temperature. The plates are then washed 6x with wash buffer, 100 microliter/well developing solution (TMB 1:1) are added, and the plates allowed to develop for 5-15 minutes. The

reaction is stopped with 50 microliter/well 1M H₃PO₄ and read at OD450. A culture is considered positive if it measured at least 50 pg of IFN-gamma/well above background and is twice the background level of expression.

CTL Expansion.

Those cultures that demonstrate specific lytic activity against peptide-pulsed targets and/or tumor targets are expanded over a two week period with anti-CD3. Briefly, 5x10⁴ CD8⁺ cells are added to a T25 flask containing the following: 1x10⁶ irradiated (4,200 rad) PBMC (autologous or allogeneic) per ml, 2x10⁵ irradiated (8,000 rad) EBV-transformed cells per ml, and OKT3 (anti-CD3) at 30ng per ml in RPMI-1640 containing 10% (v/v) human AB serum, non-essential amino acids, sodium pyruvate, 25μM 2-mercaptoethanol, L-glutamine and penicillin/streptomycin. Recombinant human IL2 is added 24 hours later at a final concentration of 200IU/ml and every three days thereafter with fresh media at 50IU/ml. The cells are split if the cell concentration exceeds 1x10⁶/ml and the cultures are assayed between days 13 and 15 at E:T ratios of 30, 10, 3 and 1:1 in the ⁵¹Cr release assay or at 1x10⁶/ml in the *in situ* IFNγ assay using the same targets as before the expansion.

Cultures are expanded in the absence of anti-CD3⁺ as follows. Those cultures that demonstrate specific lytic activity against peptide and endogenous targets are selected and 5x10⁴ CD8⁺ cells are added to a T25 flask containing the following: 1x10⁶ autologous PBMC per ml which have been peptide-pulsed with 10 μg/ml peptide for two hours at 37°C and irradiated (4,200 rad); 2x10⁵ irradiated (8,000 rad) EBV-transformed cells per ml RPMI-1640 containing 10%(v/v) human AB serum, non-essential AA, sodium pyruvate, 25mM 2-ME, L-glutamine and gentamicin.

Immunogenicity of A2 supermotif-bearing peptides

A2-supermotif cross-reactive binding peptides are tested in the cellular assay for the ability to induce peptide-specific CTL in normal individuals. In this analysis, a peptide is typically considered to be an epitope if it induces peptide-specific CTLs in at least individuals, and preferably, also recognizes the endogenously expressed peptide.

Immunogenicity can also be confirmed using PBMCs isolated from patients bearing a tumor that expresses 101P3A11. Briefly, PBMCs are isolated from patients, re-stimulated with peptide-pulsed monocytes and assayed for the ability to recognize peptide-pulsed target cells as well as transfected cells endogenously expressing the antigen.

Evaluation of A*03/A11 immunogenicity

HLA-A3 supermotif-bearing cross-reactive binding peptides are also evaluated for immunogenicity using methodology analogous for that used to evaluate the immunogenicity of the HLA-A2 supermotif peptides.

Evaluation of B7 immunogenicity

Immunogenicity screening of the B7-supertype cross-reactive binding peptides identified as set forth herein are confirmed in a manner analogous to the confirmation of A2-and A3-supermotif-bearing peptides.

Peptides bearing other supermotifs/motifs, *e.g.*, HLA-A1, HLA-A24 *etc.* are also confirmed using similar methodology

Example 10: Implementation of the Extended Supermotif to Improve the Binding Capacity of Native Epitopes by Creating Analogs

HLA motifs and supermotifs (comprising primary and/or secondary residues) are useful in the identification and preparation of highly cross-reactive native peptides, as demonstrated herein. Moreover, the definition of HLA motifs and supermotifs also allows one to engineer highly cross-reactive epitopes by identifying residues within a native

peptide sequence which can be analoged to confer upon the peptide certain characteristics, *e.g.* greater cross-reactivity within the group of HLA molecules that comprise a supertype, and/or greater binding affinity for some or all of those HLA molecules. Examples of analoging peptides to exhibit modulated binding affinity are set forth in this example.

Analoging at Primary Anchor Residues

Peptide engineering strategies are implemented to further increase the cross-reactivity of the epitopes. For example, the main anchors of A2-supermotif-bearing peptides are altered, for example, to introduce a preferred L, I, V, or M at position 2, and I or V at the C-terminus.

To analyze the cross-reactivity of the analog peptides, each engineered analog is initially tested for binding to the prototype A2 supertype allele A*0201, then, if A*0201 binding capacity is maintained, for A2-supertype cross-reactivity.

Alternatively, a peptide is confirmed as binding one or all supertype members and then analogued to modulate binding affinity to any one (or more) of the supertype members to add population coverage.

The selection of analogs for immunogenicity in a cellular screening analysis is typically further restricted by the capacity of the parent wild type (WT) peptide to bind at least weakly, *i.e.*, bind at an IC₅₀ of 5000nM or less, to three or more A2 supertype alleles. The rationale for this requirement is that the WT peptides must be present endogenously in sufficient quantity to be biologically relevant. Analoged peptides have been shown to have increased immunogenicity and cross-reactivity by T cells specific for the parent epitope (*see, e.g.*, Parkhurst *et al.*, *J. Immunol.* 157:2539, 1996; and Pogue *et al.*, *Proc. Natl. Acad. Sci. USA* 92:8166, 1995).

In the cellular screening of these peptide analogs, it is important to confirm that analog-specific CTLs are also able to recognize the wild-type peptide and, when possible, target cells that endogenously express the epitope.

Analoging of HLA-A3 and B7-supermotif-bearing peptides

Analogues of HLA-A3 supermotif-bearing epitopes are generated using strategies similar to those employed in analoging HLA-A2 supermotif-bearing peptides. For example, peptides binding to 3/5 of the A3-supertype molecules are engineered at primary anchor residues to possess a preferred residue (V, S, M, or A) at position 2.

The analog peptides are then tested for the ability to bind A*03 and A*11 (prototype A3 supertype alleles). Those peptides that demonstrate ≤ 500 nM binding capacity are then confirmed as having A3-supertype cross-reactivity.

Similarly to the A2- and A3- motif bearing peptides, peptides binding 3 or more B7-supertype alleles can be improved, where possible, to achieve increased cross-reactive binding or greater binding affinity or binding half life. B7 supermotif-bearing peptides are, for example, engineered to possess a preferred residue (V, I, L, or F) at the C-terminal primary anchor position, as demonstrated by Sidney *et al.* (*J. Immunol.* 157:3480-3490, 1996).

Analoging at primary anchor residues of other motif and/or supermotif-bearing epitopes is performed in a like manner.

The analog peptides are then be confirmed for immunogenicity, typically in a cellular screening assay. Again, it is generally important to demonstrate that analog-specific CTLs are also able to recognize the wild-type peptide and, when possible, targets that endogenously express the epitope.

Analoging at Secondary Anchor Residues

Moreover, HLA supermotifs are of value in engineering highly cross-reactive peptides and/or peptides that bind HLA molecules with increased affinity by identifying particular residues at secondary anchor positions that are

associated with such properties. For example, the binding capacity of a B7 supermotif-bearing peptide with an F residue at position 1 is analyzed. The peptide is then analogued to, for example, substitute L for F at position 1. The analogued peptide is evaluated for increased binding affinity, binding half life and/or increased cross-reactivity. Such a procedure identifies analogued peptides with enhanced properties.

Engineered analogs with sufficiently improved binding capacity or cross-reactivity can also be tested for immunogenicity in HLA-B7-transgenic mice, following for example, IFA immunization or lipopeptide immunization. Analogued peptides are additionally tested for the ability to stimulate a recall response using PBMC from patients with 101P3A11-expressing tumors.

Other analoguing strategies

Another form of peptide analoguing, unrelated to anchor positions, involves the substitution of a cysteine with α -amino butyric acid. Due to its chemical nature, cysteine has the propensity to form disulfide bridges and sufficiently alter the peptide structurally so as to reduce binding capacity. Substitution of α -amino butyric acid for cysteine not only alleviates this problem, but has been shown to improve binding and crossbinding capabilities in some instances (see, e.g., the review by Sette *et al.*, In: Persistent Viral Infections, Eds. R. Ahmed and I. Chen, John Wiley & Sons, England, 1999).

Thus, by the use of single amino acid substitutions, the binding properties and/or cross-reactivity of peptide ligands for HLA supertype molecules can be modulated.

Example 11. Identification and confirmation of 101P3A11-derived sequences with HLA-DR binding motifs

Peptide epitopes bearing an HLA class II supermotif or motif are identified and confirmed as outlined below using methodology similar to that described for HLA Class I peptides.

Selection of HLA-DR-supermotif-bearing epitopes.

To identify 101P3A11-derived, HLA class II HTL epitopes, the 101P3A11 antigen is analyzed for the presence of sequences bearing an HLA-DR-motif or supermotif. Specifically, 15-mer sequences are selected comprising a DR-supermotif, comprising a 9-mer core, and three-residue N- and C-terminal flanking regions (15 amino acids total).

Protocols for predicting peptide binding to DR molecules have been developed (Southwood *et al.*, *J. Immunol.* 160:3363-3373, 1998). These protocols, specific for individual DR molecules, allow the scoring, and ranking, of 9-mer core regions. Each protocol not only scores peptide sequences for the presence of DR-supermotif primary anchors (i.e., at position 1 and position 6) within a 9-mer core, but additionally evaluates sequences for the presence of secondary anchors. Using allele-specific selection tables (see, e.g., Southwood *et al.*, *ibid.*), it has been found that these protocols efficiently select peptide sequences with a high probability of binding a particular DR molecule. Additionally, it has been found that performing these protocols in tandem, specifically those for DR1, DR4w4, and DR7, can efficiently select DR cross-reactive peptides.

The 101P3A11-derived peptides identified above are tested for their binding capacity for various common HLA-DR molecules. All peptides are initially tested for binding to the DR molecules in the primary panel: DR1, DR4w4, and DR7. Peptides binding at least two of these three DR molecules are then tested for binding to DR2w2 β 1, DR2w2 β 2, DR6w19, and DR9 molecules in secondary assays. Finally, peptides binding at least two of the four

secondary panel DR molecules, and thus cumulatively at least four of seven different DR molecules, are screened for binding to DR4w15, DR5w11, and DR8w2 molecules in tertiary assays. Peptides binding at least seven of the ten DR molecules comprising the primary, secondary, and tertiary screening assays are considered cross-reactive DR binders. 101P3A11-derived peptides found to bind common HLA-DR alleles are of particular interest.

5 Selection of DR3 motif peptides

Because HLA-DR3 is an allele that is prevalent in Caucasian, Black, and Hispanic populations, DR3 binding capacity is a relevant criterion in the selection of HTL epitopes. Thus, peptides shown to be candidates may also be assayed for their DR3 binding capacity. However, in view of the binding specificity of the DR3 motif, peptides binding only to DR3 can also be considered as candidates for inclusion in a vaccine formulation.

10 To efficiently identify peptides that bind DR3, target 101P3A11 antigens are analyzed for sequences carrying one of the two DR3-specific binding motifs reported by Geluk *et al.* (*J. Immunol.* 152:5742-5748, 1994). The corresponding peptides are then synthesized and confirmed as having the ability to bind DR3 with an affinity of 1 μ M or better, i.e., less than 1 μ M. Peptides are found that meet this binding criterion and qualify as HLA class II high affinity binders.

15 DR3 binding epitopes identified in this manner are included in vaccine compositions with DR supermotif-bearing peptide epitopes.

Similarly to the case of HLA class I motif-bearing peptides, the class II motif-bearing peptides are analogized to improve affinity or cross-reactivity. For example, aspartic acid at position 4 of the 9-mer core sequence is an optimal residue for DR3 binding, and substitution for that residue often improves DR 3 binding.

20 Example 12: Immunogenicity of 101P3A11-derived HTL epitopes

This example determines immunogenic DR supermotif- and DR3 motif-bearing epitopes among those identified using the methodology set forth herein.

Immunogenicity of HTL epitopes are confirmed in a manner analogous to the determination of
25 immunogenicity of CTL epitopes, by assessing the ability to stimulate HTL responses and/or by using appropriate transgenic mouse models. Immunogenicity is determined by screening for: 1.) *in vitro* primary induction using normal PBMC or 2.) recall responses from patients who have 101P3A11-expressing tumors.

30 Example 13: Calculation of phenotypic frequencies of HLA-supertypes in various ethnic backgrounds to determine breadth of population coverage

This example illustrates the assessment of the breadth of population coverage of a vaccine composition comprised of multiple epitopes comprising multiple supermotifs and/or motifs.

In order to analyze population coverage, gene frequencies of HLA alleles are determined. Gene frequencies for each HLA allele are calculated from antigen or allele frequencies utilizing the binomial distribution formulae $gf=1-(SQRT(1-af))$ (see, *e.g.*, Sidney *et al.*, *Human Immunol.* 45:79-93, 1996). To obtain overall phenotypic frequencies,
35 cumulative gene frequencies are calculated, and the cumulative antigen frequencies derived by the use of the inverse formula $[af=1-(1-Cgf)^2]$.

Where frequency data is not available at the level of DNA typing, correspondence to the serologically defined antigen frequencies is assumed. To obtain total potential supertype population coverage no linkage disequilibrium is assumed, and only alleles confirmed to belong to each of the superotypes are included (minimal estimates). Estimates of total potential coverage achieved by inter-loci combinations are made by adding to the A coverage the proportion of the non-A covered population that could be expected to be covered by the B alleles considered (e.g., $\text{total} = A + B \cdot (1 - A)$). Confirmed members of the A3-like supertype are A3, A11, A31, A*3301, and A*6801. Although the A3-like supertype may also include A34, A66, and A*7401, these alleles were not included in overall frequency calculations. Likewise, confirmed members of the A2-like supertype family are A*0201, A*0202, A*0203, A*0204, A*0205, A*0206, A*0207, A*6802, and A*6901. Finally, the B7-like supertype-confirmed alleles are: B7, B*3501-03, B51, B*5301, B*5401, B*5501-2, B*5601, B*6701, and B*7801 (potentially also B*1401, B*3504-06, B*4201, and B*5602).

Population coverage achieved by combining the A2-, A3- and B7-supertypes is approximately 86% in five major ethnic groups. Coverage may be extended by including peptides bearing the A1 and A24 motifs. On average, A1 is present in 12% and A24 in 29% of the population across five different major ethnic groups (Caucasian, North American Black, Chinese, Japanese, and Hispanic). Together, these alleles are represented with an average frequency of 39% in these same ethnic populations. The total coverage across the major ethnicities when A1 and A24 are combined with the coverage of the A2-, A3- and B7-supertype alleles is >95%. An analogous approach can be used to estimate population coverage achieved with combinations of class II motif-bearing epitopes.

Immunogenicity studies in humans (e.g., Bertoni *et al.*, *J. Clin. Invest.* 100:503, 1997; Doolan *et al.*, *Immunity* 7:97, 1997; and Threlkeld *et al.*, *J. Immunol.* 159:1648, 1997) have shown that highly cross-reactive binding peptides are almost always recognized as epitopes. The use of highly cross-reactive binding peptides is an important selection criterion in identifying candidate epitopes for inclusion in a vaccine that is immunogenic in a diverse population.

With a sufficient number of epitopes (as disclosed herein and from the art), an average population coverage is predicted to be greater than 95% in each of five major ethnic populations. The game theory Monte Carlo simulation analysis, which is known in the art (see e.g., Osborne, M.J. and Rubinstein, A. "A course in game theory" MIT Press, 1994), can be used to estimate what percentage of the individuals in a population comprised of the Caucasian, North American Black, Japanese, Chinese, and Hispanic ethnic groups would recognize the vaccine epitopes described herein. A preferred percentage is 90%. A more preferred percentage is 95%.

Recombinant NIH3T3 cells stably expressing 101P3A11 (3T3/101P3A11-pSRa) were derived and were grown in SCID mice (Figure 20). Mice were injected subcutaneously with 3T3/101P3A11-pSRa cells. Tumors were allowed to grow, mice were then sacrificed and tumors harvested. RNA was isolated from LAPC-4AD and LAPC-4AI xenografts, 3T3/neo-pSRa and 3T3/101P3A11-pSRa grown in culture, as well as six different tumors derived from 3T3/101P3A11-pSRa (Tumor #1-3). Northern blots with 10 μ g of total RNA/lane were probed with 101P3A11 sequence. Results show that 101P3A11 was expressed in all 3T3-101P3A11 tumors that grew following injection into mice.

Example 14: CTL Recognition Of Endogenously Processed Antigens After Priming

This example confirms that CTL induced by native or analoged peptide epitopes identified and selected as described herein recognize endogenously synthesized, *i.e.*, native antigens.

Effector cells isolated from transgenic mice that are immunized with peptide epitopes, for example HLA-A2 supermotif-bearing epitopes, are re-stimulated *in vitro* using peptide-coated stimulator cells. Six days later, effector cells are assayed for cytotoxicity and the cell lines that contain peptide-specific cytotoxic activity are further re-stimulated. An additional six days later, these cell lines are tested for cytotoxic activity on ⁵¹Cr labeled Jurkat-A2.1/K^b target cells in the absence or presence of peptide, and also tested on ⁵¹Cr labeled target cells bearing the endogenously synthesized antigen, *i.e.* cells that are stably transfected with 101P3A11 expression vectors.

The results demonstrate that CTL lines obtained from animals primed with peptide epitope recognize endogenously synthesized 101P3A11 antigen. The choice of transgenic mouse model to be used for such an analysis depends upon the epitope(s) that are being evaluated. In addition to HLA-A*0201/K^b transgenic mice, several other transgenic mouse models including mice with human A11, which may also be used to evaluate A3 epitopes, and B7 alleles have been characterized and others (*e.g.*, transgenic mice for HLA-A1 and A24) are being developed. HLA-DR1 and HLA-DR3 mouse models have also been developed, which may be used to evaluate HTL epitopes.

Example 15: Activity Of CTL-HTL Conjugated Epitopes In Transgenic Mice

This example illustrates the induction of CTLs and HTLs in transgenic mice, by use of a 101P3A11-derived CTL and HTL peptide vaccine compositions. The vaccine composition used herein comprise peptides to be administered to a patient with a 101P3A11-expressing tumor. The peptide composition can comprise multiple CTL and/or HTL epitopes. The epitopes are identified using methodology as described herein. This example also illustrates that enhanced immunogenicity can be achieved by inclusion of one or more HTL epitopes in a CTL vaccine composition; such a peptide composition can comprise an HTL epitope conjugated to a CTL epitope. The CTL epitope can be one that binds to multiple HLA family members at an affinity of 500 nM or less, or analogs of that epitope. The peptides may be lipidated, if desired.

Immunization procedures: Immunization of transgenic mice is performed as described (Alexander *et al.*, *J. Immunol.* 159:4753-4761, 1997). For example, A2/K^b mice, which are transgenic for the human HLA A2.1 allele and are used to confirm the immunogenicity of HLA-A*0201 motif- or HLA-A2 supermotif-bearing epitopes, and are primed subcutaneously (base of the tail) with a 0.1 ml of peptide in Incomplete Freund's Adjuvant, or if the peptide composition is a lipidated CTL/HTL conjugate, in DMSO/saline, or if the peptide composition is a polypeptide, in PBS or Incomplete Freund's Adjuvant. Seven days after priming, splenocytes obtained from these animals are restimulated with syngenic irradiated LPS-activated lymphoblasts coated with peptide.

Cell lines: Target cells for peptide-specific cytotoxicity assays are Jurkat cells transfected with the HLA-A2.1/K^b chimeric gene (*e.g.*, Vitiello *et al.*, *J. Exp. Med.* 173:1007, 1991)

In vitro CTL activation: One week after priming, spleen cells (30x10⁶ cells/flask) are co-cultured at 37°C with syngeneic, irradiated (3000 rads), peptide coated lymphoblasts (10x10⁶ cells/flask) in 10 ml of culture medium/T25 flask. After six days, effector cells are harvested and assayed for cytotoxic activity.

Assay for cytotoxic activity: Target cells (1.0 to 1.5x10⁶) are incubated at 37°C in the presence of 200 µl of ⁵¹Cr. After 60 minutes, cells are washed three times and resuspended in R10 medium. Peptide is added where required at a concentration of 1 µg/ml. For the assay, 10⁴ ⁵¹Cr-labeled target cells are added to different concentrations of effector cells (final volume of 200 µl) in U-bottom 96-well plates. After a six hour incubation period at 37°C, a 0.1 ml

aliquot of supernatant is removed from each well and radioactivity is determined in a Micromedic automatic gamma counter. The percent specific lysis is determined by the formula: percent specific release = 100 x (experimental release - spontaneous release)/(maximum release - spontaneous release). To facilitate comparison between separate CTL assays run under the same conditions, % ^{51}Cr release data is expressed as lytic units/ 10^6 cells. One lytic unit is arbitrarily defined as the number of effector cells required to achieve 30% lysis of 10,000 target cells in a six hour ^{51}Cr release assay. To obtain specific lytic units/ 10^6 , the lytic units/ 10^6 obtained in the absence of peptide is subtracted from the lytic units/ 10^6 obtained in the presence of peptide. For example, if 30% ^{51}Cr release is obtained at the effector (E): target (T) ratio of 50:1 (i.e., 5×10^5 effector cells for 10,000 targets) in the absence of peptide and 5:1 (i.e., 5×10^4 effector cells for 10,000 targets) in the presence of peptide, the specific lytic units would be: $[(1/50,000) - (1/500,000)] \times 10^6 =$ 18 LU.

The results are analyzed to assess the magnitude of the CTL responses of animals injected with the immunogenic CTL/HTL conjugate vaccine preparation and are compared to the magnitude of the CTL response achieved using, for example, CTL epitopes as outlined above in the Example entitled "Confirmation of Immunogenicity". Analyses similar to this may be performed to confirm the immunogenicity of peptide conjugates containing multiple CTL epitopes and/or multiple HTL epitopes. In accordance with these procedures, it is found that a CTL response is induced, and concomitantly that an HTL response is induced upon administration of such compositions.

Example 16: Selection of CTL and HTL epitopes for inclusion in an 101P3A11-specific vaccine.

This example illustrates a procedure for selecting peptide epitopes for vaccine compositions of the invention. The peptides in the composition can be in the form of a nucleic acid sequence, either single or one or more sequences (i.e., minigene) that encodes peptide(s), or can be single and/or polyepitopic peptides.

The following principles are utilized when selecting a plurality of epitopes for inclusion in a vaccine composition. Each of the following principles is balanced in order to make the selection.

Epitopes are selected which, upon administration, mimic immune responses that are correlated with 101P3A11 clearance. The number of epitopes used depends on observations of patients who spontaneously clear 101P3A11. For example, if it has been observed that patients who spontaneously clear 101P3A11 generate an immune response to at least three (3) from 101P3A11 antigen, then three or four (3-4) epitopes should be included for HLA class I. A similar rationale is used to determine HLA class II epitopes.

Epitopes are often selected that have a binding affinity of an IC_{50} of 500 nM or less for an HLA class I molecule, or for class II, an IC_{50} of 1000 nM or less; or HLA Class I peptides with high binding scores from the BIMAS web site, at URL bimas.dcrt.nih.gov/.

In order to achieve broad coverage of the vaccine through out a diverse population, sufficient supermotif bearing peptides, or a sufficient array of allele-specific motif bearing peptides, are selected to give broad population coverage. In one embodiment, epitopes are selected to provide at least 80% population coverage. A Monte Carlo analysis, a statistical evaluation known in the art, can be employed to assess breadth, or redundancy, of population coverage.

When creating polyepitopic compositions, or a minigene that encodes same, it is typically desirable to generate the smallest peptide possible that encompasses the epitopes of interest. The principles employed are similar, if not the same, as those employed when selecting a peptide comprising nested epitopes. For example, a protein sequence for the vaccine composition is selected because it has maximal number of epitopes contained within the sequence, *i.e.*, it has a high concentration of epitopes. Epitopes may be nested or overlapping (*i.e.*, frame shifted relative to one another). For example, with overlapping epitopes, two 9-mer epitopes and one 10-mer epitope can be present in a 10 amino acid peptide. Each epitope can be exposed and bound by an HLA molecule upon administration of such a peptide. A multi-epitopic, peptide can be generated synthetically, recombinantly, or via cleavage from the native source. Alternatively, an analog can be made of this native sequence, whereby one or more of the epitopes comprise substitutions that alter the cross-reactivity and/or binding affinity properties of the polyepitopic peptide. Such a vaccine composition is administered for therapeutic or prophylactic purposes. This embodiment provides for the possibility that an as yet undiscovered aspect of immune system processing will apply to the native nested sequence and thereby facilitate the production of therapeutic or prophylactic immune response-inducing vaccine compositions. Additionally such an embodiment provides for the possibility of motif-bearing epitopes for an HLA makeup that is presently unknown. Furthermore, this embodiment (absent the creating of any analogs) directs the immune response to multiple peptide sequences that are actually present in 101P3A11, thus avoiding the need to evaluate any junctional epitopes. Lastly, the embodiment provides an economy of scale when producing nucleic acid vaccine compositions. Related to this embodiment, computer programs can be derived in accordance with principles in the art, which identify in a target sequence, the greatest number of epitopes per sequence length.

A vaccine composition comprised of selected peptides, when administered, is safe, efficacious, and elicits an immune response similar in magnitude to an immune response that controls or clears cells that bear or overexpress 101P3A11.

Example 17: Construction of "Minigene" Multi-Epitope DNA Plasmids

This example discusses the construction of a minigene expression plasmid. Minigene plasmids may, of course, contain various configurations of B cell, CTL and/or HTL epitopes or epitope analogs as described herein.

A minigene expression plasmid typically includes multiple CTL and HTL peptide epitopes. In the present example, HLA-A2, -A3, -B7 supermotif-bearing peptide epitopes and HLA-A1 and -A24 motif-bearing peptide epitopes are used in conjunction with DR supermotif-bearing epitopes and/or DR3 epitopes. HLA class I supermotif or motif-bearing peptide epitopes derived 101P3A11, are selected such that multiple supermotifs/motifs are represented to ensure broad population coverage. Similarly, HLA class II epitopes are selected from 101P3A11 to provide broad population coverage, *i.e.* both HLA DR-1-4-7 supermotif-bearing epitopes and HLA DR-3 motif-bearing epitopes are selected for inclusion in the minigene construct. The selected CTL and HTL epitopes are then incorporated into a minigene for expression in an expression vector.

Such a construct may additionally include sequences that direct the HTL epitopes to the endoplasmic reticulum. For example, the Ii protein may be fused to one or more HTL epitopes as described in the art, wherein the CLIP sequence of the Ii protein is removed and replaced with an HLA class II epitope sequence so that HLA class II epitope is directed to the endoplasmic reticulum, where the epitope binds to an HLA class II molecules.

This example illustrates the methods to be used for construction of a minigene-bearing expression plasmid. Other expression vectors that may be used for minigene compositions are available and known to those of skill in the art.

The minigene DNA plasmid of this example contains a consensus Kozak sequence and a consensus murine kappa Ig-light chain signal sequence followed by CTL and/or HTL epitopes selected in accordance with principles disclosed herein. The sequence encodes an open reading frame fused to the Myc and His antibody epitope tag coded for by the pcDNA 3.1 Myc-His vector.

Overlapping oligonucleotides that can, for example, average about 70 nucleotides in length with 15 nucleotide overlaps, are synthesized and HPLC-purified. The oligonucleotides encode the selected peptide epitopes as well as appropriate linker nucleotides, Kozak sequence, and signal sequence. The final multiepitope minigene is assembled by extending the overlapping oligonucleotides in three sets of reactions using PCR. A Perkin/Elmer 9600 PCR machine is used and a total of 30 cycles are performed using the following conditions: 95°C for 15 sec, annealing temperature (5° below the lowest calculated T_m of each primer pair) for 30 sec, and 72°C for 1 min.

For example, a minigene is prepared as follows. For a first PCR reaction, 5 µg of each of two oligonucleotides are annealed and extended: In an example using eight oligonucleotides, i.e., four pairs of primers, oligonucleotides 1+2, 3+4, 5+6, and 7+8 are combined in 100 µl reactions containing *Pfu* polymerase buffer (1x= 10 mM KCL, 10 mM (NH₄)₂SO₄, 20 mM Tris-chloride, pH 8.75, 2 mM MgSO₄, 0.1% Triton X-100, 100 µg/ml BSA), 0.25 mM each dNTP, and 2.5 U of *Pfu* polymerase. The full-length dimer products are gel-purified, and two reactions containing the product of 1+2 and 3+4, and the product of 5+6 and 7+8 are mixed, annealed, and extended for 10 cycles. Half of the two reactions are then mixed, and 5 cycles of annealing and extension carried out before flanking primers are added to amplify the full length product. The full-length product is gel-purified and cloned into pCR-blunt (Invitrogen) and individual clones are screened by sequencing.

Example 18: The Plasmid Construct and the Degree to Which It Induces Immunogenicity.

The degree to which a plasmid construct, for example a plasmid constructed in accordance with the previous Example, is able to induce immunogenicity is confirmed *in vitro* by determining epitope presentation by APC following transduction or transfection of the APC with an epitope-expressing nucleic acid construct. Such a study determines “antigenicity” and allows the use of human APC. The assay determines the ability of the epitope to be presented by the APC in a context that is recognized by a T cell by quantifying the density of epitope-HLA class I complexes on the cell surface. Quantitation can be performed by directly measuring the amount of peptide eluted from the APC (*see, e.g.,* Sijts *et al., J. Immunol.* 156:683-692, 1996; Demotz *et al., Nature* 342:682-684, 1989); or the number of peptide-HLA class I complexes can be estimated by measuring the amount of lysis or lymphokine release induced by diseased or transfected target cells, and then determining the concentration of peptide necessary to obtain equivalent levels of lysis or lymphokine release (*see, e.g.,* Kageyama *et al., J. Immunol.* 154:567-576, 1995).

Alternatively, immunogenicity is confirmed through *in vivo* injections into mice and subsequent *in vitro* assessment of CTL and HTL activity, which are analyzed using cytotoxicity and proliferation assays, respectively, as detailed *e.g.,* in Alexander *et al., Immunity* 1:751-761, 1994.

For example, to confirm the capacity of a DNA minigene construct containing at least one HLA-A2 supermotif peptide to induce CTLs *in vivo*, HLA-A2.1/K^b transgenic mice, for example, are immunized intramuscularly with 100 µg of naked cDNA. As a means of comparing the level of CTLs induced by cDNA immunization, a control group of animals is also immunized with an actual peptide composition that comprises multiple epitopes synthesized as a single polypeptide as they would be encoded by the minigene.

Splenocytes from immunized animals are stimulated twice with each of the respective compositions (peptide epitopes encoded in the minigene or the polyepitopic peptide), then assayed for peptide-specific cytotoxic activity in a ⁵¹Cr release assay. The results indicate the magnitude of the CTL response directed against the A2-restricted epitope, thus indicating the *in vivo* immunogenicity of the minigene vaccine and polyepitopic vaccine.

It is, therefore, found that the minigene elicits immune responses directed toward the HLA-A2 supermotif peptide epitopes as does the polyepitopic peptide vaccine. A similar analysis is also performed using other HLA-A3 and HLA-B7 transgenic mouse models to assess CTL induction by HLA-A3 and HLA-B7 motif or supermotif epitopes, whereby it is also found that the minigene elicits appropriate immune responses directed toward the provided epitopes.

To confirm the capacity of a class II epitope-encoding minigene to induce HTLs *in vivo*, DR transgenic mice, or for those epitopes that cross react with the appropriate mouse MHC molecule, I-A^b-restricted mice, for example, are immunized intramuscularly with 100 µg of plasmid DNA. As a means of comparing the level of HTLs induced by DNA immunization, a group of control animals is also immunized with an actual peptide composition emulsified in complete Freund's adjuvant. CD4+ T cells, *i.e.* HTLs, are purified from splenocytes of immunized animals and stimulated with each of the respective compositions (peptides encoded in the minigene). The HTL response is measured using a ³H-thymidine incorporation proliferation assay, (*see, e.g.*, Alexander et al. *Immunity* 1:751-761, 1994). The results indicate the magnitude of the HTL response, thus demonstrating the *in vivo* immunogenicity of the minigene.

DNA minigenes, constructed as described in the previous Example, can also be confirmed as a vaccine in combination with a boosting agent using a prime boost protocol. The boosting agent can consist of recombinant protein (*e.g.*, Barnett et al., *Aids Res. and Human Retroviruses* 14, Supplement 3:S299-S309, 1998) or recombinant vaccinia, for example, expressing a minigene or DNA encoding the complete protein of interest (*see, e.g.*, Hanke et al., *Vaccine* 16:439-445, 1998; Sedegah et al., *Proc. Natl. Acad. Sci USA* 95:7648-53, 1998; Hanke and McMichael, *Immunol. Letters* 66:177-181, 1999; and Robinson et al., *Nature Med.* 5:526-34, 1999).

For example, the efficacy of the DNA minigene used in a prime boost protocol is initially evaluated in transgenic mice. In this example, A2.1/K^b transgenic mice are immunized IM with 100 µg of a DNA minigene encoding the immunogenic peptides including at least one HLA-A2 supermotif-bearing peptide. After an incubation period (ranging from 3-9 weeks), the mice are boosted IP with 10⁷ pfu/mouse of a recombinant vaccinia virus expressing the same sequence encoded by the DNA minigene. Control mice are immunized with 100 µg of DNA or recombinant vaccinia without the minigene sequence, or with DNA encoding the minigene, but without the vaccinia boost. After an additional incubation period of two weeks, splenocytes from the mice are immediately assayed for peptide-specific activity in an ELISPOT assay. Additionally, splenocytes are stimulated *in vitro* with the A2-restricted peptide epitopes encoded in the minigene and recombinant vaccinia, then assayed for peptide-specific activity in an alpha, beta and/or gamma IFN ELISA.

It is found that the minigene utilized in a prime-boost protocol elicits greater immune responses toward the HLA-A2 supermotif peptides than with DNA alone. Such an analysis can also be performed using HLA-A11 or HLA-B7 transgenic mouse models to assess CTL induction by HLA-A3 or HLA-B7 motif or supermotif epitopes. The use of prime boost protocols in humans is described below in the Example entitled "Induction of CTL Responses Using a Prime Boost Protocol ."

Example 19: Peptide Composition for Prophylactic Uses

Vaccine compositions of the present invention can be used to prevent 101P3A11 expression in persons who are at risk for tumors that bear this antigen. For example, a polypeptopic peptide epitope composition (or a nucleic acid comprising the same) containing multiple CTL and HTL epitopes such as those selected in the above Examples, which are also selected to target greater than 80% of the population, is administered to individuals at risk for a 101P3A11-associated tumor.

For example, a peptide-based composition is provided as a single polypeptide that encompasses multiple epitopes. The vaccine is typically administered in a physiological solution that comprises an adjuvant, such as Incomplete Freund's Adjuvant. The dose of peptide for the initial immunization is from about 1 to about 50,000 µg, generally 100-5,000 µg, for a 70 kg patient. The initial administration of vaccine is followed by booster dosages at 4 weeks followed by evaluation of the magnitude of the immune response in the patient, by techniques that determine the presence of epitope-specific CTL populations in a PBMC sample. Additional booster doses are administered as required. The composition is found to be both safe and efficacious as a prophylaxis against 101P3A11-associated disease.

Alternatively, a composition typically comprising transfecting agents is used for the administration of a nucleic acid-based vaccine in accordance with methodologies known in the art and disclosed herein.

Example 20: Polypeptopic Vaccine Compositions Derived from Native 101P3A11 Sequences

A native 101P3A11 polyprotein sequence is analyzed, preferably using computer algorithms defined for each class I and/or class II supermotif or motif, to identify "relatively short" regions of the polyprotein that comprise multiple epitopes. The "relatively short" regions are preferably less in length than an entire native antigen. This relatively short sequence that contains multiple distinct or overlapping, "nested" epitopes is selected; it can be used to generate a minigene construct. The construct is engineered to express the peptide, which corresponds to the native protein sequence. The "relatively short" peptide is generally less than 250 amino acids in length, often less than 100 amino acids in length, preferably less than 75 amino acids in length, and more preferably less than 50 amino acids in length. The protein sequence of the vaccine composition is selected because it has maximal number of epitopes contained within the sequence, *i.e.*, it has a high concentration of epitopes. As noted herein, epitope motifs may be nested or overlapping (*i.e.*, frame shifted relative to one another). For example, with overlapping epitopes, two 9-mer epitopes and one 10-mer epitope can be present in a 10 amino acid peptide. Such a vaccine composition is administered for therapeutic or prophylactic purposes.

The vaccine composition will include, for example, multiple CTL epitopes from 101P3A11 antigen and at least one HTL epitope. This polypeptopic native sequence is administered either as a peptide or as a nucleic acid sequence

which encodes the peptide. Alternatively, an analog can be made of this native sequence, whereby one or more of the epitopes comprise substitutions that alter the cross-reactivity and/or binding affinity properties of the polyepitopic peptide.

The embodiment of this example provides for the possibility that an as yet undiscovered aspect of immune system processing will apply to the native nested sequence and thereby facilitate the production of therapeutic or prophylactic immune response-inducing vaccine compositions. Additionally such an embodiment provides for the possibility of motif-bearing epitopes for an HLA makeup that is presently unknown. Furthermore, this embodiment (excluding an analoged embodiment) directs the immune response to multiple peptide sequences that are actually present in native 101P3A11, thus avoiding the need to evaluate any junctional epitopes. Lastly, the embodiment provides an economy of scale when producing peptide or nucleic acid vaccine compositions.

Related to this embodiment, computer programs are available in the art which can be used to identify in a target sequence, the greatest number of epitopes per sequence length.

Example 21: Polyepitopic Vaccine Compositions From Multiple Antigens

The 101P3A11 peptide epitopes of the present invention are used in conjunction with epitopes from other target tumor-associated antigens, to create a vaccine composition that is useful for the prevention or treatment of cancer that expresses 101P3A11 and such other antigens. For example, a vaccine composition can be provided as a single polypeptide that incorporates multiple epitopes from 101P3A11 as well as tumor-associated antigens that are often expressed with a target cancer associated with 101P3A11 expression, or can be administered as a composition comprising a cocktail of one or more discrete epitopes. Alternatively, the vaccine can be administered as a minigene construct or as dendritic cells which have been loaded with the peptide epitopes *in vitro*.

Example 22: Use of peptides to evaluate an immune response

Peptides of the invention may be used to analyze an immune response for the presence of specific antibodies, CTL or HTL directed to 101P3A11. Such an analysis can be performed in a manner described by Ogg *et al.*, *Science* 279:2103-2106, 1998. In this Example, peptides in accordance with the invention are used as a reagent for diagnostic or prognostic purposes, not as an immunogen.

In this example highly sensitive human leukocyte antigen tetrameric complexes ("tetramers") are used for a cross-sectional analysis of, for example, 101P3A11 HLA-A*0201-specific CTL frequencies from HLA A*0201-positive individuals at different stages of disease or following immunization comprising an 101P3A11 peptide containing an A*0201 motif. Tetrameric complexes are synthesized as described (Musey *et al.*, *N. Engl. J. Med.* 337:1267, 1997). Briefly, purified HLA heavy chain (A*0201 in this example) and β 2-microglobulin are synthesized by means of a prokaryotic expression system. The heavy chain is modified by deletion of the transmembrane-cytosolic tail and COOH-terminal addition of a sequence containing a BirA enzymatic biotinylation site. The heavy chain, β 2-microglobulin, and peptide are refolded by dilution. The 45-kD refolded product is isolated by fast protein liquid chromatography and then biotinylated by BirA in the presence of biotin (Sigma, St. Louis, Missouri), adenosine 5' triphosphate and magnesium. Streptavidin-phycoerythrin conjugate is added in a 1:4 molar ratio, and the tetrameric product is concentrated to 1 mg/ml. The resulting product is referred to as tetramer-phycoerythrin.

For the analysis of patient blood samples, approximately one million PBMCs are centrifuged at 300g for 5 minutes and resuspended in 50 μ l of cold phosphate-buffered saline. Tri-color analysis is performed with the tetramer-phycoerythrin, along with anti-CD8-Tricolor, and anti-CD38. The PBMCs are incubated with tetramer and antibodies on ice for 30 to 60 min and then washed twice before formaldehyde fixation. Gates are applied to contain >99.98% of control samples. Controls for the tetramers include both A*0201-negative individuals and A*0201-positive non-diseased donors. The percentage of cells stained with the tetramer is then determined by flow cytometry. The results indicate the number of cells in the PBMC sample that contain epitope-restricted CTLs, thereby readily indicating the extent of immune response to the 101P3A11 epitope, and thus the status of exposure to 101P3A11, or exposure to a vaccine that elicits a protective or therapeutic response.

Example 23: Use of Peptide Epitopes to Evaluate Recall Responses

The peptide epitopes of the invention are used as reagents to evaluate T cell responses, such as acute or recall responses, in patients. Such an analysis may be performed on patients who have recovered from 101P3A11-associated disease or who have been vaccinated with an 101P3A11 vaccine.

For example, the class I restricted CTL response of persons who have been vaccinated may be analyzed. The vaccine may be any 101P3A11 vaccine. PBMC are collected from vaccinated individuals and HLA typed. Appropriate peptide epitopes of the invention that, optimally, bear supermotifs to provide cross-reactivity with multiple HLA supertype family members, are then used for analysis of samples derived from individuals who bear that HLA type.

PBMC from vaccinated individuals are separated on Ficoll-Histopaque density gradients (Sigma Chemical Co., St. Louis, MO), washed three times in HBSS (GIBCO Laboratories), resuspended in RPMI-1640 (GIBCO Laboratories) supplemented with L-glutamine (2mM), penicillin (50U/ml), streptomycin (50 μ g/ml), and Hepes (10mM) containing 10% heat-inactivated human AB serum (complete RPMI) and plated using microculture formats. A synthetic peptide comprising an epitope of the invention is added at 10 μ g/ml to each well and HBV core 128-140 epitope is added at 1 μ g/ml to each well as a source of T cell help during the first week of stimulation.

In the microculture format, 4×10^5 PBMC are stimulated with peptide in 8 replicate cultures in 96-well round bottom plate in 100 μ l/well of complete RPMI. On days 3 and 10, 100 μ l of complete RPMI and 20 U/ml final concentration of rIL-2 are added to each well. On day 7 the cultures are transferred into a 96-well flat-bottom plate and restimulated with peptide, rIL-2 and 10^5 irradiated (3,000 rad) autologous feeder cells. The cultures are tested for cytotoxic activity on day 14. A positive CTL response requires two or more of the eight replicate cultures to display greater than 10% specific ^{51}Cr release, based on comparison with non-diseased control subjects as previously described (Rehermann, *et al.*, *Nature Med.* 2:1104,1108, 1996; Rehermann *et al.*, *J. Clin. Invest.* 97:1655-1665, 1996; and Rehermann *et al.* *J. Clin. Invest.* 98:1432-1440, 1996).

Target cell lines are autologous and allogeneic EBV-transformed B-LCL that are either purchased from the American Society for Histocompatibility and Immunogenetics (ASHI, Boston, MA) or established from the pool of patients as described (Guilhot, *et al.* *J. Virol.* 66:2670-2678, 1992).

Cytotoxicity assays are performed in the following manner. Target cells consist of either allogeneic HLA-matched or autologous EBV-transformed B lymphoblastoid cell line that are incubated overnight with the synthetic

peptide epitope of the invention at 10 μ M, and labeled with 100 μ Ci of ^{51}Cr (Amersham Corp., Arlington Heights, IL) for 1 hour after which they are washed four times with HBSS.

Cytolytic activity is determined in a standard 4-h, split well ^{51}Cr release assay using U-bottomed 96 well plates containing 3,000 targets/well. Stimulated PBMC are tested at effector/target (E/T) ratios of 20-50:1 on day 14. Percent cytotoxicity is determined from the formula: $100 \times [(\text{experimental release} - \text{spontaneous release}) / (\text{maximum release} - \text{spontaneous release})]$. Maximum release is determined by lysis of targets by detergent (2% Triton X-100; Sigma Chemical Co., St. Louis, MO). Spontaneous release is <25% of maximum release for all experiments.

The results of such an analysis indicate the extent to which HLA-restricted CTL populations have been stimulated by previous exposure to 101P3A11 or an 101P3A11 vaccine.

Similarly, Class II restricted HTL responses may also be analyzed. Purified PBMC are cultured in a 96-well flat bottom plate at a density of 1.5×10^5 cells/well and are stimulated with 10 $\mu\text{g/ml}$ synthetic peptide of the invention, whole 101P3A11 antigen, or PHA. Cells are routinely plated in replicates of 4-6 wells for each condition. After seven days of culture, the medium is removed and replaced with fresh medium containing 10U/ml IL-2. Two days later, 1 μCi ^3H -thymidine is added to each well and incubation is continued for an additional 18 hours. Cellular DNA is then harvested on glass fiber mats and analyzed for ^3H -thymidine incorporation. Antigen-specific T cell proliferation is calculated as the ratio of ^3H -thymidine incorporation in the presence of antigen divided by the ^3H -thymidine incorporation in the absence of antigen.

Example 24: Induction Of Specific CTL Response In Humans

A human clinical trial for an immunogenic composition comprising CTL and HTL epitopes of the invention is set up as an IND Phase I, dose escalation study and carried out as a randomized, double-blind, placebo-controlled trial. Such a trial is designed, for example, as follows:

A total of about 27 individuals are enrolled and divided into 3 groups:

Group I: 3 subjects are injected with placebo and 6 subjects are injected with 5 μg of peptide composition;

Group II: 3 subjects are injected with placebo and 6 subjects are injected with 50 μg peptide composition;

Group III: 3 subjects are injected with placebo and 6 subjects are injected with 500 μg of peptide composition.

After 4 weeks following the first injection, all subjects receive a booster inoculation at the same dosage.

The endpoints measured in this study relate to the safety and tolerability of the peptide composition as well as its immunogenicity. Cellular immune responses to the peptide composition are an index of the intrinsic activity of this the peptide composition, and can therefore be viewed as a measure of biological efficacy. The following summarize the clinical and laboratory data that relate to safety and efficacy endpoints.

Safety: The incidence of adverse events is monitored in the placebo and drug treatment group and assessed in terms of degree and reversibility.

Evaluation of Vaccine Efficacy: For evaluation of vaccine efficacy, subjects are bled before and after injection. Peripheral blood mononuclear cells are isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation, aliquoted in freezing media and stored frozen. Samples are assayed for CTL and HTL activity.

The vaccine is found to be both safe and efficacious.

Example 25: Phase II Trials In Patients Expressing 101P3A11

Phase II trials are performed to study the effect of administering the CTL-HTL peptide compositions to patients having cancer that expresses 101P3A11. The main objectives of the trial are to determine an effective dose and regimen for inducing CTLs in cancer patients that express 101P3A11, to establish the safety of inducing a CTL and HTL response in these patients, and to see to what extent activation of CTLs improves the clinical picture of these patients, as manifested, e.g., by the reduction and/or shrinking of lesions. Such a study is designed, for example, as follows:

The studies are performed in multiple centers. The trial design is an open-label, uncontrolled, dose escalation protocol wherein the peptide composition is administered as a single dose followed six weeks later by a single booster shot of the same dose. The dosages are 50, 500 and 5,000 micrograms per injection. Drug-associated adverse effects (severity and reversibility) are recorded.

There are three patient groupings. The first group is injected with 50 micrograms of the peptide composition and the second and third groups with 500 and 5,000 micrograms of peptide composition, respectively. The patients within each group range in age from 21-65 and represent diverse ethnic backgrounds. All of them have a tumor that expresses 101P3A11.

Clinical manifestations or antigen-specific T-cell responses are monitored to assess the effects of administering the peptide compositions. The vaccine composition is found to be both safe and efficacious in the treatment of 101P3A11-associated disease.

Example 26: Induction of CTL Responses Using a Prime Boost Protocol

A prime boost protocol similar in its underlying principle to that used to confirm the efficacy of a DNA vaccine in transgenic mice, such as described above in the Example entitled "The Plasmid Construct and the Degree to Which It Induces Immunogenicity," can also be used for the administration of the vaccine to humans. Such a vaccine regimen can include an initial administration of, for example, naked DNA followed by a boost using recombinant virus encoding the vaccine, or recombinant protein/polypeptide or a peptide mixture administered in an adjuvant.

For example, the initial immunization may be performed using an expression vector, such as that constructed in the Example entitled "Construction of 'Minigene' Multi-Epitope DNA Plasmids" in the form of naked nucleic acid administered IM (or SC or ID) in the amounts of 0.5-5 mg at multiple sites. The nucleic acid (0.1 to 1000 µg) can also be administered using a gene gun. Following an incubation period of 3-4 weeks, a booster dose is then administered. The booster can be recombinant fowlpox virus administered at a dose of $5 \cdot 10^7$ to $5 \cdot 10^9$ pfu. An alternative recombinant virus, such as an MVA, canarypox, adenovirus, or adeno-associated virus, can also be used for the booster, or the polyepitopic protein or a mixture of the peptides can be administered. For evaluation of vaccine efficacy, patient blood samples are obtained before immunization as well as at intervals following administration of the initial vaccine and booster doses of the vaccine. Peripheral blood mononuclear cells are isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation, aliquoted in freezing media and stored frozen. Samples are assayed for CTL and HTL activity.

Analysis of the results indicates that a magnitude of response sufficient to achieve a therapeutic or protective immunity against 101P3A11 is generated.

Example 27: Administration of Vaccine Compositions Using Dendritic Cells (DC)

Vaccines comprising peptide epitopes of the invention can be administered using APCs, or "professional" APCs such as DC. In this example, peptide-pulsed DC are administered to a patient to stimulate a CTL response *in vivo*. In this method, dendritic cells are isolated, expanded, and pulsed with a vaccine comprising peptide CTL and HTL epitopes of the invention. The dendritic cells are infused back into the patient to elicit CTL and HTL responses *in vivo*. The induced CTL and HTL then destroy or facilitate destruction, respectively, of the target cells that bear the 101P3A11 protein from which the epitopes in the vaccine are derived.

For example, a cocktail of epitope-comprising peptides is administered *ex vivo* to PBMC, or isolated DC therefrom. A pharmaceutical to facilitate harvesting of DC can be used, such as Progenipoietin™ (Monsanto, St. Louis, MO) or GM-CSF/IL-4. After pulsing the DC with peptides, and prior to reinfusion into patients, the DC are washed to remove unbound peptides.

As appreciated clinically, and readily determined by one of skill based on clinical outcomes, the number of DC reinfused into the patient can vary (see, e.g., *Nature Med.* 4:328, 1998; *Nature Med.* 2:52, 1996 and *Prostate* 32:272, 1997). Although $2\text{--}50 \times 10^6$ DC per patient are typically administered, larger number of DC, such as 10^7 or 10^8 can also be provided. Such cell populations typically contain between 50-90% DC.

In some embodiments, peptide-loaded PBMC are injected into patients without purification of the DC. For example, PBMC generated after treatment with an agent such as Progenipoietin™ are injected into patients without purification of the DC. The total number of PBMC that are administered often ranges from 10^8 to 10^{10} . Generally, the cell doses injected into patients is based on the percentage of DC in the blood of each patient, as determined, for example, by immunofluorescence analysis with specific anti-DC antibodies. Thus, for example, if Progenipoietin™ mobilizes 2% DC in the peripheral blood of a given patient, and that patient is to receive 5×10^6 DC, then the patient will be injected with a total of 2.5×10^8 peptide-loaded PBMC. The percent DC mobilized by an agent such as Progenipoietin™ is typically estimated to be between 2-10%, but can vary as appreciated by one of skill in the art.

Ex vivo activation of CTL/HTL responses

Alternatively, *ex vivo* CTL or HTL responses to 101P3A11 antigens can be induced by incubating, in tissue culture, the patient's, or genetically compatible, CTL or HTL precursor cells together with a source of APC, such as DC, and immunogenic peptides. After an appropriate incubation time (typically about 7-28 days), in which the precursor cells are activated and expanded into effector cells, the cells are infused into the patient, where they will destroy (CTL) or facilitate destruction (HTL) of their specific target cells, *i.e.*, tumor cells.

Example 28: An Alternative Method of Identifying and Confirming Motif-Bearing Peptides

Another method of identifying and confirming motif-bearing peptides is to elute them from cells bearing defined MHC molecules. For example, EBV transformed B cell lines used for tissue typing have been extensively characterized to determine which HLA molecules they express. In certain cases these cells express only a single type of HLA molecule. These cells can be transfected with nucleic acids that express the antigen of interest, *e.g.* 101P3A11. Peptides produced by endogenous antigen processing of peptides produced as a result of transfection will then bind to HLA molecules within the cell and be transported and displayed on the cell's surface. Peptides are then eluted from the

HLA molecules by exposure to mild acid conditions and their amino acid sequence determined, *e.g.*, by mass spectral analysis (*e.g.*, Kubo *et al.*, *J. Immunol.* 152:3913, 1994). Because the majority of peptides that bind a particular HLA molecule are motif-bearing, this is an alternative modality for obtaining the motif-bearing peptides correlated with the particular HLA molecule expressed on the cell.

Alternatively, cell lines that do not express endogenous HLA molecules can be transfected with an expression construct encoding a single HLA allele. These cells can then be used as described, *i.e.*, they can then be transfected with nucleic acids that encode 101P3A11 to isolate peptides corresponding to 101P3A11 that have been presented on the cell surface. Peptides obtained from such an analysis will bear motif(s) that correspond to binding to the single HLA allele that is expressed in the cell.

As appreciated by one in the art, one can perform a similar analysis on a cell bearing more than one HLA allele and subsequently determine peptides specific for each HLA allele expressed. Moreover, one of skill would also recognize that means other than transfection, such as loading with a protein antigen, can be used to provide a source of antigen to the cell.

Example 29: Complementary Polynucleotides

Sequences complementary to the 101P3A11-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring 101P3A11. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using, *e.g.*, OLIGO 4.06 software (National Biosciences) and the coding sequence of 101P3A11. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the 101P3A11-encoding transcript.

Example 30: Purification of Naturally-occurring or Recombinant 101P3A11 Using 101P3A11 Specific Antibodies

Naturally occurring or recombinant 101P3A11 is substantially purified by immunoaffinity chromatography using antibodies specific for 101P3A11. An immunoaffinity column is constructed by covalently coupling anti-101P3A11 antibody to an activated chromatographic resin, such as CrBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing 101P3A11 are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of 101P3A11 (*e.g.*, high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/101P3A11 binding (*e.g.*, a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GCR.P is collected.

Example 31: Identification of Molecules Which Interact with 101P3A11

101P3A11, or biologically active fragments thereof, are labeled with 125 I Bolton-Hunter reagent. (See, *e.g.*, Bolton *et al.* (1973) *Biochem. J.* 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled 101P3A11, washed, and any wells with labeled 101P3A11 complex are assayed. Data

obtained using different concentrations of 101P3A11 are used to calculate values for the number, affinity, and association of 101P3A11 with the candidate molecules.

Example 32: *In Vivo* Assay for 101P3A11 Tumor Growth Promotion

5 The effect of the 101P3A11 protein on tumor cell growth can be confirmed *in vivo* by gene overexpression in a variety of cancer cells, including prostate, kidney, colon and bladder. For example, SCID mice can be injected SQ on each flank with 1×10^6 prostate, kidney, colon or bladder cancer cells (such as PC3, LNCaP, SCaBER, UM-UC-3, HT1376, SK-CO, Caco, RT4, T24, Caki, A-498 and SW839 cells) containing tkNeo empty vector or 101P3A11.

At least two strategies can be used:

10 (1) Constitutive 101P3A11 expression under regulation of a promoter such as a constitutive promoter obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), or from heterologous mammalian promoters, *e.g.*, the actin promoter or an immunoglobulin promoter, provided such promoters are compatible with the host cell systems.

15 (2) Regulated expression under control of an inducible vector system, such as ecdysone, tet, etc., can be used provided such promoters are compatible with the host cell systems. Tumor volume is then monitored at the appearance of palpable tumors and is followed over time to validate that 101P3A11-expressing cells grow at a faster rate and that tumors produced by 101P3A11-expressing cells demonstrate characteristics of altered aggressiveness (*e.g.*, enhanced metastasis, vascularization, reduced responsiveness to chemotherapeutic drugs). Figure 21 compares subcutaneous
20 growth of control 3T3-neo and 3T3-101P3A11 cells. One million cells stably expressing neo or 101P3A11 were injected subcutaneously in SCID mice along with matrigel. Tumor volume was evaluated by caliper measurements. This experiment demonstrates that expression of 101P3A11 in NIH 3T3 cells induces tumor formation in 6/6 mice. Figure 42 shows demonstrates that 101P3A11 induces orthotopic growth of tumors. The results indicated that expression of 101P3A11 is sufficient to induce tumor formation *in vivo*. Additionally, were implanted with the same
25 cells orthotopically in the prostate to determine if 101P3A11 has an effect on local growth in the prostate or on the ability of the cells to metastasize, specifically to lungs or lymph nodes. In an analogous manner, cells can be implanted orthotopically in , bladder, colon or kidney. (Saffran, D., *et al.*, PNAS 10:1073-1078; Fu, X., *et al.*, Int. J. Cancer, 1991. 49: p. 938-939; Chang, S., *et al.*, Anticancer Res., 1997. 17: p. 3239-3242; Peralta, E. A., *et al.*, J. Urol., 1999. 162: p. 1806-1811).

30 Furthermore, this assay is useful to confirm the 101P3A11 inhibitory effect of candidate therapeutic compositions, such as for example, 101P3A11 antibodies or intrabodies, and 101P3A11 antisense molecules or ribozymes, or 101P3A11 directed small molecules. In Figure 22, we depict the effect of a small molecule, pertussis toxin (PTX) on tumor formation by 3T3-101P3A11 cells. In this experiment, SCID mice were injected with 3T3-101P3A11 alone or in conjunction with PTX. Each mouse was given 5 doses of PTX at 3-4 days interval. Tumor
35 volume was evaluated by caliper measurements. Figure 22 shows that PTX inhibits tumor growth in a dose dependent manner. In addition to demonstrating that 101A3P11 plays an important role in tumor growth, Figures 21 and 22 identify a signaling pathway associated with 101P3A11 and indicate that 101P3A11 produced its effect on tumor growth by activating an adenylate cyclase dependent pathway.

Example 33: 101P3A11 Monoclonal Antibody-mediated Inhibition of Tumors *In Vivo*

The significant expression of 101P3A11 in cancer tissues, together with its restricted expression in normal tissues, makes 101P3A11 an excellent target for antibody therapy. In cases where the monoclonal antibody target is a cell surface protein, as is 101P3A11, antibodies have been shown to be efficacious at inhibiting tumor growth (See, e.g., Saffran, D., *et al.*, PNAS 10:1073-1078 or www.pnas.org/cgi/doi/10.1073/pnas.051624698). In cases where the target is not on the cell surface, such as PSA and PAP in prostate cancer, antibodies have also been shown to recognize and inhibit growth of cells expressing those proteins (Saffran, D.C., *et al.*, Cancer and Metastasis Reviews, 1999. 18: 437-449). As with any cellular protein with a restricted expression profile, 101P3A11 is a target for T cell-based immunotherapy.

Accordingly, the therapeutic efficacy of anti-101P3A11 mAbs in human colon, kidney, bladder and prostate cancer mouse models is modeled in 101P3A11-expressing kidney, colon, bladder or prostate cancer xenografts or cancer cell lines, such as those described in the Example entitled "*In Vivo* Assay for 101P3A11 Tumor Growth Promotion", that have been engineered to express 101P3A11.

Antibody efficacy on tumor growth and metastasis formation is confirmed, e.g., in a mouse orthotopic prostate, colon, bladder or kidney cancer xenograft model. The antibodies can be unconjugated, or can be conjugated to a therapeutic modality, as appreciated in the art. It is confirmed that anti-101P3A11 mAbs inhibit formation of 101P3A11-expressing kidney, colon, bladder and prostate tumors. Anti-101P3A11 mAbs also retard the growth of established orthotopic tumors and prolong survival of tumor-bearing mice. These results indicate the utility of anti-101P3A11 mAbs in the treatment of local and advanced stages of cancer. (See, e.g., Saffran, D., *et al.*, PNAS 10:1073-1078 or www.pnas.org/cgi/doi/10.1073/pnas.051624698)

Administration of anti-101P3A11 mAbs retard established orthotopic tumor growth and inhibit metastasis to distant sites, resulting in a significant prolongation in the survival of tumor-bearing mice. These studies indicate that 101P3A11 is an attractive target for immunotherapy and demonstrate the therapeutic potential of anti-101P3A11 mAbs for the treatment of local and metastatic kidney, colon, bladder and prostate cancer. Similar studies manifest that 101P3A11 is safe and effective when used in combination with other therapeutic modalities such as surgery, radiation therapy, hormone therapy or chemotherapy.

This example demonstrates that unconjugated 101P3A11 monoclonal antibodies effectively to inhibit the growth of human bladder tumors grown in SCID mice; accordingly a combination of such efficacious monoclonal antibodies is also effective.

Example 34: Induction Of Specific CTL Response In Humans

A human clinical trial for an immunogenic composition comprising CTL and HTL epitopes of the invention is set up as an IND Phase I, dose escalation study and carried out as a randomized, double-blind, placebo-controlled trial. Such a trial is designed, for example, as follows:

A total of about 27 individuals are enrolled and divided into 3 groups:

Group I: 3 subjects are injected with placebo and 6 subjects are injected with 5 µg of peptide composition;

Group II: 3 subjects are injected with placebo and 6 subjects are injected with 50 µg peptide composition;

Group III: 3 subjects are injected with placebo and 6 subjects are injected with 500 µg of peptide composition. After 4 weeks following the first injection, all subjects receive a booster inoculation at the same dosage.

The endpoints measured in this study relate to the safety and tolerability of the peptide composition as well as its immunogenicity. Cellular immune responses to the peptide composition are an index of the intrinsic activity of this the peptide composition, and can therefore be viewed as a measure of biological efficacy. The following summarize the clinical and laboratory data that relate to safety and efficacy endpoints.

Safety: The incidence of adverse events is monitored in the placebo and drug treatment group and assessed in terms of degree and reversibility.

Evaluation of Vaccine Efficacy: For evaluation of vaccine efficacy, subjects are bled before and after injection. Peripheral blood mononuclear cells are isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation, aliquoted in freezing media and stored frozen. Samples are assayed for CTL and HTL activity.

The vaccine is found to be both safe and efficacious.

Example 35: Splice Variants of 101P3A11

Splice variants are also called alternative transcripts. When a gene is transcribed from genomic DNA, the initial RNA is generally spliced to produce functional mRNA, which has only exons and is used for translation into an amino acid sequence. Accordingly, a given gene can have zero to many alternatively spliced mRNA products. Alternative transcripts each have a unique exon makeup, and can have different coding and/or non-coding (5' or 3' end) portions, from the original transcript. Alternative transcripts can code for similar proteins with the same or a similar function or may encode proteins with different functions, and may be expressed in the same tissue at the same time, or at different tissue at different times, proteins encoded by alternative transcripts can have similar or different cellular or extracellular localizations, e.g., be secreted.

Splice variants are identified by a variety of art-accepted methods. For example, splice variants are identified by use of EST data. First, all human ESTs were grouped into clusters which show direct or indirect identity with each other. Second, ESTs in the same cluster were further grouped into sub-clusters and assembled into a consensus sequence. The starting gene is compared to the consensus sequence(s). Each consensus sequence is a potential splice variant for that gene (see, e.g., http://www.doubletwin.com/products/c11_agentsOverview.jhtml). Even when a variant is identified that is not a full-length clone, that portion of the variant is very useful for antigen generation and for further cloning of the full-length splice variant, using techniques known in the art.

Moreover, computer programs are available in the art that identify splice variants based on genomic sequences. Genomic-based variant identification programs include FgenesH (A. Salamov and V. Solovyev, "Ab initio gene finding in Drosophila genomic DNA," Genome Research. 2000 April;10(4):516-22); Grail (<http://compbio.ornl.gov/Grail-bin/EmptyGrailForm>) and GenScan (<http://genes.mit.edu/GENSCAN.html>). For a general discussion of splice variant identification protocols see., e.g., Southan, C., "A genomic perspective on human proteases," FEBS Lett. 2001 Jun 8;498(2-3):214-8; de Souza, SJ, et al., "Identification of human chromosome 22 transcribed sequences with ORF expressed sequence tags," Proc. Natl Acad Sci U S A. 2000 Nov 7;97(23):12690-3.

For variants identified by the EST-based method, Table XXI shows the nucleotide sequences of the splice variants. Table XXII shows the alignment of the splice variant with the 101P3A11 nucleic acid sequence. Table XXIII

displays the single longest alignment of an amino acid sequence encoded by a splice variant, out of all six potential reading frames with 101P3A11. Thus, for each splice variant, a variant's reading frame that encodes the longest single contiguous peptide homology between 101P3A11 and the variant is the proper reading frame orientation for the variant. Due to the possibility of sequencing errors in EST or genomic data, other peptides in the relevant reading frame orientation (5' to 3' or 3' to 5') can also be encoded by the variant. Table XXIV lays out all three frame shifted amino acid translations of the splice variant for the identified reading frame orientation. Tables XXI through XXIV are set forth herein on a variant-by-variant basis.

For variants identified by any one of the genomic sequence-based methods, Table XXI shows the nucleotide sequences of the splice variant. Table XXII shows the alignment of the splice variant with the 101P3A11 nucleic acid sequence. Table XXIII displays the alignment of amino acid sequence of the predicted transcript(s) with 101P3A11. The genomic-based computer programs predict a transcript from genomic sequence, and not only predict exons but also set open reading frame as the first forward open reading frame. The predicted transcript does not contain 5' or 3' untranslated region (UTR). It starts with ATG and ends with a stop codon, TAG, TGA or TAA. In case the transcript is predicted on the reverse strand of the genomic sequence, the sequence of the transcript is reverse-complemented to the genomic sequence of the exons. Thus, the genomic-based programs provide the correct transcript sequence, with 5' to 3' orientation and +1 as the open reading frame. However, due to the possibility of inaccurate prediction of exons or the possibility of sequencing errors in genomic data, other peptides in other forward open reading frames can also be encoded by the variant. Table XXIV lays out all amino acid translations of the splice variant in each of the three forward reading frames. Tables XXI through XXIV are set forth herein on a variant-by-variant basis.

To further confirm the parameters of a splice variant, a variety of techniques available in the art are used, such as full-length cloning, proteomic validation, PCR-based validation, and 5' RACE validation, etc. (see e.g., Proteomic Validation: Brennan SO, Fellowes AP, George PM.; "Albumin banks peninsula: a new termination variant characterized by electrospray mass spectrometry." *Biochim Biophys Acta*. 1999 Aug 17;1433(1-2):321-6; Ferranti P, et al., "Differential splicing of pre-messenger RNA produces multiple forms of mature caprine alpha(s1)-casein." *Eur J Biochem*. 1997 Oct 1;249(1):1-7; PCR-based Validation: Wellmann S, et al., "Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology." *Clin Chem*. 2001 Apr;47(4):654-60; Jia HP, et al., Discovery of new human beta-defensins using a genomics-based approach," *Gene*. 2001 Jan 24;263(1-2):211-8; PCR-based and 5' RACE Validation: Brigle I.E., et al., "Organization of the murine reduced folate carrier gene and identification of variant splice forms," *Biochim Biophys Acta*. 1997 Aug 7; 1353(2): 191-8.

It is known in the art that genomic regions are modulated in cancers. When the genomic region to which 101P3A11 maps is modulated in a particular cancer, the splice variants of 101P3A11 are modulated as well. Disclosed herein is that 101P3A11 has a particular expression profile. Splice variants of 101P3A11 that are structurally and/or functionally similar to 101P3A11 share this expression pattern, thus serving as tumor-associated markers/antigens.

Using the EST assembly approach, we identified one splice variant.

Example 36: Splice Variant Protein Characteristics

The present variant protein set forth in Table XXI is understood to be partial, and thus to comprise domains of the full protein. Nucleotides 1-217 of variant align with nucleotides 66-290 of 101P3A11. Similarly, amino acids 3-155 of the 1-1P3A11 variant protein align with amino acids 70-222 of 101P3A11 with 100% identity, while the remaining downstream amino acids diverge from the 101P3A11. This pattern of high homology to one section of the parent protein coupled to a high divergence from the remaining portions of the parent protein form the hallmark of a splice variant.

Protein blast analysis of 101P3A11 variant shows that the 101P3A11 variant is homologous to the human olfactory receptor 52D1 (gi 14423837) with 35% identity over 68 amino acids located towards the amino terminal of 101P3A11 variant 1. 101P3A11 variant 1 shows homology to rat olfactory receptor RA1c (gi 3420759) with 53% identity over 32 amino acids. Analysis by pFam or Prosite did not identify any motifs.

Based on TMPred bioinformatic analysis the 101P3A11 variant appears to contain one transmembrane domain. In contrast, Sosui predicts no transmembrane domain but suggests that 101P3A11 variant 1 forms a soluble intracellular protein. Due to its homology to 101P3A11 and olfactory receptors, the 101P3A11 variant 1 is associated with cancer and signaling.

Example 37: Identification of 101P3A11 sequences involved in ligand binding.

As shown in Figure 4, the transmembrane regions of 101P3A11 and mouse olfactory receptor S25 (ORS25) predicted using the TMHMM algorithm are highlighted in gray. The amino acids of ORS25 predicted by Floriano, et al. to be involved in binding of the ligand hexanol and/or involved in the formation of the ligand binding pocket are italicized and bolded in Figure 4, and are listed below. (Floriano, W.B., et al, 2000, Proc. Natl. Acad. Sci., USA, 97:10712-10716)

Leu 131	Ala 230
Val 134	Ile 231
Val 135	Gly 234
Gly 138	Thr 284
Thr139	Phe 287
Ser 193	Gln 300
Ser 197,	Lys 302
Phe 225	

Sequences of 101P3A11 involved in ligand binding are identified based on homology to mouse olfactory receptor S25. Shown is the amino acid alignment of 101P3A11 with mouse olfactory receptor S25 depicting the predicted transmembrane domains of each GPCR. The amino acids of S25 involved in the recognition and binding of its ligand hexanol or that lie in the proximity of the binding pocket (Floriano, W.B., et al, 2000, Proc. Natl. Acad. Sci., USA, 97:10712-10716), are also shown. These amino acids lie close to or within the transmembrane domains of ORS25. Accordingly, the structurally homologous regions of 101P3A11 are involved in the binding of its cognate

ligand. These regions encode the amino acids of the first extracellular loop and of the amino terminal end of transmembrane domain 3 (amino acids 82-112), the amino acids at the carboxyl terminal end of transmembrane domain 4 and into the second extracellular loop (amino acids 160-185), the amino acids at the end of the second extracellular loop and into transmembrane domain 5 (amino acids 186-212), and the amino acids at the carboxyl terminal end of transmembrane domain 6, the third extracellular loop, and the amino terminal end of transmembrane domain 7 (amino acids 250-280). Thus, ligands of 101P3A11 are identified that interact with at least 3 of the following regions of 101P3A11: amino acids 82-112, amino acids 160-185, amino acids 186-212, and, amino acids 250-280.

Example 38: Homology Comparison of 101P3A11 to Known Sequences

The 101P3A11 protein of Figure 3 has 317 amino acids with calculated molecular weight of 35.2 kDa, and pI of 8.7. 101P3A11 is predicted to be a cell surface protein. Cellular localization was demonstrated by FACS analysis and immunofluorescence in cells engineered to express 101P3A11.

101P3A11 shows best homology to rat olfactory receptor RA1c (gi 3420759, <http://www.ncbi.nlm.nih.gov>) sharing 59% identity and 76% homology with that protein. 101P3A11 also shows homology to human prostate specific GPCR (gi 13540539) and human olfactory receptor 5II12 (gi 14423836), sharing 59% identities/ 77% homology, and 53% identities/ 69% homology with each, respectively (Figures 23-25).

Sequence and motif analysis indicate that 101P3A11 belongs to the family of olfactory receptors. Bioinformatic analysis revealed 101P3A11 to be a 7 transmembrane protein, with strong domain and structural homology to G-protein coupled receptors (GPCRs) (see Table XXV, TM Pred, Sosui, Pfam, Blocks, Print). Proteins that are members of the G-protein coupled receptor family exhibit an extracellular amino-terminus, three extracellular loops, three intracellular loops and an intracellular carboxyl terminus. G-protein coupled receptors are seven-transmembrane receptors that are stimulated by polypeptide hormones, neurotransmitters, chemokines and phospholipids (Civelli O et al, Trends Neurosci. 2001, 24:230; Vrecl M et al Mol Endocrinol. 1998, 12:1818). Ligand binding traditionally occurs between the first and second extracellular loops of the GPCR. Upon ligand binding GPCRs transduce signals across the cell surface membrane by associating with trimeric G proteins. Their signals are transmitted via trimeric guanine-nucleotide binding proteins (G proteins) to effector enzymes or ion channels (Simon et al., 1991, Science 252: 802). Signal transduction and biological output mediated by GPCR can be modulated through various mechanisms including peptide mimics, small molecule inhibitors and GPCR kinases or GRK (Pitcher JA et al, J Biol Chem. 1999, 3;274:34531; Fawzi AB, et al. 2001, Mol. Pharmacol., 59:30).

Recently, GPCRs have also been shown to link to mitogenic signaling pathways of tyrosine kinases (Luttrell et al., 1999, Science 283: 655; Luttrell et al., 1999 Curr Opin Cell Biol 11: 177). GPCRs are regulated by phosphorylation mediated by GPCR kinases (GRKs), which themselves are indirectly activated by the GPCRs (Pitcher et al., 1998, Ann. Rev. Biochem. 67: 653). Olfactory GPCRs transmit their signals by activating the cAMP pathway via adenylate cyclase resulting in downstream signaling to protein kinase A, and by activating the phospholipase C pathway by generating inositol 1,4,5-trisphosphate (IP3) and diacyl-glycerol (DAG) (Breer, 1993, Ciba Found Symp 179: 97; Bruch, 1996, Comp Biochem Physiol B Biochem Mol Biol 113:451). IP3 results in an increase in intracellular calcium, while DAG activates protein kinase C.

Recent studies have associated GPCRs with cellular transformation. In particular, KSHV G protein-coupled receptor was found to transform NIH 3T3 cells *in vitro* and induces multifocal KS-like lesions in KSHV-GPCR-
sd-63712

transgenic mice (Schwarz M, Murphy PM. J Immunol 2001, 167:505). KSHV-GPCR was capable of producing its effect on endothelial cells and fibroblasts by activating defined signaling pathways, including the AKT survival pathway (Montaner S et al, Cancer Res 2001, 61:2641). In addition, KSHV-GPCR induced the activation of mitogenic pathways such as AP-1 and NFkB, resulting in the expression of pro-inflammatory genes (Schwarz M, Murphy PM. J Immunol 2001, 167:505). Other GPCR associated with tumor formation include G2A, and the PAR-1, which has been found to induce transformation of NIH 3T3 cells (Whitehead I et al, Oncogene 2001, 20:1547).

This information indicates that 101P3A11 plays a role in the transformation of mammalian cells, induces mitogenic responses including activation of various signaling pathways, and regulate gene transcription by transmitting cell surface signals to the nucleus, see also, the Example entitled, "In Vivo Assay for 101P3A11 Tumor Growth Promotion".

Accordingly, when 101P3A11 functions as a regulator of cell transformation, tumor formation, or as a modulator of transcription involved in activating genes associated with inflammation, tumorigenesis or proliferation, 101P3A11 is used for therapeutic, diagnostic, prognostic and/or preventative purposes, in manners analogous to or that track other GPCRs as discussed herein and in the art..

Example 39: Identification and Confirmation of Potential Signal Transduction Pathways

Many mammalian proteins have been reported to interact with signaling molecules and to participate in regulating signaling pathways. (J Neurochem. 2001; 76:217-223). In particular, GPCRs have been reported to activate MAK cascades as well as G proteins, and been associated with the EGFR pathway in epithelial cells (Naor, Z., et al, Trends Endocrinol Metab. 2000, 11:91; Vacca F et al, Cancer Res. 2000, 60:5310; Della Rocca G.J., et al, J Biol Chem. 1999, 274:13978). Using immunoprecipitation and Western blotting techniques, proteins are identified that associate with 101P3A11 and mediate signaling events. Several pathways known to play a role in cancer biology can be regulated by 101P3A11, including phospholipid pathways such as PI3K, AKT, etc, adhesion and migration pathways, including FAK, Rho, Rac-1, etc, as well as mitogenic/survival cascades such as ERK, p38, etc (Cell Growth Differ. 2000,11:279; J Biol Chem. 1999, 274:801; Oncogene. 2000, 19:3003; J. Cell Biol. 1997, 138:913).

Using Western blotting and other techniques, the ability of 101P3A11 to regulate these pathways is confirmed. Cells expressing or lacking 101P3A11 are either left untreated or stimulated with cytokines, androgen and anti-integrin antibodies. Cell lysates were analyzed using anti-phospho-specific antibodies (Cell Signaling, Santa Cruz Biotechnology) in order to detect phosphorylation and regulation of ERK, p38, AKT, PI3K, PLC and other signaling molecules. Using such techniques, we showed that 101P3A11 alters the tyrosine phosphorylation pattern of NIH 3T3 cells (Figure 26) indicating that 101P3A11 is regulating protein kinases and phosphatases. In the experiment shown in Figure 26, control 3T3-neo and 3T3-101P3A11 cells were either treated with 0.5 or 10% FBS and whole cell lysates were analyzed by anti-phosphotyrosine Western blotting. Expression of 101P3A11 resulted in reduced phosphorylation of several proteins in NIH-3T3 cells, while inducing the phosphorylation of proteins at 79-81 and 28-32 kDa.

Using anti-Phospho-ERK antibodies, we demonstrated that expression of 101P3A11 induced ERK phosphorylation in the prostate cancer cell line PC3 (Figures 27A and Figure 27B), and that ERK phosphorylation in 101P3A11 expressing cells was regulated by GPCR ligands. In this experiment, control PC3-neo cells and PC3-101P3A11 cells were left untreated (0.1% FBS) or were stimulated with 10% FBS, lipophosphatidic acid (LPA), gastrin

releasing peptide (GRP), leukotriene (LKB4) or platelet activating factor (PAF). The cells were lysed and analyzed by Western blotting using anti-Phospho-ERK (Figure 27A) or anti-ERK (Figure 27B) mAb. The results showed that expression of 101P3A11 mediated significant ERK phosphorylation by FBS, LPA, GRP and PAF, while LKB4 resulted in a more modest level of ERK phosphorylation in PC3-101P3A11 cells. In contrast, none of the GPCR ligands induced significant ERK phosphorylation in PC3-Neo cells, demonstrating the specificity of GPCR ligands-mediated responses in 101P3A11 expressing cells. The ERK overlay demonstrated equal loading, supporting the specificity of this data. In order to delineate the signaling pathway by which 101P3A11 mediates ERK phosphorylation in cancer cells, it was confirmed which of the two pathway inhibitors: MEK inhibitor PD98059 or the p38 inhibitor SB203580 regulate 101P3A11 mediated ERK phosphorylation (Figure 28). To obtain this data, PC3-neo and PC3-101P3A11 cells were treated with media alone or in the presence of PD98059, SB203580, or genistein were stimulated with FBS or GRP. Cells were lysed and analyzed by Western blotting using anti-Phospho-ERK or anti-ERK mAb. Treatment with 10% FBS or with GRP induced the phosphorylation of ERK in PC3-101P3A11 but not in control PC3-neo cells. 101P3A11-mediated ERK phosphorylation was inhibited by the MEK-1 inhibitor PD98059 but not the p38 inhibitor SB203580 or genistein. The ERK overlay demonstrated equal loading, supporting the specificity of the results. These results were confirmed by those obtained in two additional sets of experiments. The inhibition of 101P3A11-mediated ERK phosphorylation by PD98059 demonstrates that 101P3A11 activated the classical MEK-ERK cascade, a pathway associated with mitogenesis, proliferation and tumorigenesis.

Results in Figures 26-28 indicate that 101P3A11 regulates the activity of kinases, including ERK, and phosphatases. In order to confirm the association of 101P3A11 with phosphatase activity, the effect of the protein phosphatase inhibitor sodium orthovanadate on 101P3A11 mediated ERK phosphorylation was determined (Figure 29). PC3-neo and PC3-101P3A11 cells were grown in media alone or in the presence of sodium orthovanadate (Na_3VO_4), and were stimulated with 0.1% or 10% FBS. Cells were lysed and analyzed by Western blotting using anti-Phospho-ERK or anti-ERK mAb. Treatment with Na_3VO_4 resulted in a 4.5-fold increase in ERK phosphorylation in PC3-101P3A11 cells, compared to a two-fold increase in PC3-neo cells. Results in Figure 29 confirm the contribution of protein phosphatases to 101P3A11 mediated signaling.

Several GPCRs have been shown to transactivate receptor tyrosine kinases associated with the cell membrane, such as the EGF receptor (EGFR) (Pierce K.L., et al, J Biol Chem. 2001, 276:23155; Nath, D., et al, J Cell Sci. 2001, 114:1213). In order to determine whether 101P3A11 signaling results in the activation of EGFR, we compared the effect of the EGFR inhibitor, AG1517, on EGFR- and 101P3A11-mediated ERK phosphorylation (Figure 30). In Figure 30, PC3-neo and PC3-101P3A11 cells were grown in media alone (0.1% FBS) or in the presence of AG1517. The cells were stimulated with 0.1% or 10% FBS, GRP or EGF, lysed and analyzed by Western blotting using anti-Phospho-ERK or anti-ERK mAb. Treatment with 10% FBS, GRP and EGF induced ERK phosphorylation in PC3-101P3A11 cells. ERK phosphorylation by EGF was completely inhibited by AG1517. 101P3A11 mediated ERK phosphorylation in cells treated with 10% FBS was partially inhibited by AG1517. Data in Figure 30 indicate that some cross talk occurred between 101P3A11 and EGFR signaling pathways.

In addition to activating the ERK cascade, 101P3A11 activated a parallel MAK pathway, namely p38. In Figure 31A and Figure 31B, PC3-neo and PC3-101P3A11 cells were grown in 1% or 10% FBS. Cells were lysed and analyzed by Western blotting using anti-Phospho-p38 (Figure 31A) or anti-p38 (Figure 31B) monoclonal antibody

(mAb). Our results demonstrate that expression of 101P3A11 mediated p38 phosphorylation in cells treated with 10% FBS. Equal loading was demonstrated in the p38 overlay.

Results shown in Figures 26-30 and Figure 31A-31B confirm that 101P3A11 activates several signaling pathways in cancer cells, including the ERK and p38 cascades. In addition to MAPK, 101P3A11 signaling was associated with protein phosphatase activity and EGFR transactivation. These signaling pathways have been associated with cell growth, survival and transcriptional activation, all of which play an important role in tumor initiation and progression. When 101P3A11 plays a role in the regulation of signaling pathways, whether individually or communally, it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.

To confirm that 101P3A11 directly or indirectly activates known signal transduction pathways in cells, luciferase (luc) based transcriptional reporter assays are carried out in cells expressing individual genes. These transcriptional reporters contain consensus-binding sites for known transcription factors that lie downstream of well-characterized signal transduction pathways. The reporters and examples of these associated transcription factors, signal transduction pathways, and activation stimuli are listed below.

1. NFkB-luc, NFkB/Rel; Ik-kinase/SAPK; growth/apoptosis/stress
2. SRE-luc, SRF/TCF/ELK1; MAPK/SAPK; growth/differentiation
3. AP-1-luc, FOS/JUN; MAPK/SAPK/PKC; growth/apoptosis/stress
4. ARE-luc, androgen receptor; steroids/MAPK; growth/differentiation/apoptosis
5. p53-luc, p53; SAPK; growth/differentiation/apoptosis
6. CRE-luc, CREB/ATF2; PKA/p38; growth/apoptosis/stress

Gene-mediated effects can be assayed in cells showing mRNA expression. Luciferase reporter plasmids can be introduced by lipid-mediated transfection (TFX-50, Promega). Luciferase activity, an indicator of relative transcriptional activity, is measured by incubation of cell extracts with luciferin substrate and luminescence of the reaction is monitored in a luminometer.

Signaling pathways activated by 101P3A11 are mapped and used for the identification and validation of therapeutic targets. When 101P3A11 is involved in cell signaling, it is used as target for diagnostic, prognostic, preventative and/or therapeutic purposes.

Example 40: 101P3A11 Functions as a GPCR

Sequence and homology analysis of 101P3A11 indicated that 101P3A11 is a member of the olfactory receptor family of GPCR. Olfactory receptors are known to regulate biological responses by activating adenylate cyclase. In order to confirm that 101P3A11 functions as a GPCR and mediates the activation of adenylate cyclase, cAMP accumulation in PC3 and PC3-101P3A11 cells were compared (Figure 32). Control PC3 and PC3-101P3A11 cells were grown in a low concentration of fetal bovine serum (FBS) for 14 hrs in the presence or absence of pertussis toxin (PTX). The cells were stimulated with 0.1% or 10% FBS, washed in PBS and lysed using a lysis buffer provided by Amersham Pharmacia. Intracellular concentration of cAMP was measured using a commercially available enzyme immunoassay (EIA) according to the manufacturer's recommendations (Amersham Pharmacia). Each assay was performed in duplicate.

Calculations of cAMP concentrations were based on OD450 of the standard curve. Expression of 101P3A11 induced a four-fold increase in cAMP accumulation in the absence of stimulation. Treatment with 10% FBS further enhanced cAMP accumulation in PC3-101P3A11 cells to nearly seven-fold over control PC3-neo cells. 101P3A11 mediated cAMP accumulation was inhibited by PTX. These results were confirmed by two separate sets of experiments. Results shown in Figure 32 demonstrate that 101P3A11 functions as a GPCR in prostate cancer cells and exhibits classical GPCR characteristics, such as cAMP accumulation that is inhibited by PTX.

Since adenylate cyclase activity modulates intracellular levels of cAMP and induce downstream signaling events such as activation of protein kinase A, calcium and ERK MAPK signaling (Pierce K.L., et al, *Oncogene*. 2001, 20:1532), we determined that PTX, an inhibitor of adenylate cyclase signaling, prevents 101P3A11-mediated ERK phosphorylation along with inhibiting cAMP accumulation (Figure 33 and Figure 34). PC3-neo and PC3-101P3A11 cells were grown overnight in 0.1% FBS in media alone or in the presence of pertussis toxin (PTX). Cells were stimulated with 0.1% or 10% FBS (Figure 33) or 10% FBS, EGF or GRP (Figure 34). Cells were lysed and analyzed by Western blotting using anti-Phospho-ERK mAb. Expression of 101P3A11 mediated ERK phosphorylation by 10% FBS in PC3 cells, which was inhibited by PTX (Figure 33 and Figure 34). In contrast, GRP and EGF-mediated ERK phosphorylation was relatively unaffected by PTX (Figure 34), demonstrating the specificity of 101P3A11 mediated responses. These results were replicated in additional experiments.

GPCR transmit their signal by activating trimeric G proteins. Once GPCRs are activated, the associated G α subunit binds GTP, dissociates from the receptor and participates in downstream signaling events (Schild, D., and Restrepo, D. *Physiol Rev*. 1998, 78:429-66). In order to determine that inhibition of G α subunits has an effect on 101P3A11 mediated cell growth, the effect of two G α inhibitors on the proliferation of 3T3-101P3A11 cells was investigated. Control 3T3 and 3T3-101P3A11 cells were grown in the presence or absence of suramin or its derivative NF 449 (Sigma). Cells were analyzed for proliferation 72 hours later (Figure 35). The experiment was performed in triplicate. The data showed that suramin and NF449 inhibited the proliferation of 3T3-101P3A11 cells by 60% and 80%, respectively. This response was 101P3A11 specific as suramin and NF449 had no effect on the proliferation of control 3T3 cells. Thus, as 101P3A11 is involved in GPCR activity, it is used as target for diagnostic, prognostic, preventative and/or therapeutic purposes.

GPCRs can be activated by a variety of ligands, including hormones, neuropeptides, chemokines, odorants and phospholipids. In the case of olfactory receptors, individual olfactory receptors may recognize multiple odorants, and can be activated by a diverse array of molecules. These ligands and molecules recognized by a receptor (as described above) are small molecules as described herein.

In order to identify 101P3A11 (small molecule) ligand(s), the possibility that epithelial cells may be secreting 101P3A11 activators was investigated (Figure 36A and 36B). Prostate cancer epithelial cells, (PC3, PC3-101P3A11, LAPC4^{hT}), normal prostate cells (PrEC), fibroblasts (3T3, 3T3-101P3A11), and human kidney epithelial cells (293T) were grown in the presence or absence of FBS. Cell supernatants were collected and used to stimulate PC3 and PC3-101P3A11 cells. Cell lysates from resting and supernatant treated PC3 and PC3-101P3A11 cells were lysed and analyzed by Western blotting with anti-Phospho-ERK (Figure 36A) and anti-ERK (Figure 36B) mAb. As shown in Figure 36A and Figure 36B, supernatants from normal prostate cells, PrEC, and prostate cancer cells, PC3, PC3-101P3A11 and LAPC4^{hT}, induced the phosphorylation of ERK in PC3-101P3A11 but not control PC3 cells. In

contrast, no specific ERK phosphorylation was observed using supernatants from 3T3 or 293T cells. Our results show that prostate cells, grown in the absence of serum, produce one or more factors that contribute to the activation of 101P3A11 mediated signaling events. Thus, as 101P3A11 responds to stimuli and functions in signaling and GPCR activity, it is used as target for diagnostic, prognostic, preventative and/or therapeutic purposes.

Example 41: Inhibitors of 101P3A11 GPCR Function

As mentioned in the Example entitled "Homology Comparison of 101P3A11 to Known Sequences," GPCRs are activated by ligand binding to the extracellular loops, resulting in the activation of trimeric G proteins and the initiation of several signaling cascades. Using this information, several therapeutic and small molecule strategies are utilized to inhibit GPCR activation or downstream signaling events.

One strategy inhibits receptor and ligand binding. Recent studies using several types of GPCRs, have demonstrated the effectiveness of this strategy (Fawzi AB, et al. 2001, Mol. Pharmacol., 59:30). Using a compound named SCH-202676, they inhibited agonist and antagonist binding to GPCRs by allosterically hindering ligand-GPCR interaction. Using this and even more specific allosteric (small molecule) inhibitors, signal transduction through 101P3A11 is inhibited, thereby providing therapeutic, prognostic, diagnostic and/or prophylactic benefit.

A second approach is to inhibit G alpha subunit activation. Activation of GPCRs results in the exchange of GTP for GDP on the G alpha subunit of the trimeric G protein. Inhibition of G α activation prevents the activation of downstream signaling cascades and therefore biological effects of GPCR. One molecule used to inhibit GDP exchange on G α subunits is Suranim (Freissmuth M et al, 1996, Mol. Pharmacol, 49:602). Since suranim functions as a universal G α inhibitor, it prevents the activation of most G α subunits. Using techniques described, for example and without limitation, in the present Examples entitled "*In Vivo* Assay for 101P3A11 Tumor Growth Promotion;" "Identification and Confirmation of Potential Signal Transduction Pathways," "101P3A11 Functions as a GPCR," and "Regulation of Transcription", small molecules are identified that selectively inhibit the G α subunit that associates with 101P3A11, thereby providing therapeutic, prognostic, diagnostic and/or prophylactic benefit.

A third approach is to inhibit G α subunit association with GPCR. In order for trimeric G proteins to be activated following GPCR/ligand interaction, it is necessary for them to associate with their corresponding GPCR. Mutational analysis has mapped the interaction of G α to the first and third intracellular loops of GPCRs (Heller R at al. 1996, Biochem. Biophys. Res. Commun). Several studies have used synthetic (small molecule) peptides corresponding to the intracellular sequence of loops 1 and 3 as inhibitors (Mukherjee, S., et al. 1999, J. Biol. Chem.). Using such short peptides that serve as receptor mimics, they are used to compete for binding of G α subunits to 101P3A11 and thereby provide therapeutic, prognostic, diagnostic and/or prophylactic benefit.

Thus, compounds and small molecules designed to inhibit 101P3A11 function and downstream signaling events are used for therapeutic diagnostic, prognostic and/or preventative purposes.

Example 42: Involvement in Tumor Progression

The 101P3A11 gene can contribute to the growth of cancer cells. The role of 101P3A11 in tumor growth is confirmed in a variety of primary and transfected cell lines including prostate, colon, bladder and kidney cell lines, as well as NIH 3T3 cells engineered to stably express 101P3A11. Parental cells lacking 101P3A11 and cells expressing

101P3A11 are evaluated for cell growth using a well-documented proliferation assay (Fraser SP, et al., Prostate 2000;44:61, Johnson DE, Ochieng J, Evans SL. Anticancer Drugs. 1996, 7:288). Using such a technique, we demonstrated (see Figure 37) that 101P3A11 imparts a growth advantage on NIH 3T3 cells. 3T3-neo and 3T3-101P3A11 cells were grown in 0.5% or 10% FBS and analyzed 48 hours later. The assay was performed in triplicate.

5 Expression of 101P3A11 resulted in 6-fold increase in proliferation relative to control 3T3 cells grown in 0.5% FBS.

To confirm the role of 101P3A11 in the transformation process, its effect in colony forming assays was investigated. Parental NIH-3T3 cells lacking 101P3A11 were compared to NIH-3T3 cells expressing 101P3A11, using a soft agar assay under stringent and more permissive conditions (Song Z. et al. Cancer Res. 2000;60:6730). The results are shown in Figure 43, where 101P3A11 induces colony formation of over 100 fold increase relative to neo
10 resistant controls. We previously showed that expression of 101P3A11 in NIH 3T3 cells induces the growth of these cells in soft agar (129-24usu1), indicating that 101P3A11 participates in the process of transformation.

To confirm the role of 101P3A11 in invasion and metastasis of cancer cells, a well-established assay is used. A non-limiting example is the use of an assay which provides a basement membrane or an analog thereof used to detect whether cells are invasive (e.g., a Transwell Insert System assay (Becton Dickinson) (Cancer Res. 1999; 59:6010)).

15 Control cells, including prostate, colon, bladder and kidney cell lines lacking 101P3A11 are compared to cells expressing 101P3A11. Cells are loaded with the fluorescent dye, calcein, and plated in the top well of a support structure coated with a basement membrane analog (e.g. the Transwell insert) and used in the assay. Invasion is determined by fluorescence of cells in the lower chamber relative to the fluorescence of the entire cell population.

101P3A11 can also play a role in cell cycle and apoptosis. Parental cells and cells expressing 101P3A11 are
20 compared for differences in cell cycle regulation using a well-established BrdU assay (Abdel-Malek ZA. J Cell Physiol. 1988, 136:247). In short, cells are grown under both optimal (full serum) and limiting (low serum) conditions are labeled with BrdU and stained with anti-BrdU Ab and propidium iodide. Cells are analyzed for entry into the G1, S, and G2M phases of the cell cycle. Alternatively, the effect of stress on apoptosis is evaluated in control parental cells and cells expressing 101P3A11, including normal and tumor prostate, colon and lung cells. Engineered and parental
25 cells are treated with various chemotherapeutic agents, such as etoposide, flutamide, etc, and protein synthesis inhibitors, such as cycloheximide. Cells are stained with annexin V-FITC and cell death is measured by FACS analysis. The modulation of cell death by 101P3A11 can play a critical role in regulating tumor progression and tumor load.

When 101P3A11 plays a role in cell growth, transformation, invasion or apoptosis, it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.

Example 43: Involvement in Angiogenesis

Angiogenesis or new capillary blood vessel formation is necessary for tumor growth (Hanahan ,D.; Folkman, J.; Cell. 1996, 86:353; Folkman J. Endocrinology. 1998 139:441). Several assays have been developed to measure angiogenesis *in vitro* and *in vivo*, such as the tissue culture assays endothelial cell tube formation and endothelial cell
35 proliferation. Using these assays as well as *in vitro* neo-vascularization, the role of 101P3A11 in angiogenesis, enhancement or inhibition, is confirmed .

For example, endothelial cells engineered to express 101P3A11 are evaluated using tube formation and proliferation assays. The effect of 101P3A11 is also confirmed in animal models *in vivo*. For example, cells either

expressing or lacking 101P3A11 are implanted subcutaneously in immunocompromised mice. Endothelial cell migration and angiogenesis are evaluated 5-15 days later using immunohistochemistry techniques. 101P3A11 affects angiogenesis, and it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes

Example 44: Regulation of Transcription

The cell surface localization of 101P3A11 and its similarity to GPCRs indicate that 101P3A11 is effectively used as a modulator of the transcriptional regulation of eukaryotic genes. Regulation of gene expression is confirmed, e.g., by studying gene expression in cells expressing or lacking 101P3A11. For this purpose, two types of experiments are performed.

In the first set of experiments, RNA from parental and 101P3A11-expressing cells are extracted and hybridized to commercially available gene arrays (Clontech) (Smid-Koopman E et al. Br J Cancer. 2000. 83:246). Resting cells as well as cells treated with FBS or androgen are compared. Differentially expressed genes are identified in accordance with procedures known in the art. The differentially expressed genes are then mapped to biological pathways (Chen K et al. Thyroid. 2001. 11:41.).

In the second set of experiments, specific transcriptional pathway activation is evaluated using commercially available (Stratagene) luciferase reporter constructs including: NFkB-luc, SRE-luc, ELK1-luc, ARE-luc, p53-luc, and CRE-luc. These transcriptional reporters contain consensus binding sites for known transcription factors that lie downstream of well-characterized signal transduction pathways, and represent a good tool to ascertain pathway activation and screen for positive and negative modulators of pathway activation.

Thus, 101P3A11 plays a role in gene regulation, and it is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.

Example 45: Involvement in Cell Adhesion

Cell adhesion plays a critical role in tissue colonization and metastasis. 101P3A11 can participate in cellular organization, and as a consequence cell adhesion and motility. To confirm that 101P3A11 regulates cell adhesion, control cells lacking 101P3A11 are compared to cells expressing 101P3A11, using techniques previously described (see, e.g., Haier et al, Br. J. Cancer. 1999, 80:1867; Lehr and Pienta, J. Natl. Cancer Inst. 1998, 90:118). Briefly, in one embodiment, cells labeled with a fluorescent indicator, such as calcein, are incubated on tissue culture wells coated with media alone or with matrix proteins. Adherent cells are detected by fluorimetric analysis and percent adhesion is calculated. In another embodiment, cells lacking or expressing 101P3A11 are analyzed for their ability to mediate cell-cell adhesion using similar experimental techniques as described above. Both of these experimental systems are used to identify proteins, antibodies and/or small molecules that modulate cell adhesion to extracellular matrix and cell-cell interaction. Cell adhesion plays a critical role in tumor growth, progression, and, colonization, and 101P3A11 is involved in these processes. Thus, it serves as a diagnostic, prognostic, preventative and/or therapeutic modality.

Example 46: Protein-Protein Association

Several GPCRs have been shown to interact with other proteins, thereby regulating signal transduction, gene transcription, transformation and cell adhesion (Sexton PM et al, Cell Signal. 2001, 13:73; Turner CE, J Cell Sci. 2000, 23:4139). Using immunoprecipitation techniques as well as two yeast hybrid systems, proteins are identified that associate with 101P3A11. Immunoprecipitates from cells expressing 101P3A11 and cells lacking 101P3A11 are compared for specific protein-protein associations.

Studies are performed to confirm the extent of association of 101P3A11 with effector molecules, such as receptors, adaptor proteins and paxillin, kinases, phosphates and G proteins. Studies comparing 101P3A11 positive and 101P3A11 negative cells as well as studies comparing unstimulated/resting cells and cells treated with epithelial cell activators, such as cytokines, growth factors, androgen and anti-integrin Ab reveal unique interactions.

In addition, protein-protein interactions are confirmed using two yeast hybrid methodology (Curr Opin Chem Biol. 1999, 3:64). A vector carrying a library of proteins fused to the activation domain of a transcription factor is introduced into yeast expressing a 101P3A11-DNA-binding domain fusion protein and a reporter construct. Protein-protein interaction is detected by colorimetric reporter activity. Specific association with effector molecules and transcription factors directs one of skill to the mode of action of 101P3A11, and thus identifies therapeutic, prognostic, preventative and/or diagnostic targets for cancer. This and similar assays are also used to identify and screen for small molecules that interact with 101P3A11.

Thus it is found that 101P3A11 associates with proteins and small molecules. Accordingly, 101P3A11 and these proteins and small molecules are used for diagnostic, prognostic, preventative and/or therapeutic purposes.

Example 47: Biological effect of anti-101P3A11 antibodies.

The generation of anti-101P3A11 polyclonal Ab (pAb) using an amino-terminal peptide encoding amino acids 1-14 (MVDPNGNESSATYF; SEQ ID NO:YY2880) as antigen was reported in our Priority Application. The effect of this antibody on 101P3A11 mediated ERK phosphorylation (Figure 38) and cAMP accumulation (Figure 39) was determined. 293T cells were transfected with control or 101P3A11 cDNA. Cells were allowed to rest overnight, and treated with anti-101P3A11 or control Ab in the presence of 0.5% or 10% FBS. Cells were lysed and analyzed by Western blotting with anti-Phospho-ERK and anti-ERK mAb. Figure 38 shows that expression of 101P3A11 induces ERK phosphorylation in cells treated with 0.5 or 10% FBS. Anti-101P3A11 pAb reduced the phosphorylation of ERK in 293T-101P3A11 cells treated with 0.5% FBS. The ERK overlay demonstrated equal loading, supporting the specificity of this data.

In order to confirm that anti-101P3A11 pAb has a detectable effect on cAMP accumulation, PC3 and PC3-101P3A11 cells were grown in 0.1% FBS and treated with anti-101P3A11 pAb. Cells were analyzed for cAMP content as described in Figure 32. Expression of 101P3A11 induced a 5-fold increase in cAMP accumulation in PC3 cells, which was partially inhibited by PTX. Treatment of PC3-101P3A11 cells with anti-101P3A11 pAb resulted in a 4-fold increase in cAMP accumulation in PC3-101P3A11 but not control PC3 cells. Results shown in Figure 38 and Figure 39 indicate that anti-101P3A11 pAb produces a measurable biological effect in cells expressing 101P3A11. Accordingly, 101P3A11 is used as a target for diagnostic, prognostic, preventative and/or therapeutic purposes.

Example 48: 101P3A11 Promoters

A eukaryotic cell promoter is a short DNA sequence located in the 5' region of a gene. It provides binding sites for RNA polymerase and associated transcriptional cofactors, which upon assembly promotes transcription of the gene. In humans, most genes are transcribed by RNA polymerase II. The promoter DNA sequence normally contains binding motifs for RNA polymerases and its associated cofactors and activators including a TATA-box, cap signal, CCAAT-box and the GC-box. A eukaryotic cell enhancer is DNA sequence where transcriptional factors and their associated coactivators or suppressors bind and interact with promoter-bound RNA polymerase to regulate the expression of the gene located next to the promoter. While a promoter(s) locates close to the transcription starting site(s) of a gene (usually 25-30 base pairs), enhancers can be found up to 50,000 base pairs in either direction to the transcription starting site(s) of the gene. There are many different gene regulatory proteins, namely transcription factors and their associated coactivators and cosuppressors that bind to specific enhancer sequences and regulate gene expression. These proteins, upon interaction with specific DNA regulatory sequences and with each other, allow each gene to be regulated up or down in different tissues and cell types. Chapter 9. "Control of gene expression" in Molecular Biology of the Cell. 3rd ed. Ed. by Alberts et al., (New York and London) Garland Publishing, 1994).

Tissue specific gene expression is associated with the presence of specific combinations of transcription factors and their associated coactivators and suppressors, the presence of specific binding sites present in the DNA regulatory region of the gene for these factors, and the activation or inactivation of signaling pathways that modulate their relative activity. For example, prostate specific expression of prostate specific antigen, (PSA, or human kallikrein 3), is dependent on the presence of androgen receptor binding elements in defined 5' upstream enhancer and promoter sequences of the gene and intact androgen receptor signaling pathway (Pang S, et al., Cancer Res 1997 Feb 1; 57(3):495-9). It is also dependent on the presence of other cis-acting DNA regulatory elements in the promoter region (Zhang J, et al., Nucleic Acids Res. 1997, Aug. 1; 25(15):3143-50.) and on the expression of other transcription factors, such as the prostate specific ets-like transcription factor (Oettgen P, et al., J Biol Chem. 2000, Jan. 14; 275(2):1216-25).

With the accumulation of data and knowledge on human gene expression, promoters and enhancers are identified using different algorithms and computer programs (Chapter 8 "Gene Prediction" in Bioinformatics - Sequence and Genome Analysis, ed. by David W. Mount. Cold Spring Harbor Laboratory Press, 2001). Accordingly, we identified (Table XXX) promoters in a 5.04 kB 5' upstream genomic region of the 101P3A11 coding sequence using Neural Network Promoter Prediction computer program (http://www.fruitfly.org/seq_tools/nnppAbst.html; Reese, M.G. and Eeckman, F.H. (1995) Novel Neural Network Algorithms for Improved Eukaryotic Promoter Site Recognition. Accepted talk for The Seventh International Genome Sequencing and Analysis Conference, Hyatt Regency, Hilton Head Island, South Carolina, September 16-20, 1995), indicated by the underlined sequences in Table XXIX. Using a program called SIGNAL SCAN (<http://bimas.dcrf.nih.gov/molbio/signal/>; Prestridge, D.S. (1991) SIGNAL SCAN: A computer program that scans DNA sequences for eukaryotic transcriptional elements. CABIOS 7, 203-206.), which searches a comprehensive database of regulatory element binding sites, we found numerous transcriptional binding sites for various known transcription factors in the 5.04 kB sequence 5' to the 101P3A11 gene, suggesting the presence of specific enhancer regions that may mediate tissue specific 101P3A11 transcription. Such transcription factors include, but are not limited to, NFAT, NF-1, NF-E, CP2, AP1, AP-2, Spl, OCT-1, OCT-2, NFkB, CREB, CTF, TFIIA, TFIIB, TFIID, Pit-1, C/EBP, SRF, and various steroid receptors, such as glucocorticoid receptor (GR) and androgen receptors

(AR) (Mitchell P J and Tijan R (1989) Science 245: 371). Comparison of the 5 kB upstream sequence of the 101P3A11 gene to the 5 kB upstream sequence of the PSA gene, 5 homologous regions were found that are important for prostate cell specific expression. Figure XXXI shows the alignment of the these sequences and also indicates predicted transcription factor binding sites common to both sequences identified using SIGNAL SCAN.

Experimentally, one defines the regions in the 5' genomic upstream regions of the 101P3A11 gene using various methods well known in the art, such as deletion and mutation analysis of the putative regulatory regions fused to a transcriptional reporter gene such as luciferase or chloramphenicol acetyl-transferase. These transcriptional reporter vectors are then introduced into cell lines, tissues, or transgenic animals to analyze the tissue and cell type specificity of transcription and expression of the reporter gene. To identify transcription factors and proteins that interact with specific 101P3A11 transcriptional regulatory sequences, one employs one or more of various techniques known in the art such as DNase footprinting, gel mobility shift assays, and DNA/protein affinity chromatography. Various techniques concerning use of promoters are set forth, e.g., U.S. Patent 5,919,652 which concerns embodiments of nucleic acid compositions that comprise prostate specific antigen (PSA) promoter alone or in combination with a cytomegalovirus (CMV) promoter and related uses.; and, U.S. Patent 6,110,702 which concerns PSA positive regulatory sequence (PSAR) and related uses.

Once regulatory sequences are identified that mediate 101P3A11 tissue-specific expression, these sequences are employed in various gene therapeutic strategies for cancer, such as driving tissue-specific expression of a toxic gene or a cell suicide gene. Such cell suicide strategies are currently employed using the PSA-promoter enhancer using the thymidine kinase/ganciclovir system (Suzuki S, Tadakuma T, Asano T, Hayakawa M. Cancer Res. 2001 Feb 15;61(4):1276-90). Unlike PSA, which is an androgen regulated gene, 101P3A11 does not exhibit androgen regulated expression. Thus, identification and use of regulatory sequences of the 101P3A11 gene that mediate, e.g., prostate-specific, but androgen insensitive gene expression, is useful for the treatment of both early stage androgen sensitive and late stage androgen insensitive or hormone refractory prostate cancer.

Throughout this application, various website data content, publications, patent applications and patents are referenced. (Websites are referenced by their Uniform Resource Locator, or URL, addresses on the World Wide Web.) The disclosures of each of these references are hereby incorporated by reference herein in their entireties.

The present invention is not to be limited in scope by the embodiments disclosed herein, which are intended as single illustrations of individual aspects of the invention, and any that are functionally equivalent are within the scope of the invention. Various modifications to the models and methods of the invention, in addition to those described herein, will become apparent to those skilled in the art from the foregoing description and teachings, and are similarly intended to fall within the scope of the invention. Such modifications or other embodiments can be practiced without departing from the true scope and spirit of the invention.

TABLES

5 **TABLE I: Exemplary Tissues that Express 101P3A11**

Normal Tissues:

10 Prostate
Ovary (by RT-PCR only)

Malignant Tissues:

15 Rectum
Prostate
Colon
Kidney
Breast
20 Uterus
Cervix
Stomach
Metastases Pool

25

TABLE II: AMINO ACID ABBREVIATIONS

SINGLE LETTER	THREE LETTER	FULL NAME
F	Phe	phenylalanine
L	Leu	leucine
S	Ser	serine
Y	Tyr	tyrosine
C	Cys	cysteine
W	Trp	tryptophan
P	Pro	proline
H	His	histidine
Q	Gln	glutamine
R	Arg	arginine
I	Ile	isoleucine
M	Met	methionine
T	Thr	threonine
N	Asn	asparagine
K	Lys	lysine

V	Val	valine
A	Ala	alanine
D	Asp	aspartic acid
E	Glu	glutamic acid
G	Gly	glycine

TABLE III: AMINO ACID SUBSTITUTION MATRIX

Adapted from the GCG Software 9.0 BLOSUM62 amino acid substitution matrix (block substitution matrix).

The higher the value, the more likely a substitution is found in related, natural proteins. (See URL

5 www.ikp.unibe.ch/manual/blosum62.html)

	A	C	D	E	F	G	H	I	K	L	M	N	P	Q	R	S	T	V	W	Y	.
10	4	0	-2	-1	-2	0	-2	-1	-1	-1	-1	-2	-1	-1	-1	1	0	0	-3	-2	A
		9	-3	-4	-2	-3	-3	-1	-3	-1	-1	-3	-3	-3	-3	-1	-1	-1	-2	-2	C
			6	2	-3	-1	-1	-3	-1	-4	-3	1	-1	0	-2	0	-1	-3	-4	-3	D
				5	-3	-2	0	-3	1	-3	-2	0	-1	2	0	0	-1	-2	-3	-2	E
					6	-3	-1	0	-3	0	0	-3	-4	-3	-3	-2	-2	-1	1	3	F
15					6	-2	-4	-2	-4	-3	0	-2	-2	-2	0	-2	-3	-2	-3	G	
						8	-3	-1	-3	-2	1	-2	0	0	-1	-2	-3	-2	2	H	
							4	-3	2	1	-3	-3	-3	-3	-2	-1	3	-3	-1	I	
								5	-2	-1	0	-1	1	2	0	-1	-2	-3	-2	K	
									4	2	-3	-3	-2	-2	-2	-1	1	-2	-1	L	
20										5	-2	-2	0	-1	-1	-1	1	-1	-1	M	
											6	-2	0	0	1	0	-3	-4	-2	N	
												7	-1	-2	-1	-1	-2	-4	-3	P	
													5	1	0	-1	-2	-2	-1	Q	
														5	-1	-1	-3	-3	-2	R	
25																4	1	-2	-3	-2	S
																	5	0	-2	-2	T
																		4	-3	-1	V
																			11	2	W
																				7	Y

TABLE IV (A):

SUPERMOTIFS	POSITION	POSITION	POSITION
	2 (Primary Anchor)	3 (Primary Anchor)	C Terminus (Primary Anchor)
A1	T <i>L</i> V <i>M</i> S		F <i>W</i> Y
A2	L <i>I</i> V <i>M</i> A <i>T</i> Q		I <i>V</i> M <i>ATL</i>
A3	V <i>S</i> M <i>A</i> T <i>L</i> I		R K
A24	Y <i>F</i> W <i>I</i> V <i>L</i> M <i>T</i>		F <i>I</i> Y <i>W</i> L M
B7	P		V <i>I</i> L <i>F</i> M <i>W</i> Y A
B27	R H K		F <i>Y</i> L <i>W</i> M <i>I</i> V A
B44	E D		F <i>W</i> Y <i>L</i> I M V A
B58	A T S		F <i>W</i> Y <i>L</i> I V M A
B62	Q <i>L</i> I <i>V</i> M P		F <i>W</i> Y <i>M</i> I V L A
MOTIFS			
A1	T S M		Y
A1		D E A S	Y
A2.1	L <i>M</i> V <i>Q</i> I A T		V <i>L</i> I M A T
A3	L <i>M</i> V <i>IS<i>A</i>T<i>F</i>CGD</i>		K <i>Y</i> R <i>H</i> F A
A11	V <i>T</i> M <i>L</i> I S <i>A</i> G <i>N</i> C D F		K <i>R</i> Y H
A24	Y F W M		F L I W
A*3101	M V T A L I S		R K
A*3301	M V A L F I S T		R K
A*6801	A V T M S L I		R K
B*0702	P		L M F W Y A I V
B*3501	P		L M F W Y I V A
B51	P		L I V F W Y A M
B*5301	P		I M F W Y A L V
B*5401	P		A T I V L M F W Y

- 5 Bolded residues are preferred, italicized residues are less preferred: A peptide is considered motif-bearing if it has primary anchors at each primary anchor position for a motif or supermotif as specified in the above table.

10 TABLE IV (B): HLA CLASS II SUPERMOTIF

1	6	9
W, F, Y, V, .I, L	A, V, I, L, P, C, S, T	A, V, I, L, C, S, T, M, Y

MOTIFS	1° anchor 1	2	3	4	5	1° anchor 6	7	8	9
DR4	preferred deleterious	FMYLIVW M	T	W	I	VSTCPALIM	MH		MH
DR1	preferred deleterious	MFLIVWY C	CH	FD	CWD	VMATSPLIC	M	GDE D	AVM
DR7	preferred deleterious	MFLIVWY C	W	A		IVMSACTPL	M		IV
DR3	<u>MOTIFS</u> motif a preferred motif b preferred	1° anchor 1 LIVMFY LIVMFAY	2 3	1° anchor 4 D DNQEST	5	1° anchor 6			
DR	Supermotif	MFLIVWY							

sd-63712 _____ 118

TABLE IV (D):

POSITION

	1	2	3	4	5	6	7	8	C-terminus
<u>SUPERMOTIFS</u>									
A1		1° Anchor TILVMS							1° Anchor FWY
A2		1° Anchor LIVMATQ							1° Anchor LIVMAT
A3	preferred	1° Anchor VSMA7LI	YFW(4/5)		YFW (3/5)	YFW (4/5)	P (4/5)		1° Anchor RK
	deleterious	DE (3/5); P (5/5)	DE (4/5)						
A24		1° Anchor YFWIVLMT							1° Anchor FIYWLM
B7	preferred	FWY (5/5) LIVM (3/5)	FWY(4/5)					FWY (3/5)	1° Anchor VILFMWYA
	deleterious	DE (3/5); P(5/5); G(4/5); A(3/5); QN(3/5)			DE(3/5)	G(4/5)	QN(4/5)	DE(4/5)	
B27		1° Anchor RHK							1° Anchor FYLWMIYA
B44		1° Anchor ED							1° Anchor FWYLIWVA
B58		1° Anchor ATS							1° Anchor FWYLIWMA
B62		1° Anchor QLIVMP							1° Anchor FWYMIYLA

TABLE IV (E):

	1	2	3	4	5	6	7	8	9	C-terminus
										or C-terminus
A1 9-mer	preferred	GFYW	$\frac{1^\circ \text{Anchor}}{\text{STM}}$	DEA	YFW	P	DEQN	YFW	$\frac{1^\circ \text{Anchor}}{\text{Y}}$	
	deleterious	DE	RHKLIVMP	A	G	A				
A1 9-mer	preferred	GRHK	ASTCLIVM	$\frac{1^\circ \text{Anchor}}{\text{DE4S}}$	GSTC	ASTC	LIVM	DE	$\frac{1^\circ \text{Anchor}}{\text{Y}}$	
	deleterious	A	RHKDEPYFW	DE	PQN	RHK	PG	GP		
A1 10-mer	preferred	YFW	$\frac{1^\circ \text{Anchor}}{\text{STM}}$	DEAQN	A	YFWQN	PASTC	GDE	P	$\frac{1^\circ \text{Anchor}}{\text{Y}}$
	deleterious	GP	RHKGLIVM	DE	RHK	QNA	RHKYF W	RHK	A	
A1 10-mer	preferred	YFW	STCLIVM	$\frac{1^\circ \text{Anchor}}{\text{DE4S}}$	A	YFW	PG	G	YFW	$\frac{1^\circ \text{Anchor}}{\text{Y}}$
	deleterious	RHK	RHKDEPY FW		P	G	PRHK	QN		
A2.1 9-mer	preferred	YFW	$\frac{1^\circ \text{Anchor}}{\text{LMIVQ4T}}$	STC	YFW	A	P	$\frac{1^\circ \text{Anchor}}{\text{VLLMAT}}$		
	deleterious	DEP	DERKH	DERKH	RKH	DERKH				
A2.1 10-mer	preferred	AYFW	$\frac{1^\circ \text{Anchor}}{\text{LMIVQ4T}}$	LVIM	G	FYWL VIM			$\frac{1^\circ \text{Anchor}}{\text{VLLMAT}}$	
	deleterious	DEP	DE	RKHA	P	RKH	DERKH	RKH		
A3	preferred	RHK	$\frac{1^\circ \text{Anchor}}{\text{LMVISATFCG}}$ D	YFW	PRHKYF W	P	$\frac{1^\circ \text{Anchor}}{\text{KYRHF4}}$			

	1	2	3	4	5	6	7	8	9	C-terminus
	deleterious	DEP	DE							
A11	preferred	A	^{1°Anchor} VTLMISAGNC DF	YFW	YFW	YFW	YFW	P	^{1°Anchor} KRYH	
	deleterious	DEP					A	G		
A24 9-mer	preferred	YFWRH K	^{1°Anchor} YFWM	STC		YFW	YFW	YFW	^{1°Anchor} FLIW	
	deleterious	DEG	DE	G	QNP	DERHK	G	AQN		
A24 10-mer	preferred		^{1°Anchor} YFWM	P	YFWP		P		^{1°Anchor} FLIW	
	deleterious		GDE	QN	RHK	DE	A	QN	DEA	
A3101	preferred	RHK	^{1°Anchor} MVTALIS	P		YFW	YFW	AP	^{1°Anchor} RK	
	deleterious	DEP	DE	DE	ADE	DE	DE	DE		
A3301	preferred		^{1°Anchor} MVALF/ST	YFW			AYFW		^{1°Anchor} RK	
	deleterious	GP	DE							
A6801	preferred	YFWSTC	^{1°Anchor} AVTMSLI		YFWLIV M		YFW	P	^{1°Anchor} RK	
	deleterious	GP	DEG		RHK			A		
B0702	preferred	RHKFW Y	^{1°Anchor} P	RHK	RHK	RHK	RHK	PA	^{1°Anchor} LMFWY4IV	
	deleterious	DEQNP	DEP	DE	DE	GDE	QN	DE		

	1	2	3	4	5	6	7	8	9	C-terminus
B3501	preferred	FWYLVIV M	<u>1°Anchor</u> P	FWY			FWY		<u>1°Anchor</u> LMFWYIVV	
	deleterious	AGP			G	G				
B51	preferred	LIVMFW Y	<u>1°Anchor</u> P	STC	FWY		G	FWY	<u>1°Anchor</u> LIVFWYAM	
	deleterious	AGPDER HKSTC			DE	G	DEQN	GDE		
B5301	preferred	LIVMFW Y	<u>1°Anchor</u> P	STC	FWY		LIVMFW Y	FWY	<u>1°Anchor</u> IMFWYALV	
	deleterious	AGPQN				G	RHKQN	DE		
B5401	preferred	FWY	<u>1°Anchor</u> P	FWYLVIM	LIVM		ALIVM	FWYAP	<u>1°Anchor</u> ATIVLMFWY	
	deleterious	GPQNDE		GDESTC	RHKDE	DE	QNDGE	DE		

Italicized residues indicate less preferred or "tolerated" residues. The information in this Table is specific for 9-mers unless otherwise specified.

TABLE V: HLA PEPTIDE SCORING RESULTS –101P3A11– A1, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	210	GLDSSLISF	25.000	1.
2	1	MVDPNGNES	5.000	2.
3	29	LAFPLCSLY	5.000	3.
4	21	GLEEAQFWL	4.500	4.
5	212	DSLLISFSY	3.750	5.
6	41	VLGNLTHY	2.500	6.
7	245	HVCAVFIFY	2.500	7.
8	57	LHEPMYIFL	2.250	8.
9	111	GMESTVLLA	2.250	9.
10	6	GNESSATYF	2.250	10.
11	259	LSMVHRFSK	1.500	11.
12	114	STVLLAMAF	1.250	12.
13	190	ACDDIRVNV	1.000	13.
14	74	LISTSSMPK	1.000	14.
15	158	MAPLPVFIK	1.000	15.
16	78	SSMPKMLAI	0.750	16.
17	172	RSNILSHSY	0.750	17.
18	134	HATVLTLP	0.500	18.
19	44	NLTHYIVR	0.500	19.
20	117	LLAMAFDRY	0.500	20.
21	116	VLLAMAFDR	0.500	21.
22	70	GIDILIST	0.500	22.
23	231	TREAQAKAF	0.450	23.
24	180	YCLHQDVMK	0.400	24.
25	137	VLTLPVTK	0.400	25.
26	183	HQDVMKLAC	0.375	26.
27	5	NGNESSATY	0.250	27.
28	138	LTLPRVTKI	0.250	28.
29	52	RTEHSLHEP	0.225	29.
30	145	KIGVAAVVR	0.200	30.
31	56	SLHEPMYIF	0.200	31.
32	242	CVSHVCAVF	0.200	32.
33	256	FIGLSMVHR	0.200	33.
34	287	VLNPIVYGV	0.200	34.
35	156	ALMAPLPVF	0.200	35.
36	125	YVAICHPLR	0.200	36.
37	248	AVFIFYVPF	0.200	37.
38	273	LPVILANIY	0.125	38.
39	95	QFDACLLQI	0.125	39.
40	271	SPLPVILAN	0.125	40.
41	11	ATYFILIGL	0.125	41.
42	159	APLPVFIKQ	0.125	42.
43	128	ICHPLRHAT	0.100	43.
44	157	LMAPLPVFI	0.100	44.
45	283	LVPPVLNPI	0.100	45.
46	77	TSSMPKMLA	0.075	46.
47	68	LSGIDILIS	0.075	47.
48	176	LSHSYCLHQ	0.075	48.
49	9	SSATYFILI	0.075	49.

TABLE V:
HLA PEPTIDE SCORING RESULTS -101P3A11- A1, 9-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
50	8	ESSATYFIL	0.075	50.
51	218	FSYLLILKT	0.075	51.
52	216	ISFSYLLIL	0.075	52.
53	90	NSTTIQFDA	0.075	53.
54	55	HSLHEPMYI	0.075	54.
55	270	DSPLPVILA	0.075	55.
56	285	PPVLNPIVY	0.062	56.
57	233	EAQAKAFGT	0.050	57.
58	203	IVIISAIGL	0.050	58.
59	188	KLACDDIRV	0.050	59.
60	97	DACLLQIFA	0.050	60.
61	19	LPGLEEAQF	0.050	61.
62	253	YVPFIGLSM	0.050	62.
63	98	ACLLQIFAI	0.050	63.
64	164	FIKQLPFCR	0.050	64.
65	33	LCSLYLIAV	0.050	65.
66	288	LNPIVYGVK	0.050	66.
67	260	SMVHRFSKR	0.050	67.
68	67	MLSGIDILI	0.050	68.
69	126	VAICHPLRH	0.050	69.
70	240	GTCVSHVCA	0.050	70.
71	54	EHSLHEPMY	0.050	71.
72	276	ILANIYLLV	0.050	72.
73	215	LISFSYLLI	0.050	73.
74	217	SFSYLLILK	0.050	74.
75	83	MLAIFWFNS	0.050	75.
76	39	IAVLGNLTI	0.050	76.
77	246	VCAVFIFYV	0.050	77.
78	162	PVFIKQLPF	0.050	78.
79	208	AIGLDSLLI	0.050	79.
80	250	FIFYVPFIG	0.050	80.
81	155	AALMAPLPV	0.050	81.
82	65	LCMLSGIDI	0.050	82.
83	10	SATYFILIG	0.050	83.
84	268	RRDSPLPVI	0.050	84.
85	92	TTIQFDACL	0.050	85.
86	181	CLHQDVMKL	0.050	86.
87	62	YIFLCMLSG	0.050	87.
88	197	NVVGGLIVI	0.050	88.
89	135	ATVLTLPV	0.050	89.
90	100	LLQIFAIHS	0.050	90.
91	282	LLVPPVLNP	0.050	91.
92	45	LTIIYIVRT	0.050	92.
93	205	IISAIGLDS	0.050	93.
94	22	LEEAFWLA	0.045	94.
95	297	TKEIRQRIL	0.045	95.
96	113	ESTVLLAMA	0.030	96.
97	243	VSHVCAVFI	0.030	97.
98	75	ISTSSMPKM	0.030	98.
99	34	CSLYLIAVL	0.030	99.

TABLE V: HLA PEPTIDE SCORING RESULTS -101P3A11- A1, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
100	224	LKTVLGLTR	0.025	100.

TABLE VI: HLA PEPTIDE SCORING RESULTS -101P3A11- A1, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	1	MVDPNGNESS	5.000	101.
2	157	LMAPLPVFIK	5.000	102.
3	78	SSMPKMLAIF	3.000	103.
4	40	AVLGNLTHY	2.500	104.
5	191	CDDIRVNVVY	2.500	105.
6	57	LHEPMYIFLC	2.250	106.
7	22	LEEAAQFWLAF	2.250	107.
8	297	TKEIRQRILR	2.250	108.
9	52	RTEHSLHEPM	2.250	109.
10	111	GMESTVLLAM	2.250	110.
11	287	VLNPIVYGVK	2.000	111.
12	216	ISFSYLLILK	1.500	112.
13	73	ILISTSSMPK	1.000	113.
14	258	GLSMVHRFSK	1.000	114.
15	21	GLEEAQFWLA	0.900	115.
16	113	ESTVLLAMAF	0.750	116.
17	243	VSHVCAVFIF	0.750	117.
18	284	VPPVLNPIVY	0.625	118.
19	29	LAFPLCSLYL	0.500	119.
20	70	GIDILISTSS	0.500	120.
21	116	VLLAMAFDRY	0.500	121.
22	115	TVLLAMAFDR	0.500	122.
23	210	GLDSLLISFS	0.500	123.
24	190	ACDDIRVNVV	0.500	124.
25	28	WLAFPLCSLY	0.500	125.
26	6	GNESSATYFI	0.450	126.
27	136	TVLTLPRVTK	0.400	127.
28	55	HSLHEPMYIF	0.300	128.
29	95	QFDACLLQIF	0.250	129.
30	138	LTLPRVTKIG	0.250	130.
31	128	ICHPLRHATV	0.200	131.
32	155	AALMAPLPVF	0.200	132.
33	247	CAVFIFYVPF	0.200	133.
34	283	LVPPVLNPIV	0.200	134.
35	241	TCVSHVCAVF	0.200	135.
36	18	GLPGLEEAQF	0.200	136.
37	259	LSMVHRFSKR	0.150	137.
38	43	GNLTHYIVR	0.125	138.
39	244	SHVCAVFIFY	0.125	139.
40	209	IGLDSLLISF	0.125	140.
41	161	LPVFIKQLPF	0.125	141.
42	211	LDSLLISFSY	0.125	142.
43	76	STSSMPKMLA	0.125	143.

TABLE VI: HLA PEPTIDE SCORING RESULTS -101P3A11- A1, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
44	256	FIGLSMVHRF	0.100	144.
45	282	LLVPPVLNPI	0.100	145.
46	231	TREAQAKAFG	0.090	146.
47	77	TSSMPKMLAI	0.075	147.
48	270	DSPLPVILAN	0.075	148.
49	8	ESSATYFILI	0.075	149.
50	68	LSGIDILIST	0.075	150.
51	9	SSATYFILIG	0.075	151.
52	272	PLPVILANIY	0.050	152.
53	214	LLISFSYLLI	0.050	153.
54	245	HVCAVFIFYV	0.050	154.
55	175	ILSHSYCLHQ	0.050	155.
56	289	NPIVYGVKTK	0.050	156.
57	41	VLGNLTIIYI	0.050	157.
58	105	AIHSLSGMES	0.050	158.
59	125	YVAICHPLRH	0.050	159.
60	202	LIVIIAIGL	0.050	160.
61	260	SMVHRFSKRR	0.050	161.
62	97	DACLLQIFAI	0.050	162.
63	56	SLHEPMYIFL	0.050	163.
64	35	SLYLIAVLGN	0.050	164.
65	195	RVNVVYGLIV	0.050	165.
66	215	LISFSYLLIL	0.050	166.
67	221	LLILKTVLGL	0.050	167.
68	67	MLSGIDILIS	0.050	168.
69	268	RRDSPLPVIL	0.050	169.
70	271	SPLPVILANI	0.050	170.
71	207	SAIGLDSLLI	0.050	171.
72	102	QIFAIHSLSG	0.050	172.
73	64	FLCMLSGIDI	0.050	173.
74	208	AIGLDSLLIS	0.050	174.
75	204	VIIAIGLDS	0.050	175.
76	93	TIQFDACLLQ	0.050	176.
77	275	VILANIYLLV	0.050	177.
78	10	SATYFILIGL	0.050	178.
79	198	VVYGLIVIIS	0.050	179.
80	24	EAQFWLAFPL	0.050	180.
81	154	GAALMAPLPV	0.050	181.
82	91	STTIQFDACL	0.050	182.
83	228	LGLTREAQAK	0.050	183.
84	99	CLLQIFAIHS	0.050	184.
85	38	LIAVLGNLTI	0.050	185.
86	53	TEHSLHEPMY	0.050	186.
87	223	ILKTVLGLTR	0.050	187.
88	158	MAPLPVFIKQ	0.050	188.
89	250	FIFYVPFIGL	0.050	189.
90	180	YCLHQDVMKL	0.050	190.
91	109	LSGMESTVLL	0.030	191.
92	34	CSLYLIAVLG	0.030	192.

TABLE VI:				
HLA PEPTIDE SCORING RESULTS -101P3A11- A1, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
93	225	KTVLGLTREA	0.025	193.
94	5	NGNESSATYF	0.025	194.
95	230	LTREAQAKAF	0.025	195.
96	171	CRSNILSHSY	0.025	196.
97	87	FWFNSTTIQF	0.025	197.
98	17	IGLPGLEEAQ	0.025	198.
99	82	KMLAIFWFNS	0.025	199.
100	4	PNGNESSATY	0.025	200.

TABLE VII:				
HLA PEPTIDE SCORING RESULTS -101P3A11- A-0201, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	213	SLISFSYL	825.977	201.
2	287	VLNPIVYGV	271.948	202.
3	188	KLACDDIRV	243.432	203.
4	28	WLAFLCSL	226.014	204.
5	246	VCAVFIFYV	215.192	205.
6	21	GLEEAQFWL	178.815	206.
7	276	ILANIYLLV	177.358	207.
8	220	YLLILKTVL	149.071	208.
9	214	LLISFSYLL	138.001	209.
10	14	FILIGLPGL	114.985	210.
11	157	LMAPLPVFI	70.450	211.
12	279	NIYLLVPPV	70.387	212.
13	108	SLSGMESTV	69.552	213.
14	82	KMLAIFWFN	54.625	214.
15	181	CLHQDVMKL	49.134	215.
16	25	AQFWLAFPL	46.480	216.
17	275	VILANIYLL	42.494	217.
18	222	LILKTVLGL	42.494	218.
19	37	YLIAVLGNL	29.382	219.
20	66	CMLSGIDIL	26.377	220.
21	118	LAMAFDRYV	25.398	221.
22	201	GLIVIISAI	23.995	222.
23	306	RLFHVATHA	18.382	223.
24	67	MLSGIDILI	17.736	224.
25	85	AIFWFNSTT	14.407	225.
26	49	YIVRTEHSL	13.512	226.
27	174	NILSHSYCL	10.868	227.
28	167	QLPFCRSNI	10.433	228.
29	60	PMYIFLCML	9.493	229.
30	101	LQIFAIHSL	8.469	230.
31	254	VPFIGLSMV	6.568	231.
32	120	MAFDYVAI	5.605	232.
33	83	MLAIFWFNS	4.747	233.
34	198	VVYGLIVII	4.683	234.

TABLE VII:

HLA PEPTIDE SCORING RESULTS -101P3A11- A-0201, 9-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
35	160	PLPVFIKQL	4.108	235.
36	304	ILRLFHVAT	3.659	236.
37	215	LISFSYLLI	3.658	237.
38	155	AALMAPLPV	3.574	238.
39	283	LVPPVLNPI	3.569	239.
40	98	ACLLQIFAI	3.361	240.
41	40	AVLGNLTHI	3.185	241.
42	203	IVIISAIGL	3.178	242.
43	93	TIQFDACLL	2.937	243.
44	31	FPLCSLYLI	2.666	244.
45	135	ATVLTLPV	2.222	245.
46	11	ATYFILIGL	2.184	246.
47	110	SGMESTVLL	2.115	247.
48	138	LTLPRVTKI	2.096	248.
49	253	YVPFIGLSM	2.000	249.
50	303	RILRLFHVA	1.969	250.
51	33	LCSLYLIAV	1.775	251.
52	38	LIAVLGNLT	1.742	252.
53	218	FSYLLILKT	1.647	253.
54	43	GNLTHIYIV	1.584	254.
55	119	AMAFDRYVA	1.471	255.
56	42	LGNLTHIYI	1.465	256.
57	208	AIGLDSLLI	1.435	257.
58	200	YGLIVIISA	1.270	258.
59	281	YLLVPPVLN	1.268	259.
60	92	TTIQFDACL	1.127	260.
61	7	NESSATYFI	1.116	261.
62	241	TCVSHVCAV	1.044	262.
63	197	NVVYGLIVI	0.861	263.
64	216	ISFSYLLIL	0.827	264.
65	190	ACDDIRVNV	0.745	265.
66	104	FAIHSLSGM	0.730	266.
67	243	VSHVCAVFI	0.637	267.
68	78	SSMPKMLAI	0.580	268.
69	116	VLLAMAFDR	0.544	269.
70	111	GMESTVLLA	0.528	270.
71	272	PLPVILANI	0.528	271.
72	34	CSLYLIAVL	0.487	272.
73	100	LLQIFAIHS	0.481	273.
74	69	SGIDILIST	0.459	274.
75	142	RVTKIGVAA	0.435	275.
76	150	AVVRGAALM	0.435	276.
77	65	LCMLSGIDI	0.428	277.
78	250	FIFYVPFIG	0.415	278.
79	45	LTHIYIVRT	0.405	279.
80	62	YIFLCMLSG	0.401	280.
81	112	MESTVLLAM	0.378	281.
82	168	LPFCRSNIL	0.360	282.
83	84	LAIFWFNST	0.334	283.

TABLE VII:				
HLA PEPTIDE SCORING RESULTS -101P3A11- A-0201, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
84	226	TVLGLTREA	0.322	284.
85	153	RGAAALMAPL	0.321	285.
86	284	VPPVLNPIV	0.316	286.
87	196	VNVVYGLIV	0.316	287.
88	127	AICHPLRHA	0.314	288.
89	149	AAVVRGAAL	0.297	289.
90	207	SAIGLDSLL	0.297	290.
91	76	STSSMPKML	0.297	291.
92	56	SLHEPMYIF	0.288	292.
93	206	ISAIGLDSL	0.267	293.
94	156	ALMAPLPVF	0.260	294.
95	39	IAVLGNLTI	0.246	295.
96	35	SLYLIAVLG	0.238	296.
97	17	IGLPGLEEA	0.230	297.
98	274	PVILANIYL	0.226	298.
99	186	VMKLACDDI	0.220	299.
100	99	CLLQIFAIH	0.215	300.

TABLE VIII:				
HLA PEPTIDE SCORING RESULTS -101P3A11- A-0201, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	56	SLHEPMYIFL	722.583	301.
2	117	LLAMAFDRYV	494.237	302.
3	213	SLLISFSYLL	300.355	303.
4	41	VLGNLTIIYI	224.357	304.
5	156	ALMAPLPVFI	212.307	305.
6	250	FIFYVPFIGL	94.987	306.
7	275	VILANIYLLV	90.231	307.
8	221	LLILKTVLGL	83.527	308.
9	100	LLQIFAIHSL	83.527	309.
10	139	TLPRVTKIGV	69.552	310.
11	253	YVPFIGLSMV	64.388	311.
12	94	IQFDACLLQI	62.741	312.
13	245	HVCAVFIFYV	57.690	313.
14	62	YIFLCMLSGI	56.155	314.
15	64	FLCMLSGIDI	47.991	315.
16	248	AVFIFYVPFI	42.727	316.
17	137	VLTLPRVTKI	40.792	317.
18	282	LLVPPVLNPI	40.792	318.
19	37	YLIAVLGNLT	34.279	319.
20	237	KAFGTCVSHV	28.772	320.
21	66	CMLSGIDILI	27.879	321.
22	234	AQAKAFGTCV	26.797	322.
23	214	LLISFSYLLI	26.604	323.
24	82	KMLAIFWFNS	26.114	324.
25	83	MLAIFWFNST	24.070	325.

TABLE VIII:

HLA PEPTIDE SCORING RESULTS -101P3A11- A-0201, 10-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
26	21	GLEEAQFWLA	18.576	326.
27	44	NLTIIYIVRT	17.140	327.
28	218	FSYLLILKTV	15.371	328.
29	303	RILRLFHVAT	14.407	329.
30	142	RVTKIGVAAV	13.997	330.
31	166	KQLPFCRSNI	13.698	331.
32	181	CLHQDVMKLA	11.426	332.
33	119	AMAFDRYVAI	11.302	333.
34	29	LAFPLCSLYL	10.264	334.
35	108	SLSGMESTVL	8.759	335.
36	167	QLPFCRSNIL	8.759	336.
37	227	VLGLTREACA	8.446	337.
38	301	RQRILRLFHV	7.149	338.
39	189	LACDDIRVNV	6.733	339.
40	205	IISAIGLDSL	5.628	340.
41	180	YCLHQDVMKL	5.459	341.
42	85	AIFWFNSTTI	5.308	342.
43	242	CVSHVCAVFI	5.021	343.
44	202	LIVIISAIGL	4.993	344.
45	229	GLTREACAQA	4.968	345.
46	291	IVYGVKTKEI	4.966	346.
47	215	LISFSYLLIL	4.709	347.
48	159	APLPVFIKQL	4.510	348.
49	283	LVPPVLNPV	4.242	349.
50	279	NIYLLVPPVL	3.854	350.
51	25	AQFWLAFPLC	3.541	351.
52	32	PLCSLYLIAV	3.519	352.
53	298	KEIRQRILRL	3.344	353.
54	74	LISTSSMPKM	2.671	354.
55	200	YGLIVIISAI	2.666	355.
56	195	RVNVVYGLIV	2.495	356.
57	38	LIAVLGNLTI	2.439	357.
58	240	GTCVSHVCAV	2.222	358.
59	222	LILKTVLGLT	1.927	359.
60	120	MAFDRYVAIC	1.678	360.
61	20	PGLEEAQFWL	1.485	361.
62	7	NESSATYFIL	1.482	362.
63	16	LIGLPGLEEA	1.309	363.
64	273	LPVILANIYL	1.304	364.
65	220	YLLILKTVLG	1.268	365.
66	286	PVLNPVYGV	1.139	366.
67	110	SGMESTVLLA	1.132	367.
68	91	STTIQFDACL	1.127	368.
69	99	CLLQIFAIHS	1.048	369.
70	278	ANIYLLVPPV	1.044	370.
71	127	AICHPLRHAT	1.025	371.
72	154	GAALMAPLPV	0.966	372.
73	89	FNSTTIQFDA	0.865	373.
74	197	NVVYGLIVII	0.861	374.

TABLE VIII:				
HLA PEPTIDE SCORING RESULTS -101P3A11- A-0201, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
75	232	REAQAKAFGT	0.840	375.
76	128	ICHPLRHATV	0.772	376.
77	42	LGNLTHIYIV	0.728	377.
78	190	ACDDIRVNVV	0.702	378.
79	10	SATYFILIGL	0.682	379.
80	84	LAIFWFNSTT	0.669	380.
81	187	MKLACDDIRV	0.608	381.
82	281	YLLVPPVLNP	0.583	382.
83	271	SPLPVILANI	0.580	383.
84	35	SLYLIAVLGN	0.548	384.
85	111	GMESTVLLAM	0.528	385.
86	148	VAAVVRGAAL	0.504	386.
87	162	PVFIKQLPFC	0.448	387.
88	116	VLLAMAFDRY	0.436	388.
89	150	AVVRGAALMA	0.435	389.
90	65	LCMLSGIDIL	0.405	390.
91	212	DSLLISFSYL	0.404	391.
92	112	MESTVLLAMA	0.378	392.
93	210	GLDSLLISFS	0.377	393.
94	28	WLAFPLCSLY	0.343	394.
95	31	FPLCSLYLIA	0.339	395.
96	59	EPMYIFLCML	0.338	396.
97	92	TTIQFDACLL	0.297	397.
98	79	SMPKMLAIFW	0.296	398.
99	306	RLFHVATHAS	0.276	399.
100	109	LSGMESTVLL	0.237	400.

TABLE IX:				
HLA PEPTIDE SCORING RESULTS -101P3A11- A3, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	229	GLTREAQAK	60.000	401.
2	137	VLTLPRVTK	30.000	402.
3	56	SLHEPMYIF	20.250	403.
4	260	SMVHRFSKR	18.000	404.
5	210	GLDSLLISF	18.000	405.
6	116	VLLAMAFDR	18.000	406.
7	44	NLTHIYIVR	12.000	407.
8	117	LLAMAFDRY	12.000	408.
9	21	GLEEAQFWL	8.100	409.
10	214	LLISFSYLL	8.100	410.
11	41	VLGNLTHIY	8.000	411.
12	156	ALMAPLPVF	6.750	412.
13	201	GLIVIISAI	6.075	413.
14	287	VLNPIVYGV	4.050	414.
15	74	LISTSSMPK	4.000	415.
16	181	CLHQDVMKL	3.600	416.

TABLE IX: HLA PEPTIDE SCORING RESULTS –101P3A11– A3, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
17	245	HVCAVFIFY	3.600	417.
18	111	GMESTVLLA	3.600	418.
19	79	SMPKMLAIF	3.000	419.
20	248	AVFIFYVPF	3.000	420.
21	158	MAPLPVFIK	2.700	421.
22	213	SLISFSYL	2.700	422.
23	67	MLSGIDILI	2.700	423.
24	306	RLFHVATHA	1.500	424.
25	60	PMYIFLCML	1.350	425.
26	28	WLAFLCSL	1.350	426.
27	99	CLLQIFAIH	1.350	427.
28	66	CMLSGIDIL	1.350	428.
29	82	KMLAIFWFN	1.215	429.
30	145	KIGVAAVVR	1.200	430.
31	188	KLACDDIRV	1.200	431..
32	164	FIKQLPFCR	1.200	432.
33	220	YLLILKTVL	0.900	433.
34	157	LMAPLVFI	0.900	434.
35	11	ATYFILIGL	0.675	435.
36	198	VVYGLIVII	0.675	436.
37	37	YLI AVLGNL	0.608	437.
38	167	QLPFCRSNI	0.600	438.
39	256	FIGLSMVHR	0.600	439.
40	276	ILANIYLLV	0.600	440.
41	119	AMAFDRYVA	0.600	441.
42	186	VMKLACDDI	0.600	442.
43	261	MVHRFSKRR	0.600	443.
44	222	LILKTVLGL	0.540	444.
45	259	LSMVHRFSK	0.450	445.
46	290	PIVYGVKTK	0.450	446.
47	282	LLVPPVLNP	0.405	447.
48	275	VILANIYLL	0.405	448.
49	125	YVAICHPLR	0.400	449.
50	83	MLAIFWFNS	0.360	450.
51	304	ILRLFHVAT	0.300	451.
52	29	LAFPLCSLY	0.300	452.
53	180	YCLHQDVMK	0.300	453.
54	108	SLSGMESTV	0.300	454.
55	242	CVSHVCAVF	0.300	455.
56	279	NIYLLVPPV	0.300	456.
57	114	STVLLAMAF	0.300	457.
58	174	NILSHSYCL	0.270	458.
59	25	AQFWLAFPL	0.270	459.
60	197	NVVYGLIVI	0.270	460.
61	100	LLQIFAIHS	0.240	461.
62	296	KTKEIRQRI	0.203	462.
63	138	LTLPRVTKI	0.203	463.
64	40	AVLGNLTHI	0.203	464.
65	283	LVPPVLNPI	0.203	465.

TABLE IX:				
HLA PEPTIDE SCORING RESULTS –101P3A11– A3, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
66	175	ILSHSYCLH	0.200	466.
67	162	PVFIKQLPF	0.200	467.
68	203	IVIISAIGL	0.180	468.
69	85	AIFWFNSTT	0.150	469.
70	35	SLYLI AVL G	0.150	470.
71	47	IIVIRTEH	0.150	471.
72	14	FILIGLPGL	0.135	472.
73	92	TTIQFDACL	0.135	473.
74	272	PLPVILANI	0.135	474.
75	216	ISFSYLLIL	0.135	475.
76	160	PLPVFIKQL	0.135	476.
77	208	AIGLDSLLI	0.120	477.
78	215	LISFSYLLI	0.120	478.
79	298	KEIRQRILR	0.108	479.
80	18	GLPGLEEAQ	0.090	480.
81	49	YIVRTEHSL	0.090	481.
82	303	RILRLFHVA	0.090	482.
83	134	HATVLTLP R	0.080	483.
84	223	ILKTVLGLT	0.068	484.
85	217	SFSYLLILK	0.060	485.
86	253	YVPFIGLSM	0.060	486.
87	273	LPVILANIY	0.060	487.
88	93	TIQFDACLL	0.060	488.
89	151	VVRGAALMA	0.060	489.
90	9	SSATYFILI	0.054	490.
91	299	EIRQRILRL	0.054	491.
92	237	KAFGTCVSH	0.045	492.
93	281	YLLVPPVLN	0.045	493.
94	250	FIFYVPFIG	0.045	494.
95	98	ACLLQIFAI	0.041	495.
96	212	DSLLISFSY	0.041	496.
97	31	FPLCSLYLI	0.041	497.
98	101	LQIFAIHSL	0.041	498.
99	32	PLCSLYLIA	0.040	499.
100	45	LTHYIVRT	0.034	500.

TABLE X:				
HLA PEPTIDE SCORING RESULTS –101P3A11– A3, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	157	LMAPLPVFIK	405.000	501.
2	258	GLSMVHRFSK	180.000	502.
3	73	ILISTSSMPK	60.000	503.
4	116	VLLAMAFDRY	18.000	504.
5	287	VLNPIVYGVK	13.500	505.
6	18	GLPGLEEAQF	9.000	506.
7	260	SMVHRFSKRR	9.000	507.

TABLE X: HLA PEPTIDE SCORING RESULTS -101P3A11- A3, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
8	213	SLISFSYLL	8.100	508.
9	21	GLEEAQFWLA	8.100	509.
10	223	ILKTVLGLTR	8.000	510.
11	221	LLILKTVLGL	5.400	511.
12	136	TVLTLPRVTK	4.500	512.
13	28	WLAFLCSLY	4.000	513.
14	186	VMKLACDDIR	4.000	514.
15	282	LLVPPVLNPI	3.038	515.
16	66	CMLSGIDILI	2.700	516.
17	248	AVFIFYVPFI	2.700	517.
18	111	GMESTVLLAM	2.700	518.
19	250	FIFYVPFIGL	2.700	519.
20	115	TVLLAMAFDR	1.800	520.
21	137	VLTLPRVTKI	1.800	521.
22	40	AVLGNLTHY	1.800	522.
23	56	SLHEPMYIFL	1.800	523.
24	214	LLISFSYLLI	1.800	524.
25	41	VLGNLTHIYI	1.800	525.
26	82	KMLAIFWFNS	1.620	526.
27	216	ISFSYLLILK	1.500	527.
28	64	FLCMLSGIDI	1.200	528.
29	100	LLQIFAIHSL	0.900	529.
30	108	SLSGMESTVL	0.900	530.
31	156	ALMAPLPVFI	0.900	531.
32	83	MLAIFWFNST	0.900	532.
33	256	FIGLSMVHRF	0.600	533.
34	304	ILRLFHVATH	0.600	534.
35	119	AMAFDRYVAI	0.600	535.
36	167	QLPFCRSNIL	0.600	536.
37	35	SLYLIAVLGN	0.600	537.
38	229	GLTREAQAKA	0.600	538.
39	215	LISFSYLLIL	0.540	539.
40	44	NLTHIYIVRT	0.450	540.
41	279	NIYLLVPPVL	0.450	541.
42	62	YIFLCMLSGI	0.450	542.
43	289	NPIVYGVKTK	0.450	543.
44	139	TLPRVTKIGV	0.400	544.
45	79	SMPKMLAIFW	0.400	545.
46	272	PLPVILANIY	0.400	546.
47	131	PLRHATVLT	0.360	547.
48	99	CLLQIFAIHS	0.360	548.
49	85	AIFWFNSTTI	0.300	549.
50	94	IQFDACLLQI	0.270	550.
51	281	YLLVPPVLNP	0.270	551.
52	198	VVYGLIVHIS	0.270	552.
53	245	HVCAVFIFYV	0.270	553.
54	193	DIRVNVVYGL	0.243	554.
55	181	CLHQDVMKLA	0.225	555.
56	291	IVYGVKTKEI	0.225	556.

TABLE X:				
HLA PEPTIDE SCORING RESULTS -101P3A11- A3, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
57	306	RLFHVATHAS	0.200	557.
58	227	VLGLTREAAQA	0.200	558.
59	32	PLCSLYLIAV	0.180	559.
60	294	GVKTKEIRQR	0.180	560.
61	210	GLDSSLISFS	0.180	561.
62	202	LIVIIAIGL	0.180	562.
63	67	MLSGIDILIS	0.180	563.
64	276	ILANIYLLVP	0.180	564.
65	37	YLIAVLGNLT	0.150	565.
66	15	ILIGLPGLEE	0.135	566.
67	197	NVVYGLIVII	0.135	567.
68	237	KAFGTCVSHV	0.135	568.
69	201	GLIVIIAIG	0.135	569.
70	166	KQLPFCRSNI	0.121	570.
71	175	ILSHSYCLHQ	0.120	571.
72	195	RVNVVYGLIV	0.120	572.
73	38	LIAVLGNLTI	0.120	573.
74	43	GNLTIIYIVR	0.108	574.
75	55	HSLHEPMYIF	0.101	575.
76	25	AQFWLAFPLC	0.090	576.
77	240	GTCVSHVCAV	0.090	577.
78	29	LAFPLCSLYL	0.090	578.
79	259	LSMVHRFSKR	0.090	579.
80	275	VILANIYLLV	0.090	580.
81	120	MAFDRYVAIC	0.090	581.
82	243	VSHVCAVFIF	0.090	582.
83	91	STTIQFDACL	0.090	583.
84	247	CAVFIFYVPF	0.090	584.
85	205	IISAIGLDSL	0.090	585.
86	80	MPKMLAIFWF	0.090	586.
87	284	VPPVLNPIVY	0.080	587.
88	230	LTREAQAKAF	0.075	588.
89	155	AALMAPLPVF	0.068	589.
90	242	CVSHVCAVFI	0.060	590.
91	161	LPVFIKQLPF	0.060	591.
92	117	LLAMAFDRYV	0.060	592.
93	150	AVVRGAALMA	0.060	593.
94	142	RVTKIGVAAV	0.060	594.
95	244	SHVCAVFIFY	0.054	595.
96	180	YCLHQDVMKL	0.054	596.
97	46	THIYIVRTEH	0.045	597.
98	241	TCVSHVCAVF	0.045	598.
99	92	TTIQFDACLL	0.045	599.
100	303	RILRLFHVAT	0.045	600.

TABLE XI:

HLA PEPTIDE SCORING RESULTS -101P3A11- A-1101, 9-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	229	GLTREAAQAK	1.200	601.
2	74	LISTSSMPK	0.800	602.
3	158	MAPLPVFIK	0.600	603.
4	217	SFSYLLILK	0.400	604.
5	125	YVAICHPLR	0.400	605.
6	137	VLTLPRTVK	0.400	606.
7	116	VLLAMAFDR	0.360	607.
8	180	YCLHQDVMK	0.300	608.
9	145	KIGVAAVVR	0.240	609.
10	164	FIKQLPFCR	0.240	610.
11	261	MVHRFSKRR	0.200	611.
12	44	NLTIIYIVR	0.160	612.
13	259	LSMVHRFSK	0.120	613.
14	260	SMVHRFSKR	0.120	614.
15	298	KEIRQRILR	0.108	615.
16	256	FIGLSMVHR	0.080	616.
17	134	HATVLTLPK	0.080	617.
18	142	RVTKIGVAA	0.060	618.
19	197	NVVGGLIVI	0.060	619.
20	203	IVIIISAIGL	0.060	620.
21	195	RVNVVYGLI	0.060	621.
22	151	VVRGAALMA	0.040	622.
23	245	HVCAVFIFY	0.040	623.
24	11	ATYFILIGL	0.040	624.
25	198	VVYGLIVII	0.040	625.
26	248	AVFIFYVPF	0.040	626.
27	288	LNPIVYGVK	0.040	627.
28	253	YVPFIGLSM	0.040	628.
29	301	RQRILRLFH	0.036	629.
30	21	GLEEAQFWL	0.036	630.
31	25	AQFWLAFPL	0.036	631.
32	290	PIVYGVKTK	0.030	632.
33	240	GTCVSHVCA	0.030	633.
34	296	KTKEIRQRI	0.030	634.
35	40	AVLGNLTII	0.030	635.
36	150	AVVRGAALM	0.030	636.
37	114	STVLLAMAF	0.030	637.
38	306	RLFHVATHA	0.024	638.
39	188	KLACDDIRV	0.024	639.
40	210	GLDSSLISF	0.024	640.
41	111	GMESTVLLA	0.024	641.
42	50	IVRTEHSLH	0.020	642.
43	242	CVSHVCAVF	0.020	643.
44	283	LVPPVLNPI	0.020	644.
45	303	RILRLFHVA	0.018	645.
46	124	RYVAICHPL	0.018	646.
47	201	GLIVIIISAI	0.018	647.
48	92	TTIQFDACL	0.015	648.
49	135	ATVLTLPKV	0.015	649.

TABLE XI:**HLA PEPTIDE SCORING RESULTS -101P3A11- A-1101, 9-MERS**

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
50	138	LTLPRVTKI	0.015	650.
51	237	KAFGTCVSH	0.012	651.
52	174	NILSHSYCL	0.012	652.
53	214	LLISFSYLL	0.012	653.
54	275	VILANIYLL	0.012	654.
55	222	LILKTVLGL	0.012	655.
56	294	GVKTKEIRQ	0.012	656.
57	143	VTKIGVAAV	0.010	657.
58	230	LTREAQAKA	0.010	658.
59	101	LQIFAIHSL	0.009	659.
60	98	ACLLQIFAI	0.009	660.
61	47	IYIVRTEH	0.008	661.
62	279	NIYLLVPPV	0.008	662.
63	56	SLHEPMYIF	0.008	663.
64	65	LCMLSGIDI	0.008	664.
65	67	MLSGIDILI	0.008	665.
66	208	AIGLDSLLI	0.008	666.
67	224	LKTVLGLTR	0.008	667.
68	181	CLHQDVMKL	0.008	668.
69	276	ILANIYLLV	0.008	669.
70	287	VLNPIVYGV	0.008	670.
71	156	ALMAPLPVF	0.008	671.
72	215	LISFSYLLI	0.008	672.
73	251	IFYVFIGL	0.008	673.
74	119	AMAFDRYVA	0.008	674.
75	41	VLGNLTHY	0.008	675.
76	162	PVFIKQLPF	0.008	676.
77	187	MKLACDDIR	0.006	677.
78	293	YGVKTKEIR	0.006	678.
79	213	SLISFSYL	0.006	679.
80	147	GVAADVVRGA	0.006	680.
81	39	IAVLGNLTI	0.006	681.
82	220	YLLILKTVL	0.006	682.
83	155	AALMAPLPV	0.006	683.
84	274	PVILANIYL	0.006	684.
85	66	CMLSGIDIL	0.006	685.
86	31	FPLCSLYLI	0.006	686.
87	126	VAICHPLRH	0.006	687.
88	14	FILIGLPGL	0.006	688.
89	37	YLI AVLGNL	0.006	689.
90	99	CLLQIFAIH	0.006	690.
91	280	IYLLVPPVL	0.006	691.
92	49	YIVRTEHSL	0.006	692.
93	246	VCAVFIFYV	0.006	693.
94	76	STSSMPKML	0.005	694.
95	225	KTVLGLTRE	0.005	695.
96	179	SYCLHQDVM	0.004	696.
97	29	LAFPLCSLY	0.004	697.
98	167	QLPFCRSNI	0.004	698.

TABLE XI:				
HLA PEPTIDE SCORING RESULTS -101P3A11- A-1101, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
99	28	WLAFLCSL	0.004	699.
100	117	LLAMAFDRY	0.004	700.

TABLE XII:				
HLA PEPTIDE SCORING RESULTS -101P3A11- A-1101, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	258	GLSMVHRFSK	3.600	701.
2	136	TVLTLPRVTK	3.000	702.
3	115	TVLLAMAFDR	1.800	703.
4	157	LMAPLPVFIK	1.200	704.
5	73	ILISTSSMPK	1.200	705.
6	287	VLNPIVYGVK	0.400	706.
7	179	SYCLHQDVMK	0.400	707.
8	124	RYVAICHPLR	0.360	708.
9	163	VFIKQLPFCR	0.180	709.
10	223	ILKTVLGLTR	0.160	710.
11	289	NPIVYGVKTK	0.150	711.
12	294	GVKTKEIRQR	0.120	712.
13	195	RVNVVYGLIV	0.120	713.
14	292	VYGVKTKEIR	0.080	714.
15	216	ISFSYLLILK	0.080	715.
16	186	VMKLACDDIR	0.080	716.
17	43	GNLTIYIVR	0.072	717.
18	147	GVAAVVRGAA	0.060	718.
19	245	HVCAVFIFYV	0.060	719.
20	142	RVTKIGVAAV	0.060	720.
21	150	AVVRGAALMA	0.060	721.
22	40	AVLGNLTIIY	0.060	722.
23	260	SMVHRFSKRR	0.060	723.
24	301	RQRILRLFHV	0.054	724.
25	248	AVFIFYVPFI	0.040	725.
26	125	YVAICHPLRH	0.040	726.
27	228	LGLTREAAQAK	0.030	727.
28	52	RTEHSLHEPM	0.030	728.
29	240	GTCVSHVCAV	0.030	729.
30	197	NVVYGLIVII	0.030	730.
31	166	KQLPFCRSNI	0.027	731.
32	133	RHATVLTLP	0.024	732.
33	94	IQFDACLLQI	0.024	733.
34	111	GMESTVLLAM	0.024	734.
35	21	GLEEAQFWLA	0.024	735.
36	291	IVYGVKTKEI	0.020	736.
37	242	CVSHVCAVFI	0.020	737.
38	253	YVPFIGLSMV	0.020	738.
39	76	STSSMPKMLA	0.020	739.
40	283	LVPPVLNPIV	0.020	740.
41	250	FIFYVPFIGL	0.016	741.

TABLE XII:

HLA PEPTIDE SCORING RESULTS -101P3A11- A-1101, 10-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
42	92	TTIQFDACLL	0.015	742.
43	202	LIVIISAIGL	0.012	743.
44	275	VILANIYLLV	0.012	744.
45	221	LLILKTVLGL	0.012	745.
46	229	GLTREAQAKA	0.012	746.
47	214	LLISFSYLLI	0.012	747.
48	18	GLPGLEEAQF	0.012	748.
49	154	GAALMAPLPV	0.012	749.
50	66	CMLSGIDILI	0.012	750.
51	213	SLLISFSYLL	0.012	751.
52	252	FYVPFIGLSM	0.012	752.
53	237	KAFGTCVSHV	0.012	753.
54	185	DVMKLACDDI	0.012	754.
55	91	STTIQFDACL	0.010	755.
56	143	VTKIGVAAVV	0.010	756.
57	56	SLHEPMYIFL	0.008	757.
58	79	SMPKMLAIFW	0.008	758.
59	297	TKEIRQRILR	0.008	759.
60	41	VLGNLTHIYI	0.008	760.
61	118	LAMAFDRYVA	0.008	761.
62	62	YIFLCMLSGI	0.008	762.
63	215	LISFSYLLIL	0.008	763.
64	64	FLCMLSGIDI	0.008	764.
65	199	VYGLIVIISA	0.008	765.
66	156	ALMAPLPVFI	0.008	766.
67	139	TLPRVTKIGV	0.008	767.
68	85	AIFWFNSTTI	0.008	768.
69	38	LI AVLGNLTI	0.008	769.
70	254	VPFIGLSMVH	0.008	770.
71	29	LAFPLCSLYL	0.008	771.
72	259	LSMVHRFSKR	0.008	772.
73	198	VVYGLIVIIS	0.008	773.
74	279	NIYLLVPPVL	0.008	774.
75	144	TKIGVAAVVR	0.006	775.
76	255	PFIGLSMVHR	0.006	776.
77	207	SAIGLDSLLI	0.006	777.
78	36	LYLIAVLGNL	0.006	778.
79	46	THIYIVRTEH	0.006	779.
80	286	PVLNPIVYGV	0.006	780.
81	49	YIVRTEHSLH	0.006	781.
82	80	MPKMLAIFWF	0.006	782.
83	161	LPVFIKQLPF	0.006	783.
84	264	RFSKR RDSPL	0.006	784.
85	174	NILSHSYCLH	0.006	785.
86	116	VLLAMAFDRY	0.006	786.
87	219	SYLLILKTVL	0.006	787.
88	180	YCLHQDVMKL	0.006	788.
89	31	FPLCSLYLIA	0.006	789.
90	48	IYIVRTEHSL	0.006	790.

TABLE XII:

HLA PEPTIDE SCORING RESULTS -101P3A11- A-1101, 10-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
91	274	PVILANIYLL	0.006	791.
92	273	LPVILANIYL	0.006	792.
93	282	LLVPPVLNPI	0.006	793.
94	234	AQAKAFGTCV	0.006	794.
95	82	KMLAIFWFNS	0.005	795.
96	298	KEIRQRILRL	0.005	796.
97	230	LTREAQAKAF	0.005	797.
98	225	KTVLGLTREA	0.005	798.
99	108	SLSGMESTVL	0.004	799.
100	10	SATYFILIGL	0.004	800.

TABLE XIII:

HLA PEPTIDE SCORING RESULTS -101P3A11- A24 , 9-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	124	RYVAICHPL	840.000	801.
2	280	IYLLVPPVL	420.000	802.
3	292	VYGVKTKEI	55.000	803.
4	30	AFPLCSLYL	30.000	804.
5	179	SYCLHQDVM	25.000	805.
6	251	IFYVFIGL	24.000	806.
7	88	WFNSTTIQF	15.000	807.
8	219	SYLLILKTV	10.500	808.
9	153	RGAALMAPL	9.600	809.
10	252	FYVFIGLS	9.000	810.
11	61	MYIFLCMLS	9.000	811.
12	37	YLI AVLGNL	8.400	812.
13	36	LYLIAVLGN	7.500	813.
14	249	VFIFYVPFI	7.500	814.
15	63	IFLCMLSGI	7.500	815.
16	48	IYIVRTEHS	7.500	816.
17	213	SLISFSYL	7.200	817.
18	207	SAIGLDSLL	7.200	818.
19	220	YLLILKTVL	7.200	819.
20	34	CSLYLIAVL	7.200	820.
21	21	GLEEAQFWL	7.200	821.
22	110	SGMESTVLL	7.200	822.
23	199	VYGLIVIIS	7.000	823.
24	92	TTIQFDACL	6.000	824.
25	66	CMLSGIDIL	6.000	825.
26	174	NILSHSYCL	6.000	826.
27	49	YIVRTEHSL	6.000	827.
28	275	VILANIYLL	6.000	828.
29	149	AAVVRGAAL	6.000	829.
30	101	LQIFAIHSL	6.000	830.
31	222	LILKTVLGL	6.000	831.
32	130	HPLRHATVL	6.000	832.
33	214	LLISFSYLL	6.000	833.

TABLE XIII:

HLA PEPTIDE SCORING RESULTS -101P3A11- A24 , 9-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
34	93	TIQFDACLL	6.000	834.
35	14	FILIGLPGL	6.000	835.
36	203	IVIISAIGL	6.000	836.
37	11	ATYFILIGL	5.600	837.
38	86	IFWFNSTTI	5.000	838.
39	95	QFDACLLQI	5.000	839.
40	25	AQFWLAFPL	4.800	840.
41	168	LPFCRSNIL	4.800	841.
42	181	CLHQDVMKL	4.400	842.
43	195	RVNVVYGLI	4.200	843.
44	296	KTKEIRQRI	4.032	844.
45	265	FSKRSDSPL	4.000	845.
46	206	ISAIGLDSL	4.000	846.
47	216	ISFSYLLIL	4.000	847.
48	28	WLAFPLCSL	4.000	848.
49	76	STSSMPKML	4.000	849.
50	8	ESSATYFIL	4.000	850.
51	109	LSGMESTVL	4.000	851.
52	299	EIRQRILRL	4.000	852.
53	114	STVLLAMAF	3.600	853.
54	283	LVPPVLNPI	3.024	854.
55	156	ALMAPLPVF	3.000	855.
56	257	IGLSMVHRF	3.000	856.
57	6	GNESSATYF	3.000	857.
58	79	SMPKMLAIF	3.000	858.
59	242	CVSHVCAVF	2.800	859.
60	210	GLDSSLISF	2.400	860.
61	56	SLHEPMYIF	2.400	861.
62	201	GLIVIIISAI	2.100	862.
63	19	LPGLEEAQF	2.000	863.
64	248	AVFIFYVPF	2.000	864.
65	138	LTLPRVTKI	1.980	865.
66	78	SSMPKMLAI	1.800	866.
67	197	NVVYGLIVI	1.500	867.
68	98	ACLLQIFAI	1.500	868.
69	42	LGNLTIIYI	1.500	869.
70	55	HSLHEPMYI	1.500	870.
71	65	LCMLSGIDI	1.500	871.
72	39	IAVLGNLTI	1.500	872.
73	167	QLPFCRSNI	1.500	873.
74	40	AVLGNLTII	1.500	874.
75	31	FPLCSLYLI	1.500	875.
76	157	LMAPLPVFI	1.440	876.
77	67	MLSGIDILI	1.400	877.
78	59	EPMYIFLCM	1.260	878.
79	120	MAFDRYVAI	1.200	879.
80	9	SSATYFILI	1.200	880.
81	198	VVYGLIVII	1.200	881.
82	269	RDSPLPVIL	1.152	882.

TABLE XIII:				
HLA PEPTIDE SCORING RESULTS -101P3A11- A24 , 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
83	253	YVPFIGLSM	1.050	883.
84	243	VSHVCAVFI	1.000	884.
85	208	AIGLDSLLI	1.000	885.
86	186	VMKLACDDI	1.000	886.
87	215	LISFSYLLI	1.000	887.
88	194	IRVNVVYGL	0.840	888.
89	72	DILISTSSM	0.750	889.
90	163	VFIKQLPFC	0.750	890.
91	104	FAIHSLSGM	0.750	891.
92	150	AVVRGAALM	0.750	892.
93	57	LHEPMYIFL	0.720	893.
94	12	TYFILIGLP	0.600	894.
95	160	PLPVFIKQL	0.600	895.
96	26	QFWLAFPLC	0.600	896.
97	297	TKEIRQRIL	0.600	897.
98	274	PVILANIYL	0.600	898.
99	75	ISTSSMPKM	0.550	899.
100	82	KMLAIFWFN	0.504	900.

TABLE XIV:				
HLA PEPTIDE SCORING RESULTS -101P3A11- A24 , 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	36	LYLIAVLGNL	420.000	901.
2	219	SYLLILKTVL	360.000	902.
3	48	IYIVRTEHSL	300.000	903.
4	252	FYVPFIGLSM	63.000	904.
5	264	RFSKRSDSPL	40.000	905.
6	13	YFILIGLPGL	30.000	906.
7	95	QFDACLLQIF	14.400	907.
8	296	KTKEIRQRIL	9.600	908.
9	30	AFPLCSLYLI	7.500	909.
10	280	IYLLVPPVLN	7.500	910.
11	24	EAQFWLAFPL	7.200	911.
12	167	QLPFCRSNIL	7.200	912.
13	159	APLPVFIKQL	7.200	913.
14	212	DSLLISFSYL	7.200	914.
15	199	VYGLIVIISA	7.000	915.
16	180	YCLHQDVMKL	6.600	916.
17	65	LCMLSGIDIL	6.000	917.
18	92	TTIQFDACLL	6.000	918.
19	27	FWLAFPLCSL	6.000	919.
20	213	SLISFSYLL	6.000	920.
21	59	EPMYIFLCML	6.000	921.
22	273	LPVILANIYL	6.000	922.
23	221	LLILKTVLGL	6.000	923.
24	202	LIVIISAIGL	6.000	924.

TABLE XIV:

HLA PEPTIDE SCORING RESULTS -101P3A11- A24, 10-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
25	173	SNILSHSYCL	6.000	925.
26	100	LLQIFAIHSL	6.000	926.
27	279	NIYLLVPPVL	5.600	927.
28	193	DIRVNVVYGL	5.600	928.
29	10	SATYFILIGL	5.600	929.
30	250	FIFYVPFIGL	4.800	930.
31	29	LAFPLCSLYL	4.800	931.
32	56	SLHEPMYIFL	4.800	932.
33	33	LCSLYLIAVL	4.800	933.
34	206	ISAIGLDSLL	4.800	934.
35	209	IGLDSLLISF	4.320	935.
36	241	TCVSHVCAVF	4.200	936.
37	215	LISFSYLLIL	4.000	937.
38	108	SLSGMESTVL	4.000	938.
39	148	VAAVVRGAAL	4.000	939.
40	205	IISAIGLDSL	4.000	940.
41	91	STTIQFDACL	4.000	941.
42	75	ISTSSMPKML	4.000	942.
43	109	LSGMESTVLL	4.000	943.
44	166	KQLPFCRSNI	3.600	944.
45	78	SSMPKMLAIF	3.600	945.
46	5	NGNESSATYF	3.600	946.
47	282	LLVPPVLNPI	3.024	947.
48	55	HSLHEPMYIF	3.000	948.
49	161	LPVFIKQLPF	3.000	949.
50	155	AALMAPLPVF	3.000	950.
51	247	CAVFIFYVPF	3.000	951.
52	18	GLPGLEEAQF	3.000	952.
53	299	EIRQRILRLF	2.800	953.
54	271	SPLPVILANI	2.520	954.
55	103	IFAIHSLSGM	2.500	955.
56	230	LTREAQAKAF	2.400	956.
57	113	ESTVLLAMAF	2.400	957.
58	66	CMLSGIDILI	2.100	958.
59	200	YGLIVIISAI	2.100	959.
60	256	FIGLSMVHRF	2.000	960.
61	243	VSHVCAVFIF	2.000	961.
62	87	FWFNSTTIQF	2.000	962.
63	80	MPKMLAIFWF	2.000	963.
64	156	ALMAPLPVFI	1.800	964.
65	52	RTEHSLHEPM	1.800	965.
66	197	NVVYGLIVII	1.800	966.
67	6	GNESSATYFI	1.500	967.
68	124	RYVAICHPLR	1.500	968.
69	214	LLISFSYLLI	1.500	969.
70	207	SAIGLDSLLI	1.500	970.
71	196	VNVVYGLIVI	1.500	971.
72	185	DVMKLACDDI	1.500	972.
73	39	IAVLGNLTII	1.500	973.

TABLE XIV:

HLA PEPTIDE SCORING RESULTS -101P3A11- A24, 10-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
74	94	IQFDACLLQI	1.200	974.
75	298	KEIRQRILRL	1.200	975.
76	8	ESSATYFILI	1.200	976.
77	291	IVYGVKTKEI	1.100	977.
78	137	VLTLPRVTKI	1.100	978.
79	111	GMESTVLLAM	1.050	979.
80	85	AIFWFNSTTI	1.000	980.
81	41	VLGNLTIIYI	1.000	981.
82	97	DACLLQIFAI	1.000	982.
83	119	AMAFDRYVAI	1.000	983.
84	77	TSSMPKMLAI	1.000	984.
85	38	LIAVLGNLTI	1.000	985.
86	248	AVFIFYVPFI	1.000	986.
87	64	FLCMLSGIDI	1.000	987.
88	62	YIFLCMLSGI	1.000	988.
89	242	CVSHVCAVFI	1.000	989.
90	268	RRDSPLPVIL	0.960	990.
91	61	MYIFLCMLSG	0.750	991.
92	149	AAVVRGAALM	0.750	992.
93	20	PGLEEAQFWL	0.720	993.
94	12	TYFILIGLPG	0.700	994.
95	238	AFGTCVSHVC	0.700	995.
96	217	SFSYLLILKT	0.660	996.
97	129	CHPLRHATVL	0.600	997.
98	274	PVILANIYLL	0.600	998.
99	123	DRYVAICHPL	0.560	999.
100	74	LISTSSMPKM	0.550	1000.

TABLE XV:

HLA PEPTIDE SCORING RESULTS -101P3A11- B7, 9-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	130	HPLRHATVL	80.000	1001.
2	168	LPFCRSNIL	80.000	1002.
3	59	EPMYIFLCM	60.000	1003.
4	299	EIRQRILRL	40.000	1004.
5	140	LPRVTKIGV	40.000	1005.
6	149	AAVVRGAAL	36.000	1006.
7	203	IVIISAIGL	20.000	1007.
8	150	AVVRGAALM	15.000	1008.
9	110	SGMESTVLL	12.000	1009.
10	11	ATYFILIGL	12.000	1010.
11	25	AQFWLAFPL	12.000	1011.
12	207	SAIGLDSLL	12.000	1012.
13	31	FPLCSLYLI	8.000	1013.
14	28	WLAFLCSL	6.000	1014.
15	40	AVLGNLTII	6.000	1015.
16	151	VVRGAALMA	5.000	1016.

TABLE XV: HLA PEPTIDE SCORING RESULTS -101P3A11- B7, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
17	253	YVPFIGLSM	5.000	1017.
18	109	LSGMESTVL	4.000	1018.
19	275	VILANIYLL	4.000	1019.
20	216	ISFSYLLIL	4.000	1020.
21	220	YLLILKTVL	4.000	1021.
22	181	CLHQDVMKL	4.000	1022.
23	254	VPFIGLSMV	4.000	1023.
24	222	LILKTVLGL	4.000	1024.
25	93	TIQFDACLL	4.000	1025.
26	76	STSSMPKML	4.000	1026.
27	49	YIVRTEHSL	4.000	1027.
28	153	RGAALMAPL	4.000	1028.
29	92	TTIQFDACL	4.000	1029.
30	14	FILIGLPGL	4.000	1030.
31	101	LQIFAIHSL	4.000	1031.
32	213	LLISFSYL	4.000	1032.
33	174	NILSHSYCL	4.000	1033.
34	265	FSKRRDSPL	4.000	1034.
35	37	YLI AVLGNL	4.000	1035.
36	284	VPPVLNPIV	4.000	1036.
37	214	LLISFSYLL	4.000	1037.
38	34	CSLYLIAVL	4.000	1038.
39	66	CMLSGIDIL	4.000	1039.
40	206	ISAIGLDSL	4.000	1040.
41	8	ESSATYFIL	4.000	1041.
42	104	FAIHSLSGM	3.000	1042.
43	283	LVPPVLNPI	2.000	1043.
44	289	NPIVYGVKT	2.000	1044.
45	195	RVNVVYGLI	2.000	1045.
46	197	NVVYGLIVI	2.000	1046.
47	3	DPNGNESSA	2.000	1047.
48	198	VVYGLIVII	2.000	1048.
49	274	PVILANIYL	2.000	1049.
50	118	LAMAFDRYV	1.800	1050.
51	155	AALMAPLPV	1.800	1051.
52	39	IAVLGNLTI	1.200	1052.
53	21	GLEEAQFWL	1.200	1053.
54	98	ACLLQIFAI	1.200	1054.
55	120	MAFDRYVAI	1.200	1055.
56	208	AIGLDSLLI	1.200	1056.
57	78	SSMPKMLAI	1.200	1057.
58	65	LCMLSGIDI	1.200	1058.
59	30	AFPLCSLYL	1.200	1059.
60	304	ILRLFHVAT	1.000	1060.
61	72	DILISTSSM	1.000	1061.
62	75	ISTSSMPKM	1.000	1062.
63	230	LTREAAKAKA	1.000	1063.
64	235	QAKAFGTCV	0.600	1064.
65	251	IFYVPFIGL	0.600	1065.

TABLE XV:				
HLA PEPTIDE SCORING RESULTS –101P3A11– B7, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
66	167	QLPFCRSNI	0.600	1066.
67	296	KTKEIRQRI	0.600	1067.
68	135	ATVLTLP RV	0.600	1068.
69	159	APLPVFIKQ	0.600	1069.
70	147	GVAAVVRGA	0.500	1070.
71	50	IVRTEHSLH	0.500	1071.
72	136	TVLTLP RV T	0.500	1072.
73	226	TVLGLTREA	0.500	1073.
74	142	RVTKIGVAA	0.500	1074.
75	119	AMAFDRYVA	0.450	1075.
76	127	AICHPLRHA	0.450	1076.
77	148	VAAVVRGAA	0.450	1077.
78	273	LPVILANIY	0.400	1078.
79	271	SPLPVILAN	0.400	1079.
80	215	LISFSYLLI	0.400	1080.
81	269	RDSPLPVIL	0.400	1081.
82	80	MPKMLAIFW	0.400	1082.
83	124	RYVAICHPL	0.400	1083.
84	9	SSATYFILI	0.400	1084.
85	42	LGNLTHIYI	0.400	1085.
86	60	PMYIFLCML	0.400	1086.
87	280	IYLLVPPVL	0.400	1087.
88	67	MLSGIDILI	0.400	1088.
89	132	LRHATVLT L	0.400	1089.
90	55	HSLHEPMYI	0.400	1090.
91	157	LMAPLPVFI	0.400	1091.
92	138	LTLPRVTKI	0.400	1092.
93	160	PLPVFIKQL	0.400	1093.
94	19	LPGLEEAQF	0.400	1094.
95	194	IRVNVVYGL	0.400	1095.
96	186	VMKLACDDI	0.400	1096.
97	201	GLIVII SAI	0.400	1097.
98	243	VSHVCAVFI	0.400	1098.
99	85	AIFWFNSTT	0.300	1099.
100	248	AVFIFYVPF	0.300	1100.

TABLE XVI:				
HLA PEPTIDE SCORING RESULTS –101P3A11– B7, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	59	EPMYIFLCML	240.000	1101.
2	159	APLPVFIKQL	240.000	1102.
3	273	LPVILANIYL	80.000	1103.
4	193	DIRVNVVYGL	40.000	1104.
5	140	LPRVTKIGVA	20.000	1105.
6	65	LCMLSGIDIL	12.000	1106.
7	10	SATYFILIGL	12.000	1107.
8	24	EAQFWLAFPL	12.000	1108.

TABLE XVI:				
HLA PEPTIDE SCORING RESULTS -101P3A11- B7, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
9	29	LAFPLCSLYL	12.000	1109.
10	148	VAAVVRGAAL	12.000	1110.
11	149	AAVVRGAALM	9.000	1111.
12	271	SPLPVILANI	8.000	1112.
13	185	DVMKLACDDI	6.000	1113.
14	250	FIFYVPFIGL	6.000	1114.
15	248	AVFIFYVPFI	6.000	1115.
16	108	SLSGMESTVL	4.000	1116.
17	91	STTIQFDACL	4.000	1117.
18	92	TTIQFDACLL	4.000	1118.
19	206	ISAIGLDSLL	4.000	1119.
20	202	LIVIISAIGL	4.000	1120.
21	296	KTKEIRQRIL	4.000	1121.
22	212	DSLLISFSYL	4.000	1122.
23	205	IISAIGLDSL	4.000	1123.
24	131	PLRHATVLT	4.000	1124.
25	100	LLQIFAIHSL	4.000	1125.
26	109	LSGMESTVLL	4.000	1126.
27	33	LCSLYLIAVL	4.000	1127.
28	221	LLILKTVLGL	4.000	1128.
29	56	SLHEPMYIFL	4.000	1129.
30	215	LISFSYLLIL	4.000	1130.
31	173	SNILSHSYCL	4.000	1131.
32	167	QLPFCRSNIL	4.000	1132.
33	279	NIYLLVPPVL	4.000	1133.
34	75	ISTSSMPKML	4.000	1134.
35	213	SLLISFSYLL	4.000	1135.
36	180	YCLHQDVMKL	4.000	1136.
37	156	ALMAPLPVFI	3.600	1137.
38	274	PVILANIYLL	2.000	1138.
39	301	RQRILRLFHV	2.000	1139.
40	197	NVVGGLIVII	2.000	1140.
41	130	HPLRHATVLT	2.000	1141.
42	31	FPLCSLYLIA	2.000	1142.
43	242	CVSHVCAVFI	2.000	1143.
44	291	IVYGVKTKEI	2.000	1144.
45	3	DPNGNESSAT	2.000	1145.
46	150	AVVRGAALMA	1.500	1146.
47	118	LAMAFDRYVA	1.350	1147.
48	39	IAVLGNLTII	1.200	1148.
49	97	DACLLQIFAI	1.200	1149.
50	85	AIFWFNSTTI	1.200	1150.
51	119	AMAFDRYVAI	1.200	1151.
52	207	SAIGLDSLLI	1.200	1152.
53	195	RVNVVYGLIV	1.000	1153.
54	178	HSYCLHQDVM	1.000	1154.
55	253	YVPFIGLSMV	1.000	1155.
56	142	RVTKIGVAAV	1.000	1156.
57	283	LVPPVLNPIV	1.000	1157.

TABLE XVI:				
HLA PEPTIDE SCORING RESULTS –101P3A11– B7, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
58	245	HVCAVFIFYV	1.000	1158.
59	74	LISTSSMPKM	1.000	1159.
60	189	LACDDIRVNV	0.900	1160.
61	147	GVAAVVRGAA	0.750	1161.
62	27	FWLAFPLCSL	0.600	1162.
63	154	GAALMAPLPV	0.600	1163.
64	278	ANIYLLVPPV	0.600	1164.
65	166	KQLPFCRSNI	0.600	1165.
66	134	HATVLTLPV	0.600	1166.
67	267	KRRDSPLPVI	0.600	1167.
68	237	KAFGTCVSHV	0.600	1168.
69	234	AQAKAFGTCV	0.600	1169.
70	50	IVRTEHSLHE	0.500	1170.
71	151	VVRGAALMAP	0.500	1171.
72	127	AICHPLRHAT	0.450	1172.
73	126	VAICHPLRHA	0.450	1173.
74	36	LYLIAVLGNL	0.400	1174.
75	7	NESSATYFIL	0.400	1175.
76	129	CHPLRHATVL	0.400	1176.
77	214	LLISFSYLLI	0.400	1177.
78	80	MPKMLAIFWF	0.400	1178.
79	66	CMLSGIDILI	0.400	1179.
80	77	TSSMPKMLAI	0.400	1180.
81	168	LPFCRSNILS	0.400	1181.
82	137	VLTLPVTKI	0.400	1182.
83	19	LPGLEEAQFW	0.400	1183.
84	8	ESSATYFILI	0.400	1184.
85	123	DRYVAICHPL	0.400	1185.
86	298	KEIRQRILRL	0.400	1186.
87	20	PGLEEAQFWL	0.400	1187.
88	94	IQFDACLLQI	0.400	1188.
89	284	VPPVLNPIVY	0.400	1189.
90	196	VNVVYGLIVI	0.400	1190.
91	41	VLGNLTHIYI	0.400	1191.
92	264	RFSKRRDSPL	0.400	1192.
93	38	LIAVLGNLTI	0.400	1193.
94	282	LLVPPVLNPI	0.400	1194.
95	48	IYIVRTEHSL	0.400	1195.
96	13	YFILIGLPGL	0.400	1196.
97	62	YIFLCMLSGI	0.400	1197.
98	64	FLCMLSGIDI	0.400	1198.
99	161	LPVFIKQLPF	0.400	1199.
100	152	VRGAALMAPL	0.400	1200.

TABLE XVII:

HLA PEPTIDE SCORING RESULTS -101P3A11- B-3501, 9-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	273	LPVILANIY	40.000	1201.
2	59	EPMYIFLCM	40.000	1202.
3	19	LPGLEEAQF	30.000	1203.
4	80	MPKMLAIFW	30.000	1204.
5	130	HPLRHATVL	20.000	1205.
6	172	RSNILSHSY	20.000	1206.
7	168	LPFCRSNIL	20.000	1207.
8	265	FSKRRDSPL	15.000	1208.
9	140	LPRVTKIGV	12.000	1209.
10	212	DSLLISFSY	10.000	1210.
11	75	ISTSSMPKM	10.000	1211.
12	31	FPLCSLYLI	8.000	1212.
13	109	LSGMESTVL	7.500	1213.
14	29	LAFPLCSLY	6.000	1214.
15	104	FAIHSLSGM	6.000	1215.
16	34	CSLYLIAVL	5.000	1216.
17	8	ESSATYFIL	5.000	1217.
18	206	ISAIGLDSL	5.000	1218.
19	216	ISFSYLLIL	5.000	1219.
20	296	KTKEIRQRI	4.800	1220.
21	284	VPPVLNPIV	4.000	1221.
22	5	NGNESSATY	4.000	1222.
23	254	VPFIGLSMV	4.000	1223.
24	285	PPVLNPIVY	4.000	1224.
25	299	EIRQIRLRL	3.000	1225.
26	55	HSLHEPMYI	3.000	1226.
27	149	AAVVRGAAL	3.000	1227.
28	207	SAIGLDSLL	3.000	1228.
29	120	MAFDRYVAI	2.400	1229.
30	110	SGMESTVLL	2.000	1230.
31	150	AVVRGAALM	2.000	1231.
32	56	SLHEPMYIF	2.000	1232.
33	78	SSMPKMLAI	2.000	1233.
34	117	LLAMAFDRY	2.000	1234.
35	245	HVCAVFIFY	2.000	1235.
36	243	VSHVCAVFI	2.000	1236.
37	41	VLGNLTHIY	2.000	1237.
38	271	SPLPVILAN	2.000	1238.
39	3	DPNGNESSA	2.000	1239.
40	72	DILISTSSM	2.000	1240.
41	153	RGAALMAPL	2.000	1241.
42	253	YVPFIGLSM	2.000	1242.
43	9	SSATYFILI	2.000	1243.
44	289	NPIVYGVKT	2.000	1244.
45	235	QAKAFGTCV	1.800	1245.
46	181	CLHQDVMKL	1.500	1246.
47	93	TIQFDACLL	1.500	1247.
48	39	IAVLGNLTI	1.200	1248.
49	186	VMKLACDDI	1.200	1249.

TABLE XVII: HLA PEPTIDE SCORING RESULTS –101P3A11– B-3501, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
50	275	VILANIYLL	1.000	1250.
51	66	CMLSGIDIL	1.000	1251.
52	49	YIVRTEHSL	1.000	1252.
53	242	CVSHVCAVF	1.000	1253.
54	203	IVIISAIGL	1.000	1254.
55	14	FILIGLPGL	1.000	1255.
56	222	LILKTVLGL	1.000	1256.
57	25	AQFWLAFPL	1.000	1257.
58	214	LLISFSYLL	1.000	1258.
59	114	STVLLAMAF	1.000	1259.
60	101	LQIFAIHSL	1.000	1260.
61	92	TTIQFDACL	1.000	1261.
62	257	IGLSMVHRF	1.000	1262.
63	28	WLAFLCSL	1.000	1263.
64	79	SMPKMLAIF	1.000	1264.
65	178	HSYCLHQDV	1.000	1265.
66	37	YLI AVLGNL	1.000	1266.
67	174	NILSHSYCL	1.000	1267.
68	156	ALMAPLPVF	1.000	1268.
69	213	SLISFSYL	1.000	1269.
70	220	YLLILKTVL	1.000	1270.
71	248	AVFIFYVPF	1.000	1271.
72	76	STSSMPKML	1.000	1272.
73	11	ATYFILIGL	1.000	1273.
74	189	LACDDIRVN	0.900	1274.
75	195	RVNVVYGLI	0.800	1275.
76	68	LSGIDILIS	0.750	1276.
77	118	LAMAFDRYV	0.600	1277.
78	143	VTKIGVAAV	0.600	1278.
79	21	GLEEAQFWL	0.600	1279.
80	188	KLACDDIRV	0.600	1280.
81	208	AIGLDSLLI	0.600	1281.
82	155	AALMAPLPV	0.600	1282.
83	230	LTREAQAKA	0.600	1283.
84	113	ESTVLLAMA	0.500	1284.
85	90	NSTTIQFDA	0.500	1285.
86	218	FSYLLILKT	0.500	1286.
87	77	TSSMPKMLA	0.500	1287.
88	107	HSLSGMEST	0.500	1288.
89	270	DSPLPVILA	0.500	1289.
90	167	QLPFCRSNI	0.400	1290.
91	198	VVYGLIVII	0.400	1291.
92	201	GLIVIIISAI	0.400	1292.
93	197	NVVYGLIVI	0.400	1293.
94	98	ACLLQIFAI	0.400	1294.
95	67	MLSGIDILI	0.400	1295.
96	138	LTLPRVTKI	0.400	1296.
97	157	LMAPLPVFI	0.400	1297.
98	283	LVPPVLNPI	0.400	1298.

TABLE XVII:				
HLA PEPTIDE SCORING RESULTS -101P3A11- B-3501, 9-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
99	40	AVLGNLTI	0.400	1299.
100	215	LISFSYLLI	0.400	1300.

TABLE XVIII:				
HLA PEPTIDE SCORING RESULTS -101P3A11- B-3501, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
1	80	MPKMLAIFWF	60.000	1301.
2	284	VPPVLNPIVY	40.000	1302.
3	273	LPVILANIYL	20.000	1303.
4	159	APLPVFIKQL	20.000	1304.
5	59	EPMYIFLCML	20.000	1305.
6	161	LPVFIKQLPF	20.000	1306.
7	19	LPGLEEAQFW	15.000	1307.
8	296	KTKEIRQRIL	12.000	1308.
9	178	HSYCLHQDVM	10.000	1309.
10	271	SPLPVILANI	8.000	1310.
11	140	LPRVTKIGVA	6.000	1311.
12	230	LTREAQAKAF	6.000	1312.
13	149	AAVVRGAALM	6.000	1313.
14	206	ISAIGLDSLL	5.000	1314.
15	75	ISTSSMPKML	5.000	1315.
16	243	VSHVCAVFIF	5.000	1316.
17	212	DSLLISFSYL	5.000	1317.
18	113	ESTVLLAMAF	5.000	1318.
19	78	SSMPKMLAIF	5.000	1319.
20	55	HSLHEPMYIF	5.000	1320.
21	109	LSGMESTVLL	5.000	1321.
22	10	SATYFILIGL	3.000	1322.
23	193	DIRVNVVYGL	3.000	1323.
24	155	AALMAPLPVF	3.000	1324.
25	299	EIRQRILRLF	3.000	1325.
26	3	DPNGNESSAT	3.000	1326.
27	148	VAAVVRGAAL	3.000	1327.
28	29	LAFPLCSLYL	3.000	1328.
29	24	EAQFWLAFPL	3.000	1329.
30	247	CAVFIFYVPF	3.000	1330.
31	56	SLHEPMYIFL	2.000	1331.
32	74	LISTSSMPKM	2.000	1332.
33	130	HPLRHATVLT	2.000	1333.
34	77	TSSMPKMLAI	2.000	1334.
35	5	NGNESSATYF	2.000	1335.
36	116	VLLAMAFDRY	2.000	1336.
37	28	WLAFLCSLY	2.000	1337.
38	31	FPLCSLYLIA	2.000	1338.
39	168	LPFCRSNILS	2.000	1339.
40	8	ESSATYFILI	2.000	1340.
41	40	AVLGNLTHY	2.000	1341.

TABLE XVIII:

HLA PEPTIDE SCORING RESULTS -101P3A11- B-3501, 10-MERS

RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
42	209	IGLDSLLISF	2.000	1342.
43	207	SAIGLDSLLI	1.800	1343.
44	18	GLPGLEEAQF	1.500	1344.
45	108	SLSGMESTVL	1.500	1345.
46	180	YCLHQDVMKL	1.500	1346.
47	92	TTIQFDACLL	1.500	1347.
48	237	KAFGTCVSHV	1.200	1348.
49	97	DACLLQIFAI	1.200	1349.
50	39	IAVLGNLTII	1.200	1350.
51	301	RQRILRLFHV	1.200	1351.
52	52	RTEHSLHEPM	1.200	1352.
53	189	LACDDIRVNV	1.200	1353.
54	218	FSYLLILKTV	1.000	1354.
55	241	TCVSHVCAVF	1.000	1355.
56	215	LISFSYLLIL	1.000	1356.
57	33	LCSLYLIAVL	1.000	1357.
58	202	LIVIISAIGL	1.000	1358.
59	221	LLILKTVLGL	1.000	1359.
60	172	RSNILSHSYC	1.000	1360.
61	100	LLQIFAIHSL	1.000	1361.
62	173	SNILSHSYCL	1.000	1362.
63	279	NIYLLVPPVL	1.000	1363.
64	107	HSLSGMESTV	1.000	1364.
65	65	LCMLSGIDIL	1.000	1365.
66	205	IISAIGLDSL	1.000	1366.
67	91	STTIQFDACL	1.000	1367.
68	250	FIFYVPFIGL	1.000	1368.
69	213	SLLISFSYLL	1.000	1369.
70	256	FIGLSMVHRF	1.000	1370.
71	167	QLPFCRSNIL	1.000	1371.
72	235	QAKAFGTCVS	0.900	1372.
73	94	IQFDACLLQI	0.800	1373.
74	166	KQLPFCRSNI	0.800	1374.
75	134	HATVLTLPV	0.600	1375.
76	111	GMESTVLLAM	0.600	1376.
77	154	GAALMAPLPV	0.600	1377.
78	143	VTKIGVAAVV	0.600	1378.
79	120	MAFDYVAIC	0.600	1379.
80	68	LSGIDILIST	0.500	1380.
81	90	NSTTIQFDAC	0.500	1381.
82	79	SMPKMLAIFW	0.500	1382.
83	270	DSPLPVILAN	0.500	1383.
84	267	KRRDSPLPVI	0.480	1384.
85	118	LAMAFDRYVA	0.450	1385.
86	291	IVYGVKTKEI	0.400	1386.
87	282	LLVPPVLNPI	0.400	1387.
88	242	CVSHVCAVFI	0.400	1388.
89	64	FLCMLSGIDI	0.400	1389.
90	85	AIFWFNSTTI	0.400	1390.

TABLE XVIII: HLA PEPTIDE SCORING RESULTS –101P3A11– B-3501, 10-MERS				
RANK	START POSITION	SUBSEQUENCE RESIDUE LISTING	SCORE (ESTIMATE OF HALF TIME OF DISASSOCIATION OF A MOLECULE CONTAINING THIS SUBSEQUENCE)	SEQ.ID#
91	142	RVTKIGVAAV	0.400	1391.
92	137	VLTLPRVTKI	0.400	1392.
93	38	LIAVLGNLTI	0.400	1393.
94	62	YIFLCMLSGI	0.400	1394.
95	214	LLISFSYLLI	0.400	1395.
96	156	ALMAPLPVFI	0.400	1396.
97	41	VLGNLTHIYI	0.400	1397.
98	196	VNVVYGLIVI	0.400	1398.
99	248	AVFIFYVPFI	0.400	1399.
100	200	YGLIVIISAI	0.400	1400.

Table XIX: Motifs and Post-translational Modifications of 101P3A11

- 5 N-glycosylation site
Number of matches: 3
- 1 7-10 NESS (SEQ ID NO: 2881)
 - 2 44-47 NLTI (SEQ ID NO: 2882)
 - 3 90-93 NSTT (SEQ ID NO: 2883)
- 10 cAMP- and cGMP-dependent protein kinase phosphorylation site
268-271 RRDS (SEQ ID NO: 2884)
- Protein kinase C phosphorylation site
- 15 266-268 SKR (SEQ ID NO: 2885)
- Casein kinase II phosphorylation site
Number of matches: 3
- 1 56-59 SLHE (SEQ ID NO: 2886)
 - 2 69-72 SGID (SEQ ID NO: 2887)
 - 3 110-113 SGME (SEQ ID NO: 2888)
- 20 N-myristoylation site
Number of matches: 4
- 1 6-11 GNESSA (SEQ ID NO: 2889)
 - 2 21-26 GLEEAQ (SEQ ID NO: 2890)
 - 3 111-116 GMESTV (SEQ ID NO: 2891)
 - 4 240-245 GTCVSH
- 30 G-protein coupled receptors family 1 signature
112-128 MESTVLLAMAFDRYVAI (SEQ ID NO: 2892)

Table XX: Frequently Occurring Motifs			
Name	avrg. % identity	Description	Potential Function
<u>zf-C2H2</u>	34%	Zinc finger, C2H2 type	Nucleic acid-binding protein functions as transcription factor, nuclear location probable
<u>cytochrome b N</u>	68%	Cytochrome b(N-terminal)/b6/petB	membrane bound oxidase, generate superoxide
<u>ig</u>	19%	Immunoglobulin domain	domains are one hundred amino acids long and include a conserved intradomain disulfide bond.
<u>WD40</u>	18%	WD domain, G-beta repeat	tandem repeats of about 40 residues, each containing a Trp-Asp motif. Function in signal transduction and protein interaction
<u>PDZ</u>	23%	PDZ domain	may function in targeting signaling molecules to sub-membranous sites
<u>LRR</u>	28%	Leucine Rich Repeat	short sequence motifs involved in protein-protein interactions
<u>pkinase</u>	23%	Protein kinase domain	conserved catalytic core common to both serine/threonine and tyrosine protein kinases containing an ATP binding site and a catalytic site
<u>PH</u>	16%	PH domain	pleckstrin homology involved in intracellular signaling or as constituents of the cytoskeleton
<u>EGF</u>	34%	EGF-like domain	30-40 amino-acid long found in the extracellular domain of membrane-bound proteins or in secreted proteins
<u>rvt</u>	49%	Reverse transcriptase (RNA-dependent DNA polymerase)	
<u>ank</u>	25%	Ank repeat	Cytoplasmic protein, associates integral membrane proteins to the cytoskeleton
<u>oxidored_q1</u>	32%	NADH-Ubiquinone/plastoquinone (complex I), various chains	membrane associated. Involved in proton translocation across the membrane

Table XX: Frequently Occurring Motifs			
Name	avrg. % identity	Description	Potential Function
<u>efhand</u>	24%	EF hand	calcium-binding domain, consists of a 12 residue loop flanked on both sides by a 12 residue alpha-helical domain
<u>rvp</u>	79%	Retroviral aspartyl protease	Aspartyl or acid proteases, centered on a catalytic aspartyl residue
<u>Collagen</u>	42%	Collagen triple helix repeat (20 copies)	extracellular structural proteins involved in formation of connective tissue. The sequence consists of the G-X-Y and the polypeptide chains forms a triple helix.
<u>fn3</u>	20%	Fibronectin type III domain	Located in the extracellular ligand-binding region of receptors and is about 200 amino acid residues long with two pairs of cysteines involved in disulfide bonds
<u>7tm_1</u>	19%	7 transmembrane receptor (rhodopsin family)	seven hydrophobic transmembrane regions, with the N-terminus located extracellularly while the C-terminus is cytoplasmic. Signal through G proteins

Table XXI: Nucleotide sequence of the splice variant. (SEQ ID NO: 1401)

```

1 CACATTCCTT CCATACGGTT GAGCCTCTAC CTGCCTGGTG CTGGTCACAG TTCAGCTTCT
5      61 TCATGATGGT GGATCCCAAT GGCAATGAAT CCAGTGCTAC ATACTTCATC CTAATAGGCC
      121 TCCCTGGTTT AGAAGAGGCT CAGTTCTGGT TGGCCTCCCA TTGTGCTCCC TCTANCTATG
      181 CTGTGCTAGT AATTGACAAT CATCTACATG TGCGGACGAG CACGNCGCNG AGCCCNGTAT
      241 NATTCTGCNG CTTCAGCATG ACACCCTNCA GTCTCAGCCA AAGNGCATCT CNGTCAATCA
      301 NACACNTGAG CTGTCTGACG AGTTGCATCA TCCTANGGCA GGATCAATGT GCGGNAGGCN
10      361 TGACGCACTG CACGTACCAT GGCAGCAAGA CAGGGCCGGT ACAAATGGGG GCGAGNCGGG
      421 GTGAAGATGN ACCCTCGGGT CANAGAGTGC CTCTGCGCCA AAACCTCCAT CATGNNAAAC
      481 GNGTATAACG GCGNAGAATC GGNNANGCGC AAGGCTAAGG AAANNCCCAA NNCNGGTACT
      541 TTAACCCNGC AAANGGCANC NAAACGGNG GGTNANTGAA CAAGGAAGGN NTGNAACTGG
      601 GCCAAAACGG GNTGGGCAAN NNAAGGACTC ATGGGNCCAA GGGACGGNAA AAGGGGNAAN
15      661 CGGGGCGAAA TGNNAAAAAC CGGGNCCCGG GGAANAANGA AGGGGAANAN GNGTGAAGGA
      721 CNGGGTTCAA GGGAAAAGNA AAACCANGGG NNAGAAACCN TTCNAANGGC CCGGGNANGA
      781 AAGGAANTNN GNNNGGNGAA AAAATCNAAA AAAAGCNGNG GCNNAAAAAN GGGGGGAANN
      841 NAAANACCNN GGNCGNAAA AAACNNAANG NGGGGGGANT ANACACGGAA ANNNANGGGC
      901 GNNNAAGGGA AATAANNCGG GAACNAAAGN GCAAACCGNA CGGNAGGAAC GAAACCCACC
20      961 GGAGNCGCNN AACGCCNNNC NNANCCCGAG CNGAGGTNG

```

Table XXII: Nucleotide sequence alignment of 101P3A11 (SEQ ID NO: 1402) with the splice variant (SEQ ID NO: 1403).

Score = 337 bits (175), Expect = 4e-89
Identities = 215/223 (96%), Gaps = 6/223 (2%)
Strand = Plus / Plus

```

30 101P3A11: 68 cacattccttccatacggttgagcctctacctgctggtgctggtcacagttcagcttct 127
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Variant : 1  cacattccttccatacggttgagcctctacctgctggtgctggtcacagttcagcttct 60

35 101P3A11: 128 tcatgatggtggatcccaatggcaatgaatccagtgtacatacttcatcctaattaggcc 187
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Variant : 61  tcatgatggtggatcccaatggcaatgaatccagtgtacatacttcatcctaattaggcc 120

40 101P3A11: 188 tccctggtttagaagaggctcagttctggttgcccttccattgtgctccctctacctta 247
      ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Variant : 121 tccctggtttagaagaggctcagttctggttggcc-tccattgtgctccctctanct-- 177

45 101P3A11: 248 ttgctgtgctaggtaacttgacaatcatctacattgtgcggac 290
      ||||||||| |||| ||||||||||||||| |||||||||
Variant : 178 atgctgtgcta-gtaa-ttgacaatcatctaca-tgtgcggac 217

```

Table XXIII: Longest single amino acid sequence alignment of 101P3A11 (SEQ ID NO: 1404) and the splice variant (SEQ ID NO: 1405).

Score = 134 bits (287), Expect(2) = 3e-29
Identities = 51/51 (100%)
Frame = +1 / +3

```

55 101P3A11: 70 HSFHTVEPLPAWCWSQFSFFMMVDPNGNESSATYFILIGLPGLEEAQFWLA 222
      HSFHTVEPLPAWCWSQFSFFMMVDPNGNESSATYFILIGLPGLEEAQFWLA
Variant : 3  HSFHTVEPLPAWCWSQFSFFMMVDPNGNESSATYFILIGLPGLEEAQFWLA 155

```

Table XXIV: Peptide sequences from the translation of the nucleotide sequence of the splice variant .

Open reading frame	Amino acid sequences
Frame 1 <u>SEQ ID NO: 1406</u>	HIPSIRLSLYLPGAGHSSASS*WWIPMAMNPVLHTSS**ASLV*KRLSSGWPPIVLPLXM LC**LTIIYMCGRARRXAXYXSAASA*HPXVSAKXHLXQSXT*AVVRVASSXGRINVRXA *RSARTMAARQGRYKWGRXGVKMXPRVXECLCAKTSIMXTXYNGXESXXRKAKEXPXXGT LTXQXAXKRXGX*TRKXXNWAKTGWAXXGLMGPRDGKRGXRGEMXKTGXRGXXKGXXXEG XGSREKXNXGXETXXXARXXKEXXXKKSKSXGXKXGGXXXPXXXKNXXGXTRKXXG XXGK*XGNXXANRTXGTKPTGXAXRXXXPEXR
Frame 2 <u>SEQ ID NO: 1407</u>	TFLPYG*ASTCLVLVTQLLHDGGSQWQ*IQCYILHPNRPPWFRRGSVLVGLPLCSLXLC CASN*QSSTCADEHXAEPXXILXLQHDTLQSQPKXISVNXTXELSYELHHPXAGSMCGRX DAVHVPWQQDRAGTNGGEXG*RTLGSXSASAPKPPSXXQXITAXNRXXARLRKXPXXVL *PXKXXNXGXVXEQGRXXTGPKRXGQXKDSWXQGTXXKGXXGAKXXKPGPGEXXRGXVKD XVQGXKXTXGXKPFXXPGXERXXXXXKNXKKAXAXKXGEXKXXGRXKTXGXXHGXXA XKGNXXGTKXQTXRXERNPPEXXNAXXXPSXG
Frame 3 <u>SEQ ID NO: 1408</u>	HSFHTVEPLPAWCWSQFSFFMMVDPNGNESSATYFILIGLPGLEEAQFWLASHCAPSXYA VLVIDNHLHVRTSTXXSPVXFCXFSMTPIXLSQXASXSIXHXSCRTSCIILXQDQCAXGX TQCTYHGSKTGPVQMGAXRGEDXPSGXRVPRLRQNLHHXNXV*RRRIGXAQG*GXXQXXYF NPAXGXXTGGXXNKEGXXLGQNGXGXRTHGXXKGRXKGXXGRNXKNRXPGXEGEXX*RT GFKGKXKPXXRNXSXGPGXKGXXGEXKIXKKXXXKXGGXXTXXXKKXXXGGXXTEXXGR XREIXREXKXKPXGRNETHRXRXTXXXXRAEV

Note: Frame 3 gives the longest subsequence that is identical with 101P3A11 amino acid sequence. In this Table each (*) indicates the product of a single stop codon, and 'X' indicates a single unknown amino acid.

TABLE XXV: Properties of 101P3A11

	Bioinformatic Program	URL	Outcome
ORF	ORF Finder	http://www.ncbi.nlm.gov/gorf	133-1086 (includes stop)
Protein Length	n/a	n/a	317 amino acids
Transmembrane region	TM Pred	http://www.ch.embnet.org/	7 TM at aa : 27-52, 63-88, 104-129, 146-165, 196-224, 239-262, 273-295
	HMMTop	http://www.enzim.hu/hmmtop/	7 TM at aa: 27-50, 63-86, 99-121, 146-165, 201-224, 239-262, 275-294
	Sosui	http://www.genome.ad.jp/SOSui/	7 TM, at aa: 29-51, 63-85, 100-122, 203-225, 239-261, 273-295
	TMHMM	http://www.cbs.dtu.dk/services/TMHMM	7 TM, at aa: 29-51, 63-85, 100-122, 143-165, 202-224, 236-258, 273-295
Signal Peptide	Signal P	http://www.cbs.dtu.dk/services/SignalP/	indicates no signal
pI	pI/MW tool	http://www.expasy.ch/tools/	pI 8.7
Molecular weight	pI/MW tool	http://www.expasy.ch/tools/	35.2 kDa
Localization	PSORT	http://psort.nibb.ac.jp/	Plasma membrane 64%
	PSORT II	http://psort.nibb.ac.jp/	Plasma membrane 56.4%
Motifs	Pfam	http://www.sanger.ac.uk/Pfam/	7 transmembrane receptor (rhodopsin family)
	Prints	http://www.biochem.ucl.ac.uk/	Rhodopsin-like GPCR superfamily
	Blocks	http://www.blocks.fhcrc.org/	Rhodopsin-like GPCR superfamily
	Prosite	http://www.genome.ad.jp/	G-protein coupled receptors family 1

Table XXVI:
HLA Class I Nonamers

SEQ ID NO:	HLA-A1 nonomers											
	Pos	1	2	3	4	5	6	7	8	9	score	
<u>1409</u>	1	245	H	<u>V</u>	C	A	V	F	<u>I</u>	F	Y	24
<u>1410</u>	2	29	L	<u>A</u>	F	P	L	C	<u>S</u>	L	Y	21
<u>1411</u>	3	41	V	<u>L</u>	G	N	L	T	<u>I</u>	I	Y	21
<u>1412</u>	4	285	P	<u>P</u>	V	L	N	P	<u>I</u>	V	Y	20
<u>1413</u>	5	111	G	<u>M</u>	E	S	T	V	<u>L</u>	L	A	19
<u>1414</u>	6	117	L	<u>L</u>	A	M	A	F	<u>D</u>	R	Y	19
<u>1415</u>	7	172	R	<u>S</u>	N	I	L	S	<u>H</u>	S	Y	19
<u>1416</u>	8	192	D	<u>D</u>	I	R	V	N	<u>V</u>	V	Y	19
<u>1417</u>	9	212	D	<u>S</u>	L	L	I	S	<u>F</u>	S	Y	19
<u>1418</u>	10	57	L	<u>H</u>	E	P	M	Y	<u>I</u>	F	L	18
<u>1419</u>	11	22	L	<u>E</u>	E	A	Q	F	<u>W</u>	L	A	17
<u>1420</u>	12	9	S	<u>S</u>	A	T	Y	F	<u>I</u>	L	I	16
<u>1421</u>	13	52	R	<u>T</u>	E	H	S	L	<u>H</u>	E	P	16
<u>1422</u>	14	54	E	<u>H</u>	S	L	H	E	P	M	Y	16
<u>1423</u>	15	78	S	<u>S</u>	M	P	K	M	<u>L</u>	A	I	16
<u>1424</u>	16	95	Q	<u>F</u>	D	A	C	L	<u>L</u>	Q	I	16
<u>1425</u>	17	159	A	<u>P</u>	L	P	V	F	<u>I</u>	K	Q	16
<u>1426</u>	18	183	H	<u>Q</u>	D	V	M	K	<u>L</u>	A	C	16
<u>1427</u>	19	1	M	<u>V</u>	D	P	N	G	<u>N</u>	E	S	15
<u>1428</u>	20	5	N	<u>G</u>	N	E	S	S	A	T	Y	15
<u>1429</u>	21	210	G	<u>L</u>	D	S	L	L	<u>I</u>	S	F	15
<u>1430</u>	22	273	L	<u>P</u>	V	I	L	A	N	I	Y	15
<u>1431</u>	23	271	S	<u>P</u>	L	P	V	I	<u>L</u>	A	N	14
<u>1432</u>	24	91	S	<u>T</u>	T	I	Q	F	<u>D</u>	A	C	13
<u>1433</u>	25	121	A	<u>F</u>	D	R	Y	V	<u>A</u>	I	C	13
<u>1434</u>	26	138	L	<u>T</u>	L	P	R	V	<u>T</u>	K	I	13
<u>1435</u>	27	218	F	<u>S</u>	Y	L	L	I	<u>L</u>	K	T	13
<u>1436</u>	28	282	L	<u>L</u>	V	P	P	V	<u>L</u>	N	P	13
<u>1437</u>	29	190	A	<u>C</u>	D	D	I	R	<u>V</u>	N	V	12
<u>1438</u>	30	191	C	<u>D</u>	D	I	R	V	<u>N</u>	V	V	12
<u>1439</u>	31	231	T	<u>R</u>	E	A	Q	A	K	A	F	12
<u>1440</u>	32	268	R	<u>R</u>	D	S	P	L	<u>P</u>	V	I	12
<u>1441</u>	33	270	D	<u>S</u>	P	L	P	V	I	L	A	12

5

HLA-A*0201 nonomers

Pos		1	2	3	4	5	6	7	8	9	score
1	287	V	L	N	P	I	V	Y	G	V	30
2	14	F	I	L	I	G	L	P	C	L	29
3	28	W	L	A	F	P	L	C	S	L	28
4	37	Y	L	I	A	V	L	C	N	L	28
5	222	L	I	L	K	T	V	L	G	L	28
6	66	C	M	L	S	C	I	D	I	L	26
7	108	S	L	S	C	M	E	S	T	V	26
8	181	C	L	H	Q	D	V	M	K	L	26
9	201	C	L	I	V	I	I	S	A	I	26
10	214	L	L	I	S	F	S	Y	L	L	26

HLA-A*0201 nonomers

Pos		1	2	3	4	5	6	7	8	9	score
11	275	V	I	L	A	N	I	Y	L	L	26
12	157	L	M	A	P	L	P	V	F	I	25
13	220	Y	L	L	I	L	K	T	V	L	25
14	276	I	L	A	N	I	Y	L	L	V	25
15	279	N	I	Y	L	L	V	P	P	V	25
16	138	L	T	L	P	R	V	T	K	I	24
17	213	S	L	L	I	S	F	S	Y	L	24
18	49	Y	I	V	R	T	E	H	S	L	23
19	143	V	T	K	I	C	V	A	A	V	23
20	188	K	L	A	C	D	D	I	R	V	23
21	198	V	V	Y	C	L	I	V	I	I	23
22	21	G	L	E	E	A	Q	F	W	L	22
23	40	A	V	L	C	N	L	T	I	I	22
24	206	I	S	A	I	C	L	D	S	L	22
25	11	A	T	Y	F	I	L	I	C	L	21
26	60	P	M	Y	I	F	L	C	M	L	21
27	135	A	T	V	L	T	L	P	R	V	21
28	160	P	L	P	V	F	I	K	Q	L	21
29	174	N	I	L	S	H	S	Y	C	L	21
30	207	S	A	I	C	L	D	S	L	L	21
31	272	P	L	P	V	I	L	A	N	I	21
32	283	L	V	P	P	V	L	N	P	I	21
33	67	M	L	S	C	I	D	I	L	I	20
34	101	L	Q	I	F	A	I	H	S	L	20
35	282	L	L	V	P	P	V	L	N	P	20
36	299	E	I	R	Q	R	I	L	R	L	20
37	304	I	L	R	L	F	H	V	A	T	20
38	39	I	A	V	L	C	N	L	T	I	19
39	45	L	T	I	I	Y	I	V	R	T	19
40	92	T	T	I	Q	F	D	A	C	L	19
41	110	S	C	M	E	S	T	V	L	L	19
42	127	A	I	C	H	P	L	R	H	A	19
43	132	L	R	H	A	T	V	L	T	L	19
44	149	A	A	V	V	R	C	A	A	L	19
45	155	A	A	L	M	A	P	L	P	V	19
46	156	A	L	M	A	P	L	P	V	F	19
47	203	I	V	I	I	S	A	I	C	L	19
48	208	A	I	C	L	D	S	L	L	I	19
49	216	I	S	F	S	Y	L	L	I	L	19
50	219	S	Y	L	L	I	L	K	T	V	19
51	221	L	L	I	L	K	T	V	L	G	19
52	223	I	L	K	T	V	L	C	L	T	19
53	17	I	C	L	P	C	L	E	E	A	18
54	33	L	C	S	L	Y	L	I	A	V	18
55	34	C	S	L	Y	L	I	A	V	L	18
56	38	L	I	A	V	L	C	N	L	T	18
57	43	C	N	L	T	I	I	Y	I	V	18
58	85	A	I	F	W	F	N	S	T	T	18
59	118	L	A	M	A	F	D	R	Y	V	18
60	194	I	R	V	N	V	V	Y	C	L	18
61	210	C	L	D	S	L	L	I	S	F	18
62	215	L	I	S	F	S	Y	L	L	I	18

HLA-A*0201-nonomers

	Pes	1 2 3 4 5 6 7 8 9	score
63	246	V C A V F I F Y V	18
64	254	V P F I G L S M V	18
65	15	I L I G L P G L E	17
66	63	I F L C M L S C I	17
67	72	D I L I S T S S M	17
68	93	T I Q F D A C L L	17
69	98	A C L L Q I F A I	17
70	111	C M E S T V L L A	17
71	120	M A F D R Y V A I	17
72	167	Q L P F C R S N I	17
73	197	N V V Y G L I V I	17
74	226	T V L G L T R E A	17
75	281	Y L L V P P V L N	17
76	31	F P L C S L Y L I	16
77	56	S L H E P M Y I F	16
78	70	G I D I L I S T S	16
79	78	S S M P K M L A I	16
80	79	S M P K M L A I F	16
81	104	F A I H S L S G M	16
82	119	A M A F D R Y V A	16
83	144	T K I G V A A V V	16
84	147	G V A A V V R G A	16
85	186	V M K L A C D D I	16
86	230	L T R E A Q A K A	16
87	238	A F C T C V S H V	16
88	249	V F I F Y V P F I	16
89	302	Q R I L R L F H V	16
90	303	R I L R L F H V A	16
91	18	G L P G L E E A Q	15
92	35	S L Y L I A V L G	15
93	42	L C N L T I I Y I	15
94	46	T I I Y I V R T E	15
95	69	S G I D I L I S T	15
96	76	S T S S M P K M L	15
97	131	P L R H A T V L T	15
98	137	V L T L P R V T K	15
99	153	R C A A L M A P L	15
100	190	A C D D I R V N V	15
101	191	C D D I R V N V V	15
102	204	V I I S A I G L D	15
103	241	T C V S H V C A V	15
104	251	I F Y V P F I G L	15
105	269	R D S P L P V I L	15
106	280	I Y L L V P P V L	15
107	306	R L F H V A T H A	15

HLA-A*0203-nonomers

	Pes	1 2 3 4 5 6 7 8 9	score
1	148	V A A V V R C A A	14
2	119	A M A F D R Y V A	13
3	147	C V A A V V R C A	12

HLA-A*0203-nonomers

	Pes	1 2 3 4 5 6 7 8 9	score
4	97	D A C L L Q I F A	11
5	127	A I C H P L R H A	10
6	3	D P N C N E S S A	9
7	17	I G L P G L E E A	9
8	22	L E E A Q F W L A	9
9	32	P L C S L Y L I A	9
10	77	T S S M P K M L A	9
11	90	N S T T I Q F D A	9
12	111	C M E S T V L L A	9
13	113	E S T V L L A M A	9
14	141	P R V T K I C V A	9
15	142	R V T K I C V A A	9
16	151	V V R C A A L M A	9
17	182	L H Q D V M K L A	9
18	200	Y G L I V I I S A	9
19	226	T V L G L T R E A	9
20	228	L G L T R E A Q A	9
21	230	L T R E A Q A K A	9
22	240	C T C V S H V C A	9
23	270	D S P L P V I L A	9
24	303	R I L R L F H V A	9
25	306	R L F H V A T H A	9

HLA-A26-nonomers

	Pes	1 2 3 4 5 6 7 8 9	score
1	299	E I R Q R I L R L	30
2	72	D I L I S T S S M	27
3	248	A V F I F Y V P F	27
4	210	G L D S L L I S F	26
5	14	F I L I G L P G L	24
6	56	S L H E P M Y I F	24
7	117	L L A M A F D R Y	24
8	222	L I L K T V L G L	24
9	245	H V C A V F I F Y	24
10	11	A T Y F I L I G L	23
11	37	Y L I A V L C N L	23
12	114	S T V L L A M A F	23
13	156	A L M A P L P V F	23
14	162	P V F I K Q L P F	23
15	181	C L H Q D V M K L	23
16	28	W L A F P L C S L	22
17	92	T T I Q F D A C L	22
18	160	P L P V F I K Q L	22
19	203	I V I I S A I G L	22
20	213	S L L I S F S Y L	22
21	275	V I L A N I Y L L	22
22	193	D I R V N V V Y G	21
23	242	C V S H V C A V F	21
24	76	S T S S M P K M L	20
25	253	Y V P F I G L S M	20
26	274	P V I L A N I Y L	20

HLA-A26 nonomers

	Pes	1 2 3 4 5 6 7 8 9	score
27	23	E E A Q F W L A F	19
28	41	V L G N L T I I Y	19
29	49	Y I V R T E H S L	19
30	150	A V V R G A A L M	19
31	174	N I L S H S Y C L	19
32	192	D D I R V N V V Y	19
33	214	L L I S F S Y L L	19
34	251	I F Y V P F I G L	19
35	8	E S S A T Y F I L	18
36	21	G L E E A Q F W L	18
37	45	L T I I Y I V R T	18
38	54	E H S L H E P M Y	18
39	59	E P M Y I F L C M	18
40	88	W F N S T T I Q F	18
41	93	T I Q F D A C L L	18
42	185	D V M K L A C D D	18
43	198	V V Y G L I V I I	18
44	62	Y I F L C M L S G	17
45	70	G I D I L I S T S	17
46	79	S M P K M L A I F	17
47	96	F D A C L L Q I F	17
48	104	F A I H S L S G M	17
49	138	L T L P R V T K I	17
50	143	V T K I C V A A V	17
51	204	V I I S A I C L D	17
52	212	D S L L I S F S Y	17
53	220	Y L L I L K T V L	17
54	256	F I G L S M V H R	17
55	283	L V P P V L N P I	17
56	29	L A F P L C S L Y	16
57	40	A V L G N L T I I	16
58	46	T I I Y I V R T E	16
59	52	R T E H S L H E P	16
60	75	I S T S S M P K M	16
61	91	S T T I Q F D A C	16
62	135	A T V L T L P R V	16
63	147	C V A A V V R G A	16
64	201	G L I V I I S A I	16
65	257	I C L S M V H R F	16
66	279	N I Y L L V P P V	16
67	30	A F P L C S L Y L	15
68	101	L Q I F A I H S L	15
69	115	T V L L A M A F D	15
70	127	A I C H P L R H A	15
71	153	R G A A L M A P L	15
72	163	V F I K Q L P F C	15
73	215	L I S F S Y L L I	15
74	216	I S F S Y L L I L	15
75	225	K T V L C L T R E	15
76	272	P L P V I L A N I	15
77	282	L L V P P V L N P	15
78	286	P V L N P I V Y C	15

HLA-A26 nonomers

	Pes	1 2 3 4 5 6 7 8 9	score
79	287	V L N P I V Y G V	15
80	296	K T K E I R Q R I	15
81	303	R I L R L F H V A	15

HLA-A3 nonomers

	Pes	1 2 3 4 5 6 7 8 9	score
1	137	V L T L P R V T K	30
2	229	G L T R E A Q A K	27
3	145	K I G V A A V V R	26
4	150	A V V R G A A L M	24
5	290	P I V Y G V K T K	24
6	35	S L Y L I A V L G	23
7	156	A L M A P L P V F	23
8	47	I I Y I V R T E H	22
9	50	I V R T E H S L H	22
10	142	R V T K I G V A A	22
11	151	V V R G A A L M A	22
12	242	C V S H V C A V F	22
13	248	A V F I F Y V P F	22
14	116	V L L A M A F D R	21
15	192	D D I R V N V V Y	21
16	303	R I L R L F H V A	21
17	304	I L R L F H V A T	21
18	108	S L S C M E S T V	20
19	198	V V Y G L I V I I	20
20	291	I V Y G V K T K E	20
21	15	I L I G L P C L E	19
22	44	N L T I I Y I V R	19
23	73	I L I S T S S M P	19
24	74	L I S T S S M P K	19
25	99	C L L Q I F A I H	19
26	162	P V F I K Q L P F	19
27	203	I V I I S A I C L	19
28	221	L L I L K T V L G	19
29	245	H V C A V F I F Y	19
30	306	R L F H V A T H A	19
31	40	A V L G N L T I I	18
32	85	A I F W F N S T T	18
33	205	I I S A I C L D S	18
34	220	Y L L I L K T V L	18
35	253	Y V P F I G L S M	18
36	37	Y L I A V L G N L	17
37	41	V L G N L T I I Y	17
38	117	L L A M A F D R Y	17
39	131	P L R H A T V L T	17
40	136	T V L T L P R V T	17
41	180	Y C L H Q D V M K	17
42	201	G L I V I I S A I	17
43	213	S L L I S F S Y L	17
44	256	F I G L S M V H R	17
45	261	M V H R F S K R R	17

HLA-A3 nonomers

Pos		1	2	3	4	5	6	7	8	9	score
46	276	I	L	A	N	I	Y	L	L	V	17
47	281	Y	L	L	V	P	P	V	L	N	17
48	286	P	V	L	N	P	I	V	Y	G	17
49	288	L	N	P	I	V	Y	G	V	K	17
50	309	H	V	A	T	H	A	S	E	P	17
51	1	M	V	D	P	N	G	N	E	S	16
52	56	S	L	H	E	P	M	Y	I	F	16
53	70	G	I	D	I	L	I	S	T	S	16
54	72	D	I	L	I	S	T	S	S	M	16
55	115	T	V	L	L	A	M	A	F	D	16
56	125	Y	V	A	I	C	H	P	L	R	16
57	144	T	K	I	C	V	A	A	V	V	16
58	167	Q	L	P	F	C	R	S	N	I	16
59	175	I	L	S	H	S	Y	C	L	H	16
60	195	R	V	N	V	V	Y	C	L	I	16
61	197	N	V	V	Y	C	L	I	V	I	16
62	210	G	L	D	S	L	L	I	S	F	16
63	282	L	L	V	P	P	V	L	N	P	16
64	299	E	I	R	Q	R	I	L	R	L	16
65	301	R	Q	R	I	L	R	L	F	H	16
66	16	L	I	C	L	P	C	L	E	E	15
67	46	T	I	I	Y	I	V	R	T	E	15
68	102	Q	I	F	A	I	H	S	L	S	15
69	193	D	I	R	V	N	V	V	Y	G	15
70	208	A	I	C	L	D	S	L	L	I	15
71	223	I	L	K	T	V	L	C	L	T	15
72	237	K	A	F	G	T	C	V	S	H	15

HLA-B*0702 nonomers

Pos		1	2	3	4	5	6	7	8	9	score
1	130	H	P	L	R	H	A	T	V	L	22
2	59	E	P	M	Y	I	F	L	C	M	21
3	168	L	P	F	C	R	S	N	I	L	20
4	289	N	P	I	V	Y	C	V	K	T	19
5	3	D	P	N	G	N	E	S	S	A	18
6	19	L	P	C	L	E	E	A	Q	F	18
7	140	L	P	R	V	T	K	I	G	V	18
8	284	V	P	P	V	L	N	P	I	V	17
9	31	F	P	L	C	S	L	Y	L	I	16
10	254	V	P	F	I	C	L	S	M	V	16
11	269	R	D	S	P	L	P	V	I	L	16
12	149	A	A	V	V	R	C	A	A	L	15
13	153	R	G	A	A	L	M	A	P	L	15
14	156	A	L	M	A	P	L	P	V	F	15
15	251	I	F	Y	V	P	F	I	C	L	15
16	299	E	I	R	Q	R	I	L	R	L	15
17	8	E	S	S	A	T	Y	F	I	L	14
18	28	W	L	A	F	P	L	C	S	L	14
19	30	A	F	P	L	C	S	L	Y	L	14
20	110	S	G	M	E	S	T	V	L	L	14
21	132	L	R	H	A	T	V	L	T	L	14

HLA-B*0702 nonomers

Pos		1	2	3	4	5	6	7	8	9	score
22	159	A	P	L	P	V	F	I	K	Q	14
23	222	L	I	L	K	T	V	L	G	L	14
24	271	S	P	L	P	V	I	L	A	N	14
25	25	A	Q	F	W	L	A	F	P	L	13
26	109	L	S	C	M	E	S	T	V	L	13
27	124	R	Y	V	A	I	C	H	P	L	13
28	216	I	S	F	S	Y	L	L	I	L	13
29	268	R	R	D	S	P	L	P	V	I	13
30	280	I	Y	L	L	V	P	P	V	L	13
31	11	A	T	Y	F	I	L	I	G	L	12
32	34	C	S	L	Y	L	I	A	V	L	12
33	57	L	H	E	P	M	Y	I	F	L	12
34	76	S	T	S	S	M	P	K	M	L	12
35	142	R	V	T	K	I	C	V	A	A	12
36	151	V	V	R	G	A	A	L	M	A	12
37	190	A	C	D	D	I	R	V	N	V	12
38	194	I	R	V	N	V	V	Y	C	L	12
39	206	I	S	A	I	C	L	D	S	L	12
40	207	S	A	I	C	L	D	S	L	L	12
41	220	Y	L	L	I	L	K	T	V	L	12
42	267	K	R	R	D	S	P	L	P	V	12
43	304	I	L	R	L	F	H	V	A	T	12
44	14	F	I	L	I	C	L	P	C	L	11
45	23	E	E	A	Q	F	W	L	A	F	11
46	37	Y	L	I	A	V	L	C	N	L	11
47	40	A	V	L	C	N	L	T	I	I	11
48	77	T	S	S	M	P	K	M	L	A	11
49	78	S	S	M	P	K	M	L	A	I	11
50	80	M	P	K	M	L	A	I	F	W	11
51	92	T	T	I	Q	F	D	A	C	L	11
52	112	M	E	S	T	V	L	L	A	M	11
53	119	A	M	A	F	D	R	Y	V	A	11
54	127	A	I	C	H	P	L	R	H	A	11
55	131	P	L	R	H	A	T	V	L	T	11
56	155	A	A	L	M	A	P	L	P	V	11
57	157	L	M	A	P	L	P	V	F	I	11
58	181	C	L	H	Q	D	V	M	K	L	11
59	203	I	V	I	I	S	A	I	C	L	11
60	208	A	I	C	L	D	S	L	L	I	11
61	213	S	L	L	I	S	F	S	Y	L	11
62	248	A	V	F	I	F	Y	V	P	F	11
63	265	F	S	K	R	R	D	S	P	L	11
64	275	V	I	L	A	N	I	Y	L	L	11
65	285	P	P	V	L	N	P	I	V	Y	11

HLA-B*08 nonomers

Pos	1	2	3	4	5	6	7	8	9	score
1	299	E	I	R	Q	R	I	L	R	31
2	265	F	S	K	R	R	D	S	P	29
3	149	A	A	V	V	R	C	A	A	24
4	168	L	P	F	C	R	S	N	I	24

HLA-B*08 nonomers

Pos		1	2	3	4	5	6	7	8	9	score
5	294	G	V	K	T	K	E	I	R	Q	21
6	120	M	A	F	D	R	Y	V	A	I	20
7	292	V	Y	G	V	K	T	K	E	I	20
8	21	G	L	E	E	A	Q	F	W	L	19
9	78	S	S	M	P	K	M	L	A	I	19
10	160	P	L	P	V	F	I	K	Q	L	19
11	186	V	M	K	L	A	C	D	D	I	18
12	213	S	L	L	I	S	F	S	Y	L	18
13	221	L	L	I	L	K	T	V	L	G	18
14	296	K	T	K	E	I	R	Q	R	I	18
15	297	T	K	E	I	R	Q	R	I	L	18
16	130	H	P	L	R	H	A	T	V	L	17
17	181	C	L	H	Q	D	V	M	K	L	17
18	223	I	L	K	T	V	L	C	L	T	17
19	28	W	L	A	F	P	L	C	S	L	16
20	37	Y	L	I	A	V	L	C	N	L	16
21	56	S	L	H	E	P	M	Y	I	F	16
22	80	M	P	K	M	L	A	I	F	W	16
23	162	P	V	F	I	K	Q	L	P	F	16
24	201	G	L	I	V	I	I	S	A	I	16
25	207	S	A	I	G	L	D	S	L	L	16
26	214	L	L	I	S	F	S	Y	L	L	16
27	220	Y	L	L	I	L	K	T	V	L	16
28	233	E	A	Q	A	K	A	F	G	T	16
29	275	V	I	L	A	N	I	Y	L	L	16
30	304	I	L	R	L	F	H	V	A	T	16
31	14	F	I	L	I	G	L	P	C	L	15
32	110	S	G	M	E	S	T	V	L	L	15
33	138	L	T	L	P	R	V	T	K	I	15
34	164	F	I	K	Q	L	P	F	C	R	15
35	222	L	I	L	K	T	V	L	C	L	15

HLA-B*1510 nonomers

Pos		1	2	3	4	5	6	7	8	9	score
1	57	L	H	E	P	M	Y	I	F	L	23
2	244	S	H	V	C	A	V	F	I	F	17
3	269	R	D	S	P	L	P	V	I	L	16
4	280	I	Y	L	L	V	P	P	V	L	16
5	262	V	H	R	F	S	K	R	R	D	15
6	299	E	I	R	Q	R	I	L	R	L	15
7	106	I	H	S	L	S	C	M	E	S	14
8	206	I	S	A	I	G	L	D	S	L	14
9	220	Y	L	L	I	L	K	T	V	L	14
10	251	I	F	Y	V	P	F	I	G	L	14
11	297	T	K	E	I	R	Q	R	I	L	14
12	21	G	L	E	E	A	Q	F	W	L	13
13	34	C	S	L	Y	L	I	A	V	L	13
14	54	E	H	S	L	H	E	P	M	Y	13
15	110	S	G	M	E	S	T	V	L	L	13
16	194	I	R	V	N	V	V	Y	C	L	13
17	8	E	S	S	A	T	Y	F	I	L	12

HLA-B*1510 nonomers

Pos		1	2	3	4	5	6	7	8	9	score
18	14	F	I	L	I	G	L	P	C	L	12
19	28	W	L	A	F	P	L	C	S	L	12
20	66	C	M	L	S	C	I	D	I	L	12
21	76	S	T	S	S	M	P	K	M	L	12
22	92	T	T	I	Q	F	D	A	C	L	12
23	109	L	S	C	M	E	S	T	V	L	12
24	130	H	P	L	R	H	A	T	V	L	12
25	132	L	R	H	A	T	V	L	T	L	12
26	149	A	A	V	V	R	C	A	A	L	12
27	153	R	C	A	A	L	M	A	P	L	12
28	160	P	L	P	V	F	I	K	Q	L	12
29	181	C	L	H	Q	D	V	M	K	L	12
30	182	L	H	Q	D	V	M	K	L	A	12
31	203	I	V	I	I	S	A	I	C	L	12
32	216	I	S	F	S	Y	L	L	I	L	12
33	222	L	I	L	K	T	V	L	C	L	12
34	275	V	I	L	A	N	I	Y	L	L	12
35	37	Y	L	I	A	V	L	C	N	L	11
36	49	Y	I	V	R	T	E	H	S	L	11
37	93	T	I	Q	F	D	A	C	L	L	11
38	101	L	Q	I	F	A	I	H	S	L	11
39	129	C	H	P	L	R	H	A	T	V	11
40	133	R	H	A	T	V	L	T	L	P	11
41	177	S	H	S	Y	C	L	H	Q	D	11
42	207	S	A	I	G	L	D	S	L	L	11
43	257	I	C	L	S	M	V	H	R	F	11

HLA-B*2705 nonomers

Pos		1	2	3	4	5	6	7	8	9	score
1	194	I	R	V	N	V	V	Y	C	L	25
2	268	R	R	D	S	P	L	P	V	I	24
3	132	L	R	H	A	T	V	L	T	L	23
4	300	I	R	Q	R	I	L	R	L	F	23
5	305	L	R	L	F	H	V	A	T	H	23
6	231	T	R	E	A	Q	A	K	A	F	21
7	34	C	S	L	Y	L	I	A	V	L	18
8	299	E	I	R	Q	R	I	L	R	L	18
9	6	C	N	E	S	S	A	T	Y	F	17
10	66	C	M	L	S	C	I	D	I	L	17
11	162	P	V	F	I	K	Q	L	P	F	17
12	207	S	A	I	G	L	D	S	L	L	17
13	210	C	L	D	S	L	L	I	S	F	17
14	220	Y	L	L	I	L	K	T	V	L	17
15	237	K	A	F	G	T	C	V	S	H	17
16	269	R	D	S	P	L	P	V	I	L	17
17	280	I	Y	L	L	V	P	P	V	L	17
18	295	V	K	T	K	E	I	R	Q	R	17
19	11	A	T	Y	F	I	L	I	C	L	16
20	14	F	I	L	I	G	L	P	C	L	16
21	21	G	L	E	E	A	Q	F	W	L	16
22	25	A	Q	F	W	L	A	F	P	L	16

HLA-B*2705 nonomers

Pos		1	2	3	4	5	6	7	8	9	score
23	37	Y	L	I	A	V	L	G	N	L	16
24	92	T	T	I	Q	F	D	A	C	L	16
25	101	L	Q	I	F	A	I	H	S	L	16
26	124	R	Y	V	A	I	C	H	P	L	16
27	130	H	P	L	R	H	A	T	V	L	16
28	141	P	R	V	T	K	I	G	V	A	16
29	153	R	G	A	A	L	M	A	P	L	16
30	181	C	L	H	Q	D	V	M	K	L	16
31	201	G	L	I	V	I	I	S	A	I	16
32	203	I	V	I	I	S	A	I	C	L	16
33	216	I	S	F	S	Y	L	L	I	L	16
34	222	L	I	L	K	T	V	L	G	L	16
35	255	P	F	I	C	L	S	M	V	H	16
36	257	I	C	L	S	M	V	H	R	F	16
37	275	V	I	L	A	N	I	Y	L	L	16
38	47	I	I	Y	I	V	R	T	E	H	15
39	109	L	S	G	M	E	S	T	V	L	15
40	114	S	T	V	L	L	A	M	A	F	15
41	123	D	R	Y	V	A	I	C	H	P	15
42	145	K	I	C	V	A	A	V	V	R	15
43	156	A	L	M	A	P	L	P	V	F	15
44	168	L	P	F	C	R	S	N	I	L	15
45	172	R	S	N	I	L	S	H	S	Y	15
46	198	V	V	Y	G	L	I	V	I	I	15
47	206	I	S	A	I	C	L	D	S	L	15
48	229	C	L	T	R	E	A	Q	A	K	15
49	248	A	V	F	I	F	Y	V	P	F	15
50	251	I	F	Y	V	P	F	I	G	L	15
51	274	P	V	I	L	A	N	I	Y	L	15
52	290	P	I	V	Y	G	V	K	T	K	15
53	298	K	E	I	R	Q	R	I	L	R	15
54	19	L	P	G	L	E	E	A	Q	F	14
55	29	L	A	F	P	L	C	S	L	Y	14
56	30	A	F	P	L	C	S	L	Y	L	14
57	39	I	A	V	L	G	N	L	T	I	14
58	40	A	V	L	G	N	L	T	I	I	14
59	79	S	M	P	K	M	L	A	I	F	14
60	81	P	K	M	L	A	I	F	W	F	14
61	99	C	L	L	Q	I	F	A	I	H	14
62	137	V	L	T	L	P	R	V	T	K	14
63	138	L	T	L	P	R	V	T	K	I	14
64	150	A	V	V	R	G	A	A	L	M	14
65	160	P	L	P	V	F	I	K	Q	L	14
66	174	N	I	L	S	H	S	Y	C	L	14
67	180	Y	C	L	H	Q	D	V	M	K	14
68	192	D	D	I	R	V	N	V	V	Y	14
69	212	D	S	L	L	I	S	F	S	Y	14
70	213	S	L	L	I	S	F	S	Y	L	14
71	214	L	L	I	S	F	S	Y	L	L	14
72	260	S	M	V	H	R	F	S	K	R	14
73	263	H	R	F	S	K	R	R	D	S	14
74	267	K	R	R	D	S	P	L	P	V	14

HLA-B*2705 nonomers

Pos		1	2	3	4	5	6	7	8	9	score
75	293	Y	G	V	K	T	K	E	I	R	14
76	301	R	Q	R	I	L	R	L	F	H	14
77	302	Q	R	I	L	R	L	F	H	V	14
78	5	N	G	N	E	S	S	A	T	Y	13
79	23	E	E	A	Q	F	W	L	A	F	13
80	28	W	L	A	F	P	L	C	S	L	13
81	44	N	L	T	I	I	Y	I	V	R	13
82	51	V	R	T	E	H	S	L	H	E	13
83	56	S	L	H	E	P	M	Y	I	F	13
84	60	P	M	Y	I	F	L	C	M	L	13
85	72	D	I	L	I	S	T	S	S	M	13
86	74	L	I	S	T	S	S	M	P	K	13
87	75	I	S	T	S	S	M	P	K	M	13
88	98	A	C	L	L	Q	I	F	A	I	13
89	104	F	A	I	H	S	L	S	C	M	13
90	110	S	G	M	E	S	T	V	L	L	13
91	116	V	L	L	A	M	A	F	D	R	13
92	126	V	A	I	C	H	P	L	R	H	13
93	149	A	A	V	V	R	C	A	A	L	13
94	158	M	A	P	L	P	V	F	I	K	13
95	164	F	I	K	Q	L	P	F	C	R	13
96	170	F	C	R	S	N	I	L	S	H	13
97	171	C	R	S	N	I	L	S	H	S	13
98	187	M	K	L	A	C	D	D	I	R	13
99	217	S	F	S	Y	L	L	I	L	K	13
100	224	L	K	T	V	L	G	L	T	R	13
101	242	C	V	S	H	V	C	A	V	F	13
102	256	F	I	C	L	S	M	V	H	R	13
103	261	M	V	H	R	F	S	K	R	R	13
104	49	Y	I	V	R	T	E	H	S	L	12
105	57	L	H	E	P	M	Y	I	F	L	12
106	88	W	F	N	S	T	T	I	Q	F	12
107	96	F	D	A	C	L	L	Q	I	F	12
108	134	H	A	T	V	L	T	L	P	R	12
109	152	V	R	G	A	A	L	M	A	P	12
110	179	S	Y	C	L	H	Q	D	V	M	12
111	197	N	V	V	Y	G	L	I	V	I	12
112	244	S	H	V	C	A	V	F	I	F	12
113	265	F	S	K	R	R	D	S	P	L	12
114	273	L	P	V	I	L	A	N	I	Y	12
115	285	P	P	V	L	N	P	I	V	Y	12
116	288	L	N	P	I	V	Y	C	V	K	12
117	296	K	T	K	E	I	R	Q	R	I	12
118	297	T	K	E	I	R	Q	R	I	L	12

HLA-B*2709 nonomers

Pos	1	2	3	4	5	6	7	8	9	score	
1	194	I	R	V	N	V	V	Y	G	L	24
2	268	R	R	D	S	P	L	P	V	I	24
3	132	L	R	H	A	T	V	L	T	L	22

HLA-B*2709 nonomers

	Pos	1 2 3 4 5 6 7 8 9	score
4	267	K R R D S P L P V	21
5	300	I R Q R I L R L F	20
6	231	T R E A Q A K A F	19
7	302	Q R I L R L F H V	19
8	124	R Y V A I C H P L	16
9	269	R D S P L P V I L	16
10	43	C N L T I I Y I V	15
11	216	I S F S Y L L I L	15
12	11	A T Y F I L I G L	14
13	25	A Q F W L A F P L	14
14	153	R G A A L M A P L	14
15	174	N I L S H S Y C L	14
16	222	L I L K T V L G L	14
17	257	I G L S M V H R F	14
18	280	I Y L L V P P V L	14
19	6	C N E S S A T Y F	13
20	14	F I L I G L P G L	13
21	21	C L E E A Q F W L	13
22	66	C M L S C I D I L	13
23	130	H P L R H A T V L	13
24	201	C L I V I I S A I	13
25	203	I V I I S A I G L	13
26	214	L L I S F S Y L L	13
27	251	I F Y V P F I G L	13
28	263	H R F S K R R D S	13
29	275	V I L A N I Y L L	13
30	305	L R L F H V A T H	13
31	30	A F P L C S L Y L	12
32	34	C S L Y L I A V L	12
33	37	Y L I A V L G N L	12
34	51	V R T E H S L H E	12
35	60	P M Y I F L G M L	12
36	75	I S T S S M P K M	12
37	93	T I Q F D A C L L	12
38	123	D R Y V A I C H P	12
39	135	A T V L T L P R V	12
40	138	L T L P R V T K I	12
41	149	A A V V R G A A L	12
42	155	A A L M A P L P V	12
43	168	L P F C R S N I L	12
44	181	C L H Q D V M K L	12
45	188	K L A C D D I R V	12
46	190	A C D D I R V N V	12
47	195	R V N V V Y G L I	12
48	210	C L D S L L I S F	12
49	213	S L L I S F S Y L	12
50	220	Y L L I L K T V L	12
51	248	A V F I F Y V P F	12
52	279	N I Y L L V P P V	12
53	287	V L N P I V Y G V	12
54	296	K T K E I R Q R I	12
55	299	E I R Q R I L R L	12

HLA-B*5101 nonomers

	Pos	1 2 3 4 5 6 7 8 9	score
1	39	I A V L G N L T I	26
2	31	F P L C S L Y L I	25
3	120	M A F D R Y V A I	24
4	130	H P L R H A T V L	23
5	118	L A M A F D R Y V	22
6	140	L P R V T K I G V	22
7	155	A A L M A P L P V	22
8	42	L G N L T I I Y I	21
9	254	V P F I G L S M V	21
10	284	V P P V L N P I V	21
11	168	L P F C R S N I L	20
12	235	Q A K A F C T C V	20
13	138	L T L P R V T K I	19
14	159	A P L P V F I K Q	18
15	189	L A C D D I R V N	18
16	198	V V Y G L I V I I	18
17	277	L A N I Y L L V P	18
18	207	S A I G L D S L L	17
19	283	L V P P V L N P I	17
20	63	I F L G M L S C I	16
21	86	I F W F N S T T I	16
22	110	S G M E S T V L L	16
23	144	T K I G V A A V V	16
24	149	A A V V R G A A L	16
25	197	N V V Y G L I V I	16
26	271	S P L P V I L A N	16
27	280	I Y L L V P P V L	16
28	3	D P N G N E S S A	15
29	40	A V L G N L T I I	15
30	97	D A C L L Q I F A	15
31	132	L R H A T V L T L	15
32	222	L I L K T V L C L	15
33	279	N I Y L L V P P V	15
34	285	P P V L N P I V Y	15
35	289	N P I V Y C V K T	15
36	9	S S A T Y F I L I	14
37	65	L C M L S C I D I	14
38	84	L A I F W F N S T	14
39	126	V A I C H P L R H	14
40	157	L M A P L P V F I	14
41	158	M A P L P V F I K	14
42	191	C D D I R V N V V	14
43	200	Y G L I V I I S A	14
44	209	I G L D S L L I S	14
45	215	L I S F S Y L L I	14
46	219	S Y L L I L K T V	14
47	220	Y L L I L K T V L	14
48	237	K A F G T C V S H	14
49	247	C A V F I F Y V P	14
50	249	V F I F Y V P F I	14
51	251	I F Y V P F I G L	14

HLA-B*5101 nonomers

	Pos	1	2	3	4	5	6	7	8	9	score
52	257	I	G	L	S	M	V	H	R	F	14
53	268	R	R	D	S	P	L	P	V	I	14
54	273	L	P	V	I	L	A	N	I	Y	14
55	29	L	A	F	P	L	C	S	L	Y	13
56	33	L	C	S	L	Y	L	I	A	V	13
57	55	H	S	L	H	E	P	M	Y	I	13
58	67	M	L	S	G	I	D	I	L	I	13
59	80	M	P	K	M	L	A	I	F	W	13
60	95	Q	F	D	A	C	L	L	Q	I	13
61	98	A	C	L	L	Q	I	F	A	I	13
62	104	F	A	I	H	S	L	S	G	M	13
63	146	I	G	V	A	A	V	V	R	G	13
64	148	V	A	A	V	V	R	C	A	A	13
65	153	R	C	A	A	L	M	A	P	L	13
66	233	E	A	Q	A	K	A	F	C	T	13
67	243	V	S	H	V	C	A	V	F	I	13
68	292	V	Y	C	V	K	T	K	E	I	13
69	296	K	T	K	E	I	R	Q	R	I	13

SEQ

ID

NO:

HLA-A*0201 nonomers

	Pos	1	2	3	4	5	6	7	8	9	score
1442	1	287	V	L	N	P	I	V	Y	G	30
1443	2	14	F	I	L	I	G	L	P	G	29
1444	3	28	W	L	A	F	P	L	C	S	28
1445	4	37	Y	L	I	A	V	L	G	N	28
1446	5	222	L	I	L	K	T	V	L	G	28
1447	6	66	C	M	L	S	G	I	D	I	26
1448	7	108	S	L	S	G	M	E	S	T	26
1449	8	181	C	L	H	Q	D	V	M	K	26
1450	9	201	G	L	I	V	I	I	S	A	26
1451	10	214	L	L	I	S	F	S	Y	L	26
1452	11	275	V	I	L	A	N	I	Y	L	26
1453	12	157	L	M	A	P	L	P	V	F	25
1454	13	220	Y	L	L	I	L	K	T	V	25
1455	14	276	I	L	A	N	I	Y	L	L	25
1456	15	279	N	I	Y	L	L	V	P	P	25
1457	16	138	L	T	L	P	R	V	T	K	24
1458	17	213	S	L	L	I	S	F	S	Y	24
1459	18	49	Y	I	V	R	T	E	H	S	23
1460	19	143	V	T	K	I	G	V	A	A	23
1461	20	188	K	L	A	C	D	D	I	R	23
1462	21	198	V	V	Y	G	L	I	V	I	23
1463	22	21	G	L	E	E	A	Q	F	W	22
1464	23	40	A	V	L	G	N	L	T	I	22
1465	24	206	I	S	A	I	G	L	D	S	22
1466	25	11	A	T	Y	F	I	L	I	G	21
1467	26	60	P	M	Y	I	F	L	C	M	21
1468	27	135	A	T	V	L	T	L	P	R	21
1469	28	160	P	L	P	V	F	I	K	Q	21
1470	29	174	N	I	L	S	H	S	Y	C	21

HLA-B*5101 nonomers

	Pos	1	2	3	4	5	6	7	8	9	score
1471	30	207	S	A	I	G	L	D	S	L	21
1472	31	272	P	L	P	V	I	L	A	N	21
1473	32	283	L	V	P	P	V	L	N	P	21
1474	33	67	M	L	S	G	I	D	I	L	20
1475	34	101	L	Q	I	F	A	I	H	S	20
1476	35	282	L	L	V	P	P	V	L	N	20
1477	36	299	E	I	R	Q	R	I	L	R	20
1478	37	304	I	L	R	L	F	H	V	A	20
1479	38	39	I	A	V	L	G	N	L	T	19
1480	39	45	L	T	I	I	Y	I	V	R	19
1481	40	92	T	T	I	Q	F	D	A	C	19
1482	41	110	S	G	M	E	S	T	V	L	19
1483	42	127	A	I	C	H	P	L	R	H	19
1484	43	132	L	R	H	A	T	V	L	T	19
1485	44	149	A	A	V	V	R	G	A	A	19
1486	45	155	A	A	L	M	A	P	L	P	19
1487	46	156	A	L	M	A	P	L	P	V	19
1488	47	203	I	V	I	I	S	A	I	G	19
1489	48	208	A	I	G	L	D	S	L	L	19
1490	49	216	I	S	F	S	Y	L	L	I	19
1491	50	219	S	Y	L	L	I	L	K	T	19
1492	51	221	L	L	I	L	K	T	V	L	19
1493	52	223	I	L	K	T	V	L	G	L	19
1494	53	17	I	G	L	P	G	L	E	E	18
1495	54	33	L	C	S	L	Y	L	I	A	18
1496	55	34	C	S	L	Y	L	I	A	V	18
1497	56	38	L	I	A	V	L	G	N	L	18
1498	57	43	G	N	L	T	I	I	Y	I	18
1499	58	85	A	I	F	W	F	N	S	T	18
1500	59	118	L	A	M	A	F	D	R	Y	18
1501	60	194	I	R	V	N	V	V	Y	G	18
1502	61	210	G	L	D	S	L	L	I	S	18
1503	62	215	L	I	S	F	S	Y	L	L	18
1504	63	246	V	C	A	V	F	I	F	Y	18
1505	64	254	V	P	F	I	G	L	S	M	18
1506	65	15	I	L	I	G	L	P	G	L	17
1507	66	63	I	F	L	C	M	L	S	G	17
1508	67	72	D	I	L	I	S	T	S	S	17
1509	68	93	T	I	Q	F	D	A	C	L	17
1510	69	98	A	C	L	L	Q	I	F	A	17
1511	70	111	G	M	E	S	T	V	L	L	17
1512	71	120	M	A	F	D	R	Y	V	A	17
1513	72	167	Q	L	P	F	C	R	S	N	17
1514	73	197	N	V	V	Y	G	L	I	V	17
1515	74	226	T	V	L	G	L	T	R	E	17
1516	75	281	Y	L	L	V	P	P	V	L	17
1517	76	31	F	P	L	C	S	L	Y	L	16
1518	77	56	S	L	H	E	P	M	Y	I	16
1519	78	70	G	I	D	I	L	I	S	T	16
1520	79	78	S	S	M	P	K	M	L	A	16
1521	80	79	S	M	P	K	M	L	A	I	16
1522	81	104	F	A	I	H	S	L	S	G	16

HLA-B*5101 nonomers

	Pos		1	2	3	4	5	6	7	8	9	score
1523	82	119	A	M	A	F	D	R	Y	V	A	16
1524	83	144	T	K	I	G	V	A	A	V	V	16
1525	84	147	G	V	A	A	V	V	R	G	A	16
1526	85	186	V	M	K	L	A	C	D	D	I	16
1527	86	230	L	T	R	E	A	Q	A	K	A	16
1528	87	238	A	F	G	T	C	V	S	H	V	16
1529	88	249	V	F	I	F	Y	V	P	F	I	16
1530	89	302	Q	R	I	L	R	L	F	H	V	16
1531	90	303	R	I	L	R	L	F	H	V	A	16
1532	91	18	G	L	P	G	L	E	E	A	Q	15
1533	92	35	S	L	Y	L	I	A	V	L	G	15
1534	93	42	L	G	N	L	T	I	I	Y	I	15
1535	94	46	T	I	I	Y	I	V	R	T	E	15
1536	95	69	S	G	I	D	I	L	I	S	T	15
1537	96	76	S	T	S	S	M	P	K	M	L	15
1538	97	131	P	L	R	H	A	T	V	L	T	15
1539	98	137	V	L	T	L	P	R	V	T	K	15
1540	99	153	R	G	A	A	L	M	A	P	L	15
1541	100	190	A	C	D	D	I	R	V	N	V	15
1542	101	191	C	D	D	I	R	V	N	V	V	15
1543	102	204	V	I	I	S	A	I	G	L	D	15
1544	103	241	T	C	V	S	H	V	C	A	V	15
1545	104	251	I	F	Y	V	P	F	I	G	L	15
1546	105	269	R	D	S	P	L	P	V	I	L	15
1547	106	280	I	Y	L	L	V	P	P	V	L	15
1548	107	306	R	L	F	H	V	A	T	H	A	15

SEQ
ID
NO:

HLA A*0203 nonomers

	Pos		1	2	3	4	5	6	7	8	9	score
1549	1	148	V	A	A	V	V	R	G	A	A	14
1550	2	119	A	M	A	F	D	R	Y	V	A	13
1551	3	147	G	V	A	A	V	V	R	G	A	12
1552	4	97	D	A	C	L	L	Q	I	F	A	11
1553	5	127	A	I	C	H	P	L	R	H	A	10
1554	6	3	D	P	N	G	N	E	S	S	A	9
1555	7	17	I	G	L	P	G	L	E	E	A	9
1556	8	22	L	E	E	A	Q	F	W	L	A	9
1557	9	32	P	L	C	S	L	Y	L	I	A	9
1558	10	77	T	S	S	M	P	K	M	L	A	9
1559	11	90	N	S	T	T	I	Q	F	D	A	9
1560	12	111	G	M	E	S	T	V	L	L	A	9
1561	13	113	E	S	T	V	L	L	A	M	A	9
1562	14	141	P	R	V	T	K	I	G	V	A	9
1563	15	142	R	V	T	K	I	G	V	A	A	9
1564	16	151	V	V	R	G	A	A	L	M	A	9
1565	17	182	L	H	Q	D	V	M	K	L	A	9
1566	18	200	Y	G	L	I	V	I	I	S	A	9
1567	19	226	T	V	L	G	L	T	R	E	A	9
1568	20	228	L	G	L	T	R	E	A	Q	A	9

SEQ
ID
NO:

HLA A*0203 nonomers

	Pos		1	2	3	4	5	6	7	8	9	score
1569	21	230	L	T	R	E	A	Q	A	K	A	9
1570	22	240	G	T	C	V	S	H	V	C	A	9
1571	23	270	D	S	P	L	P	V	I	L	A	9
1572	24	303	R	I	L	R	L	F	H	V	A	9
1573	25	306	R	L	F	H	V	A	T	H	A	9

SEQ
ID
NO:

HLA-A26 nonomers

	Pos		1	2	3	4	5	6	7	8	9	score
1574	1	299	E	I	R	Q	R	I	L	R	L	30
1575	2	72	D	I	L	I	S	T	S	S	M	27
1576	3	248	A	V	F	I	F	Y	V	P	F	27
1577	4	210	G	L	D	S	L	L	I	S	F	26
1578	5	14	F	I	L	I	G	L	P	G	L	24
1579	6	56	S	L	H	E	P	M	Y	I	F	24
1580	7	117	L	L	A	M	A	F	D	R	Y	24
1581	8	222	L	I	L	K	T	V	L	G	L	24
1582	9	245	H	V	C	A	V	F	I	F	Y	24
1583	10	11	A	T	Y	F	I	L	I	G	L	23
1584	11	37	Y	L	I	A	V	L	G	N	L	23
1585	12	114	S	T	V	L	L	A	M	A	F	23
1586	13	156	A	L	M	A	P	L	P	V	F	23
1587	14	162	P	V	F	I	K	Q	L	P	F	23
1588	15	181	C	L	H	Q	D	V	M	K	L	23
1589	16	28	W	L	A	F	P	L	C	S	L	22
1590	17	92	T	T	I	Q	F	D	A	C	L	22
1591	18	160	P	L	P	V	F	I	K	Q	L	22
1592	19	203	I	V	I	I	S	A	I	G	L	22
1593	20	213	S	L	L	I	S	F	S	Y	L	22
1594	21	275	V	I	L	A	N	I	Y	L	L	22
1595	22	193	D	I	R	V	N	V	V	Y	G	21
1596	23	242	C	V	S	H	V	C	A	V	F	21
1597	24	76	S	T	S	S	M	P	K	M	L	20
1598	25	253	Y	V	P	F	I	G	L	S	M	20
1599	26	274	P	V	I	L	A	N	I	Y	L	20
1600	27	23	E	E	A	Q	F	W	L	A	F	19
1601	28	41	V	L	G	N	L	T	I	I	Y	19
1602	29	49	Y	I	V	R	T	E	H	S	L	19
1603	30	150	A	V	V	R	G	A	A	L	M	19
1604	31	174	N	I	L	S	H	S	Y	C	L	19
1605	32	192	D	D	I	R	V	N	V	V	Y	19
1606	33	214	L	L	I	S	F	S	Y	L	L	19
1607	34	251	I	F	Y	V	P	F	I	G	L	19
1608	35	8	E	S	S	A	T	Y	F	I	L	18
1609	36	21	G	L	E	E	A	Q	F	W	L	18
1610	37	45	L	T	I	I	Y	I	V	R	T	18
1611	38	54	E	H	S	L	H	E	P	M	Y	18
1612	39	59	E	P	M	Y	I	F	L	C	M	18
1613	40	88	W	F	N	S	T	T	I	Q	F	18

<u>SEQ</u> <u>ID</u> <u>NO:</u>	<u>HLA-A26 nonomers</u>										<u>score</u>	<u>SEQ</u> <u>ID</u> <u>NO:</u>	<u>HLA-A3 nonomers</u>										<u>score</u>		
	<u>Pos</u>		1	2	3	4	5	6	7	8	9		<u>Pos</u>		1	2	3	4	5	6	7	8	9		
<u>1614</u>	<u>41</u>	<u>93</u>	<u>T</u>	<u>I</u>	<u>Q</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>18</u>	<u>1659</u>	<u>5</u>	<u>290</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>24</u>
<u>1615</u>	<u>42</u>	<u>185</u>	<u>D</u>	<u>V</u>	<u>M</u>	<u>K</u>	<u>L</u>	<u>A</u>	<u>C</u>	<u>D</u>	<u>D</u>	<u>18</u>	<u>1660</u>	<u>6</u>	<u>35</u>	<u>S</u>	<u>L</u>	<u>Y</u>	<u>L</u>	<u>I</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>23</u>
<u>1616</u>	<u>43</u>	<u>198</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>18</u>	<u>1661</u>	<u>7</u>	<u>156</u>	<u>A</u>	<u>L</u>	<u>M</u>	<u>A</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>F</u>	<u>23</u>
<u>1617</u>	<u>44</u>	<u>62</u>	<u>Y</u>	<u>I</u>	<u>F</u>	<u>L</u>	<u>C</u>	<u>M</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>17</u>	<u>1662</u>	<u>8</u>	<u>47</u>	<u>I</u>	<u>I</u>	<u>Y</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>H</u>	<u>22</u>
<u>1618</u>	<u>45</u>	<u>70</u>	<u>G</u>	<u>I</u>	<u>D</u>	<u>I</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>T</u>	<u>S</u>	<u>17</u>	<u>1663</u>	<u>9</u>	<u>50</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>H</u>	<u>22</u>
<u>1619</u>	<u>46</u>	<u>79</u>	<u>S</u>	<u>M</u>	<u>P</u>	<u>K</u>	<u>M</u>	<u>L</u>	<u>A</u>	<u>I</u>	<u>F</u>	<u>17</u>	<u>1664</u>	<u>10</u>	<u>142</u>	<u>R</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>22</u>
<u>1620</u>	<u>47</u>	<u>96</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>17</u>	<u>1665</u>	<u>11</u>	<u>151</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>A</u>	<u>A</u>	<u>L</u>	<u>M</u>	<u>A</u>	<u>22</u>
<u>1621</u>	<u>48</u>	<u>104</u>	<u>F</u>	<u>A</u>	<u>I</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>M</u>	<u>17</u>	<u>1666</u>	<u>12</u>	<u>242</u>	<u>C</u>	<u>V</u>	<u>S</u>	<u>H</u>	<u>V</u>	<u>C</u>	<u>A</u>	<u>V</u>	<u>F</u>	<u>22</u>
<u>1622</u>	<u>49</u>	<u>138</u>	<u>L</u>	<u>T</u>	<u>L</u>	<u>P</u>	<u>R</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>I</u>	<u>17</u>	<u>1667</u>	<u>13</u>	<u>248</u>	<u>A</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>F</u>	<u>Y</u>	<u>V</u>	<u>P</u>	<u>F</u>	<u>22</u>
<u>1623</u>	<u>50</u>	<u>143</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>17</u>	<u>1668</u>	<u>14</u>	<u>116</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>F</u>	<u>D</u>	<u>R</u>	<u>21</u>
<u>1624</u>	<u>51</u>	<u>204</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>17</u>	<u>1669</u>	<u>15</u>	<u>192</u>	<u>D</u>	<u>D</u>	<u>I</u>	<u>R</u>	<u>V</u>	<u>N</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>21</u>
<u>1625</u>	<u>52</u>	<u>212</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>17</u>	<u>1670</u>	<u>16</u>	<u>303</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>R</u>	<u>L</u>	<u>F</u>	<u>H</u>	<u>V</u>	<u>A</u>	<u>21</u>
<u>1626</u>	<u>53</u>	<u>220</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>17</u>	<u>1671</u>	<u>17</u>	<u>304</u>	<u>I</u>	<u>L</u>	<u>R</u>	<u>L</u>	<u>F</u>	<u>H</u>	<u>V</u>	<u>A</u>	<u>T</u>	<u>21</u>
<u>1627</u>	<u>54</u>	<u>256</u>	<u>F</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>S</u>	<u>M</u>	<u>V</u>	<u>H</u>	<u>R</u>	<u>17</u>	<u>1672</u>	<u>18</u>	<u>108</u>	<u>S</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>M</u>	<u>E</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>20</u>
<u>1628</u>	<u>55</u>	<u>283</u>	<u>L</u>	<u>V</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>17</u>	<u>1673</u>	<u>19</u>	<u>198</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>20</u>
<u>1629</u>	<u>56</u>	<u>29</u>	<u>L</u>	<u>A</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>Y</u>	<u>16</u>	<u>1674</u>	<u>20</u>	<u>291</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>20</u>
<u>1630</u>	<u>57</u>	<u>40</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>I</u>	<u>16</u>	<u>1675</u>	<u>21</u>	<u>15</u>	<u>I</u>	<u>L</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>P</u>	<u>G</u>	<u>L</u>	<u>E</u>	<u>19</u>
<u>1631</u>	<u>58</u>	<u>46</u>	<u>T</u>	<u>I</u>	<u>I</u>	<u>Y</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>16</u>	<u>1676</u>	<u>22</u>	<u>44</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>I</u>	<u>Y</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>19</u>
<u>1632</u>	<u>59</u>	<u>52</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>H</u>	<u>E</u>	<u>P</u>	<u>16</u>	<u>1677</u>	<u>23</u>	<u>73</u>	<u>I</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>T</u>	<u>S</u>	<u>S</u>	<u>M</u>	<u>P</u>	<u>19</u>
<u>1633</u>	<u>60</u>	<u>75</u>	<u>I</u>	<u>S</u>	<u>T</u>	<u>S</u>	<u>S</u>	<u>M</u>	<u>P</u>	<u>K</u>	<u>M</u>	<u>16</u>	<u>1678</u>	<u>24</u>	<u>74</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>T</u>	<u>S</u>	<u>S</u>	<u>M</u>	<u>P</u>	<u>K</u>	<u>19</u>
<u>1634</u>	<u>61</u>	<u>91</u>	<u>S</u>	<u>T</u>	<u>T</u>	<u>I</u>	<u>Q</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>16</u>	<u>1679</u>	<u>25</u>	<u>99</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>A</u>	<u>I</u>	<u>H</u>	<u>19</u>
<u>1635</u>	<u>62</u>	<u>135</u>	<u>A</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>T</u>	<u>L</u>	<u>P</u>	<u>R</u>	<u>V</u>	<u>16</u>	<u>1680</u>	<u>26</u>	<u>162</u>	<u>P</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>K</u>	<u>Q</u>	<u>L</u>	<u>P</u>	<u>F</u>	<u>19</u>
<u>1636</u>	<u>63</u>	<u>147</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>A</u>	<u>16</u>	<u>1681</u>	<u>27</u>	<u>203</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>19</u>
<u>1637</u>	<u>64</u>	<u>201</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>16</u>	<u>1682</u>	<u>28</u>	<u>221</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>19</u>
<u>1638</u>	<u>65</u>	<u>257</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>S</u>	<u>M</u>	<u>V</u>	<u>H</u>	<u>R</u>	<u>F</u>	<u>16</u>	<u>1683</u>	<u>29</u>	<u>245</u>	<u>H</u>	<u>V</u>	<u>C</u>	<u>A</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>F</u>	<u>Y</u>	<u>19</u>
<u>1639</u>	<u>66</u>	<u>279</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>16</u>	<u>1684</u>	<u>30</u>	<u>306</u>	<u>R</u>	<u>L</u>	<u>F</u>	<u>H</u>	<u>V</u>	<u>A</u>	<u>T</u>	<u>H</u>	<u>A</u>	<u>19</u>
<u>1640</u>	<u>67</u>	<u>30</u>	<u>A</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>Y</u>	<u>L</u>	<u>15</u>	<u>1685</u>	<u>31</u>	<u>40</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>I</u>	<u>18</u>
<u>1641</u>	<u>68</u>	<u>101</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>A</u>	<u>I</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>15</u>	<u>1686</u>	<u>32</u>	<u>85</u>	<u>A</u>	<u>I</u>	<u>F</u>	<u>W</u>	<u>F</u>	<u>N</u>	<u>S</u>	<u>T</u>	<u>T</u>	<u>18</u>
<u>1642</u>	<u>69</u>	<u>115</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>F</u>	<u>D</u>	<u>15</u>	<u>1687</u>	<u>33</u>	<u>205</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>18</u>
<u>1643</u>	<u>70</u>	<u>127</u>	<u>A</u>	<u>I</u>	<u>C</u>	<u>H</u>	<u>P</u>	<u>L</u>	<u>R</u>	<u>H</u>	<u>A</u>	<u>15</u>	<u>1688</u>	<u>34</u>	<u>220</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>18</u>
<u>1644</u>	<u>71</u>	<u>153</u>	<u>R</u>	<u>G</u>	<u>A</u>	<u>A</u>	<u>L</u>	<u>M</u>	<u>A</u>	<u>P</u>	<u>L</u>	<u>15</u>	<u>1689</u>	<u>35</u>	<u>253</u>	<u>Y</u>	<u>V</u>	<u>P</u>	<u>F</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>S</u>	<u>M</u>	<u>18</u>
<u>1645</u>	<u>72</u>	<u>163</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>K</u>	<u>Q</u>	<u>L</u>	<u>P</u>	<u>F</u>	<u>C</u>	<u>15</u>	<u>1690</u>	<u>36</u>	<u>37</u>	<u>Y</u>	<u>L</u>	<u>I</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>L</u>	<u>17</u>
<u>1646</u>	<u>73</u>	<u>215</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>15</u>	<u>1691</u>	<u>37</u>	<u>41</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>I</u>	<u>Y</u>	<u>17</u>
<u>1647</u>	<u>74</u>	<u>216</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>15</u>	<u>1692</u>	<u>38</u>	<u>117</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>F</u>	<u>D</u>	<u>R</u>	<u>Y</u>	<u>17</u>
<u>1648</u>	<u>75</u>	<u>225</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>R</u>	<u>E</u>	<u>15</u>	<u>1693</u>	<u>39</u>	<u>131</u>	<u>P</u>	<u>L</u>	<u>R</u>	<u>H</u>	<u>A</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>T</u>	<u>17</u>
<u>1649</u>	<u>76</u>	<u>272</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>I</u>	<u>L</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>15</u>	<u>1694</u>	<u>40</u>	<u>136</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>T</u>	<u>L</u>	<u>P</u>	<u>R</u>	<u>V</u>	<u>T</u>	<u>17</u>
<u>1650</u>	<u>77</u>	<u>282</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>15</u>	<u>1695</u>	<u>41</u>	<u>180</u>	<u>Y</u>	<u>C</u>	<u>L</u>	<u>H</u>	<u>Q</u>	<u>D</u>	<u>V</u>	<u>M</u>	<u>K</u>	<u>17</u>
<u>1651</u>	<u>78</u>	<u>286</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>15</u>	<u>1696</u>	<u>42</u>	<u>201</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>17</u>
<u>1652</u>	<u>79</u>	<u>287</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>15</u>	<u>1697</u>	<u>43</u>	<u>213</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>17</u>
<u>1653</u>	<u>80</u>	<u>296</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>I</u>	<u>15</u>	<u>1698</u>	<u>44</u>	<u>256</u>	<u>F</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>S</u>	<u>M</u>	<u>V</u>	<u>H</u>	<u>R</u>	<u>17</u>
<u>1654</u>	<u>81</u>	<u>303</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>R</u>	<u>L</u>	<u>F</u>	<u>H</u>	<u>V</u>	<u>A</u>	<u>15</u>	<u>1699</u>	<u>45</u>	<u>261</u>	<u>M</u>	<u>V</u>	<u>H</u>	<u>R</u>	<u>F</u>	<u>S</u>	<u>K</u>	<u>R</u>	<u>R</u>	<u>17</u>
													<u>1700</u>	<u>46</u>	<u>276</u>	<u>I</u>	<u>L</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>17</u>
													<u>1701</u>	<u>47</u>	<u>281</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>17</u>
													<u>1702</u>	<u>48</u>	<u>286</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>17</u>
													<u>1703</u>	<u>49</u>	<u>288</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>17</u>
													<u>1704</u>	<u>50</u>	<u>309</u>	<u>H</u>	<u>V</u>	<u>A</u>	<u>T</u>	<u>H</u>	<u>A</u>	<u>S</u>	<u>E</u>	<u>P</u>	<u>17</u>
													<u>1705</u>	<u>51</u>	<u>1</u>	<u>M</u>	<u>V</u>	<u>D</u>	<u>P</u>	<u>N</u>	<u>G</u>	<u>N</u>	<u>E</u>	<u>S</u>	<u>16</u>
													<u>1706</u>	<u>52</u>	<u>56</u>	<u>S</u>	<u>L</u>								

SEQ
ID
NO:

HLA-A3 nonomers

	<u>Pos</u>		<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>	<u>score</u>
1709	55	115	T	V	L	L	A	M	A	F	D	16
1710	56	125	Y	V	A	I	C	H	P	L	R	16
1711	57	144	T	K	I	G	V	A	A	V	V	16
1712	58	167	Q	L	P	F	C	R	S	N	I	16
1713	59	175	I	L	S	H	S	Y	C	L	H	16
1714	60	195	R	V	N	V	V	Y	G	L	I	16
1715	61	197	N	V	V	Y	G	L	I	V	I	16
1716	62	210	G	L	D	S	L	L	I	S	F	16
1717	63	282	L	L	V	P	P	V	L	N	P	16
1718	64	299	E	I	R	Q	R	I	L	R	L	16
1719	65	301	R	Q	R	I	L	R	L	F	H	16
1720	66	16	L	I	G	L	P	G	L	E	E	15
1721	67	46	T	I	I	Y	I	V	R	T	E	15
1722	68	102	Q	I	F	A	I	H	S	L	S	15
1723	69	193	D	I	R	V	N	V	V	Y	G	15
1724	70	208	A	I	G	L	D	S	L	L	I	15
1725	71	223	I	L	K	T	V	L	G	L	T	15
1726	72	237	K	A	F	G	T	C	V	S	H	15

SEQ
ID
NO:

HLA-B*0702 nonomers

	<u>Pos</u>		<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>	<u>score</u>
1727	1	130	H	P	L	R	H	A	T	V	L	22
1728	2	59	E	P	M	Y	I	F	L	C	M	21
1729	3	168	L	P	F	C	R	S	N	I	L	20
1730	4	289	N	P	I	V	Y	G	V	K	T	19
1731	5	3	D	P	N	G	N	E	S	S	A	18
1732	6	19	L	P	G	L	E	E	A	Q	F	18
1733	7	140	L	P	R	V	T	K	I	G	V	18
1734	8	284	V	P	P	V	L	N	P	I	V	17
1735	9	31	F	P	L	C	S	L	Y	L	I	16
1736	10	254	V	P	F	I	G	L	S	M	V	16
1737	11	269	R	D	S	P	L	P	V	I	L	16
1738	12	149	A	A	V	V	R	G	A	A	L	15
1739	13	153	R	G	A	A	L	M	A	P	L	15
1740	14	156	A	L	M	A	P	L	P	V	F	15
1741	15	251	I	F	Y	V	P	F	I	G	L	15
1742	16	299	E	I	R	Q	R	I	L	R	L	15
1743	17	8	E	S	S	A	T	Y	F	I	L	14
1744	18	28	W	L	A	F	P	L	C	S	L	14
1745	19	30	A	F	P	L	C	S	L	Y	L	14
1746	20	110	S	G	M	E	S	T	V	L	L	14
1747	21	132	L	R	H	A	T	V	L	T	L	14
1748	22	159	A	P	L	P	V	F	I	K	Q	14
1749	23	222	L	I	L	K	T	V	L	G	L	14
1750	24	271	S	P	L	P	V	I	L	A	N	14
1751	25	25	A	Q	F	W	L	A	F	P	L	13
1752	26	109	L	S	G	M	E	S	T	V	L	13
1753	27	124	R	Y	V	A	I	C	H	P	L	13

SEQ
ID
NO:

HLA-B*0702 nonomers

	<u>Pos</u>		<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>	<u>score</u>
1754	28	216	I	S	F	S	Y	L	L	I	L	13
1755	29	268	R	R	D	S	P	L	P	V	I	13
1756	30	280	I	Y	L	L	V	P	P	V	L	13
1757	31	11	A	T	Y	F	I	L	I	G	L	12
1758	32	34	C	S	L	Y	L	I	A	V	L	12
1759	33	57	L	H	E	P	M	Y	I	F	L	12
1760	34	76	S	T	S	S	M	P	K	M	L	12
1761	35	142	R	V	T	K	I	G	V	A	A	12
1762	36	151	V	V	R	G	A	A	L	M	A	12
1763	37	190	A	C	D	D	I	R	V	N	V	12
1764	38	194	I	R	V	N	V	V	Y	G	L	12
1765	39	206	I	S	A	I	G	L	D	S	L	12
1766	40	207	S	A	I	G	L	D	S	L	L	12
1767	41	220	Y	L	L	I	L	K	T	V	L	12
1768	42	267	K	R	R	D	S	P	L	P	V	12
1769	43	304	I	L	R	L	F	H	V	A	T	12
1770	44	14	F	I	L	I	G	L	P	G	L	11
1771	45	23	E	E	A	Q	F	W	L	A	F	11
1772	46	37	Y	L	I	A	V	L	G	N	L	11
1773	47	40	A	V	L	G	N	L	T	I	I	11
1774	48	77	T	S	S	M	P	K	M	L	A	11
1775	49	78	S	S	M	P	K	M	L	A	I	11
1776	50	80	M	P	K	M	L	A	I	F	W	11
1777	51	92	T	T	I	Q	F	D	A	C	L	11
1778	52	112	M	E	S	T	V	L	L	A	M	11
1779	53	119	A	M	A	F	D	R	Y	V	A	11
1780	54	127	A	I	C	H	P	L	R	H	A	11
1781	55	131	P	L	R	H	A	T	V	L	T	11
1782	56	155	A	A	L	M	A	P	L	P	V	11
1783	57	157	L	M	A	P	L	P	V	F	I	11
1784	58	181	C	L	H	Q	D	V	M	K	L	11
1785	59	203	I	V	I	I	S	A	I	G	L	11
1786	60	208	A	I	G	L	D	S	L	L	I	11
1787	61	213	S	L	L	I	S	F	S	Y	L	11
1788	62	248	A	V	F	I	F	Y	V	P	F	11
1789	63	265	F	S	K	R	R	D	S	P	L	11
1790	64	275	V	I	L	A	N	I	Y	L	L	11
1791	65	285	P	P	V	L	N	P	I	V	Y	11

SEQ
ID
NO:

HLA-B*08 nonomers

	<u>Pos</u>		<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>	<u>score</u>
1792	1	299	E	I	R	Q	R	I	L	R	L	31
1793	2	265	F	S	K	R	R	D	S	P	L	29
1794	3	149	A	A	V	V	R	G	A	A	L	24
1795	4	168	L	P	F	C	R	S	N	I	L	24
1796	5	294	G	V	K	T	K	E	I	R	Q	21
1797	6	120	M	A	F	D	R	Y	V	A	I	20
1798	7	292	V	Y	G	V	K	T	K	E	I	20

SEQ
ID
NO:

HLA-B*08 nonomers

	Pos		1	2	3	4	5	6	7	8	9	score
1799	8	21	G	L	E	E	A	Q	F	W	L	19
1800	9	78	S	S	M	P	K	M	L	A	I	19
1801	10	160	P	L	P	V	F	I	K	Q	L	19
1802	11	186	V	M	K	L	A	C	D	D	I	18
1803	12	213	S	L	L	I	S	F	S	Y	L	18
1804	13	221	L	L	I	L	K	T	V	L	G	18
1805	14	296	K	T	K	E	I	R	Q	R	I	18
1806	15	297	T	K	E	I	R	Q	R	I	L	18
1807	16	130	H	P	L	R	H	A	T	V	L	17
1808	17	181	C	L	H	Q	D	V	M	K	L	17
1809	18	223	I	L	K	T	V	L	G	L	T	17
1810	19	28	W	L	A	F	P	L	C	S	L	16
1811	20	37	Y	L	I	A	V	L	G	N	L	16
1812	21	56	S	L	H	E	P	M	Y	I	F	16
1813	22	80	M	P	K	M	L	A	I	F	W	16
1814	23	162	P	V	F	I	K	Q	L	P	F	16
1815	24	201	G	L	I	V	I	I	S	A	I	16
1816	25	207	S	A	I	G	L	D	S	L	L	16
1817	26	214	L	L	I	S	F	S	Y	L	L	16
1818	27	220	Y	L	L	I	L	K	T	V	L	16
1819	28	233	E	A	Q	A	K	A	F	G	T	16
1820	29	275	V	I	L	A	N	I	Y	L	L	16
1821	30	304	I	L	R	L	F	H	V	A	T	16
1822	31	14	F	I	L	I	G	L	P	G	L	15
1823	32	110	S	G	M	E	S	T	V	L	L	15
1824	33	138	L	T	L	P	R	V	T	K	I	15
1825	34	164	F	I	K	Q	L	P	F	C	R	15
1826	35	222	L	I	L	K	T	V	L	G	L	15

SEQ
ID
NO:

HLA-B*1510 nonomers

	Pos		1	2	3	4	5	6	7	8	9	score
1827	1	57	L	H	E	P	M	Y	I	F	L	23
1828	2	244	S	H	V	C	A	V	F	I	F	17
1829	3	269	R	D	S	P	L	P	V	I	L	16
1830	4	280	I	Y	L	L	V	P	P	V	L	16
1831	5	262	V	H	R	F	S	K	R	R	D	15
1832	6	299	E	I	R	Q	R	I	L	R	L	15
1833	7	106	I	H	S	L	S	G	M	E	S	14
1834	8	206	I	S	A	I	G	L	D	S	L	14
1835	9	220	Y	L	L	I	L	K	T	V	L	14
1836	10	251	I	F	Y	V	P	F	I	G	L	14
1837	11	297	T	K	E	I	R	Q	R	I	L	14
1838	12	21	G	L	E	E	A	Q	F	W	L	13
1839	13	34	C	S	L	Y	L	I	A	V	L	13
1840	14	54	E	H	S	L	H	E	P	M	Y	13
1841	15	110	S	G	M	E	S	T	V	L	L	13
1842	16	194	I	R	V	N	V	V	Y	G	L	13
1843	17	8	E	S	S	A	T	Y	F	I	L	12

SEQ
ID
NO:

HLA-B*1510 nonomers

	Pos		1	2	3	4	5	6	7	8	9	score
1844	18	14	F	I	L	I	G	L	P	G	L	12
1845	19	28	W	L	A	F	P	L	C	S	L	12
1846	20	66	C	M	L	S	G	I	D	I	L	12
1847	21	76	S	T	S	S	M	P	K	M	L	12
1848	22	92	T	T	I	Q	F	D	A	C	L	12
1849	23	109	L	S	G	M	E	S	T	V	L	12
1850	24	130	H	P	L	R	H	A	T	V	L	12
1851	25	132	L	R	H	A	T	V	L	T	L	12
1852	26	149	A	A	V	V	R	G	A	A	L	12
1853	27	153	R	G	A	A	L	M	A	P	L	12
1854	28	160	P	L	P	V	F	I	K	Q	L	12
1855	29	181	C	L	H	Q	D	V	M	K	L	12
1856	30	182	L	H	Q	D	V	M	K	L	A	12
1857	31	203	I	V	I	I	S	A	I	G	L	12
1858	32	216	I	S	F	S	Y	L	L	I	L	12
1859	33	222	L	I	L	K	T	V	L	G	L	12
1860	34	275	V	I	L	A	N	I	Y	L	L	12
1861	35	37	Y	L	I	A	V	L	G	N	L	11
1862	36	49	Y	I	V	R	T	E	H	S	L	11
1863	37	93	T	I	Q	F	D	A	C	L	L	11
1864	38	101	L	Q	I	F	A	I	H	S	L	11
1865	39	129	C	H	P	L	R	H	A	T	V	11
1866	40	133	R	H	A	T	V	L	T	L	P	11
1867	41	177	S	H	S	Y	C	L	H	Q	D	11
1868	42	207	S	A	I	G	L	D	S	L	L	11
1869	43	257	I	G	L	S	M	V	H	R	F	11

SEQ
ID
NO:

HLA-B*2705 nonomers

	Pos		1	2	3	4	5	6	7	8	9	score
1870	1	194	I	R	V	N	V	V	Y	G	L	25
1871	2	268	R	R	D	S	P	L	P	V	I	24
1872	3	132	L	R	H	A	T	V	L	T	L	23
1873	4	300	I	R	Q	R	I	L	R	L	F	23
1874	5	305	L	R	L	F	H	V	A	T	H	23
1875	6	231	T	R	E	A	Q	A	K	A	F	21
1876	7	34	C	S	L	Y	L	I	A	V	L	18
1877	8	299	E	I	R	Q	R	I	L	R	L	18
1878	9	6	G	N	E	S	S	A	T	Y	F	17
1879	10	66	C	M	L	S	G	I	D	I	L	17
1880	11	162	P	V	F	I	K	Q	L	P	F	17
1881	12	207	S	A	I	G	L	D	S	L	L	17
1882	13	210	G	L	D	S	L	L	I	S	F	17
1883	14	220	Y	L	L	I	L	K	T	V	L	17
1884	15	237	K	A	F	G	T	C	V	S	H	17
1885	16	269	R	D	S	P	L	P	V	I	L	17
1886	17	280	I	Y	L	L	V	P	P	V	L	17
1887	18	295	V	K	T	K	E	I	R	Q	R	17
1888	19	11	A	T	Y	F	I	L	I	G	L	16

SEQ
ID
NO:

HLA-B*2705 nonomers

	<u>Pos</u>		<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>	<u>score</u>
<u>1889</u>	<u>20</u>	<u>14</u>	<u>F</u>	<u>I</u>	<u>L</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>P</u>	<u>G</u>	<u>L</u>	<u>16</u>
<u>1890</u>	<u>21</u>	<u>21</u>	<u>G</u>	<u>L</u>	<u>E</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>F</u>	<u>W</u>	<u>L</u>	<u>16</u>
<u>1891</u>	<u>22</u>	<u>25</u>	<u>A</u>	<u>Q</u>	<u>F</u>	<u>W</u>	<u>L</u>	<u>A</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>16</u>
<u>1892</u>	<u>23</u>	<u>37</u>	<u>Y</u>	<u>L</u>	<u>I</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>L</u>	<u>16</u>
<u>1893</u>	<u>24</u>	<u>92</u>	<u>T</u>	<u>T</u>	<u>I</u>	<u>Q</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>16</u>
<u>1894</u>	<u>25</u>	<u>101</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>A</u>	<u>I</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>16</u>
<u>1895</u>	<u>26</u>	<u>124</u>	<u>R</u>	<u>Y</u>	<u>V</u>	<u>A</u>	<u>I</u>	<u>C</u>	<u>H</u>	<u>P</u>	<u>L</u>	<u>16</u>
<u>1896</u>	<u>27</u>	<u>130</u>	<u>H</u>	<u>P</u>	<u>L</u>	<u>R</u>	<u>H</u>	<u>A</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>16</u>
<u>1897</u>	<u>28</u>	<u>141</u>	<u>P</u>	<u>R</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>16</u>
<u>1898</u>	<u>29</u>	<u>153</u>	<u>R</u>	<u>G</u>	<u>A</u>	<u>A</u>	<u>L</u>	<u>M</u>	<u>A</u>	<u>P</u>	<u>L</u>	<u>16</u>
<u>1899</u>	<u>30</u>	<u>181</u>	<u>C</u>	<u>L</u>	<u>H</u>	<u>Q</u>	<u>D</u>	<u>V</u>	<u>M</u>	<u>K</u>	<u>L</u>	<u>16</u>
<u>1900</u>	<u>31</u>	<u>201</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>16</u>
<u>1901</u>	<u>32</u>	<u>203</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>16</u>
<u>1902</u>	<u>33</u>	<u>216</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>16</u>
<u>1903</u>	<u>34</u>	<u>222</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>16</u>
<u>1904</u>	<u>35</u>	<u>255</u>	<u>P</u>	<u>F</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>S</u>	<u>M</u>	<u>V</u>	<u>H</u>	<u>16</u>
<u>1905</u>	<u>36</u>	<u>257</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>S</u>	<u>M</u>	<u>V</u>	<u>H</u>	<u>R</u>	<u>F</u>	<u>16</u>
<u>1906</u>	<u>37</u>	<u>275</u>	<u>V</u>	<u>I</u>	<u>L</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>16</u>
<u>1907</u>	<u>38</u>	<u>47</u>	<u>I</u>	<u>I</u>	<u>Y</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>H</u>	<u>15</u>
<u>1908</u>	<u>39</u>	<u>109</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>M</u>	<u>E</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>15</u>
<u>1909</u>	<u>40</u>	<u>114</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>F</u>	<u>15</u>
<u>1910</u>	<u>41</u>	<u>123</u>	<u>D</u>	<u>R</u>	<u>Y</u>	<u>V</u>	<u>A</u>	<u>I</u>	<u>C</u>	<u>H</u>	<u>P</u>	<u>15</u>
<u>1911</u>	<u>42</u>	<u>145</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>15</u>
<u>1912</u>	<u>43</u>	<u>156</u>	<u>A</u>	<u>L</u>	<u>M</u>	<u>A</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>F</u>	<u>15</u>
<u>1913</u>	<u>44</u>	<u>168</u>	<u>L</u>	<u>P</u>	<u>F</u>	<u>C</u>	<u>R</u>	<u>S</u>	<u>N</u>	<u>I</u>	<u>L</u>	<u>15</u>
<u>1914</u>	<u>45</u>	<u>172</u>	<u>R</u>	<u>S</u>	<u>N</u>	<u>I</u>	<u>L</u>	<u>S</u>	<u>H</u>	<u>S</u>	<u>Y</u>	<u>15</u>
<u>1915</u>	<u>46</u>	<u>198</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>15</u>
<u>1916</u>	<u>47</u>	<u>206</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>15</u>
<u>1917</u>	<u>48</u>	<u>229</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>R</u>	<u>E</u>	<u>A</u>	<u>O</u>	<u>A</u>	<u>K</u>	<u>15</u>
<u>1918</u>	<u>49</u>	<u>248</u>	<u>A</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>F</u>	<u>Y</u>	<u>V</u>	<u>P</u>	<u>F</u>	<u>15</u>
<u>1919</u>	<u>50</u>	<u>251</u>	<u>I</u>	<u>F</u>	<u>Y</u>	<u>V</u>	<u>P</u>	<u>F</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>15</u>
<u>1920</u>	<u>51</u>	<u>274</u>	<u>P</u>	<u>V</u>	<u>I</u>	<u>L</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>L</u>	<u>15</u>
<u>1921</u>	<u>52</u>	<u>290</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>15</u>
<u>1922</u>	<u>53</u>	<u>298</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>R</u>	<u>15</u>
<u>1923</u>	<u>54</u>	<u>19</u>	<u>L</u>	<u>P</u>	<u>G</u>	<u>L</u>	<u>E</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>F</u>	<u>14</u>
<u>1924</u>	<u>55</u>	<u>29</u>	<u>L</u>	<u>A</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>Y</u>	<u>14</u>
<u>1925</u>	<u>56</u>	<u>30</u>	<u>A</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>Y</u>	<u>L</u>	<u>14</u>
<u>1926</u>	<u>57</u>	<u>39</u>	<u>I</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>14</u>
<u>1927</u>	<u>58</u>	<u>40</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>I</u>	<u>14</u>
<u>1928</u>	<u>59</u>	<u>79</u>	<u>S</u>	<u>M</u>	<u>P</u>	<u>K</u>	<u>M</u>	<u>L</u>	<u>A</u>	<u>I</u>	<u>F</u>	<u>14</u>
<u>1929</u>	<u>60</u>	<u>81</u>	<u>P</u>	<u>K</u>	<u>M</u>	<u>L</u>	<u>A</u>	<u>I</u>	<u>F</u>	<u>W</u>	<u>F</u>	<u>14</u>
<u>1930</u>	<u>61</u>	<u>99</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>A</u>	<u>I</u>	<u>H</u>	<u>14</u>
<u>1931</u>	<u>62</u>	<u>137</u>	<u>V</u>	<u>L</u>	<u>T</u>	<u>L</u>	<u>P</u>	<u>R</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>14</u>
<u>1932</u>	<u>63</u>	<u>138</u>	<u>L</u>	<u>T</u>	<u>L</u>	<u>P</u>	<u>R</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>I</u>	<u>14</u>
<u>1933</u>	<u>64</u>	<u>150</u>	<u>A</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>A</u>	<u>A</u>	<u>L</u>	<u>M</u>	<u>14</u>
<u>1934</u>	<u>65</u>	<u>160</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>K</u>	<u>Q</u>	<u>L</u>	<u>14</u>
<u>1935</u>	<u>66</u>	<u>174</u>	<u>N</u>	<u>I</u>	<u>L</u>	<u>S</u>	<u>H</u>	<u>S</u>	<u>Y</u>	<u>C</u>	<u>L</u>	<u>14</u>
<u>1936</u>	<u>67</u>	<u>180</u>	<u>Y</u>	<u>C</u>	<u>L</u>	<u>H</u>	<u>Q</u>	<u>D</u>	<u>V</u>	<u>M</u>	<u>K</u>	<u>14</u>
<u>1937</u>	<u>68</u>	<u>192</u>	<u>D</u>	<u>D</u>	<u>I</u>	<u>R</u>	<u>V</u>	<u>N</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>14</u>
<u>1938</u>	<u>69</u>	<u>212</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>14</u>

SEQ
ID
NO:

HLA-B*2705 nonomers

	<u>Pos</u>		<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>	<u>score</u>
<u>1939</u>	<u>70</u>	<u>213</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>14</u>
<u>1940</u>	<u>71</u>	<u>214</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>14</u>
<u>1941</u>	<u>72</u>	<u>260</u>	<u>S</u>	<u>M</u>	<u>V</u>	<u>H</u>	<u>R</u>	<u>F</u>	<u>S</u>	<u>K</u>	<u>R</u>	<u>14</u>
<u>1942</u>	<u>73</u>	<u>263</u>	<u>H</u>	<u>R</u>	<u>F</u>	<u>S</u>	<u>K</u>	<u>R</u>	<u>R</u>	<u>D</u>	<u>S</u>	<u>14</u>
<u>1943</u>	<u>74</u>	<u>267</u>	<u>K</u>	<u>R</u>	<u>R</u>	<u>D</u>	<u>S</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>14</u>
<u>1944</u>	<u>75</u>	<u>293</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>14</u>
<u>1945</u>	<u>76</u>	<u>301</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>R</u>	<u>L</u>	<u>F</u>	<u>H</u>	<u>14</u>
<u>1946</u>	<u>77</u>	<u>302</u>	<u>Q</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>R</u>	<u>L</u>	<u>F</u>	<u>H</u>	<u>V</u>	<u>14</u>
<u>1947</u>	<u>78</u>	<u>5</u>	<u>N</u>	<u>G</u>	<u>N</u>	<u>E</u>	<u>S</u>	<u>S</u>	<u>A</u>	<u>T</u>	<u>Y</u>	<u>13</u>
<u>1948</u>	<u>79</u>	<u>23</u>	<u>E</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>F</u>	<u>W</u>	<u>L</u>	<u>A</u>	<u>F</u>	<u>13</u>
<u>1949</u>	<u>80</u>	<u>28</u>	<u>W</u>	<u>L</u>	<u>A</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>13</u>
<u>1950</u>	<u>81</u>	<u>44</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>I</u>	<u>Y</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>13</u>
<u>1951</u>	<u>82</u>	<u>51</u>	<u>V</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>H</u>	<u>E</u>	<u>13</u>
<u>1952</u>	<u>83</u>	<u>56</u>	<u>S</u>	<u>L</u>	<u>H</u>	<u>E</u>	<u>P</u>	<u>M</u>	<u>Y</u>	<u>I</u>	<u>F</u>	<u>13</u>
<u>1953</u>	<u>84</u>	<u>60</u>	<u>P</u>	<u>M</u>	<u>Y</u>	<u>I</u>	<u>F</u>	<u>L</u>	<u>C</u>	<u>M</u>	<u>L</u>	<u>13</u>
<u>1954</u>	<u>85</u>	<u>72</u>	<u>D</u>	<u>I</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>T</u>	<u>S</u>	<u>S</u>	<u>M</u>	<u>13</u>
<u>1955</u>	<u>86</u>	<u>74</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>T</u>	<u>S</u>	<u>S</u>	<u>M</u>	<u>P</u>	<u>K</u>	<u>13</u>
<u>1956</u>	<u>87</u>	<u>75</u>	<u>I</u>	<u>S</u>	<u>T</u>	<u>S</u>	<u>S</u>	<u>M</u>	<u>P</u>	<u>K</u>	<u>M</u>	<u>13</u>
<u>1957</u>	<u>88</u>	<u>98</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>A</u>	<u>I</u>	<u>13</u>
<u>1958</u>	<u>89</u>	<u>104</u>	<u>F</u>	<u>A</u>	<u>I</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>M</u>	<u>13</u>
<u>1959</u>	<u>90</u>	<u>110</u>	<u>S</u>	<u>G</u>	<u>M</u>	<u>E</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>13</u>
<u>1960</u>	<u>91</u>	<u>116</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>F</u>	<u>D</u>	<u>R</u>	<u>13</u>
<u>1961</u>	<u>92</u>	<u>126</u>	<u>V</u>	<u>A</u>	<u>I</u>	<u>C</u>	<u>H</u>	<u>P</u>	<u>L</u>	<u>R</u>	<u>H</u>	<u>13</u>
<u>1962</u>	<u>93</u>	<u>149</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>A</u>	<u>A</u>	<u>L</u>	<u>13</u>
<u>1963</u>	<u>94</u>	<u>158</u>	<u>M</u>	<u>A</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>K</u>	<u>13</u>
<u>1964</u>	<u>95</u>	<u>164</u>	<u>F</u>	<u>I</u>	<u>K</u>	<u>Q</u>	<u>L</u>	<u>P</u>	<u>F</u>	<u>C</u>	<u>R</u>	<u>13</u>
<u>1965</u>	<u>96</u>	<u>170</u>	<u>F</u>	<u>C</u>	<u>R</u>	<u>S</u>	<u>N</u>	<u>I</u>	<u>L</u>	<u>S</u>	<u>H</u>	<u>13</u>
<u>1966</u>	<u>97</u>	<u>171</u>	<u>C</u>	<u>R</u>	<u>S</u>	<u>N</u>	<u>I</u>	<u>L</u>	<u>S</u>	<u>H</u>	<u>S</u>	<u>13</u>
<u>1967</u>	<u>98</u>	<u>187</u>	<u>M</u>	<u>K</u>	<u>L</u>	<u>A</u>	<u>C</u>	<u>D</u>	<u>D</u>	<u>I</u>	<u>R</u>	<u>13</u>
<u>1968</u>	<u>99</u>	<u>217</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>13</u>
<u>1969</u>	<u>100</u>	<u>224</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>R</u>	<u>13</u>
<u>1970</u>	<u>101</u>	<u>242</u>	<u>C</u>	<u>V</u>	<u>S</u>	<u>H</u>	<u>V</u>	<u>C</u>	<u>A</u>	<u>V</u>	<u>F</u>	<u>13</u>
<u>1971</u>	<u>102</u>	<u>256</u>	<u>F</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>S</u>	<u>M</u>	<u>V</u>	<u>H</u>	<u>R</u>	<u>13</u>
<u>1972</u>	<u>103</u>	<u>261</u>	<u>M</u>	<u>V</u>	<u>H</u>	<u>R</u>	<u>F</u>	<u>S</u>	<u>K</u>	<u>R</u>	<u>R</u>	<u>13</u>
<u>1973</u>	<u>104</u>	<u>49</u>	<u>Y</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>12</u>
<u>1974</u>	<u>105</u>	<u>57</u>	<u>L</u>	<u>H</u>	<u>E</u>	<u>P</u>	<u>M</u>	<u>Y</u>	<u>I</u>	<u>F</u>	<u>L</u>	<u>12</u>
<u>1975</u>	<u>106</u>	<u>88</u>	<u>W</u>	<u>F</u>	<u>N</u>	<u>S</u>	<u>T</u>	<u>T</u>	<u>I</u>	<u>Q</u>	<u>F</u>	<u>12</u>
<u>1976</u>	<u>107</u>	<u>96</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>12</u>
<u>1977</u>	<u>108</u>	<u>134</u>	<u>H</u>	<u>A</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>T</u>	<u>L</u>	<u>P</u>	<u>R</u>	<u>12</u>
<u>1978</u>	<u>109</u>	<u>152</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>A</u>	<u>A</u>	<u>L</u>	<u>M</u>	<u>A</u>	<u>P</u>	<u>12</u>
<u>1979</u>	<u>110</u>	<u>179</u>	<u>S</u>	<u>Y</u>	<u>C</u>	<u>L</u>	<u>H</u>	<u>Q</u>	<u>D</u>	<u>V</u>	<u>M</u>	<u>12</u>
<u>1980</u>	<u>111</u>	<u>197</u>	<u>N</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>12</u>
<u>1981</u>	<u>112</u>	<u>244</u>	<u>S</u>	<u>H</u>	<u>V</u>	<u>C</u>	<u>A</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>F</u>	<u>12</u>
<u>1982</u>	<u>113</u>	<u>265</u>	<u>F</u>	<u>S</u>	<u>K</u>	<u>R</u>	<u>R</u>	<u>D</u>	<u>S</u>	<u>P</u>	<u>L</u>	<u>12</u>
<u>1983</u>	<u>114</u>	<u>273</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>I</u>	<u>L</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>12</u>
<u>1984</u>	<u>115</u>	<u>285</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>12</u>
<u>1985</u>	<u>116</u>	<u>288</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>12</u>
<u>1986</u>	<u>117</u>	<u>296</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>I</u>	<u>12</u>
<u>1987</u>	<u>118</u>	<u>297</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>12</u>

SEQ
ID
NO:

HLA-B*2709 nonomers

	Pos		1	2	3	4	5	6	7	8	9	score
1988	1	194	I	R	V	N	V	V	Y	G	L	24
1989	2	268	R	R	D	S	P	L	P	V	I	24
1990	3	132	L	R	H	A	T	V	L	T	L	22
1991	4	267	K	R	R	D	S	P	L	P	V	21
1992	5	300	I	R	Q	R	I	L	R	L	F	20
1993	6	231	T	R	E	A	Q	A	K	A	F	19
1994	7	302	Q	R	I	L	R	L	F	H	V	19
1995	8	124	R	Y	V	A	I	C	H	P	L	16
1996	9	269	R	D	S	P	L	P	V	I	L	16
1997	10	43	G	N	L	T	I	I	Y	I	V	15
1998	11	216	I	S	F	S	Y	L	L	I	L	15
1999	12	11	A	T	Y	F	I	L	I	G	L	14
2000	13	25	A	Q	F	W	L	A	F	P	L	14
2001	14	153	R	G	A	A	L	M	A	P	L	14
2002	15	174	N	I	L	S	H	S	Y	C	L	14
2003	16	222	L	I	L	K	T	V	L	G	L	14
2004	17	257	I	G	L	S	M	V	H	R	F	14
2005	18	280	I	Y	L	L	V	P	P	V	L	14
2006	19	6	G	N	E	S	S	A	T	Y	F	13
2007	20	14	F	I	L	I	G	L	P	G	L	13
2008	21	21	G	L	E	E	A	Q	F	W	L	13
2009	22	66	C	M	L	S	G	I	D	I	L	13
2010	23	130	H	P	L	R	H	A	T	V	L	13
2011	24	201	G	L	I	V	I	I	S	A	I	13
2012	25	203	I	V	I	I	S	A	I	G	L	13
2013	26	214	L	L	I	S	F	S	Y	L	L	13
2014	27	251	I	F	Y	V	P	F	I	G	L	13
2015	28	263	H	R	F	S	K	R	R	D	S	13
2016	29	275	V	I	L	A	N	I	Y	L	L	13
2017	30	305	L	R	L	F	H	V	A	T	H	13
2018	31	30	A	F	P	L	C	S	L	Y	L	12
2019	32	34	C	S	L	Y	L	I	A	V	L	12
2020	33	37	Y	L	I	A	V	L	G	N	L	12
2021	34	51	V	R	T	E	H	S	L	H	E	12
2022	35	60	P	M	Y	I	F	L	C	M	L	12
2023	36	75	I	S	T	S	S	M	P	K	M	12
2024	37	93	T	I	Q	F	D	A	C	L	L	12
2025	38	123	D	R	Y	V	A	I	C	H	P	12
2026	39	135	A	T	V	L	T	L	P	R	V	12
2027	40	138	L	T	L	P	R	V	T	K	I	12
2028	41	149	A	A	V	V	R	G	A	A	L	12
2029	42	155	A	A	L	M	A	P	L	P	V	12
2030	43	168	L	P	F	C	R	S	N	I	L	12
2031	44	181	C	L	H	Q	D	V	M	K	L	12
2032	45	188	K	L	A	C	D	D	I	R	V	12
2033	46	190	A	C	D	D	I	R	V	N	V	12
2034	47	195	R	V	N	V	V	Y	G	L	I	12
2035	48	210	G	L	D	S	L	L	I	S	F	12
2036	49	213	S	L	L	I	S	F	S	Y	L	12
2037	50	220	Y	L	L	I	L	K	T	V	L	12

SEQ
ID
NO:

HLA-B*2709 nonomers

	Pos		1	2	3	4	5	6	7	8	9	score
2038	51	248	A	V	F	I	F	Y	V	P	F	12
2039	52	279	N	I	Y	L	L	V	P	P	V	12
2040	53	287	V	L	N	P	I	V	Y	G	V	12
2041	54	296	K	T	K	E	I	R	Q	R	I	12
2042	55	299	E	I	R	Q	R	I	L	R	L	12

SEQ
ID
NO:

HLA-B*5101 nonomers

	Pos		1	2	3	4	5	6	7	8	9	score
2043	1	39	I	A	V	L	G	N	L	T	I	26
2044	2	31	F	P	L	C	S	L	Y	L	I	25
2045	3	120	M	A	F	D	R	Y	V	A	I	24
2046	4	130	H	P	L	R	H	A	T	V	L	23
2047	5	118	L	A	M	A	F	D	R	Y	V	22
2048	6	140	L	P	R	V	T	K	I	G	V	22
2049	7	155	A	A	L	M	A	P	L	P	V	22
2050	8	42	L	G	N	L	T	I	I	Y	I	21
2051	9	254	V	P	F	I	G	L	S	M	V	21
2052	10	284	V	P	P	V	L	N	P	I	V	21
2053	11	168	L	P	F	C	R	S	N	I	L	20
2054	12	235	Q	A	K	A	F	G	T	C	V	20
2055	13	138	L	T	L	P	R	V	T	K	I	19
2056	14	159	A	P	L	P	V	F	I	K	Q	18
2057	15	189	L	A	C	D	D	I	R	V	N	18
2058	16	198	V	V	Y	G	L	I	V	I	I	18
2059	17	277	L	A	N	I	Y	L	L	V	P	18
2060	18	207	S	A	I	G	L	D	S	L	L	17
2061	19	283	L	V	P	P	V	L	N	P	I	17
2062	20	63	I	F	L	C	M	L	S	G	I	16
2063	21	86	I	F	W	F	N	S	T	T	I	16
2064	22	110	S	G	M	E	S	T	V	L	L	16
2065	23	144	T	K	I	G	V	A	A	V	V	16
2066	24	149	A	A	V	V	R	G	A	A	L	16
2067	25	197	N	V	V	Y	G	L	I	V	I	16
2068	26	271	S	P	L	P	V	I	L	A	N	16
2069	27	280	I	Y	L	L	V	P	P	V	L	16
2070	28	3	D	P	N	G	N	E	S	S	A	15
2071	29	40	A	V	L	G	N	L	T	I	I	15
2072	30	97	D	A	C	L	L	Q	I	F	A	15
2073	31	132	L	R	H	A	T	V	L	T	L	15
2074	32	222	L	I	L	K	T	V	L	G	L	15
2075	33	279	N	I	Y	L	L	V	P	P	V	15
2076	34	285	P	P	V	L	N	P	I	V	Y	15
2077	35	289	N	P	I	V	Y	G	V	K	T	15
2078	36	9	S	S	A	T	Y	F	I	L	I	14
2079	37	65	L	C	M	L	S	G	I	D	I	14
2080	38	84	L	A	I	F	W	F	N	S	T	14
2081	39	126	V	A	I	C	H	P	L	R	H	14
2082	40	157	L	M	A	P	L	P	V	F	I	14

SEO
ID
NO:

HLA-B*5101 nonomers

	<u>Pos</u>		<u>1 2 3 4 5 6 7 8 9</u>	<u>score</u>
<u>2083</u>	<u>41</u>	<u>158</u>	<u>M A P L P V F I K</u>	<u>14</u>
<u>2084</u>	<u>42</u>	<u>191</u>	<u>C D D I R V N V V</u>	<u>14</u>
<u>2085</u>	<u>43</u>	<u>200</u>	<u>Y G L I V I I S A</u>	<u>14</u>
<u>2086</u>	<u>44</u>	<u>209</u>	<u>I G L D S L L I S</u>	<u>14</u>
<u>2087</u>	<u>45</u>	<u>215</u>	<u>L I S F S Y L L I</u>	<u>14</u>
<u>2088</u>	<u>46</u>	<u>219</u>	<u>S Y L L I L K T V</u>	<u>14</u>
<u>2089</u>	<u>47</u>	<u>220</u>	<u>Y L L I L K T V L</u>	<u>14</u>
<u>2090</u>	<u>48</u>	<u>237</u>	<u>K A F G T C V S H</u>	<u>14</u>
<u>2091</u>	<u>49</u>	<u>247</u>	<u>C A V F I F Y V P</u>	<u>14</u>
<u>2092</u>	<u>50</u>	<u>249</u>	<u>V F I F Y V P F I</u>	<u>14</u>
<u>2093</u>	<u>51</u>	<u>251</u>	<u>I F Y V P F I G L</u>	<u>14</u>
<u>2094</u>	<u>52</u>	<u>257</u>	<u>I G L S M V H R F</u>	<u>14</u>
<u>2095</u>	<u>53</u>	<u>268</u>	<u>R R D S P L P V I</u>	<u>14</u>
<u>2096</u>	<u>54</u>	<u>273</u>	<u>L P V I L A N I Y</u>	<u>14</u>
<u>2097</u>	<u>55</u>	<u>29</u>	<u>L A F P L C S L Y</u>	<u>13</u>
<u>2098</u>	<u>56</u>	<u>33</u>	<u>L C S L Y L I A V</u>	<u>13</u>
<u>2099</u>	<u>57</u>	<u>55</u>	<u>H S L H E P M Y I</u>	<u>13</u>
<u>2100</u>	<u>58</u>	<u>67</u>	<u>M L S G I D I L I</u>	<u>13</u>
<u>2101</u>	<u>59</u>	<u>80</u>	<u>M P K M L A I F W</u>	<u>13</u>
<u>2102</u>	<u>60</u>	<u>95</u>	<u>Q F D A C L L Q I</u>	<u>13</u>
<u>2103</u>	<u>61</u>	<u>98</u>	<u>A C L L Q I F A I</u>	<u>13</u>
<u>2104</u>	<u>62</u>	<u>104</u>	<u>F A I H S L S G M</u>	<u>13</u>
<u>2105</u>	<u>63</u>	<u>146</u>	<u>I G V A A V V R G</u>	<u>13</u>
<u>2106</u>	<u>64</u>	<u>148</u>	<u>V A A V V R G A A</u>	<u>13</u>
<u>2107</u>	<u>65</u>	<u>153</u>	<u>R G A A L M A P L</u>	<u>13</u>
<u>2108</u>	<u>66</u>	<u>233</u>	<u>E A Q A K A F G T</u>	<u>13</u>
<u>2109</u>	<u>67</u>	<u>243</u>	<u>V S H V C A V F I</u>	<u>13</u>
<u>2110</u>	<u>68</u>	<u>292</u>	<u>V Y G V K T K E I</u>	<u>13</u>
<u>2111</u>	<u>69</u>	<u>296</u>	<u>K T K E I R Q R I</u>	<u>13</u>

Table XXVII:
HLA Class I decamers

<u>HLA-A1 decamers</u>												
	Pos	1	2	3	4	5	6	7	8	9	0	score
1	191	C	D	D	I	R	V	N	V	V	Y	27
2	244	S	H	V	C	A	V	F	I	F	Y	24
3	40	A	V	L	G	N	L	T	I	I	Y	21
4	284	V	P	P	V	L	N	P	I	V	Y	21
5	116	V	L	L	A	M	A	F	D	R	Y	20
6	28	W	L	A	F	P	L	C	S	L	Y	18
7	297	T	K	E	I	R	Q	R	I	L	R	17
8	21	G	L	E	E	A	Q	F	W	L	A	16
9	22	L	E	E	A	Q	F	W	L	A	F	16
10	52	R	T	E	H	S	L	H	E	P	M	16
11	53	T	E	H	S	L	H	E	P	M	Y	16
12	57	L	H	E	P	M	Y	I	F	L	C	16
13	111	G	M	E	S	T	V	L	L	A	M	16
14	272	P	L	P	V	I	L	A	N	I	Y	16
15	1	M	V	D	P	N	G	N	E	S	S	15
16	4	P	N	G	N	E	S	S	A	T	Y	15
17	121	A	F	D	R	Y	V	A	I	C	H	15
18	171	C	R	S	N	I	L	S	H	S	Y	15
19	211	L	D	S	L	L	I	S	F	S	Y	15
20	8	E	S	S	A	T	Y	F	I	L	I	13
21	190	A	C	D	D	I	R	V	N	V	V	13

HLA-A*0201 decamers												
Pos		1	2	3	4	5	6	7	8	9	0	score
1	221	L	L	I	L	K	T	V	L	G	L	30
2	100	L	L	Q	I	F	A	I	H	S	L	29
3	282	L	L	V	P	P	V	L	N	P	I	27
4	205	I	I	S	A	I	C	L	D	S	L	26
5	213	S	L	L	I	S	F	S	Y	L	L	25
6	56	S	L	H	E	P	M	Y	I	F	L	24
7	62	Y	I	F	L	C	M	L	S	C	I	24
8	108	S	L	S	C	M	E	S	T	V	L	24
9	117	L	L	A	M	A	F	D	R	Y	V	24
10	131	P	L	R	H	A	T	V	L	T	L	24
11	137	V	L	T	L	P	R	V	T	K	I	24
12	215	L	I	S	F	S	Y	L	L	I	L	24
13	38	L	I	A	V	L	C	N	L	T	I	23
14	41	V	L	C	N	L	T	I	I	Y	I	23
15	156	A	L	M	A	P	L	P	V	F	I	23
16	193	D	I	R	V	N	V	V	Y	G	L	23
17	214	L	L	I	S	F	S	Y	L	L	I	23
18	32	P	L	C	S	L	Y	L	I	A	V	22
19	119	A	M	A	F	D	R	Y	V	A	I	22
20	237	K	A	F	C	T	C	V	S	H	V	22
21	275	V	I	L	A	N	I	Y	L	L	V	22
22	85	A	I	F	W	F	N	S	T	T	I	21
23	139	T	L	P	R	V	T	K	I	G	V	21
24	202	L	I	V	I	I	S	A	I	G	L	21
25	13	Y	F	I	L	I	C	L	P	G	L	20
26	16	L	I	C	L	P	C	L	E	E	A	20

HLA-A*0201 decamers												
Pos		1	2	3	4	5	6	7	8	9	0	score
27	29	L	A	F	P	L	C	S	L	Y	L	20
28	142	R	V	T	K	I	C	V	A	A	V	20
29	148	V	A	A	V	V	R	C	A	A	L	20
30	167	Q	L	P	F	C	R	S	N	I	L	20
31	180	Y	C	L	H	Q	D	V	M	K	L	20
32	222	L	I	L	K	T	V	L	C	L	T	20
33	240	G	T	C	V	S	H	V	C	A	V	20
34	248	A	V	F	I	F	Y	V	P	F	I	20
35	250	F	I	F	Y	V	P	F	I	G	L	20
36	271	S	P	L	P	V	I	L	A	N	I	20
37	279	N	I	Y	L	L	V	P	P	V	L	20
38	304	I	L	R	L	F	H	V	A	T	H	20
39	10	S	A	T	Y	F	I	L	I	G	L	19
40	15	I	L	I	C	L	P	C	L	E	E	19
41	27	F	W	L	A	F	P	L	C	S	L	19
42	35	S	L	Y	L	I	A	V	L	C	N	19
43	37	Y	L	I	A	V	L	C	N	L	T	19
44	44	N	L	T	I	I	Y	I	V	R	T	19
45	64	F	L	C	M	L	S	C	I	D	I	19
46	83	M	L	A	I	F	W	F	N	S	T	19
47	159	A	P	L	P	V	F	I	K	Q	L	19
48	189	L	A	C	D	D	I	R	V	N	V	19
49	207	S	A	I	C	L	D	S	L	L	I	19
50	253	Y	V	P	F	I	C	L	S	M	V	19
51	276	I	L	A	N	I	Y	L	L	V	P	19
52	281	Y	L	L	V	P	P	V	L	N	P	19
53	283	L	V	P	P	V	L	N	P	I	V	19
54	286	P	V	L	N	P	I	V	Y	G	V	19
55	33	L	C	S	L	Y	L	I	A	V	L	18
56	36	L	Y	L	I	A	V	L	C	N	L	18
57	39	I	A	V	L	C	N	L	T	I	I	18
58	42	L	C	N	L	T	I	I	Y	I	V	18
59	66	C	M	L	S	C	I	D	I	L	I	18
60	111	G	M	E	S	T	V	L	L	A	M	18
61	128	I	C	H	P	L	R	H	A	T	V	18
62	134	H	A	T	V	L	T	L	P	R	V	18
63	154	G	A	A	L	M	A	P	L	P	V	18
64	157	L	M	A	P	L	P	V	F	I	K	18
65	190	A	C	D	D	I	R	V	N	V	V	18
66	229	G	L	T	R	E	A	Q	A	K	A	18
67	245	H	V	C	A	V	F	I	F	Y	V	18
68	274	P	V	I	L	A	N	I	Y	L	L	18
69	278	A	N	I	Y	L	L	V	P	P	V	18
70	291	I	V	Y	C	V	K	T	K	E	I	18
71	298	K	E	I	R	Q	R	I	L	R	L	18
72	48	I	Y	I	V	R	T	E	H	S	L	17
73	65	L	C	M	L	S	C	I	D	I	L	17
74	67	M	L	S	C	I	D	I	L	I	S	17
75	74	L	I	S	T	S	S	M	P	K	M	17
76	91	S	T	T	I	Q	F	D	A	C	L	17
77	94	I	Q	F	D	A	C	L	L	Q	I	17
78	188	K	L	A	C	D	D	I	R	V	N	17
79	197	N	V	V	Y	C	L	I	V	I	I	17

<u>HLA-A*0201-decamers</u>											
	Pos	-1	2	3	4	5	6	7	8	9	0
80	200	Y	C	L	I	V	I	I	S	A	I
91	218	F	S	Y	L	L	I	L	K	T	V
92	227	V	L	G	L	T	R	E	A	Q	A
93	303	R	I	L	R	L	F	H	V	A	T
94	21	C	L	E	E	A	Q	F	W	L	A
95	92	T	T	I	Q	F	D	A	C	L	L
96	97	D	A	C	L	L	Q	I	F	A	I
97	127	A	I	C	H	P	L	R	H	A	T
98	143	V	T	K	I	G	V	A	A	V	V
99	195	R	V	N	V	V	Y	C	L	I	V
90	220	Y	L	L	I	L	K	T	V	L	G
91	296	K	T	K	E	I	R	Q	R	I	L
92	18	G	L	P	C	L	E	E	A	Q	F
93	30	A	F	P	L	C	S	L	Y	L	I
94	126	V	A	I	C	H	P	L	R	H	A
95	145	K	I	G	V	A	A	V	V	R	G
96	173	S	N	I	L	S	H	S	Y	C	L
97	201	G	L	I	V	I	I	S	A	I	C
98	208	A	I	G	L	D	S	L	L	I	S
99	210	G	L	D	S	L	L	I	S	F	S
100	267	K	R	R	D	S	P	L	P	V	I

<u>HLA-A*0203-decamers</u>											
	Pos	-1	2	3	4	5	6	7	8	9	0
1	141	P	R	V	T	K	I	G	V	A	A
2	147	G	V	A	A	V	V	R	G	A	A
3	112	M	E	S	T	V	L	L	A	M	A
4	227	V	L	G	L	T	R	E	A	Q	A
5	229	G	L	T	R	E	A	Q	A	K	A
6	142	R	V	T	K	I	G	V	A	A	V
7	148	V	A	A	V	V	R	G	A	A	L
8	2	V	D	P	N	C	N	E	S	S	A
9	16	L	I	G	L	P	C	L	E	E	A
10	21	G	L	E	E	A	Q	F	W	L	A
11	31	F	P	L	C	S	L	Y	L	I	A
12	76	S	T	S	S	M	P	K	M	L	A
13	89	F	N	S	T	T	I	Q	F	D	A
14	96	F	D	A	C	L	L	Q	I	F	A
15	110	S	C	M	E	S	T	V	L	L	A
16	118	L	A	M	A	F	D	R	Y	V	A
17	126	V	A	I	C	H	P	L	R	H	A
18	140	L	P	R	V	T	K	I	G	V	A
19	146	I	G	V	A	A	V	V	R	G	A
20	150	A	V	V	R	G	A	A	L	M	A
21	181	C	L	H	Q	D	V	M	K	L	A
22	199	V	Y	C	L	I	V	I	I	S	A
23	225	K	T	V	L	G	L	T	R	E	A
24	239	F	G	T	C	V	S	H	V	C	A
25	269	R	D	S	P	L	P	V	I	L	A
26	302	Q	R	I	L	R	L	F	H	V	A
27	305	L	R	L	F	H	V	A	T	H	A
28	3	D	P	N	C	N	E	S	S	A	T
29	17	I	C	L	P	C	L	E	E	A	Q

<u>HLA-A*0203-decamers</u>											
	Pos	-1	2	3	4	5	6	7	8	9	0
30	22	L	E	E	A	Q	F	W	L	A	F
31	32	P	L	C	S	L	Y	L	I	A	V
32	77	T	S	S	M	P	K	M	L	A	I
33	90	N	S	T	T	I	Q	F	D	A	C
34	97	D	A	C	L	L	Q	I	F	A	I
35	111	C	M	E	S	T	V	L	L	A	M
36	113	E	S	T	V	L	L	A	M	A	F
37	119	A	M	A	F	D	R	Y	V	A	I
38	127	A	I	C	H	P	L	R	H	A	T
39	151	V	V	R	G	A	A	L	M	A	P
40	182	L	H	Q	D	V	M	K	L	A	C
41	200	Y	C	L	I	V	I	I	S	A	I
42	226	T	V	L	G	L	T	R	E	A	Q
43	228	L	G	L	T	R	E	A	Q	A	K
44	230	L	T	R	E	A	Q	A	K	A	F
45	240	C	T	C	V	S	H	V	C	A	V
46	270	D	S	P	L	P	V	I	L	A	N
47	303	R	I	L	R	L	F	H	V	A	T
48	306	R	L	F	H	V	A	T	H	A	S

<u>HLA-A26-decamers</u>											
	Pos	-1	2	3	4	5	6	7	8	9	0
1	299	E	I	R	Q	R	I	L	R	L	F
2	193	D	I	R	V	N	V	V	Y	C	L
3	250	F	I	F	Y	V	P	F	I	C	L
4	256	F	I	G	L	S	M	V	H	R	F
5	74	L	I	S	T	S	S	M	P	K	M
6	274	P	V	I	L	A	N	I	Y	L	L
7	18	G	L	P	C	L	E	E	A	Q	F
8	116	V	L	L	A	M	A	F	D	R	Y
9	205	I	I	S	A	I	C	L	D	S	L
10	221	L	L	I	L	K	T	V	L	G	L
11	230	L	T	R	E	A	Q	A	K	A	F
12	13	Y	F	I	L	I	C	L	P	C	L
13	40	A	V	L	C	N	L	T	I	I	Y
14	56	S	L	H	E	P	M	Y	I	F	L
15	95	Q	F	D	A	C	L	L	Q	I	F
16	215	L	I	S	F	S	Y	L	L	I	L
17	92	T	T	I	Q	F	D	A	C	L	L
18	100	L	L	Q	I	F	A	I	H	S	L
19	103	I	F	A	I	H	S	L	S	C	M
20	296	K	T	K	E	I	R	Q	R	I	L
21	28	W	L	A	F	P	L	C	S	L	Y
22	131	P	L	R	H	A	T	V	L	T	L
23	59	E	P	M	Y	I	F	L	C	M	L
24	91	S	T	T	I	Q	F	D	A	C	L
25	202	L	I	V	I	I	S	A	I	C	L
26	212	D	S	L	L	I	S	F	S	Y	L
27	272	P	L	P	V	I	L	A	N	I	Y
28	279	N	I	Y	L	L	V	P	P	V	L
29	52	R	T	E	H	S	L	H	E	P	M
30	62	Y	I	F	L	C	M	L	S	C	I

HLA-A26-decamers

Pos		1	2	3	4	5	6	7	8	9	0	score
31	72	D	I	L	I	S	T	S	S	M	P	18
32	108	S	L	S	C	M	E	S	T	V	L	18
33	113	E	S	T	V	L	L	A	M	A	F	18
34	151	V	V	R	C	A	A	L	M	A	P	18
35	78	S	S	M	P	K	M	L	A	I	F	17
36	142	R	V	T	K	I	G	V	A	A	V	17
37	162	P	V	F	I	K	Q	L	P	F	C	17
38	164	F	I	K	Q	L	P	F	C	R	S	17
39	167	Q	L	P	F	C	R	S	N	I	L	17
40	185	D	V	M	K	L	A	C	D	D	I	17
41	248	A	V	F	I	F	Y	V	P	F	I	17
42	253	Y	V	P	F	I	G	L	S	M	V	17
43	45	L	T	I	I	Y	I	V	R	T	E	16
44	145	K	I	G	V	A	A	V	V	R	C	16
45	198	V	V	Y	G	L	I	V	I	I	S	16
46	203	I	V	I	I	S	A	I	G	L	D	16
47	209	I	G	L	D	S	L	L	I	S	F	16
48	213	S	L	L	I	S	F	S	Y	L	L	16
49	255	P	F	I	G	L	S	M	V	H	R	16
50	264	R	F	S	K	R	R	D	S	P	L	16
51	294	G	V	K	T	K	E	I	R	Q	R	16
52	16	L	I	G	L	P	G	L	E	E	A	15
53	80	M	P	K	M	L	A	I	F	W	F	15
54	114	S	T	V	L	L	A	M	A	F	D	15
55	155	A	A	L	M	A	P	L	P	V	F	15
56	159	A	P	L	P	V	F	I	K	Q	L	15
57	174	N	I	L	S	H	S	Y	C	L	H	15
58	197	N	V	V	Y	G	L	I	V	I	I	15
59	210	G	L	D	S	L	L	I	S	F	S	15
60	214	L	L	I	S	F	S	Y	L	L	I	15
61	222	L	I	L	K	T	V	L	G	L	T	15
62	240	G	T	C	V	S	H	V	C	A	V	15
63	247	C	A	V	F	I	F	Y	V	P	F	15
64	286	P	V	L	N	P	I	V	Y	C	V	15
65	298	K	E	I	R	O	R	I	L	R	L	15

HLA-A3-decamers

Pos		1	2	3	4	5	6	7	8	9	0	score
1	136	T	V	L	T	L	P	R	V	T	K	31
2	287	V	L	N	P	I	V	Y	G	V	K	28
3	223	I	L	K	T	V	L	G	L	T	R	27
4	304	I	L	R	L	F	H	V	A	T	H	27
5	73	I	L	I	S	T	S	S	M	P	K	26
6	15	I	L	I	C	L	P	G	L	E	E	23
7	40	A	V	L	C	N	L	T	I	I	Y	23
8	150	A	V	V	R	C	A	A	L	M	A	23
9	258	G	L	S	M	V	H	R	F	S	K	23
10	18	G	L	P	C	L	E	E	A	Q	F	22
11	303	R	I	L	R	L	F	H	V	A	T	22
12	276	I	L	A	N	I	Y	L	L	V	P	21
13	28	W	L	A	F	P	L	C	S	L	Y	20
14	115	T	V	L	L	A	M	A	F	D	R	20
15	116	V	L	L	A	M	A	F	D	R	Y	20

HLA-A3-decamers

	Pos	1	2	3	4	5	6	7	8	9	0	score
16	125	Y	V	A	I	C	H	P	L	R	H	20
17	131	P	L	R	H	A	T	V	L	T	L	20
18	144	T	K	I	G	V	A	A	V	V	R	20
19	156	A	L	M	A	P	L	P	V	F	I	20
20	195	R	V	N	V	V	Y	G	L	I	V	20
21	35	S	L	Y	L	I	A	V	L	C	N	19
22	272	P	L	P	V	I	L	A	N	I	Y	19
23	37	Y	L	I	A	V	L	C	N	L	T	18
24	49	Y	I	V	R	T	E	H	S	L	H	18
25	50	I	V	R	T	E	H	S	L	H	E	18
26	108	S	L	S	C	M	E	S	T	V	L	18
27	142	R	V	T	K	I	G	V	A	A	V	18
28	188	K	L	A	C	D	D	I	R	V	N	18
29	279	N	I	Y	L	L	V	P	P	V	L	18
30	291	I	V	Y	C	V	K	T	K	E	I	18
31	294	G	V	K	T	K	E	I	R	Q	R	18
32	46	T	I	I	Y	I	V	R	T	E	H	17
33	102	Q	I	F	A	I	H	S	L	S	C	17
34	151	V	V	R	C	A	A	L	M	A	P	17
35	179	S	Y	C	L	H	Q	D	V	M	K	17
36	203	I	V	I	I	S	A	I	C	L	D	17
37	204	V	I	I	S	A	I	C	L	D	S	17
38	220	Y	L	L	I	L	K	T	V	L	C	17
39	221	L	L	I	L	K	T	V	L	C	L	17
40	227	V	L	C	L	T	R	E	A	Q	A	17
41	242	C	V	S	H	V	C	A	V	F	I	17
42	289	N	P	I	V	Y	C	V	K	T	K	17
43	38	L	I	A	V	L	C	N	L	T	I	16
44	85	A	I	F	W	F	N	S	T	T	I	16
45	147	G	V	A	A	V	V	R	C	A	A	16
46	198	V	V	Y	G	L	I	V	I	I	S	16
47	201	G	L	I	V	I	I	S	A	I	C	16
48	214	L	L	I	S	F	S	Y	L	L	I	16
49	226	T	V	L	C	L	T	R	E	A	Q	16
50	228	L	C	L	T	R	E	A	Q	A	K	16
51	229	C	L	T	R	E	A	Q	A	K	A	16
52	1	M	V	D	P	N	C	N	E	S	S	15
53	44	N	L	T	I	I	Y	I	V	R	T	15
54	47	I	I	Y	I	V	R	T	E	H	S	15
55	67	M	L	S	C	I	D	I	L	I	S	15
56	72	D	I	L	I	S	T	S	S	M	P	15
57	99	C	L	L	Q	I	F	A	I	H	S	15
58	105	A	I	H	S	L	S	G	M	E	S	15
59	145	K	I	G	V	A	A	V	V	R	C	15
60	175	I	L	S	H	S	Y	C	L	H	Q	15
61	191	C	D	D	I	R	V	N	V	V	Y	15
62	208	A	I	C	L	D	S	L	L	I	S	15
63	275	V	I	L	A	N	I	Y	L	L	V	15
64	281	Y	L	L	V	P	P	V	L	N	P	15
65	299	E	I	R	Q	R	I	L	R	L	F	15
66	306	R	L	F	H	V	A	T	H	A	S	15

HLA-B*0702-decamers

	Pos	1	2	3	4	5	6	7	8	9	0	score
1	159	A	P	L	P	V	F	I	K	Q	L	23
2	59	E	P	M	Y	I	F	L	C	M	L	22
3	273	L	P	V	I	L	A	N	I	Y	L	20
4	3	D	P	N	C	N	E	S	S	A	T	19
5	130	H	P	L	R	H	A	T	V	L	T	19
6	140	L	P	R	V	T	K	I	C	V	A	19
7	161	L	P	V	F	I	K	Q	L	P	F	19
8	31	F	P	L	C	S	L	Y	L	I	A	18
9	271	S	P	L	P	V	I	L	A	N	I	18
10	80	M	P	K	M	L	A	I	F	W	F	16
11	108	S	L	S	G	M	E	S	T	V	L	16
12	131	P	L	R	H	A	T	V	L	T	L	15
13	264	R	F	S	K	R	R	D	S	P	L	15
14	33	L	C	S	L	Y	L	I	A	V	L	14
15	109	L	S	G	M	E	S	T	V	L	L	14
16	152	V	R	G	A	A	L	M	A	P	L	14
17	205	I	I	S	A	I	C	L	D	S	L	14
18	215	L	I	S	F	S	Y	L	L	I	L	14
19	268	R	R	D	S	P	L	P	V	I	L	14
20	29	L	A	F	P	L	C	S	L	Y	L	13
21	148	V	A	A	V	V	R	G	A	A	L	13
22	156	A	L	M	A	P	L	P	V	F	I	13
23	193	D	I	R	V	N	V	V	Y	G	L	13
24	221	L	L	I	L	K	T	V	L	G	L	13
25	298	K	E	I	R	Q	R	I	L	R	L	13
26	7	N	E	S	S	A	T	Y	F	I	L	12
27	19	L	P	G	L	E	E	A	Q	F	W	12
28	24	E	A	Q	F	W	L	A	F	P	L	12
29	119	A	M	A	F	D	R	Y	V	A	I	12
30	129	C	H	P	L	R	H	A	T	V	L	12
31	206	I	S	A	I	C	L	D	S	L	L	12
32	219	S	Y	L	L	I	L	K	T	V	L	12
33	279	N	I	Y	L	L	V	P	P	V	L	12
34	285	P	P	V	L	N	P	I	V	Y	G	12
35	8	E	S	S	A	T	Y	F	I	L	I	11
36	13	Y	F	I	L	I	C	L	P	C	L	11
37	27	F	W	L	A	F	P	L	C	S	L	11
38	48	I	Y	I	V	R	T	E	H	S	L	11
39	56	S	L	H	E	P	M	Y	I	F	L	11
40	65	L	C	M	L	S	C	I	D	I	L	11
41	75	I	S	T	S	S	M	P	K	M	L	11
42	77	T	S	S	M	P	K	M	L	A	I	11
43	91	S	T	T	I	Q	F	D	A	C	L	11
44	123	D	R	Y	V	A	I	C	H	P	L	11
45	142	R	V	T	K	I	C	V	A	A	V	11
46	180	Y	C	L	H	Q	D	V	M	K	L	11
47	190	A	C	D	D	I	R	V	N	V	V	11
48	212	D	S	L	L	I	S	F	S	Y	L	11
49	234	A	Q	A	K	A	F	C	T	C	V	11
50	242	C	V	S	H	V	C	A	V	F	I	11
51	248	A	V	F	I	F	Y	V	P	F	I	11
52	250	F	I	F	Y	V	P	F	I	C	L	11
53	254	V	P	F	I	C	L	S	M	V	H	11
54	266	S	K	R	R	D	S	P	L	P	V	11

HLA-B*0702 decamers

	Pos	1	2	3	4	5	6	7	8	9	0	score
55	267	K	R	R	D	S	P	L	P	V	I	11
56	269	R	D	S	P	L	P	V	I	L	A	11
57	278	A	N	I	Y	L	L	V	P	P	V	11
58	284	V	P	P	V	L	N	P	I	V	Y	11
59	289	N	P	I	V	Y	C	V	K	T	K	11
60	296	K	T	K	E	I	R	Q	R	I	L	11

SEQ
ID
NO:

HLA-A1 decamers

	<u>Pos</u>	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>	<u>0</u>	<u>score</u>
<u>2112</u>	<u>1</u>	<u>191</u>	<u>C</u>	<u>D</u>	<u>D</u>	<u>I</u>	<u>R</u>	<u>V</u>	<u>N</u>	<u>V</u>	<u>V</u>	<u>27</u>
<u>2113</u>	<u>2</u>	<u>244</u>	<u>S</u>	<u>H</u>	<u>V</u>	<u>C</u>	<u>A</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>F</u>	<u>24</u>
<u>2114</u>	<u>3</u>	<u>40</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>I</u>	<u>21</u>
<u>2115</u>	<u>4</u>	<u>284</u>	<u>V</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>21</u>
<u>2116</u>	<u>5</u>	<u>116</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>F</u>	<u>D</u>	<u>R</u>	<u>20</u>
<u>2117</u>	<u>6</u>	<u>28</u>	<u>W</u>	<u>L</u>	<u>A</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>18</u>
<u>2118</u>	<u>7</u>	<u>297</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>17</u>
<u>2119</u>	<u>8</u>	<u>21</u>	<u>G</u>	<u>L</u>	<u>E</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>F</u>	<u>W</u>	<u>L</u>	<u>16</u>
<u>2120</u>	<u>9</u>	<u>22</u>	<u>L</u>	<u>E</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>F</u>	<u>W</u>	<u>L</u>	<u>A</u>	<u>16</u>
<u>2121</u>	<u>10</u>	<u>52</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>H</u>	<u>E</u>	<u>P</u>	<u>16</u>
<u>2122</u>	<u>11</u>	<u>53</u>	<u>T</u>	<u>E</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>H</u>	<u>E</u>	<u>P</u>	<u>M</u>	<u>16</u>
<u>2123</u>	<u>12</u>	<u>57</u>	<u>L</u>	<u>H</u>	<u>E</u>	<u>P</u>	<u>M</u>	<u>Y</u>	<u>I</u>	<u>F</u>	<u>L</u>	<u>16</u>
<u>2124</u>	<u>13</u>	<u>111</u>	<u>G</u>	<u>M</u>	<u>E</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>16</u>
<u>2125</u>	<u>14</u>	<u>272</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>I</u>	<u>L</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>16</u>
<u>2126</u>	<u>15</u>	<u>1</u>	<u>M</u>	<u>V</u>	<u>D</u>	<u>P</u>	<u>N</u>	<u>G</u>	<u>N</u>	<u>E</u>	<u>S</u>	<u>15</u>
<u>2127</u>	<u>16</u>	<u>4</u>	<u>P</u>	<u>N</u>	<u>G</u>	<u>N</u>	<u>E</u>	<u>S</u>	<u>S</u>	<u>A</u>	<u>T</u>	<u>15</u>
<u>2128</u>	<u>17</u>	<u>121</u>	<u>A</u>	<u>F</u>	<u>D</u>	<u>R</u>	<u>Y</u>	<u>V</u>	<u>A</u>	<u>I</u>	<u>C</u>	<u>15</u>
<u>2129</u>	<u>18</u>	<u>171</u>	<u>C</u>	<u>R</u>	<u>S</u>	<u>N</u>	<u>I</u>	<u>L</u>	<u>S</u>	<u>H</u>	<u>S</u>	<u>15</u>
<u>2130</u>	<u>19</u>	<u>211</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>15</u>
<u>2131</u>	<u>20</u>	<u>8</u>	<u>E</u>	<u>S</u>	<u>S</u>	<u>A</u>	<u>T</u>	<u>Y</u>	<u>F</u>	<u>I</u>	<u>L</u>	<u>13</u>
<u>2132</u>	<u>21</u>	<u>190</u>	<u>A</u>	<u>C</u>	<u>D</u>	<u>D</u>	<u>I</u>	<u>R</u>	<u>V</u>	<u>N</u>	<u>V</u>	<u>13</u>

SEQ
ID
NO:

HLA-A*0201 decamers

		<u>Pos</u>	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>	<u>0</u>	<u>score</u>
<u>2133</u>	<u>1</u>	<u>221</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>30</u>
<u>2134</u>	<u>2</u>	<u>100</u>	<u>L</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>A</u>	<u>I</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>29</u>
<u>2135</u>	<u>3</u>	<u>282</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>27</u>
<u>2136</u>	<u>4</u>	<u>205</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>26</u>
<u>2137</u>	<u>5</u>	<u>213</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>25</u>
<u>2138</u>	<u>6</u>	<u>56</u>	<u>S</u>	<u>L</u>	<u>H</u>	<u>E</u>	<u>P</u>	<u>M</u>	<u>Y</u>	<u>I</u>	<u>F</u>	<u>L</u>	<u>24</u>
<u>2139</u>	<u>7</u>	<u>62</u>	<u>Y</u>	<u>I</u>	<u>F</u>	<u>L</u>	<u>C</u>	<u>M</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>I</u>	<u>24</u>
<u>2140</u>	<u>8</u>	<u>108</u>	<u>S</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>M</u>	<u>E</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>24</u>
<u>2141</u>	<u>9</u>	<u>117</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>F</u>	<u>D</u>	<u>R</u>	<u>Y</u>	<u>V</u>	<u>24</u>
<u>2142</u>	<u>10</u>	<u>131</u>	<u>P</u>	<u>L</u>	<u>R</u>	<u>H</u>	<u>A</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>T</u>	<u>L</u>	<u>24</u>
<u>2143</u>	<u>11</u>	<u>137</u>	<u>V</u>	<u>L</u>	<u>T</u>	<u>L</u>	<u>P</u>	<u>R</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>I</u>	<u>24</u>
<u>2144</u>	<u>12</u>	<u>215</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>24</u>
<u>2145</u>	<u>13</u>	<u>38</u>	<u>L</u>	<u>I</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>23</u>
<u>2146</u>	<u>14</u>	<u>41</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>I</u>	<u>Y</u>	<u>I</u>	<u>23</u>
<u>2147</u>	<u>15</u>	<u>156</u>	<u>A</u>	<u>L</u>	<u>M</u>	<u>A</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>23</u>
<u>2148</u>	<u>16</u>	<u>193</u>	<u>D</u>	<u>I</u>	<u>R</u>	<u>V</u>	<u>N</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>L</u>	<u>23</u>
<u>2149</u>	<u>17</u>	<u>214</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>23</u>
<u>2150</u>	<u>18</u>	<u>32</u>	<u>P</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>Y</u>	<u>L</u>	<u>I</u>	<u>A</u>	<u>V</u>	<u>22</u>

SEQ
ID
NO:

HLA-A*0201 decamers

		Pos	1	2	3	4	5	6	7	8	9	0	score
<u>2151</u>	19	<u>119</u>	A	M	A	F	D	R	Y	V	A	I	22
<u>2152</u>	20	<u>237</u>	K	A	F	G	T	C	V	S	H	V	22
<u>2153</u>	21	<u>275</u>	V	I	L	A	N	I	Y	L	L	V	22
<u>2154</u>	22	<u>85</u>	A	I	F	W	F	N	S	T	T	I	22
<u>2155</u>	23	<u>139</u>	T	L	P	R	V	T	K	I	G	V	22
<u>2156</u>	24	<u>202</u>	L	I	V	I	I	S	A	I	G	L	22
<u>2157</u>	25	<u>13</u>	Y	F	I	L	I	G	L	P	G	L	20
<u>2158</u>	26	<u>16</u>	L	I	G	L	P	G	L	E	E	A	20
<u>2159</u>	27	<u>29</u>	L	A	F	P	L	C	S	L	Y	L	20
<u>2160</u>	28	<u>142</u>	R	V	T	K	I	G	V	A	A	V	20
<u>2161</u>	29	<u>148</u>	V	A	A	V	V	R	G	A	A	L	20
<u>2162</u>	30	<u>167</u>	Q	L	P	F	C	R	S	N	I	L	20
<u>2163</u>	31	<u>180</u>	Y	C	L	H	Q	D	V	M	K	L	20
<u>2164</u>	32	<u>222</u>	L	I	L	K	T	V	L	G	L	T	20
<u>2165</u>	33	<u>240</u>	G	T	C	V	S	H	V	C	A	V	20
<u>2166</u>	34	<u>248</u>	A	V	F	I	F	Y	V	P	F	I	20
<u>2167</u>	35	<u>250</u>	F	I	F	Y	V	P	F	I	G	L	20
<u>2168</u>	36	<u>271</u>	S	P	L	P	V	I	L	A	N	I	20
<u>2169</u>	37	<u>279</u>	N	I	Y	L	L	V	P	P	V	L	20
<u>2170</u>	38	<u>304</u>	I	L	R	L	F	H	V	A	T	H	20
<u>2171</u>	39	<u>10</u>	S	A	T	Y	F	I	L	I	G	L	19
<u>2172</u>	40	<u>15</u>	I	L	I	G	L	P	G	L	E	E	19
<u>2173</u>	41	<u>27</u>	F	W	L	A	F	P	L	C	S	L	19
<u>2174</u>	42	<u>35</u>	S	L	Y	L	I	A	V	L	G	N	19
<u>2175</u>	43	<u>37</u>	Y	L	I	A	V	L	G	N	L	T	19
<u>2176</u>	44	<u>44</u>	N	L	T	I	I	Y	I	V	R	T	19
<u>2177</u>	45	<u>64</u>	F	L	C	M	L	S	G	I	D	I	19
<u>2178</u>	46	<u>83</u>	M	L	A	I	F	W	F	N	S	T	19
<u>2179</u>	47	<u>159</u>	A	P	L	P	V	F	I	K	Q	L	19
<u>2180</u>	48	<u>189</u>	L	A	C	D	D	I	R	V	N	V	19
<u>2181</u>	49	<u>207</u>	S	A	I	G	L	D	S	L	L	I	19
<u>2182</u>	50	<u>253</u>	Y	V	P	F	I	G	L	S	M	V	19
<u>2183</u>	51	<u>276</u>	I	L	A	N	I	Y	L	L	V	P	19
<u>2184</u>	52	<u>281</u>	Y	L	L	V	P	P	V	L	N	P	19
<u>2185</u>	53	<u>283</u>	L	V	P	P	V	L	N	P	I	V	19
<u>2186</u>	54	<u>286</u>	P	V	L	N	P	I	V	Y	G	V	19
<u>2187</u>	55	<u>33</u>	L	C	S	L	Y	L	I	A	V	L	18
<u>2188</u>	56	<u>36</u>	L	Y	L	I	A	V	L	G	N	L	18
<u>2189</u>	57	<u>39</u>	I	A	V	L	G	N	L	T	I	I	18
<u>2190</u>	58	<u>42</u>	L	G	N	L	T	I	I	Y	I	V	18
<u>2191</u>	59	<u>66</u>	C	M	L	S	G	I	D	I	L	I	18
<u>2192</u>	60	<u>111</u>	G	M	E	S	T	V	L	L	A	M	18
<u>2193</u>	61	<u>128</u>	I	C	H	P	L	R	H	A	T	V	18
<u>2194</u>	62	<u>134</u>	H	A	T	V	L	T	L	P	R	V	18
<u>2195</u>	63	<u>154</u>	G	A	A	L	M	A	P	L	P	V	18
<u>2196</u>	64	<u>157</u>	L	M	A	P	L	P	V	F	I	K	18
<u>2197</u>	65	<u>190</u>	A	C	D	D	I	R	V	N	V	V	18
<u>2198</u>	66	<u>229</u>	G	L	T	R	E	A	Q	A	K	A	18
<u>2199</u>	67	<u>245</u>	H	V	C	A	V	F	I	F	Y	V	18
<u>2200</u>	68	<u>274</u>	P	V	I	L	A	N	I	Y	L	L	18
<u>2201</u>	69	<u>278</u>	A	N	I	Y	L	L	V	P	P	V	18

SEQ
ID
NO:

HLA-A*0201 decamers

		<u>Pos</u>	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>	<u>0</u>	<u>score</u>
<u>2202</u>	<u>70</u>	<u>291</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>18</u>
<u>2203</u>	<u>71</u>	<u>298</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>R</u>	<u>L</u>	<u>18</u>
<u>2204</u>	<u>72</u>	<u>48</u>	<u>I</u>	<u>Y</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>17</u>
<u>2205</u>	<u>73</u>	<u>65</u>	<u>L</u>	<u>C</u>	<u>M</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>I</u>	<u>D</u>	<u>I</u>	<u>L</u>	<u>17</u>
<u>2206</u>	<u>74</u>	<u>67</u>	<u>M</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>I</u>	<u>D</u>	<u>I</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>17</u>
<u>2207</u>	<u>75</u>	<u>74</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>T</u>	<u>S</u>	<u>S</u>	<u>M</u>	<u>P</u>	<u>K</u>	<u>M</u>	<u>17</u>
<u>2208</u>	<u>76</u>	<u>91</u>	<u>S</u>	<u>T</u>	<u>T</u>	<u>I</u>	<u>Q</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>17</u>
<u>2209</u>	<u>77</u>	<u>94</u>	<u>I</u>	<u>Q</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>17</u>
<u>2210</u>	<u>78</u>	<u>188</u>	<u>K</u>	<u>L</u>	<u>A</u>	<u>C</u>	<u>D</u>	<u>D</u>	<u>I</u>	<u>R</u>	<u>V</u>	<u>N</u>	<u>17</u>
<u>2211</u>	<u>79</u>	<u>197</u>	<u>N</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>17</u>
<u>2212</u>	<u>80</u>	<u>200</u>	<u>Y</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>17</u>
<u>2213</u>	<u>81</u>	<u>218</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>17</u>
<u>2214</u>	<u>82</u>	<u>227</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>R</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>A</u>	<u>17</u>
<u>2215</u>	<u>83</u>	<u>303</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>R</u>	<u>L</u>	<u>F</u>	<u>H</u>	<u>V</u>	<u>A</u>	<u>T</u>	<u>17</u>
<u>2216</u>	<u>84</u>	<u>21</u>	<u>G</u>	<u>L</u>	<u>E</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>F</u>	<u>W</u>	<u>L</u>	<u>A</u>	<u>16</u>
<u>2217</u>	<u>85</u>	<u>92</u>	<u>T</u>	<u>T</u>	<u>I</u>	<u>Q</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>16</u>
<u>2218</u>	<u>86</u>	<u>97</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>A</u>	<u>I</u>	<u>16</u>
<u>2219</u>	<u>87</u>	<u>127</u>	<u>A</u>	<u>I</u>	<u>C</u>	<u>H</u>	<u>P</u>	<u>L</u>	<u>R</u>	<u>H</u>	<u>A</u>	<u>T</u>	<u>16</u>
<u>2220</u>	<u>88</u>	<u>143</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>V</u>	<u>16</u>
<u>2221</u>	<u>89</u>	<u>195</u>	<u>R</u>	<u>V</u>	<u>N</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>16</u>
<u>2222</u>	<u>90</u>	<u>220</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>16</u>
<u>2223</u>	<u>91</u>	<u>296</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>16</u>
<u>2224</u>	<u>92</u>	<u>18</u>	<u>G</u>	<u>L</u>	<u>P</u>	<u>G</u>	<u>L</u>	<u>E</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>F</u>	<u>15</u>
<u>2225</u>	<u>93</u>	<u>30</u>	<u>A</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>Y</u>	<u>L</u>	<u>I</u>	<u>15</u>
<u>2226</u>	<u>94</u>	<u>126</u>	<u>V</u>	<u>A</u>	<u>I</u>	<u>C</u>	<u>H</u>	<u>P</u>	<u>L</u>	<u>R</u>	<u>H</u>	<u>A</u>	<u>15</u>
<u>2227</u>	<u>95</u>	<u>145</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>15</u>
<u>2228</u>	<u>96</u>	<u>173</u>	<u>S</u>	<u>N</u>	<u>I</u>	<u>L</u>	<u>S</u>	<u>H</u>	<u>S</u>	<u>Y</u>	<u>C</u>	<u>L</u>	<u>15</u>
<u>2229</u>	<u>97</u>	<u>201</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>15</u>
<u>2230</u>	<u>98</u>	<u>208</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>15</u>
<u>2231</u>	<u>99</u>	<u>210</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>15</u>
<u>2232</u>	<u>100</u>	<u>267</u>	<u>K</u>	<u>R</u>	<u>R</u>	<u>D</u>	<u>S</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>I</u>	<u>15</u>

SEQ
ID
NO:

HLA-A*0203 decamers

	<u>Pos</u>	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>	<u>0</u>	<u>score</u>	
<u>2233</u>	<u>1</u>	<u>141</u>	<u>P</u>	<u>R</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>19</u>
<u>2234</u>	<u>2</u>	<u>147</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>A</u>	<u>A</u>	<u>19</u>
<u>2235</u>	<u>3</u>	<u>112</u>	<u>M</u>	<u>E</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>18</u>
<u>2236</u>	<u>4</u>	<u>227</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>R</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>A</u>	<u>18</u>
<u>2237</u>	<u>5</u>	<u>229</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>R</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>A</u>	<u>K</u>	<u>A</u>	<u>18</u>
<u>2238</u>	<u>6</u>	<u>142</u>	<u>R</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>17</u>
<u>2239</u>	<u>7</u>	<u>148</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>A</u>	<u>A</u>	<u>L</u>	<u>17</u>
<u>2240</u>	<u>8</u>	<u>2</u>	<u>V</u>	<u>D</u>	<u>P</u>	<u>N</u>	<u>G</u>	<u>N</u>	<u>E</u>	<u>S</u>	<u>S</u>	<u>A</u>	<u>10</u>
<u>2241</u>	<u>9</u>	<u>16</u>	<u>L</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>P</u>	<u>G</u>	<u>L</u>	<u>E</u>	<u>E</u>	<u>A</u>	<u>10</u>
<u>2242</u>	<u>10</u>	<u>21</u>	<u>G</u>	<u>L</u>	<u>E</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>F</u>	<u>W</u>	<u>L</u>	<u>A</u>	<u>10</u>
<u>2243</u>	<u>11</u>	<u>31</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>Y</u>	<u>L</u>	<u>I</u>	<u>A</u>	<u>10</u>
<u>2244</u>	<u>12</u>	<u>76</u>	<u>S</u>	<u>T</u>	<u>S</u>	<u>S</u>	<u>M</u>	<u>P</u>	<u>K</u>	<u>M</u>	<u>L</u>	<u>A</u>	<u>10</u>
<u>2245</u>	<u>13</u>	<u>89</u>	<u>F</u>	<u>N</u>	<u>S</u>	<u>T</u>	<u>T</u>	<u>I</u>	<u>Q</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>10</u>
<u>2246</u>	<u>14</u>	<u>96</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>A</u>	<u>10</u>
<u>2247</u>	<u>15</u>	<u>110</u>	<u>S</u>	<u>G</u>	<u>M</u>	<u>E</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>10</u>
<u>2248</u>	<u>16</u>	<u>118</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>F</u>	<u>D</u>	<u>R</u>	<u>Y</u>	<u>V</u>	<u>A</u>	<u>10</u>

SEQ
ID
NO:

HLA-A*0203 decamers

	Pos		1	2	3	4	5	6	7	8	9	0	score
<u>2249</u>	<u>17</u>	<u>126</u>	V	A	I	C	H	P	L	R	H	A	10
<u>2250</u>	<u>18</u>	<u>140</u>	L	P	R	V	T	K	I	G	V	A	10
<u>2251</u>	<u>19</u>	<u>146</u>	I	G	V	A	A	V	V	R	G	A	10
<u>2252</u>	<u>20</u>	<u>150</u>	A	V	V	R	G	A	A	L	M	A	10
<u>2253</u>	<u>21</u>	<u>181</u>	C	L	H	Q	D	V	M	K	L	A	10
<u>2254</u>	<u>22</u>	<u>199</u>	V	Y	G	L	I	V	I	I	S	A	10
<u>2255</u>	<u>23</u>	<u>225</u>	K	T	V	L	G	L	T	R	E	A	10
<u>2256</u>	<u>24</u>	<u>239</u>	F	G	T	C	V	S	H	V	C	A	10
<u>2257</u>	<u>25</u>	<u>269</u>	R	D	S	P	L	P	V	I	L	A	10
<u>2258</u>	<u>26</u>	<u>302</u>	Q	R	I	L	R	L	F	H	V	A	10
<u>2259</u>	<u>27</u>	<u>305</u>	L	R	L	F	H	V	A	T	H	A	10
<u>2260</u>	<u>28</u>	<u>3</u>	D	P	N	G	N	E	S	S	A	T	9
<u>2261</u>	<u>29</u>	<u>17</u>	I	G	L	P	G	L	E	E	A	Q	9
<u>2262</u>	<u>30</u>	<u>22</u>	L	E	E	A	Q	F	W	L	A	F	9
<u>2263</u>	<u>31</u>	<u>32</u>	P	L	C	S	L	Y	L	I	A	V	9
<u>2264</u>	<u>32</u>	<u>77</u>	T	S	S	M	P	K	M	L	A	I	9
<u>2265</u>	<u>33</u>	<u>90</u>	N	S	T	T	I	Q	F	D	A	C	9
<u>2266</u>	<u>34</u>	<u>97</u>	D	A	C	L	L	Q	I	F	A	I	9
<u>2267</u>	<u>35</u>	<u>111</u>	G	M	E	S	T	V	L	L	A	M	9
<u>2268</u>	<u>36</u>	<u>113</u>	E	S	T	V	L	L	A	M	A	F	9
<u>2269</u>	<u>37</u>	<u>119</u>	A	M	A	F	D	R	Y	V	A	I	9
<u>2270</u>	<u>38</u>	<u>127</u>	A	I	C	H	P	L	R	H	A	T	9
<u>2271</u>	<u>39</u>	<u>151</u>	V	V	R	G	A	A	L	M	A	P	9
<u>2272</u>	<u>40</u>	<u>182</u>	L	H	Q	D	V	M	K	L	A	C	9
<u>2273</u>	<u>41</u>	<u>200</u>	Y	G	L	I	V	I	I	S	A	I	9
<u>2274</u>	<u>42</u>	<u>226</u>	T	V	L	G	L	T	R	E	A	Q	9
<u>2275</u>	<u>43</u>	<u>228</u>	L	G	L	T	R	E	A	Q	A	K	9
<u>2276</u>	<u>44</u>	<u>230</u>	L	T	R	E	A	Q	A	K	A	F	9
<u>2277</u>	<u>45</u>	<u>240</u>	G	T	C	V	S	H	V	C	A	V	9
<u>2278</u>	<u>46</u>	<u>270</u>	D	S	P	L	P	V	I	L	A	N	9
<u>2279</u>	<u>47</u>	<u>303</u>	R	I	L	R	L	F	H	V	A	T	9
<u>2280</u>	<u>48</u>	<u>306</u>	R	L	F	H	V	A	T	H	A	S	9

SEQ
ID
NO:

HLA-A26 decamers

		<u>Pos</u>	1	2	3	4	5	6	7	8	9	0	<u>score</u>
<u>2281</u>	<u>1</u>	<u>299</u>	E	I	R	Q	R	I	L	R	L	F	<u>31</u>
<u>2282</u>	<u>2</u>	<u>193</u>	D	I	R	V	N	V	V	Y	G	L	<u>29</u>
<u>2283</u>	<u>3</u>	<u>250</u>	F	I	F	Y	V	P	F	I	G	L	<u>25</u>
<u>2284</u>	<u>4</u>	<u>256</u>	F	I	G	L	S	M	V	H	R	F	<u>25</u>
<u>2285</u>	<u>5</u>	<u>74</u>	L	I	S	T	S	S	M	P	K	M	<u>24</u>
<u>2286</u>	<u>6</u>	<u>274</u>	P	V	I	L	A	N	I	Y	L	L	<u>24</u>
<u>2287</u>	<u>7</u>	<u>18</u>	G	L	P	G	L	E	E	A	Q	F	<u>23</u>
<u>2288</u>	<u>8</u>	<u>116</u>	V	L	L	A	M	A	F	D	R	Y	<u>23</u>
<u>2289</u>	<u>9</u>	<u>205</u>	I	I	S	A	I	G	L	D	S	L	<u>23</u>
<u>2290</u>	<u>10</u>	<u>221</u>	L	L	I	L	K	T	V	L	G	L	<u>23</u>
<u>2291</u>	<u>11</u>	<u>230</u>	L	T	R	E	A	Q	A	K	A	F	<u>23</u>
<u>2292</u>	<u>12</u>	<u>13</u>	Y	F	I	L	I	G	L	P	G	L	<u>22</u>
<u>2293</u>	<u>13</u>	<u>40</u>	A	V	L	G	N	L	T	I	I	Y	<u>22</u>
<u>2294</u>	<u>14</u>	<u>56</u>	S	L	H	E	P	M	Y	I	F	L	<u>22</u>

SEQ
ID
NO:

HLA-A26 decamers

		<u>Pos</u>	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>	<u>0</u>	<u>score</u>
<u>2295</u>	<u>15</u>	<u>95</u>	<u>Q</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>22</u>
<u>2296</u>	<u>16</u>	<u>215</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>22</u>
<u>2297</u>	<u>17</u>	<u>92</u>	<u>T</u>	<u>T</u>	<u>I</u>	<u>Q</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>21</u>
<u>2298</u>	<u>18</u>	<u>100</u>	<u>L</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>A</u>	<u>I</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>21</u>
<u>2299</u>	<u>19</u>	<u>103</u>	<u>I</u>	<u>F</u>	<u>A</u>	<u>I</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>M</u>	<u>21</u>
<u>2300</u>	<u>20</u>	<u>296</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>21</u>
<u>2301</u>	<u>21</u>	<u>28</u>	<u>W</u>	<u>L</u>	<u>A</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>Y</u>	<u>20</u>
<u>2302</u>	<u>22</u>	<u>131</u>	<u>P</u>	<u>L</u>	<u>R</u>	<u>H</u>	<u>A</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>T</u>	<u>L</u>	<u>20</u>
<u>2303</u>	<u>23</u>	<u>59</u>	<u>E</u>	<u>P</u>	<u>M</u>	<u>Y</u>	<u>I</u>	<u>F</u>	<u>L</u>	<u>C</u>	<u>M</u>	<u>L</u>	<u>19</u>
<u>2304</u>	<u>24</u>	<u>91</u>	<u>S</u>	<u>T</u>	<u>T</u>	<u>I</u>	<u>Q</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>19</u>
<u>2305</u>	<u>25</u>	<u>202</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>19</u>
<u>2306</u>	<u>26</u>	<u>212</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>19</u>
<u>2307</u>	<u>27</u>	<u>272</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>I</u>	<u>L</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>19</u>
<u>2308</u>	<u>28</u>	<u>279</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>19</u>
<u>2309</u>	<u>29</u>	<u>52</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>H</u>	<u>E</u>	<u>P</u>	<u>M</u>	<u>18</u>
<u>2310</u>	<u>30</u>	<u>62</u>	<u>Y</u>	<u>I</u>	<u>F</u>	<u>L</u>	<u>C</u>	<u>M</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>I</u>	<u>18</u>
<u>2311</u>	<u>31</u>	<u>72</u>	<u>D</u>	<u>I</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>T</u>	<u>S</u>	<u>S</u>	<u>M</u>	<u>P</u>	<u>18</u>
<u>2312</u>	<u>32</u>	<u>108</u>	<u>S</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>M</u>	<u>E</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>18</u>
<u>2313</u>	<u>33</u>	<u>113</u>	<u>E</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>F</u>	<u>18</u>
<u>2314</u>	<u>34</u>	<u>151</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>A</u>	<u>A</u>	<u>L</u>	<u>M</u>	<u>A</u>	<u>P</u>	<u>18</u>
<u>2315</u>	<u>35</u>	<u>78</u>	<u>S</u>	<u>S</u>	<u>M</u>	<u>P</u>	<u>K</u>	<u>M</u>	<u>L</u>	<u>A</u>	<u>I</u>	<u>F</u>	<u>17</u>
<u>2316</u>	<u>36</u>	<u>142</u>	<u>R</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>17</u>
<u>2317</u>	<u>37</u>	<u>162</u>	<u>P</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>K</u>	<u>Q</u>	<u>L</u>	<u>P</u>	<u>F</u>	<u>C</u>	<u>17</u>
<u>2318</u>	<u>38</u>	<u>164</u>	<u>F</u>	<u>I</u>	<u>K</u>	<u>Q</u>	<u>L</u>	<u>P</u>	<u>F</u>	<u>C</u>	<u>R</u>	<u>S</u>	<u>17</u>
<u>2319</u>	<u>39</u>	<u>167</u>	<u>Q</u>	<u>L</u>	<u>P</u>	<u>F</u>	<u>C</u>	<u>R</u>	<u>S</u>	<u>N</u>	<u>I</u>	<u>L</u>	<u>17</u>
<u>2320</u>	<u>40</u>	<u>185</u>	<u>D</u>	<u>V</u>	<u>M</u>	<u>K</u>	<u>L</u>	<u>A</u>	<u>C</u>	<u>D</u>	<u>D</u>	<u>I</u>	<u>17</u>
<u>2321</u>	<u>41</u>	<u>248</u>	<u>A</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>F</u>	<u>Y</u>	<u>V</u>	<u>P</u>	<u>F</u>	<u>I</u>	<u>17</u>
<u>2322</u>	<u>42</u>	<u>253</u>	<u>Y</u>	<u>V</u>	<u>P</u>	<u>F</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>S</u>	<u>M</u>	<u>V</u>	<u>17</u>
<u>2323</u>	<u>43</u>	<u>45</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>I</u>	<u>Y</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>16</u>
<u>2324</u>	<u>44</u>	<u>145</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>16</u>
<u>2325</u>	<u>45</u>	<u>198</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>16</u>
<u>2326</u>	<u>46</u>	<u>203</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>16</u>
<u>2327</u>	<u>47</u>	<u>209</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>16</u>
<u>2328</u>	<u>48</u>	<u>213</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>16</u>
<u>2329</u>	<u>49</u>	<u>255</u>	<u>P</u>	<u>F</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>S</u>	<u>M</u>	<u>V</u>	<u>H</u>	<u>R</u>	<u>16</u>
<u>2330</u>	<u>50</u>	<u>264</u>	<u>R</u>	<u>F</u>	<u>S</u>	<u>K</u>	<u>R</u>	<u>R</u>	<u>D</u>	<u>S</u>	<u>P</u>	<u>L</u>	<u>16</u>
<u>2331</u>	<u>51</u>	<u>294</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>16</u>
<u>2332</u>	<u>52</u>	<u>16</u>	<u>L</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>P</u>	<u>G</u>	<u>L</u>	<u>E</u>	<u>E</u>	<u>A</u>	<u>15</u>
<u>2333</u>	<u>53</u>	<u>80</u>	<u>M</u>	<u>P</u>	<u>K</u>	<u>M</u>	<u>L</u>	<u>A</u>	<u>I</u>	<u>F</u>	<u>W</u>	<u>F</u>	<u>15</u>
<u>2334</u>	<u>54</u>	<u>114</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>F</u>	<u>D</u>	<u>15</u>
<u>2335</u>	<u>55</u>	<u>155</u>	<u>A</u>	<u>A</u>	<u>L</u>	<u>M</u>	<u>A</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>F</u>	<u>15</u>
<u>2336</u>	<u>56</u>	<u>159</u>	<u>A</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>K</u>	<u>Q</u>	<u>L</u>	<u>15</u>
<u>2337</u>	<u>57</u>	<u>174</u>	<u>N</u>	<u>I</u>	<u>L</u>	<u>S</u>	<u>H</u>	<u>S</u>	<u>Y</u>	<u>C</u>	<u>L</u>	<u>H</u>	<u>15</u>
<u>2338</u>	<u>58</u>	<u>197</u>	<u>N</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>15</u>
<u>2339</u>	<u>59</u>	<u>210</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>15</u>
<u>2340</u>	<u>60</u>	<u>214</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>15</u>
<u>2341</u>	<u>61</u>	<u>222</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>15</u>
<u>2342</u>	<u>62</u>	<u>240</u>	<u>G</u>	<u>T</u>	<u>C</u>	<u>V</u>	<u>S</u>	<u>H</u>	<u>V</u>	<u>C</u>	<u>A</u>	<u>V</u>	<u>15</u>
<u>2343</u>	<u>63</u>	<u>247</u>	<u>C</u>	<u>A</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>F</u>	<u>Y</u>	<u>V</u>	<u>P</u>	<u>F</u>	<u>15</u>
<u>2344</u>	<u>64</u>	<u>286</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>15</u>
<u>2345</u>	<u>65</u>	<u>298</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>R</u>	<u>L</u>	<u>15</u>

SEQ
ID
NO:

NO:	HLA-A3 decamers												
	Pos	1	2	3	4	5	6	7	8	9	0	score	
<u>2346</u>	<u>1</u>	<u>136</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>T</u>	<u>L</u>	<u>P</u>	<u>R</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>3</u>
<u>2347</u>	<u>2</u>	<u>287</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>2</u>
<u>2348</u>	<u>3</u>	<u>223</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>R</u>	<u>2</u>
<u>2349</u>	<u>4</u>	<u>304</u>	<u>I</u>	<u>L</u>	<u>R</u>	<u>L</u>	<u>F</u>	<u>H</u>	<u>V</u>	<u>A</u>	<u>T</u>	<u>H</u>	<u>2</u>
<u>2350</u>	<u>5</u>	<u>73</u>	<u>I</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>T</u>	<u>S</u>	<u>S</u>	<u>M</u>	<u>P</u>	<u>K</u>	<u>2</u>
<u>2351</u>	<u>6</u>	<u>15</u>	<u>I</u>	<u>L</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>P</u>	<u>G</u>	<u>L</u>	<u>E</u>	<u>E</u>	<u>2</u>
<u>2352</u>	<u>7</u>	<u>40</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>I</u>	<u>Y</u>	<u>2</u>
<u>2353</u>	<u>8</u>	<u>150</u>	<u>A</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>A</u>	<u>A</u>	<u>L</u>	<u>M</u>	<u>A</u>	<u>2</u>
<u>2354</u>	<u>9</u>	<u>258</u>	<u>G</u>	<u>L</u>	<u>S</u>	<u>M</u>	<u>V</u>	<u>H</u>	<u>R</u>	<u>F</u>	<u>S</u>	<u>K</u>	<u>2</u>
<u>2355</u>	<u>10</u>	<u>18</u>	<u>G</u>	<u>L</u>	<u>P</u>	<u>G</u>	<u>L</u>	<u>E</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>F</u>	<u>2</u>
<u>2356</u>	<u>11</u>	<u>303</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>R</u>	<u>L</u>	<u>F</u>	<u>H</u>	<u>V</u>	<u>A</u>	<u>T</u>	<u>2</u>
<u>2357</u>	<u>12</u>	<u>276</u>	<u>I</u>	<u>L</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>P</u>	<u>2</u>
<u>2358</u>	<u>13</u>	<u>28</u>	<u>W</u>	<u>L</u>	<u>A</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>Y</u>	<u>2</u>
<u>2359</u>	<u>14</u>	<u>115</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>F</u>	<u>D</u>	<u>R</u>	<u>2</u>
<u>2360</u>	<u>15</u>	<u>116</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>F</u>	<u>D</u>	<u>R</u>	<u>Y</u>	<u>2</u>
<u>2361</u>	<u>16</u>	<u>125</u>	<u>Y</u>	<u>V</u>	<u>A</u>	<u>I</u>	<u>C</u>	<u>H</u>	<u>P</u>	<u>L</u>	<u>R</u>	<u>H</u>	<u>2</u>
<u>2362</u>	<u>17</u>	<u>131</u>	<u>P</u>	<u>L</u>	<u>R</u>	<u>H</u>	<u>A</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>T</u>	<u>L</u>	<u>2</u>
<u>2363</u>	<u>18</u>	<u>144</u>	<u>T</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>2</u>
<u>2364</u>	<u>19</u>	<u>156</u>	<u>A</u>	<u>L</u>	<u>M</u>	<u>A</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>2</u>
<u>2365</u>	<u>20</u>	<u>195</u>	<u>R</u>	<u>V</u>	<u>N</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>2</u>
<u>2366</u>	<u>21</u>	<u>35</u>	<u>S</u>	<u>L</u>	<u>Y</u>	<u>L</u>	<u>I</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>1</u>
<u>2367</u>	<u>22</u>	<u>272</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>I</u>	<u>L</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>1</u>
<u>2368</u>	<u>23</u>	<u>37</u>	<u>Y</u>	<u>L</u>	<u>I</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>1</u>
<u>2369</u>	<u>24</u>	<u>49</u>	<u>Y</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>H</u>	<u>1</u>
<u>2370</u>	<u>25</u>	<u>50</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>H</u>	<u>E</u>	<u>1</u>
<u>2371</u>	<u>26</u>	<u>108</u>	<u>S</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>M</u>	<u>E</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>1</u>
<u>2372</u>	<u>27</u>	<u>142</u>	<u>R</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>1</u>
<u>2373</u>	<u>28</u>	<u>188</u>	<u>K</u>	<u>L</u>	<u>A</u>	<u>C</u>	<u>D</u>	<u>D</u>	<u>I</u>	<u>R</u>	<u>V</u>	<u>N</u>	<u>1</u>
<u>2374</u>	<u>29</u>	<u>279</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>1</u>
<u>2375</u>	<u>30</u>	<u>291</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>1</u>
<u>2376</u>	<u>31</u>	<u>294</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>1</u>
<u>2377</u>	<u>32</u>	<u>46</u>	<u>T</u>	<u>I</u>	<u>I</u>	<u>Y</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>H</u>	<u>1</u>
<u>2378</u>	<u>33</u>	<u>102</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>A</u>	<u>I</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>1</u>
<u>2379</u>	<u>34</u>	<u>151</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>A</u>	<u>A</u>	<u>L</u>	<u>M</u>	<u>A</u>	<u>P</u>	<u>1</u>
<u>2380</u>	<u>35</u>	<u>179</u>	<u>S</u>	<u>Y</u>	<u>C</u>	<u>L</u>	<u>H</u>	<u>Q</u>	<u>D</u>	<u>V</u>	<u>M</u>	<u>K</u>	<u>1</u>
<u>2381</u>	<u>36</u>	<u>203</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>1</u>
<u>2382</u>	<u>37</u>	<u>204</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>1</u>
<u>2383</u>	<u>38</u>	<u>220</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>1</u>
<u>2384</u>	<u>39</u>	<u>221</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>1</u>
<u>2385</u>	<u>40</u>	<u>227</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>R</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>A</u>	<u>1</u>
<u>2386</u>	<u>41</u>	<u>242</u>	<u>C</u>	<u>V</u>	<u>S</u>	<u>H</u>	<u>V</u>	<u>C</u>	<u>A</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>1</u>
<u>2387</u>	<u>42</u>	<u>289</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>1</u>
<u>2388</u>	<u>43</u>	<u>38</u>	<u>L</u>	<u>I</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>1</u>
<u>2389</u>	<u>44</u>	<u>85</u>	<u>A</u>	<u>I</u>	<u>F</u>	<u>W</u>	<u>F</u>	<u>N</u>	<u>S</u>	<u>T</u>	<u>T</u>	<u>I</u>	<u>1</u>
<u>2390</u>	<u>45</u>	<u>147</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>A</u>	<u>A</u>	<u>1</u>
<u>2391</u>	<u>46</u>	<u>198</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>1</u>
<u>2392</u>	<u>47</u>	<u>201</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>1</u>
<u>2393</u>	<u>48</u>	<u>214</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>1</u>
<u>2394</u>	<u>49</u>	<u>226</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>R</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>1</u>
<u>2395</u>	<u>50</u>	<u>228</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>R</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>A</u>	<u>K</u>	<u>1</u>

SEQ
ID
NO:

NO:	HLA-A3 decamers												
	Pos		1	2	3	4	5	6	7	8	9	0	score
<u>2396</u>	<u>51</u>	<u>229</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>R</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>A</u>	<u>K</u>	<u>A</u>	<u>16</u>
<u>2397</u>	<u>52</u>	<u>1</u>	<u>M</u>	<u>V</u>	<u>D</u>	<u>P</u>	<u>N</u>	<u>G</u>	<u>N</u>	<u>E</u>	<u>S</u>	<u>S</u>	<u>15</u>
<u>2398</u>	<u>53</u>	<u>44</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>I</u>	<u>Y</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>T</u>	<u>15</u>
<u>2399</u>	<u>54</u>	<u>47</u>	<u>I</u>	<u>I</u>	<u>Y</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>H</u>	<u>S</u>	<u>15</u>
<u>2400</u>	<u>55</u>	<u>67</u>	<u>M</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>I</u>	<u>D</u>	<u>I</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>15</u>
<u>2401</u>	<u>56</u>	<u>72</u>	<u>D</u>	<u>I</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>T</u>	<u>S</u>	<u>S</u>	<u>M</u>	<u>P</u>	<u>15</u>
<u>2402</u>	<u>57</u>	<u>99</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>A</u>	<u>I</u>	<u>H</u>	<u>S</u>	<u>15</u>
<u>2403</u>	<u>58</u>	<u>105</u>	<u>A</u>	<u>I</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>M</u>	<u>E</u>	<u>S</u>	<u>15</u>
<u>2404</u>	<u>59</u>	<u>145</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>15</u>
<u>2405</u>	<u>60</u>	<u>175</u>	<u>I</u>	<u>L</u>	<u>S</u>	<u>H</u>	<u>S</u>	<u>Y</u>	<u>C</u>	<u>L</u>	<u>H</u>	<u>Q</u>	<u>15</u>
<u>2406</u>	<u>61</u>	<u>191</u>	<u>C</u>	<u>D</u>	<u>D</u>	<u>I</u>	<u>R</u>	<u>V</u>	<u>N</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>15</u>
<u>2407</u>	<u>62</u>	<u>208</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>15</u>
<u>2408</u>	<u>63</u>	<u>275</u>	<u>V</u>	<u>I</u>	<u>L</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>15</u>
<u>2409</u>	<u>64</u>	<u>281</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>15</u>
<u>2410</u>	<u>65</u>	<u>299</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>R</u>	<u>L</u>	<u>F</u>	<u>15</u>
<u>2411</u>	<u>66</u>	<u>306</u>	<u>R</u>	<u>L</u>	<u>F</u>	<u>H</u>	<u>V</u>	<u>A</u>	<u>T</u>	<u>H</u>	<u>A</u>	<u>S</u>	<u>15</u>

SEQ
ID
NO:

NO:	HLA-B*0702 decamers												
	Pos	1	2	3	4	5	6	7	8	9	0	score	
<u>2412</u>	<u>1</u>	<u>159</u>	<u>A</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>K</u>	<u>Q</u>	<u>L</u>	<u>23</u>
<u>2413</u>	<u>2</u>	<u>59</u>	<u>E</u>	<u>P</u>	<u>M</u>	<u>Y</u>	<u>I</u>	<u>F</u>	<u>L</u>	<u>C</u>	<u>M</u>	<u>L</u>	<u>22</u>
<u>2414</u>	<u>3</u>	<u>273</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>I</u>	<u>L</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>L</u>	<u>20</u>
<u>2415</u>	<u>4</u>	<u>3</u>	<u>D</u>	<u>P</u>	<u>N</u>	<u>G</u>	<u>N</u>	<u>E</u>	<u>S</u>	<u>S</u>	<u>A</u>	<u>T</u>	<u>19</u>
<u>2416</u>	<u>5</u>	<u>130</u>	<u>H</u>	<u>P</u>	<u>L</u>	<u>R</u>	<u>H</u>	<u>A</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>T</u>	<u>19</u>
<u>2417</u>	<u>6</u>	<u>140</u>	<u>L</u>	<u>P</u>	<u>R</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>19</u>
<u>2418</u>	<u>7</u>	<u>161</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>K</u>	<u>Q</u>	<u>L</u>	<u>P</u>	<u>F</u>	<u>19</u>
<u>2419</u>	<u>8</u>	<u>31</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>Y</u>	<u>L</u>	<u>I</u>	<u>A</u>	<u>18</u>
<u>2420</u>	<u>9</u>	<u>271</u>	<u>S</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>I</u>	<u>L</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>18</u>
<u>2421</u>	<u>10</u>	<u>80</u>	<u>M</u>	<u>P</u>	<u>K</u>	<u>M</u>	<u>L</u>	<u>A</u>	<u>I</u>	<u>F</u>	<u>W</u>	<u>F</u>	<u>16</u>
<u>2422</u>	<u>11</u>	<u>108</u>	<u>S</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>M</u>	<u>E</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>16</u>
<u>2423</u>	<u>12</u>	<u>131</u>	<u>P</u>	<u>L</u>	<u>R</u>	<u>H</u>	<u>A</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>T</u>	<u>L</u>	<u>15</u>
<u>2424</u>	<u>13</u>	<u>264</u>	<u>R</u>	<u>F</u>	<u>S</u>	<u>K</u>	<u>R</u>	<u>R</u>	<u>D</u>	<u>S</u>	<u>P</u>	<u>L</u>	<u>15</u>
<u>2425</u>	<u>14</u>	<u>33</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>Y</u>	<u>L</u>	<u>I</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>14</u>
<u>2426</u>	<u>15</u>	<u>109</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>M</u>	<u>E</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>14</u>
<u>2427</u>	<u>16</u>	<u>152</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>A</u>	<u>A</u>	<u>L</u>	<u>M</u>	<u>A</u>	<u>P</u>	<u>L</u>	<u>14</u>
<u>2428</u>	<u>17</u>	<u>205</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>14</u>
<u>2429</u>	<u>18</u>	<u>215</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>14</u>
<u>2430</u>	<u>19</u>	<u>268</u>	<u>R</u>	<u>R</u>	<u>D</u>	<u>S</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>I</u>	<u>L</u>	<u>14</u>
<u>2431</u>	<u>20</u>	<u>29</u>	<u>L</u>	<u>A</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>Y</u>	<u>L</u>	<u>13</u>
<u>2432</u>	<u>21</u>	<u>148</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>V</u>	<u>R</u>	<u>G</u>	<u>A</u>	<u>A</u>	<u>L</u>	<u>13</u>
<u>2433</u>	<u>22</u>	<u>156</u>	<u>A</u>	<u>L</u>	<u>M</u>	<u>A</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>13</u>
<u>2434</u>	<u>23</u>	<u>193</u>	<u>D</u>	<u>I</u>	<u>R</u>	<u>V</u>	<u>N</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>L</u>	<u>13</u>
<u>2435</u>	<u>24</u>	<u>221</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>13</u>
<u>2436</u>	<u>25</u>	<u>298</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>R</u>	<u>L</u>	<u>13</u>
<u>2437</u>	<u>26</u>	<u>7</u>	<u>N</u>	<u>E</u>	<u>S</u>	<u>S</u>	<u>A</u>	<u>T</u>	<u>Y</u>	<u>F</u>	<u>I</u>	<u>L</u>	<u>12</u>
<u>2438</u>	<u>27</u>	<u>19</u>	<u>L</u>	<u>P</u>	<u>G</u>	<u>L</u>	<u>E</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>F</u>	<u>W</u>	<u>12</u>
<u>2439</u>	<u>28</u>	<u>24</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>F</u>	<u>W</u>	<u>L</u>	<u>A</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>12</u>
<u>2440</u>	<u>29</u>	<u>119</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>F</u>	<u>D</u>	<u>R</u>	<u>Y</u>	<u>V</u>	<u>A</u>	<u>I</u>	<u>12</u>
<u>2441</u>	<u>30</u>	<u>129</u>	<u>C</u>	<u>H</u>	<u>P</u>	<u>L</u>	<u>R</u>	<u>H</u>	<u>A</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>12</u>
<u>2442</u>	<u>31</u>	<u>206</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>12</u>

<u>SEQ</u> <u>ID</u> <u>NO:</u>	<u>HLA-B*0702 decamers</u>													<u>score</u>	<u>SEQ</u> <u>ID</u> <u>NO:</u>	<u>HLA-B*0702 decamers</u>													<u>score</u>
	<u>Pos</u>		<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>	<u>0</u>			<u>Pos</u>		<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>	<u>0</u>			
<u>2443</u>	<u>32</u>	<u>219</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>12</u>	<u>2460</u>	<u>49</u>	<u>234</u>	<u>A</u>	<u>Q</u>	<u>A</u>	<u>K</u>	<u>A</u>	<u>F</u>	<u>G</u>	<u>T</u>	<u>C</u>	<u>V</u>	<u>11</u>		
<u>2444</u>	<u>33</u>	<u>279</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>12</u>	<u>2461</u>	<u>50</u>	<u>242</u>	<u>C</u>	<u>V</u>	<u>S</u>	<u>H</u>	<u>V</u>	<u>C</u>	<u>A</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>11</u>		
<u>2445</u>	<u>34</u>	<u>285</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>12</u>	<u>2462</u>	<u>51</u>	<u>248</u>	<u>A</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>F</u>	<u>Y</u>	<u>V</u>	<u>P</u>	<u>F</u>	<u>I</u>	<u>11</u>		
<u>2446</u>	<u>35</u>	<u>8</u>	<u>E</u>	<u>S</u>	<u>S</u>	<u>A</u>	<u>T</u>	<u>Y</u>	<u>F</u>	<u>I</u>	<u>L</u>	<u>I</u>	<u>11</u>	<u>2463</u>	<u>52</u>	<u>250</u>	<u>F</u>	<u>I</u>	<u>F</u>	<u>Y</u>	<u>V</u>	<u>P</u>	<u>F</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>11</u>		
<u>2447</u>	<u>36</u>	<u>13</u>	<u>Y</u>	<u>F</u>	<u>I</u>	<u>L</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>P</u>	<u>G</u>	<u>L</u>	<u>11</u>	<u>2464</u>	<u>53</u>	<u>254</u>	<u>V</u>	<u>P</u>	<u>F</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>S</u>	<u>M</u>	<u>V</u>	<u>H</u>	<u>11</u>		
<u>2448</u>	<u>37</u>	<u>27</u>	<u>F</u>	<u>W</u>	<u>L</u>	<u>A</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>11</u>	<u>2465</u>	<u>54</u>	<u>266</u>	<u>S</u>	<u>K</u>	<u>R</u>	<u>R</u>	<u>D</u>	<u>S</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>11</u>		
<u>2449</u>	<u>38</u>	<u>48</u>	<u>I</u>	<u>Y</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>T</u>	<u>E</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>11</u>	<u>2466</u>	<u>55</u>	<u>267</u>	<u>K</u>	<u>R</u>	<u>R</u>	<u>D</u>	<u>S</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>I</u>	<u>11</u>		
<u>2450</u>	<u>39</u>	<u>56</u>	<u>S</u>	<u>L</u>	<u>H</u>	<u>E</u>	<u>P</u>	<u>M</u>	<u>Y</u>	<u>I</u>	<u>F</u>	<u>L</u>	<u>11</u>	<u>2467</u>	<u>56</u>	<u>269</u>	<u>R</u>	<u>D</u>	<u>S</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>I</u>	<u>L</u>	<u>A</u>	<u>11</u>		
<u>2451</u>	<u>40</u>	<u>65</u>	<u>L</u>	<u>C</u>	<u>M</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>I</u>	<u>D</u>	<u>I</u>	<u>L</u>	<u>11</u>	<u>2468</u>	<u>57</u>	<u>278</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>11</u>		
<u>2452</u>	<u>41</u>	<u>75</u>	<u>I</u>	<u>S</u>	<u>T</u>	<u>S</u>	<u>S</u>	<u>M</u>	<u>P</u>	<u>K</u>	<u>M</u>	<u>L</u>	<u>11</u>	<u>2469</u>	<u>58</u>	<u>284</u>	<u>V</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>11</u>		
<u>2453</u>	<u>42</u>	<u>77</u>	<u>T</u>	<u>S</u>	<u>S</u>	<u>M</u>	<u>P</u>	<u>K</u>	<u>M</u>	<u>L</u>	<u>A</u>	<u>I</u>	<u>11</u>	<u>2470</u>	<u>59</u>	<u>289</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>11</u>		
<u>2454</u>	<u>43</u>	<u>91</u>	<u>S</u>	<u>T</u>	<u>T</u>	<u>I</u>	<u>Q</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>11</u>	<u>2471</u>	<u>60</u>	<u>296</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>11</u>		
<u>2455</u>	<u>44</u>	<u>123</u>	<u>D</u>	<u>R</u>	<u>Y</u>	<u>V</u>	<u>A</u>	<u>I</u>	<u>C</u>	<u>H</u>	<u>P</u>	<u>L</u>	<u>11</u>																
<u>2456</u>	<u>45</u>	<u>142</u>	<u>R</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>A</u>	<u>A</u>	<u>V</u>	<u>11</u>																
<u>2457</u>	<u>46</u>	<u>180</u>	<u>Y</u>	<u>C</u>	<u>L</u>	<u>H</u>	<u>Q</u>	<u>D</u>	<u>V</u>	<u>M</u>	<u>K</u>	<u>L</u>	<u>11</u>																
<u>2458</u>	<u>47</u>	<u>190</u>	<u>A</u>	<u>C</u>	<u>D</u>	<u>D</u>	<u>I</u>	<u>R</u>	<u>V</u>	<u>N</u>	<u>V</u>	<u>V</u>	<u>11</u>																
<u>2459</u>	<u>48</u>	<u>212</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>11</u>																

5

Table XXVIII:
HLA Class II Epitopes (sample 15-mer length)

<u>HLA-DRB1*0101-15-mers</u>															score			
Pos		1	2	3	4	5	6	7	8	9	10	11	12	13		14	15	
1	200	-	Y	G	L	I	V	I	I	S	A	I	G	L	D	S	L	36
2	68	-	L	S	C	I	D	I	L	I	S	T	S	S	M	P	K	34
3	62	-	Y	I	F	L	C	M	L	S	C	I	D	I	L	I	S	33
4	103	-	I	F	A	I	H	S	L	S	G	M	E	S	T	V	L	32
5	45	-	L	T	I	I	Y	I	V	R	T	E	H	S	L	H	E	31
6	193	-	D	I	R	V	N	V	V	Y	C	L	I	V	I	I	S	31
7	277	-	L	A	N	I	Y	L	L	V	P	P	V	L	N	P	I	31
8	97	-	D	A	C	L	L	Q	I	F	A	I	H	S	L	S	G	30
9	106	-	I	H	S	L	S	G	M	E	S	T	V	L	L	A	M	30
10	240	-	G	T	C	V	S	H	V	C	A	V	F	I	F	Y	V	30
11	10	-	S	A	T	Y	F	I	L	I	C	L	P	C	L	E	E	29
12	289	-	N	P	I	V	Y	G	V	K	T	K	E	I	R	Q	R	29
13	11	-	A	T	Y	F	I	L	I	C	L	P	C	L	E	E	A	28
14	250	-	F	I	F	Y	V	P	F	I	C	L	S	M	V	H	R	27
15	140	-	L	P	R	V	T	K	I	G	V	A	A	V	V	R	G	26
16	183	-	H	Q	D	V	M	K	L	A	C	D	D	I	R	V	N	26
17	217	-	S	F	S	Y	L	L	I	L	K	T	V	L	C	L	T	26
18	16	-	L	I	C	L	P	C	L	E	E	A	Q	F	W	L	A	25
19	24	-	E	A	Q	F	W	L	A	F	P	L	C	S	L	Y	L	25
20	36	-	L	Y	L	I	A	V	L	G	N	L	T	I	I	Y	I	25
21	70	-	G	I	D	I	L	I	S	T	S	S	M	P	K	M	L	25
22	111	-	G	M	E	S	T	V	L	L	A	M	A	F	D	R	Y	25
23	148	-	V	A	A	V	V	R	G	A	A	L	M	A	P	L	P	25
24	162	-	P	V	F	I	K	Q	L	P	F	C	R	S	N	I	L	25
25	197	-	N	V	V	Y	C	L	I	V	I	I	S	A	I	G	L	25
26	211	-	L	D	S	L	L	I	S	F	S	Y	L	L	I	L	K	25
27	218	-	F	S	Y	L	L	I	L	K	T	V	L	C	L	T	R	25
28	13	-	Y	F	I	L	I	C	L	P	C	L	E	E	A	Q	F	24
29	30	-	A	F	P	L	C	S	L	Y	L	I	A	V	L	G	N	24
30	39	-	I	A	V	L	G	N	L	T	I	I	Y	I	V	R	T	24
31	77	-	T	S	S	M	P	K	M	L	A	I	F	W	F	N	S	24
32	85	-	A	I	F	W	F	N	S	T	T	I	Q	F	D	A	C	24
33	137	-	V	L	T	L	P	R	V	T	K	I	G	V	A	A	V	24
34	151	-	V	V	R	G	A	A	L	M	A	P	L	P	V	F	I	24
35	161	-	L	P	V	F	I	K	Q	L	P	F	C	R	S	N	I	24
36	196	-	V	N	V	V	Y	C	L	I	V	I	I	S	A	I	G	24
37	202	-	L	I	V	I	I	S	A	I	C	L	D	S	L	L	I	24
38	208	-	A	I	G	L	D	S	L	L	I	S	F	S	Y	L	L	24
39	248	-	A	V	F	I	F	Y	V	P	F	I	C	L	S	M	V	24
40	251	-	I	F	Y	V	P	F	I	C	L	S	M	V	H	R	F	24
41	83	-	M	L	A	I	F	W	F	N	S	T	T	I	Q	F	D	23
42	101	-	L	Q	I	F	A	I	H	S	L	S	G	M	E	S	T	23
43	165	-	I	K	Q	L	P	F	C	R	S	N	I	L	S	H	S	23
44	203	-	I	V	I	I	S	A	I	C	L	D	S	L	L	I	S	23
45	221	-	L	L	I	L	K	T	V	L	C	L	T	R	E	A	Q	23
46	278	-	A	N	I	Y	L	L	V	P	P	V	L	N	P	I	V	23
47	27	-	F	W	L	A	F	P	L	C	S	L	Y	L	I	A	V	22
48	35	-	S	L	Y	L	I	A	V	L	G	N	L	T	I	I	Y	22
49	61	-	M	Y	I	F	L	C	M	L	S	C	I	D	I	L	I	22

HLA-DRB1*0101 15-mers

	Pos		score
		-1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	
50	65	-LCMLSGLDILISTSS	22
51	80	-MPKMLAIFWFNSTTI	22
52	145	-KICVAAVVRGAALMA	22
53	146	-ICVAAVVRGAALMAP	22
54	154	-GAALMAPLPVFIKQL	22
55	205	-IISAIGLDSLLISFS	22
56	243	-VSHVCAVFIFYVFFI	22
57	270	-DSPLPVILANIYLLV	22
58	274	-PVILANIYLLVPPVL	22
59	281	-YLLVPPVNLNPIVYGV	22
60	34	-CSLYLIAVLGNLTI	21
61	69	-SGIDILISTSSMPKM	21
62	152	-VRGAALMAPLPVFIK	21
63	299	-EIRQRI LRLFHVA TH	21
64	100	-LLQIFA IHSLSGME S	20
65	135	-ATVLTLP RVTKIGVA	20
66	141	-PRVTKIGVAAVVRGA	20
67	191	-GDDIRVNVVYGLIVI	20
68	199	-VYGLIVIIISAIGLDS	20
69	262	-VHREFSKRRD SPLPVI	20
70	271	-SPLPVILANIYLLVP	20
71	28	-WLAFLPLCSLYLIAVL	19
72	58	-HEPMYIFFLCMLSGLD	19
73	59	-EPMYIFFLCMLSGLDI	19
74	60	-PMYIFFLCMLSGLDIL	19
75	98	-ACLLQIFA IHSLSGM	19
76	215	-LISFSYLLILKTVLGL	19
77	219	-SYLLILKTVLGLTRE	19
78	228	-LGLTRE AQA KAFCTC	19
79	232	-REAQA KAFCTCVSHV	19
80	246	-VCAVFIFYVFFICLS	19
81	297	-TKEIRQRI LRLFHVA	19
82	3	-DPNCGNESSATYFILI	18
83	14	-FILIGLPGLEEAQFW	18
84	25	-AQFWLAFLPLCSLYLI	18
85	42	-LGNLTI IYIVRTEHS	18
86	46	-TIIYIVRTEHSLHEP	18
87	78	-SSMPKMLAIFWFNST	18
88	84	-LAIFWFNSTTIQFDA	18
89	89	-FNSTTIQFDACLLQI	18
90	93	-TIQFDACLLQIFA I H	18
91	115	-TVLLAMAFDRYVAIC	18
92	119	-AMAFDRYVAICHPLR	18
93	127	-AICHPLRHATVLTLP	18
94	129	-CHPLRHATVLTLP RV	18
95	147	-GVAAVVRGAALMAPL	18
96	149	-AAVVRGAALMAPLPV	18
97	216	-ISFSYLLILKTVLGL	18
98	227	-VLGLTRE AQA KAFCT	18
99	249	-VFIFYVFFICLSMVH	18
100	253	-YVPFFICLSMVH RFSK	18
101	284	-VPPVNLNPIVYGVKTK	18

HLA-DRB1*0101 15-mers

	Pes		score
	1 2 3 4 5 6 7 8 9 0 1 2 3 4 5		
102 286	P V L N P I V Y G V K T K E I	18	
103 303	R I L R L F H V A T H A S E P	18	

HLA-DRB1*0301 (DR17) 15-mers

	Pes		score
	1 2 3 4 5 6 7 8 9 0 1 2 3 4 5		
1 16	L I G L P G L E E A Q F W L A	26	
2 206	I S A I G L D S L L I S F S Y	23	
3 91	S T T I Q F D A C L L Q I F A	22	
4 117	L L A M A F D R Y V A I C H P	22	
5 38	L I A V L G N L T I I Y I V R	21	
6 179	S Y C L H Q D V M K L A C D D	21	
7 211	L D S L L I S F S Y L L I L K	21	
8 219	S Y L L I L K T V L C L T R E	21	
9 272	P L P V I L A N I Y L L V P P	21	
10 26	Q F W L A F P L C S L Y L I A	20	
11 114	S T V L L A M A F D R Y V A I	20	
12 129	C H P L R H A T V L T L P R V	20	
13 134	H A T V L T L P R V T K I C V	20	
14 186	V M K L A C D D I R V N V V Y	20	
15 200	Y G L I V I I S A I G L D S L	20	
16 270	D S P L P V I L A N I Y L L V	20	
17 297	T K E I R Q R I L R L F H V A	20	
18 11	A T Y F I L I G L P G L E E A	19	
19 54	E H S L H E P M Y I F L C M L	19	
20 106	I H S L S G M E S T V L L A M	19	
21 165	I K Q L P F C R S N I L S H S	19	
22 191	C D D I R V N V V Y G L I V I	19	
23 203	I V I I S A I G L D S L L I S	19	
24 213	S L L I S F S Y L L I L K T V	19	
25 224	L K T V L G L T R E A Q A K A	19	
26 227	V L G L T R E A Q A K A F C T	19	
27 248	A V F I F Y V P F I G L S M V	19	
28 254	V P F I G L S M V H R F S K R	19	
29 277	L A N I Y L L V P P V L N P I	19	
30 36	L Y L I A V L G N L T I I Y I	18	
31 93	T I Q F D A C L L Q I F A I H	18	
32 98	A C L L Q I F A I H S L S C M	18	
33 125	Y V A I C H P L R H A T V L T	18	
34 158	M A P L P V F I K Q L P F C R	18	
35 187	M K L A C D D I R V N V V Y C	18	
36 217	S F S Y L L I L K T V L C L T	18	
37 225	K T V L G L T R E A Q A K A F	18	
38 281	Y L L V P P V L N P I V Y C V	18	
39 288	L N P I V Y G V K T K E I R Q	18	
40 18	G L P G L E E A Q F W L A F P	17	
41 44	N L T I I Y I V R T E H S L H	17	
42 145	K I G V A A V V R C A A L M A	17	
43 159	A P L P V F I K Q L P F C R S	17	
44 256	F I G L S M V H R F S K R R D	17	
45 259	L S M V H R F S K R R D S P L	17	
46 137	V L T L P R V T K I G V A A V	16	

HLA-DRB1*0301 (DR17) 15-mers

	Pes	1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	score
47	262	V H R F S K R R D S P L P V I	16
48	294	G V K T K E I R Q R I L R L F	16
49	46	T I I Y I V R T E H S L H E P	15
50	51	V R T E H S L H E P M Y I F L	15
51	172	R S N I L S H S Y C L H Q D V	15
52	189	L A C D D I R V N V V Y C L I	15
53	212	D S L L I S F S Y L L I L K T	15
54	218	F S Y L L I L K T V L C L T R	15
55	271	S P L P V I L A N I Y L L V P	15
56	279	N I Y L L V P P V L N P I V Y	15
57	12	T Y F I L I G L P C L E E A Q	14
58	35	S L Y L I A V L G N L T I I Y	14
59	64	F L C M L S C I D I L I S T S	14
60	140	L P R V T K I G V A A V V R G	14
61	273	L P V I L A N I Y L L V P P V	14
62	301	R Q R I L R L F H V A T H A S	14
63	13	Y F I L I G L P C L E E A Q F	13
64	47	I I Y I V R T E H S L H E P M	13
65	71	I D I L I S T S S M P K M L A	13
66	80	M P K M L A I F W F N S T T I	13
67	109	L S C M E S T V L L A M A F D	13
68	113	E S T V L L A M A F D R Y V A	13
69	135	A T V L T L P R V T K I G V A	13
70	195	R V N V V Y C L I V I I S A I	13
71	202	L I V I I S A I C L D S L L I	13
72	220	Y L L I L K T V L C L T R E A	13
73	221	L L I L K T V L C L T R E A Q	13
74	264	R F S K R R D S P L P V I L A	13
75	280	I Y L L V P P V L N P I V Y C	13
76	302	Q R I L R L F H V A T H A S E	13

HLA-DRB1*0401 (DR4Dw4) 15-mers

	Pes	1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	score
1	36	L Y L I A V L G N L T I I Y I	26
2	45	L T I I Y I V R T E H S L H E	26
3	68	L S C I D I L I S T S S M P K	26
4	83	M L A I F W F N S T T I Q F D	26
5	134	H A T V L T L P R V T K I G V	26
6	145	K I G V A A V V R G A A L M A	26
7	224	L K T V L C L T R E A Q A K A	26
8	227	V L G L T R E A Q A K A F G T	26
9	256	F I G L S M V H R F S K R R D	26
10	281	Y L L V P P V L N P I V Y C V	26
11	289	N P I V Y G V K T K E I R Q R	26
12	301	R Q R I L R L F H V A T H A S	26
13	11	A T Y F I L I G L P C L E E A	22
14	24	E A Q F W L A F P L C S L Y L	22
15	25	A Q F W L A F P L C S L Y L I	22
16	34	G S L Y L I A V L G N L T I I	22
17	84	L A I F W F N S T T I Q F D A	22
18	122	F D R Y V A I C H P L R H A T	22

HLA-DRB1*0401 (DR4Dw4) 15-mers

	Pes		score
		-1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	
19	197	-N V V Y G L I V I I S A I G L	22
20	215	-L I S F S Y L L I L K T V L G	22
21	217	-S F S Y L L I L K T V L G L T	22
22	250	-F I F Y V P F I G L S M V H R	22
23	278	-A N I Y L L V P P V L N P I V	22
24	19	-L P G L E E A Q F W L A F P L	20
25	30	-A F P L C S L Y L I A V L G N	20
26	33	-L C S L Y L I A V L G N L T I	20
27	35	-S L Y L I A V L G N L T I I Y	20
28	39	-I A V L G N L T I I Y I V R T	20
29	42	-L G N L T I I Y I V R T E H S	20
30	44	-N L T I I Y I V R T E H S L H	20
31	48	-I Y I V R T E H S L H E P M Y	20
32	58	-H E P M Y I F L C M L S G I D	20
33	62	-Y I F L C M L S G I D I L I S	20
34	65	-L C M L S G I D I L I S T S S	20
35	71	-I D I L I S T S S M P K M L A	20
36	80	-M P K M L A I F W F N S T T I	20
37	81	-P K M L A I F W F N S T T I Q	20
38	91	-S T T I Q F D A C L L Q I F A	20
39	97	-D A C L L Q I F A I H S L S G	20
40	98	-A C L L Q I F A I H S L S G M	20
41	100	-L L Q I F A I H S L S G M E S	20
42	103	-I F A I H S L S G M E S T V L	20
43	106	-I H S L S G M E S T V L L A M	20
44	115	-T V L L A M A F D R Y V A I C	20
45	117	-L L A M A F D R Y V A I C H P	20
46	125	-Y V A I C H P L R H A T V L T	20
47	129	-C H P L R H A T V L T L P R V	20
48	137	-V L T L P R V T K I G V A A V	20
49	140	-L P R V T K I G V A A V V R C	20
50	155	-A A L M A P L P V F I K Q L P	20
51	162	-P V F I K Q L P F C R S N I L	20
52	165	-I K Q L P F C R S N I L S H S	20
53	179	-S Y C L H Q D V M K L A C D D	20
54	183	-H Q D V M K L A C D D I R V N	20
55	186	-V M K L A C D D I R V N V V Y	20
56	193	-D I R V N V V Y G L I V I I S	20
57	196	-V N V V Y G L I V I I S A I G	20
58	199	-V Y G L I V I I S A I G L D S	20
59	200	-Y G L I V I I S A I G L D S L	20
60	202	-L I V I I S A I G L D S L L I	20
61	203	-I V I I S A I G L D S L L I S	20
62	206	-I S A I G L D S L L I S F S Y	20
63	208	-A I G L D S L L I S F S Y L L	20
64	211	-L D S L L I S F S Y L L I L K	20
65	212	-D S L L I S F S Y L L I L K T	20
66	218	-F S Y L L I L K T V L G L T R	20
67	240	-G T C V S H V C A V F I F Y V	20
68	243	-V S H V C A V F I F Y V P F I	20
69	246	-V C A V F I F Y V P F I G L S	20
70	248	-A V F I F Y V P F I G L S M V	20

HLA-DRB1*0401 (DR4Dw4) 15-mers

	Pes		score
		-1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	
71	251	-I F Y V P F I G L S M V H R F	20
72	272	-P L P V I L A N I Y L L V P P	20
73	277	-L A N I Y L L V P P V L N P I	20
74	285	-P P V L N P I V Y C V K T K E	20
75	18	-G L P G L E E A Q F W L A F P	18
76	27	-F W L A F P L C S L Y L I A V	18
77	69	-S C I D I L I S T S S M P K M	18
78	94	-I Q F D A C L L Q I F A I H S	18
79	99	-C L L Q I F A I H S L S G M E	18
80	107	-H S L S G M E S T V L L A M A	18
81	116	-V L L A M A F D R Y V A I C H	18
82	126	-V A I C H P L R H A T V L T L	18
83	164	-F I K Q L P F C R S N I L S H	18
84	176	-L S H S Y C L H Q D V M K L A	18
85	187	-M K L A C D D I R V N V V Y C	18
86	205	-I I S A I G L D S L L I S F S	18
87	233	-E A Q A K A F G T C V S H V C	18
88	237	-K A F G T C V S H V C A V F I	18
89	271	-S P L P V I L A N I Y L L V P	18
90	293	-Y G V K T K E I R Q R I L R L	18
91	294	-G V K T K E I R Q R I L R L F	18
92	10	-S A T Y F I L I C L P G L E E	16
93	28	-W L A F P L C S L Y L I A V L	16
94	59	-E P M Y I F L C M L S G I D I	16
95	61	-M Y I F L C M L S G I D I L I	16
96	85	-A I F W F N S T T I Q F D A C	16
97	101	-L Q I F A I H S L S G M E S T	16
98	177	-S H S Y C L H Q D V M K L A C	16
99	236	-A K A F G T C V S H V C A V F	16
100	249	-V F I F Y V P F I G L S M V H	16
101	253	-Y V P F I G L S M V H R F S K	16
102	13	-Y F I L I C L P G L E E A Q F	14
103	14	-F I L I C L P G L E E A Q F W	14
104	16	-L I C L P G L E E A Q F W L A	14
105	38	-L I A V L C N L T I I Y I V R	14
106	47	-I I Y I V R T E H S L H E P M	14
107	54	-E H S L H E P M Y I F L C M L	14
108	60	-P M Y I F L C M L S G I D I L	14
109	64	-F L C M L S G I D I L I S T S	14
110	70	-G I D I L I S T S S M P K M L	14
111	72	-D I L I S T S S M P K M L A I	14
112	109	-L S G M E S T V L L A M A F D	14
113	113	-E S T V L L A M A F D R Y V A	14
114	135	-A T V L T L P R V T K I G V A	14
115	143	-V T K I G V A A V V R C A A L	14
116	148	-V A A V V R C A A L M A P L P	14
117	149	-A A V V R C A A L M A P L P V	14
118	154	-G A A L M A P L P V F I K Q L	14
119	158	-M A P L P V F I K Q L P F C R	14
120	173	-S N I L S H S Y C L H Q D V M	14
121	184	-Q D V M K L A C D D I R V N V	14
122	191	-C D D I R V N V V Y C L I V I	14

HLA-DRB1*0401 (DR4Dw4) 15-mers

	Pes		score
	1 2 3 4 5 6 7 8 9 0 1 2 3 4 5		
123	195	R V N V V Y G L I V I I S A I	14
124	213	S L L I S F S Y L L I L K T V	14
125	220	Y L L I L K T V L G L T R E A	14
126	221	L L I L K T V L G L T R E A Q	14
127	225	K T V L G L T R E A Q A K A F	14
128	259	L S M V H R F S K R R D S P L	14
129	270	D S P L P V I L A N I Y L L V	14
130	273	L P V I L A N I Y L L V P P V	14
131	274	P V I L A N I Y L L V P P V L	14
132	280	I Y L L V P P V L N P I V Y G	14
133	284	V P P V L N P I V Y G V K T K	14
134	302	Q R I L R L F H V A T H A S E	14

HLA-DRB1*1101 15-mers

	Pes		score
	1 2 3 4 5 6 7 8 9 0 1 2 3 4 5		
1	145	K I C V A A V V R G A A L M A	28
2	122	F D R Y V A I C H P L R H A T	25
3	217	S F S Y L L I L K T V L G L T	25
4	197	N V V Y G L I V I I S A I G L	24
5	10	S A T Y F I L I G L P G L E E	23
6	255	P F I G L S M V H R F S K R R	23
7	44	N L T I I Y I V R T E H S L H	22
8	59	E P M Y I F L C M L S G I D I	22
9	158	M A P L P V F I K Q L P F C R	22
10	237	K A F G T C V S H V C A V F I	22
11	74	L I S T S S M P K M L A I F W	21
12	134	H A T V L T L P R V T K I G V	20
13	137	V L T L P R V T K I C V A A V	20
14	162	P V F I K Q L P F C R S N I L	20
15	199	V Y G L I V I I S A I G L D S	20
16	224	L K T V L G L T R E A Q A K A	20
17	256	F I G L S M V H R F S K R R D	20
18	290	P I V Y G V K T K E I R Q R I	20
19	301	R Q R I L R L F H V A T H A S	20
20	65	L C M L S G I D I L I S T S S	19
21	100	L L Q I F A I H S L S C M E S	19
22	196	V N V V Y G L I V I I S A I G	19
23	218	F S Y L L I L K T V L G L T R	19
24	247	G A V F I F Y V P F I G L S M	19
25	274	P V I L A N I Y L L V P P V L	19
26	45	L T I I Y I V R T E H S L H E	18
27	68	L S G I D I L I S T S S M P K	18
28	80	M P K M L A I F W F N S T T I	18
29	97	D A C L L Q I F A I H S L S G	18
30	103	I F A I H S L S C M E S T V L	18
31	208	A I G L D S L L I S F S Y L L	18
32	249	V F I F Y V P F I G L S M V H	18
33	61	M Y I F L C M L S G I D I L I	17
34	215	L I S F S Y L L I L K T V L G	17
35	259	L S M V H R F S K R R D S P L	17
36	278	A N I Y L L V P P V L N P I V	17

HLA-DRB1*1101 15-mers

	Pes		score
		1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	
37	288	L N P I V Y G V K T K E I R Q	17
38	11	A T Y F I L I G L P G L E E A	16
39	24	E A Q F W L A F P L C S L Y L	16
40	42	L G N L T I I Y I V R T E H S	16
41	253	Y V P F I G L S M V H R F S K	16
42	47	I I Y I V R T E H S L H E P M	15
43	99	G L L Q I F A I H S L S G M E	15
44	116	V L L A M A F D R Y V A I C H	15
45	143	V T K I G V A A V V R G A A L	15
46	179	S Y C L H Q D V M K L A C D D	15
47	227	V L G L T R E A Q A K A F G T	15
48	260	S M V H R F S K R R D S P L P	15
49	261	M V H R F S K R R D S P L P V	15
50	277	L A N I Y L L V P P V L N P I	15
51	285	P P V L N P I V Y G V K T K E	15
52	114	S T V L L A M A F D R Y V A I	14
53	125	Y V A I C H P L R H A T V L T	14
54	126	V A I C H P L R H A T V L T L	14
55	140	L P R V T K I G V A A V V R G	14
56	170	F C R S N I L S H S Y C L H Q	14
57	180	Y C L H Q D V M K L A C D D I	14
58	193	D I R V N V V Y G L I V I I S	14
59	229	G L T R E A Q A K A F G T C V	14
60	270	D S P L P V I L A N I Y L L V	14
61	298	K E I R Q R I L R L F H V A T	14

SEQ
ID
NO:

HLA-DRB1*0101 15-mers

	<u>Pos</u>		<u>score</u>
		1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	
2472	1	200 Y G L I V I I S A I G L D S L	36
2473	2	68 L S G I D I L I S T S S M P K	34
2474	3	62 Y I F L C M L S G I D I L I S	33
2475	4	103 I F A I H S L S G M E S T V L	32
2476	5	45 L T I I Y I V R T E H S L H E	31
2477	6	193 D I R V N V V Y G L I V I I S	31
2478	7	277 L A N I Y L L V P P V L N P I	31
2479	8	97 D A C L L Q I F A I H S L S G	30
2480	9	106 I H S L S G M E S T V L L A M	30
2481	10	240 G T C V S H V C A V F I F Y V	30
2482	11	10 S A T Y F I L I G L P G L E E	29
2483	12	289 N P I V Y G V K T K E I R Q R	29
2484	13	11 A T Y F I L I G L P G L E E A	28
2485	14	250 F I F Y V P F I G L S M V H R	27
2486	15	140 L P R V T K I G V A A V V R G	26
2487	16	183 H Q D V M K L A C D D I R V N	26
2488	17	217 S F S Y L L I L K T V L G L T	26
2489	18	16 L I G L P G L E E A Q F W L A	25
2490	19	24 E A Q F W L A F P L C S L Y L	25
2491	20	36 L Y L I A V L G N L T I I Y I	25
2492	21	70 G I D I L I S T S S M P K M L	25
2493	22	111 G M E S T V L L A M A F D R Y	25
2494	23	148 V A A V V R G A A L M A P L P	25
2495	24	162 P V F I K Q L P F C R S N I L	25
2496	25	197 N V V Y G L I V I I S A I G L	25
2497	26	211 L D S L L I S F S Y L L I L K	25
2498	27	218 F S Y L L I L K T V L G L T R	25
2499	28	13 Y F I L I G L P G L E E A Q F	24
2500	29	30 A F P L C S L Y L I A V L G N	24
2501	30	39 I A V L G N L T I I Y I V R T	24
2502	31	77 T S S M P K M L A I F W F N S	24
2503	32	85 A I F W F N S T T I Q F D A C	24
2504	33	137 V L T L P R V T K I G V A A V	24
2505	34	151 V V R G A A L M A P L P V F I	24
2506	35	161 L P V F I K Q L P F C R S N I	24
2507	36	196 V N V V Y G L I V I I S A I G	24
2508	37	202 L I V I I S A I G L D S L L I	24
2509	38	208 A I G L D S L L I S F S Y L L	24
2510	39	248 A V F I F Y V P F I G L S M V	24
2511	40	251 I F Y V P F I G L S M V H R F	24
2512	41	83 M L A I F W F N S T T I Q F D	23
2513	42	101 L Q I F A I H S L S G M E S T	23
2514	43	165 I K Q L P F C R S N I L S H S	23
2515	44	203 I V I I S A I G L D S L L I S	23
2516	45	221 L L I L K T V L G L T R E A Q	23
2517	46	278 A N I Y L L V P P V L N P I V	23
2518	47	27 F W L A F P L C S L Y L I A V	22
2519	48	35 S L Y L I A V L G N L T I I Y	22
2520	49	61 M Y I F L C M L S G I D I L I	22

SEQ

ID

NO:

HLA-DRB1*0101 15-mers

		<u>Pos</u>	1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	<u>score</u>
2521	50	65	L C M L S G I D I L I S T S S	22
2522	51	80	M P K M L A I F W F N S T T I	22
2523	52	145	K I G V A A V V R G A A L M A	22
2524	53	146	I G V A A V V R G A A L M A P	22
2525	54	154	G A A L M A P L P V F I K Q L	22
2526	55	205	I I S A I G L D S L L I S F S	22
2527	56	243	V S H V C A V F I F Y V P F I	22
2528	57	270	D S P L P V I L A N I Y L L V	22
2529	58	274	P V I L A N I Y L L V P P V L	22
2530	59	281	Y L L V P P V L N P I V Y G V	22
2531	60	34	C S L Y L I A V L G N L T I I	21
2532	61	69	S G I D I L I S T S S M P K M	21
2533	62	152	V R G A A L M A P L P V F I K	21
2534	63	299	E I R Q R I L R L F H V A T H	21
2535	64	100	L L Q I F A I H S L S G M E S	20
2536	65	135	A T V L T L P R V T K I G V A	20
2537	66	141	P R V T K I G V A A V V R G A	20
2538	67	191	C D D I R V N V Y G L I V I	20
2539	68	199	V Y G L I V I I S A I G L D S	20
2540	69	262	V H R F S K R R D S P L P V I	20
2541	70	271	S P L P V I L A N I Y L L V P	20
2542	71	28	W L A F P L C S L Y L I A V L	19
2543	72	58	H E P M Y I F L C M L S G I D	19
2544	73	59	E P M Y I F L C M L S G I D I	19
2545	74	60	P M Y I F L C M L S G I D I L	19
2546	75	98	A C L L Q I F A I H S L S G M	19
2547	76	215	L I S F S Y L L I L K T V L G	19
2548	77	219	S Y L L I L K T V L G L T R E	19
2549	78	228	L G L T R E A Q A K A F G T C	19
2550	79	232	R E A Q A K A F G T C V S H V	19
2551	80	246	V C A V F I F Y V P F I G L S	19
2552	81	297	T K E I R Q R I L R L F H V A	19
2553	82	3	D P N G N E S S A T Y F I L I	18
2554	83	14	F I L I G L P G L E E A Q F W	18
2555	84	25	A Q F W L A F P L C S L Y L I	18
2556	85	42	L G N L T I I Y I V R T E H S	18
2557	86	46	T I I Y I V R T E H S L H E P	18
2558	87	78	S S M P K M L A I F W F N S T	18
2559	88	84	L A I F W F N S T T I O F D A	18
2560	89	89	F N S T T I O F D A C L L Q I	18
2561	90	93	T I O F D A C L L Q I F A I H	18
2562	91	115	T V L L A M A F D R Y V A I C	18
2563	92	119	A M A F D R Y V A I C H P L R	18
2564	93	127	A I C H P L R H A T V L T L P	18
2565	94	129	C H P L R H A T V L T L P R V	18
2566	95	147	G V A A V V R G A A L M A P L	18
2567	96	149	A A V V R G A A L M A P L P V	18
2568	97	216	I S F S Y L L I L K T V L G L	18
2569	98	227	V L G L T R E A Q A K A F G T	18
2570	99	249	V F I F Y V P F I G L S M V H	18

SEQ

ID

NO: HLA-DRB1*0101 15-mers

	<u>Pos</u>		1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	<u>score</u>
<u>2571100</u>	<u>253</u>		<u>Y</u>	<u>V</u>	<u>P</u>	<u>F</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>S</u>	<u>M</u>	<u>V</u>	<u>H</u>	<u>R</u>	<u>F</u>	<u>S</u>	<u>K</u>	<u>18</u>
<u>2572101</u>	<u>284</u>		<u>V</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>18</u>
<u>2573102</u>	<u>286</u>		<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>18</u>
<u>2574103</u>	<u>303</u>		<u>R</u>	<u>I</u>	<u>L</u>	<u>R</u>	<u>L</u>	<u>F</u>	<u>H</u>	<u>V</u>	<u>A</u>	<u>T</u>	<u>H</u>	<u>A</u>	<u>S</u>	<u>E</u>	<u>P</u>	<u>18</u>

SEQ

ID

NO: HLA-DRB1*0301 (DR17) 15-mers

	<u>Pos</u>		1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	<u>score</u>
<u>2575</u>	<u>1</u>	<u>16</u>	<u>L</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>P</u>	<u>G</u>	<u>L</u>	<u>E</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>F</u>	<u>W</u>	<u>L</u>	<u>A</u>	<u>26</u>
<u>2576</u>	<u>2</u>	<u>206</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>23</u>
<u>2577</u>	<u>3</u>	<u>91</u>	<u>S</u>	<u>T</u>	<u>T</u>	<u>I</u>	<u>Q</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>A</u>	<u>22</u>
<u>2578</u>	<u>4</u>	<u>117</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>F</u>	<u>D</u>	<u>R</u>	<u>Y</u>	<u>V</u>	<u>A</u>	<u>I</u>	<u>C</u>	<u>H</u>	<u>P</u>	<u>22</u>
<u>2579</u>	<u>5</u>	<u>38</u>	<u>L</u>	<u>I</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>I</u>	<u>Y</u>	<u>I</u>	<u>V</u>	<u>R</u>	<u>21</u>
<u>2580</u>	<u>6</u>	<u>179</u>	<u>S</u>	<u>Y</u>	<u>C</u>	<u>L</u>	<u>H</u>	<u>Q</u>	<u>D</u>	<u>V</u>	<u>M</u>	<u>K</u>	<u>L</u>	<u>A</u>	<u>C</u>	<u>D</u>	<u>D</u>	<u>21</u>
<u>2581</u>	<u>7</u>	<u>211</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>21</u>
<u>2582</u>	<u>8</u>	<u>219</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>R</u>	<u>E</u>	<u>21</u>
<u>2583</u>	<u>9</u>	<u>272</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>I</u>	<u>L</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>P</u>	<u>P</u>	<u>21</u>
<u>2584</u>	<u>10</u>	<u>26</u>	<u>Q</u>	<u>F</u>	<u>W</u>	<u>L</u>	<u>A</u>	<u>F</u>	<u>P</u>	<u>L</u>	<u>C</u>	<u>S</u>	<u>L</u>	<u>Y</u>	<u>L</u>	<u>I</u>	<u>A</u>	<u>20</u>
<u>2585</u>	<u>11</u>	<u>114</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>A</u>	<u>F</u>	<u>D</u>	<u>R</u>	<u>Y</u>	<u>V</u>	<u>A</u>	<u>I</u>	<u>20</u>
<u>2586</u>	<u>12</u>	<u>129</u>	<u>C</u>	<u>H</u>	<u>P</u>	<u>L</u>	<u>R</u>	<u>H</u>	<u>A</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>T</u>	<u>L</u>	<u>P</u>	<u>R</u>	<u>V</u>	<u>20</u>
<u>2587</u>	<u>13</u>	<u>134</u>	<u>H</u>	<u>A</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>T</u>	<u>L</u>	<u>P</u>	<u>R</u>	<u>V</u>	<u>T</u>	<u>K</u>	<u>I</u>	<u>G</u>	<u>V</u>	<u>20</u>
<u>2588</u>	<u>14</u>	<u>186</u>	<u>V</u>	<u>M</u>	<u>K</u>	<u>L</u>	<u>A</u>	<u>C</u>	<u>D</u>	<u>D</u>	<u>I</u>	<u>R</u>	<u>V</u>	<u>N</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>20</u>
<u>2589</u>	<u>15</u>	<u>200</u>	<u>Y</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>20</u>
<u>2590</u>	<u>16</u>	<u>270</u>	<u>D</u>	<u>S</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>I</u>	<u>L</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>20</u>
<u>2591</u>	<u>17</u>	<u>297</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>Q</u>	<u>R</u>	<u>I</u>	<u>L</u>	<u>R</u>	<u>L</u>	<u>F</u>	<u>H</u>	<u>V</u>	<u>A</u>	<u>20</u>
<u>2592</u>	<u>18</u>	<u>11</u>	<u>A</u>	<u>T</u>	<u>Y</u>	<u>F</u>	<u>I</u>	<u>L</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>P</u>	<u>G</u>	<u>L</u>	<u>E</u>	<u>E</u>	<u>A</u>	<u>19</u>
<u>2593</u>	<u>19</u>	<u>54</u>	<u>E</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>H</u>	<u>E</u>	<u>P</u>	<u>M</u>	<u>Y</u>	<u>I</u>	<u>F</u>	<u>L</u>	<u>C</u>	<u>M</u>	<u>L</u>	<u>19</u>
<u>2594</u>	<u>20</u>	<u>106</u>	<u>I</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>M</u>	<u>E</u>	<u>S</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>L</u>	<u>A</u>	<u>M</u>	<u>19</u>
<u>2595</u>	<u>21</u>	<u>165</u>	<u>I</u>	<u>K</u>	<u>Q</u>	<u>L</u>	<u>P</u>	<u>F</u>	<u>C</u>	<u>R</u>	<u>S</u>	<u>N</u>	<u>I</u>	<u>L</u>	<u>S</u>	<u>H</u>	<u>S</u>	<u>19</u>
<u>2596</u>	<u>22</u>	<u>191</u>	<u>C</u>	<u>D</u>	<u>D</u>	<u>I</u>	<u>R</u>	<u>V</u>	<u>N</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>L</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>19</u>
<u>2597</u>	<u>23</u>	<u>203</u>	<u>I</u>	<u>V</u>	<u>I</u>	<u>I</u>	<u>S</u>	<u>A</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>D</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>19</u>
<u>2598</u>	<u>24</u>	<u>213</u>	<u>S</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>19</u>
<u>2599</u>	<u>25</u>	<u>224</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>R</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>A</u>	<u>K</u>	<u>A</u>	<u>19</u>
<u>2600</u>	<u>26</u>	<u>227</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>R</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>A</u>	<u>K</u>	<u>A</u>	<u>F</u>	<u>G</u>	<u>T</u>	<u>19</u>
<u>2601</u>	<u>27</u>	<u>248</u>	<u>A</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>F</u>	<u>Y</u>	<u>V</u>	<u>P</u>	<u>F</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>S</u>	<u>M</u>	<u>V</u>	<u>19</u>
<u>2602</u>	<u>28</u>	<u>254</u>	<u>V</u>	<u>P</u>	<u>F</u>	<u>I</u>	<u>G</u>	<u>L</u>	<u>S</u>	<u>M</u>	<u>V</u>	<u>H</u>	<u>R</u>	<u>F</u>	<u>S</u>	<u>K</u>	<u>R</u>	<u>19</u>
<u>2603</u>	<u>29</u>	<u>277</u>	<u>L</u>	<u>A</u>	<u>N</u>	<u>I</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>19</u>
<u>2604</u>	<u>30</u>	<u>36</u>	<u>L</u>	<u>Y</u>	<u>L</u>	<u>I</u>	<u>A</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>N</u>	<u>L</u>	<u>T</u>	<u>I</u>	<u>I</u>	<u>Y</u>	<u>I</u>	<u>18</u>
<u>2605</u>	<u>31</u>	<u>93</u>	<u>T</u>	<u>I</u>	<u>Q</u>	<u>F</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>A</u>	<u>I</u>	<u>H</u>	<u>18</u>
<u>2606</u>	<u>32</u>	<u>98</u>	<u>A</u>	<u>C</u>	<u>L</u>	<u>L</u>	<u>Q</u>	<u>I</u>	<u>F</u>	<u>A</u>	<u>I</u>	<u>H</u>	<u>S</u>	<u>L</u>	<u>S</u>	<u>G</u>	<u>M</u>	<u>18</u>
<u>2607</u>	<u>33</u>	<u>125</u>	<u>Y</u>	<u>V</u>	<u>A</u>	<u>I</u>	<u>C</u>	<u>H</u>	<u>P</u>	<u>L</u>	<u>R</u>	<u>H</u>	<u>A</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>T</u>	<u>18</u>
<u>2608</u>	<u>34</u>	<u>158</u>	<u>M</u>	<u>A</u>	<u>P</u>	<u>L</u>	<u>P</u>	<u>V</u>	<u>F</u>	<u>I</u>	<u>K</u>	<u>Q</u>	<u>L</u>	<u>P</u>	<u>F</u>	<u>C</u>	<u>R</u>	<u>18</u>
<u>2609</u>	<u>35</u>	<u>187</u>	<u>M</u>	<u>K</u>	<u>L</u>	<u>A</u>	<u>C</u>	<u>D</u>	<u>D</u>	<u>I</u>	<u>R</u>	<u>V</u>	<u>N</u>	<u>V</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>18</u>
<u>2610</u>	<u>36</u>	<u>217</u>	<u>S</u>	<u>F</u>	<u>S</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>I</u>	<u>L</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>18</u>
<u>2611</u>	<u>37</u>	<u>225</u>	<u>K</u>	<u>T</u>	<u>V</u>	<u>L</u>	<u>G</u>	<u>L</u>	<u>T</u>	<u>R</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>A</u>	<u>K</u>	<u>A</u>	<u>F</u>	<u>18</u>
<u>2612</u>	<u>38</u>	<u>281</u>	<u>Y</u>	<u>L</u>	<u>L</u>	<u>V</u>	<u>P</u>	<u>P</u>	<u>V</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>18</u>
<u>2613</u>	<u>39</u>	<u>288</u>	<u>L</u>	<u>N</u>	<u>P</u>	<u>I</u>	<u>V</u>	<u>Y</u>	<u>G</u>	<u>V</u>	<u>K</u>	<u>T</u>	<u>K</u>	<u>E</u>	<u>I</u>	<u>R</u>	<u>O</u>	<u>18</u>
<u>2614</u>	<u>40</u>	<u>18</u>	<u>G</u>	<u>L</u>	<u>P</u>	<u>G</u>	<u>L</u>	<u>E</u>	<u>E</u>	<u>A</u>	<u>Q</u>	<u>F</u>	<u>W</u>	<u>L</u>	<u>A</u>	<u>F</u>	<u>P</u>	<u>17</u>

SEQ

ID

NO: HLA-DRB1*0301 (DR17) 15-mers

		<u>Pos</u>	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	<u>score</u>
<u>2615</u>	<u>41</u>	<u>44</u>	N	L	T	I	I	Y	I	V	R	T	E	H	S	L	H	17
<u>2616</u>	<u>42</u>	<u>145</u>	K	I	G	V	A	A	V	V	R	G	A	A	L	M	A	17
<u>2617</u>	<u>43</u>	<u>159</u>	A	P	L	P	V	F	I	K	Q	L	P	F	C	R	S	17
<u>2618</u>	<u>44</u>	<u>256</u>	F	I	G	L	S	M	V	H	R	F	S	K	R	R	D	17
<u>2619</u>	<u>45</u>	<u>259</u>	L	S	M	V	H	R	F	S	K	R	R	D	S	P	L	17
<u>2620</u>	<u>46</u>	<u>137</u>	V	L	T	L	P	R	V	T	K	I	G	V	A	A	V	16
<u>2621</u>	<u>47</u>	<u>262</u>	V	H	R	F	S	K	R	R	D	S	P	L	P	V	I	16
<u>2622</u>	<u>48</u>	<u>294</u>	G	V	K	T	K	E	I	R	Q	R	I	L	R	L	F	16
<u>2623</u>	<u>49</u>	<u>46</u>	T	I	I	Y	I	V	R	T	E	H	S	L	H	E	P	15
<u>2624</u>	<u>50</u>	<u>51</u>	V	R	T	E	H	S	L	H	E	P	M	Y	I	F	L	15
<u>2625</u>	<u>51</u>	<u>172</u>	R	S	N	I	L	S	H	S	Y	C	L	H	Q	D	V	15
<u>2626</u>	<u>52</u>	<u>189</u>	L	A	C	D	D	I	R	V	N	V	V	Y	G	L	I	15
<u>2627</u>	<u>53</u>	<u>212</u>	D	S	L	L	I	S	F	S	Y	L	L	I	L	K	T	15
<u>2628</u>	<u>54</u>	<u>218</u>	F	S	Y	L	L	I	L	K	T	V	L	G	L	T	R	15
<u>2629</u>	<u>55</u>	<u>271</u>	S	P	L	P	V	I	L	A	N	I	Y	L	L	V	P	15
<u>2630</u>	<u>56</u>	<u>279</u>	N	I	Y	L	L	V	P	P	V	L	N	P	I	V	Y	15
<u>2631</u>	<u>57</u>	<u>12</u>	T	Y	F	I	L	I	G	L	P	G	L	E	E	A	Q	14
<u>2632</u>	<u>58</u>	<u>35</u>	S	L	Y	L	I	A	V	L	G	N	L	T	I	I	Y	14
<u>2633</u>	<u>59</u>	<u>64</u>	F	L	C	M	L	S	G	I	D	I	L	I	S	T	S	14
<u>2634</u>	<u>60</u>	<u>140</u>	L	P	R	V	T	K	I	G	V	A	A	V	V	R	G	14
<u>2635</u>	<u>61</u>	<u>273</u>	L	P	V	I	L	A	N	I	Y	L	L	V	P	P	V	14
<u>2636</u>	<u>62</u>	<u>301</u>	R	Q	R	I	L	R	L	F	H	V	A	T	H	A	S	14
<u>2637</u>	<u>63</u>	<u>13</u>	Y	F	I	L	I	G	L	P	G	L	E	E	A	Q	F	13
<u>2638</u>	<u>64</u>	<u>47</u>	I	I	Y	I	V	R	T	E	H	S	L	H	E	P	M	13
<u>2639</u>	<u>65</u>	<u>71</u>	I	D	I	L	I	S	T	S	S	M	P	K	M	L	A	13
<u>2640</u>	<u>66</u>	<u>80</u>	M	P	K	M	L	A	I	F	W	F	N	S	T	T	I	13
<u>2641</u>	<u>67</u>	<u>109</u>	L	S	G	M	E	S	T	V	L	L	A	M	A	F	D	13
<u>2642</u>	<u>68</u>	<u>113</u>	E	S	T	V	L	L	A	M	A	F	D	R	Y	V	A	13
<u>2643</u>	<u>69</u>	<u>135</u>	A	T	V	L	T	L	P	R	V	T	K	I	G	V	A	13
<u>2644</u>	<u>70</u>	<u>195</u>	R	V	N	V	V	Y	G	L	I	V	I	I	S	A	I	13
<u>2645</u>	<u>71</u>	<u>202</u>	L	I	V	I	I	S	A	I	G	L	D	S	L	L	I	13
<u>2646</u>	<u>72</u>	<u>220</u>	Y	L	L	I	L	K	T	V	L	G	L	T	R	E	A	13
<u>2647</u>	<u>73</u>	<u>221</u>	L	L	I	L	K	T	V	L	G	L	T	R	E	A	Q	13
<u>2648</u>	<u>74</u>	<u>264</u>	R	F	S	K	R	R	D	S	P	L	P	V	I	L	A	13
<u>2649</u>	<u>75</u>	<u>280</u>	I	Y	L	L	V	P	P	V	L	N	P	I	V	Y	G	13
<u>2650</u>	<u>76</u>	<u>302</u>	Q	R	I	L	R	L	F	H	V	A	T	H	A	S	E	13

SEQ

ID

NO: HLA-DRB1*0401 (DR4Dw4) 15-mers

		<u>Pos</u>	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	<u>score</u>
<u>2651</u>	<u>1</u>	<u>36</u>	L	Y	L	I	A	V	L	G	N	L	T	I	I	Y	I	26
<u>2652</u>	<u>2</u>	<u>45</u>	L	T	I	I	Y	I	V	R	T	E	H	S	L	H	E	26
<u>2653</u>	<u>3</u>	<u>68</u>	L	S	G	I	D	I	L	I	S	T	S	S	M	P	K	26
<u>2654</u>	<u>4</u>	<u>83</u>	M	L	A	I	F	W	F	N	S	T	T	I	Q	F	D	26
<u>2655</u>	<u>5</u>	<u>134</u>	H	A	T	V	L	T	L	P	R	V	T	K	I	G	V	26
<u>2656</u>	<u>6</u>	<u>145</u>	K	I	G	V	A	A	V	V	R	G	A	A	L	M	A	26
<u>2657</u>	<u>7</u>	<u>224</u>	L	K	T	V	L	G	L	T	R	E	A	Q	A	K	A	26
<u>2658</u>	<u>8</u>	<u>227</u>	V	L	G	L	T	R	E	A	Q	A	K	A	F	G	T	26

SEQ
ID
NO:

HLA-DRB1*0401 (DR4Dw4) 15-mers

		<u>Pos</u>	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	<u>score</u>
2659	9	256	F	I	G	L	S	M	V	H	R	F	S	K	R	R	D	26
2660	10	281	Y	L	L	V	P	P	V	L	N	P	I	V	Y	G	V	26
2661	11	289	N	P	I	V	Y	G	V	K	T	K	E	I	R	O	R	26
2662	12	301	R	O	R	I	L	R	L	F	H	V	A	T	H	A	S	26
2663	13	11	A	T	Y	F	I	L	I	G	L	P	G	L	E	E	A	22
2664	14	24	E	A	O	F	W	L	A	F	P	L	C	S	L	Y	L	22
2665	15	25	A	O	F	W	L	A	F	P	L	C	S	L	Y	L	I	22
2666	16	34	C	S	L	Y	L	I	A	V	L	G	N	L	T	I	I	22
2667	17	84	L	A	I	F	W	F	N	S	T	T	I	O	F	D	A	22
2668	18	122	F	D	R	Y	V	A	I	C	H	P	L	R	H	A	T	22
2669	19	197	N	V	V	Y	G	L	I	V	I	I	S	A	I	G	L	22
2670	20	215	L	I	S	F	S	Y	L	L	I	L	K	T	V	L	G	22
2671	21	217	S	F	S	Y	L	L	I	L	K	T	V	L	G	L	T	22
2672	22	250	F	I	F	Y	V	P	F	I	G	L	S	M	V	H	R	22
2673	23	278	A	N	I	Y	L	L	V	P	P	V	L	N	P	I	V	22
2674	24	19	L	P	G	L	E	E	A	O	F	W	L	A	F	P	L	20
2675	25	30	A	F	P	L	C	S	L	Y	L	I	A	V	L	G	N	20
2676	26	33	L	C	S	L	Y	L	I	A	V	L	G	N	L	T	I	20
2677	27	35	S	L	Y	L	I	A	V	L	G	N	L	T	I	I	Y	20
2678	28	39	I	A	V	L	G	N	L	T	I	I	Y	I	V	R	T	20
2679	29	42	L	G	N	L	T	I	I	Y	I	V	R	T	E	H	S	20
2680	30	44	N	L	T	I	I	Y	I	V	R	T	E	H	S	L	H	20
2681	31	48	I	Y	I	V	R	T	E	H	S	L	H	E	P	M	Y	20
2682	32	58	H	E	P	M	Y	I	F	L	C	M	L	S	G	I	D	20
2683	33	62	Y	I	F	L	C	M	L	S	G	I	D	I	L	I	S	20
2684	34	65	L	C	M	L	S	G	I	D	I	L	I	S	T	S	S	20
2685	35	71	I	D	I	L	I	S	T	S	S	M	P	K	M	L	A	20
2686	36	80	M	P	K	M	L	A	I	F	W	F	N	S	T	T	I	20
2687	37	81	P	K	M	L	A	I	F	W	F	N	S	T	T	I	O	20
2688	38	91	S	T	T	I	O	F	D	A	C	L	L	O	I	F	A	20
2689	39	97	D	A	C	L	L	O	I	F	A	I	H	S	L	S	G	20
2690	40	98	A	C	L	L	O	I	F	A	I	H	S	L	S	G	M	20
2691	41	100	L	L	O	I	F	A	I	H	S	L	S	G	M	E	S	20
2692	42	103	I	F	A	I	H	S	L	S	G	M	E	S	T	V	L	20
2693	43	106	I	H	S	L	S	G	M	E	S	T	V	L	L	A	M	20
2694	44	115	T	V	L	L	A	M	A	F	D	R	Y	V	A	I	C	20
2695	45	117	L	L	A	M	A	F	D	R	Y	V	A	I	C	H	P	20
2696	46	125	Y	V	A	I	C	H	P	L	R	H	A	T	V	L	T	20
2697	47	129	C	H	P	L	R	H	A	T	V	L	T	L	P	R	V	20
2698	48	137	V	L	T	L	P	R	V	T	K	I	G	V	A	A	V	20
2699	49	140	L	P	R	V	T	K	I	G	V	A	A	V	V	R	G	20
2700	50	155	A	A	L	M	A	P	L	P	V	F	I	K	Q	L	P	20
2701	51	162	P	V	F	I	K	Q	L	P	F	C	R	S	N	I	L	20
2702	52	165	I	K	Q	L	P	F	C	R	S	N	I	L	S	H	S	20
2703	53	179	S	Y	C	L	H	Q	D	V	M	K	L	A	C	D	D	20
2704	54	183	H	Q	D	V	M	K	L	A	C	D	D	I	R	V	N	20
2705	55	186	V	M	K	L	A	C	D	D	I	R	V	N	V	V	Y	20
2706	56	193	D	I	R	V	N	V	Y	G	L	I	V	I	I	S		20
2707	57	196	V	N	V	Y	G	L	I	V	I	I	S	A	I	G		20
2708	58	199	V	Y	G	L	I	V	I	I	S	A	I	G	L	D	S	20

SEQ
ID
NO:

HLA-DRB1*0401 (DR4Dw4) 15-mers

		<u>Pos</u>	<u>1 2 3 4 5 6 7 8 9 0 1 2 3 4 5</u>	<u>score</u>
2709	59	200	Y G L I V I I S A I G L D S L	20
2710	60	202	L I V I I S A I G L D S L L I	20
2711	61	203	I V I I S A I G L D S L L I S	20
2712	62	206	I S A I G L D S L L I S F S Y	20
2713	63	208	A I G L D S L L I S F S Y L L	20
2714	64	211	L D S L L I S F S Y L L I L K	20
2715	65	212	D S L L I S F S Y L L I L K T	20
2716	66	218	F S Y L L I L K T V L G L T R	20
2717	67	240	G T C V S H V C A V F I F Y V	20
2718	68	243	V S H V C A V F I F Y V P F I	20
2719	69	246	V C A V F I F Y V P F I G L S	20
2720	70	248	A V F I F Y V P F I G L S M V	20
2721	71	251	I F Y V P F I G L S M V H R F	20
2722	72	272	P L P V I L A N I Y L L V P P	20
2723	73	277	L A N I Y L L V P P V L N P I	20
2724	74	285	P P V L N P I V Y G V K T K E	20
2725	75	18	G L P G L E E A Q F W L A F P	18
2726	76	27	F W L A F P L C S L Y L I A V	18
2727	77	69	S G I D I L I S T S S M P K M	18
2728	78	94	I Q F D A C L L Q I F A I H S	18
2729	79	99	C L L Q I F A I H S L S G M E	18
2730	80	107	H S L S G M E S T V L L A M A	18
2731	81	116	V L L A M A F D R Y V A I C H	18
2732	82	126	V A I C H P L R H A T V L T L	18
2733	83	164	F I K Q L P E C R S N I L S H	18
2734	84	176	L S H S Y C L H Q D V M K L A	18
2735	85	187	M K L A C D D I R V N V V Y G	18
2736	86	205	I I S A I G L D S L L I S F S	18
2737	87	233	E A Q A K A E G T C V S H V C	18
2738	88	237	K A F G T C V S H V C A V F I	18
2739	89	271	S P L P V I L A N I Y L L V P	18
2740	90	293	Y G V K T K E I R Q R I L R L	18
2741	91	294	G V K T K E I R Q R I L R L F	18
2742	92	10	S A T Y F I L I G L P G L E E	16
2743	93	28	W L A F P L C S L Y L I A V L	16
2744	94	59	E P M Y I F L C M L S G I D I	16
2745	95	61	M Y I F L C M L S G I D I L I	16
2746	96	85	A I F W F N S T T I Q F D A C	16
2747	97	101	L Q I F A I H S L S G M E S T	16
2748	98	177	S H S Y C L H Q D V M K L A C	16
2749	99	236	A K A F G T C V S H V C A V F	16
2750	100	249	V F I F Y V P F I G L S M V H	16
2751	101	253	Y V P F I G L S M V H R F S K	16
2752	102	13	Y F I L I G L P G L E E A Q F	14
2753	103	14	F I L I G L P G L E E A Q F W	14
2754	104	16	L I G L P G L E E A Q F W L A	14
2755	105	38	L I A V L G N L T I I Y I V R	14
2756	106	47	I I Y I V R T E H S L H E P M	14
2757	107	54	E H S L H E P M Y I F L C M L	14
2758	108	60	P M Y I F L C M L S G I D I L	14

SEQ
ID
NO:

HLA-DRB1*0401 (DR4Dw4) 15-mers

		<u>Pos</u>	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>	<u>0</u>	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>score</u>
2759	109	64	F	L	C	M	L	S	G	I	D	I	L	I	S	T	S	14
2760	110	70	G	I	D	I	L	I	S	T	S	S	M	P	K	M	L	14
2761	111	72	D	I	L	I	S	T	S	S	M	P	K	M	L	A	I	14
2762	112	109	L	S	G	M	E	S	T	V	L	L	A	M	A	F	D	14
2763	113	113	E	S	T	V	L	L	A	M	A	F	D	R	Y	V	A	14
2764	114	135	A	T	V	L	T	L	P	R	V	T	K	I	G	V	A	14
2765	115	143	V	T	K	I	G	V	A	A	V	V	R	G	A	A	L	14
2766	116	148	V	A	A	V	V	R	G	A	A	L	M	A	P	L	P	14
2767	117	149	A	A	V	V	R	G	A	A	L	M	A	P	L	P	V	14
2768	118	154	G	A	A	L	M	A	P	L	P	V	F	I	K	Q	L	14
2769	119	158	M	A	P	L	P	V	F	I	K	Q	L	P	F	C	R	14
2770	120	173	S	N	I	L	S	H	S	Y	C	L	H	Q	D	V	M	14
2771	121	184	Q	D	V	M	K	L	A	C	D	D	I	R	V	N	V	14
2772	122	191	C	D	D	I	R	V	N	V	V	Y	G	L	I	V	I	14
2773	123	195	R	V	N	V	V	Y	G	L	I	V	I	I	S	A	I	14
2774	124	213	S	L	L	I	S	F	S	Y	L	L	I	L	K	T	V	14
2775	125	220	Y	L	L	I	L	K	T	V	L	G	L	T	R	E	A	14
2776	126	221	L	L	I	L	K	T	V	L	G	L	T	R	E	A	Q	14
2777	127	225	K	T	V	L	G	L	T	R	E	A	Q	A	K	A	F	14
2778	128	259	L	S	M	V	H	R	F	S	K	R	R	D	S	P	L	14
2779	129	270	D	S	P	L	P	V	I	L	A	N	I	Y	L	L	V	14
2780	130	273	L	P	V	I	L	A	N	I	Y	L	L	V	P	P	V	14
2781	131	274	P	V	I	L	A	N	I	Y	L	L	V	P	P	V	L	14
2782	132	280	I	Y	L	L	V	P	P	V	L	N	P	I	V	Y	G	14
2783	133	284	V	P	P	V	L	N	P	I	V	Y	G	V	K	T	K	14
2784	134	302	Q	R	I	L	R	L	F	H	V	A	T	H	A	S	E	14

SEQ
ID
NO:

HLA-DRB1*1101 15-mers

		<u>Pos</u>	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>6</u>	<u>7</u>	<u>8</u>	<u>9</u>	<u>0</u>	<u>1</u>	<u>2</u>	<u>3</u>	<u>4</u>	<u>5</u>	<u>score</u>
2785	1	145	K	I	G	V	A	A	V	V	R	G	A	A	L	M	A	28
2786	2	122	F	D	R	Y	V	A	I	C	H	P	L	R	H	A	T	25
2787	3	217	S	F	S	Y	L	L	I	L	K	T	V	L	G	L	T	25
2788	4	197	N	V	V	Y	G	L	I	V	I	I	S	A	I	G	L	24
2789	5	10	S	A	T	Y	F	I	L	I	G	L	P	G	L	E	E	23
2790	6	255	P	F	I	G	L	S	M	V	H	R	F	S	K	R	R	23
2791	7	44	N	L	T	I	I	Y	I	V	R	T	E	H	S	L	H	22
2792	8	59	E	P	M	Y	I	F	L	C	M	L	S	G	I	D	I	22
2793	9	158	M	A	P	L	P	V	F	I	K	Q	L	P	F	C	R	22
2794	10	237	K	A	F	G	T	C	V	S	H	V	C	A	V	F	I	22
2795	11	74	L	I	S	T	S	S	M	P	K	M	L	A	I	F	W	21
2796	12	134	H	A	T	V	L	T	L	P	R	V	T	K	I	G	V	20
2797	13	137	V	L	T	L	P	R	V	T	K	I	G	V	A	A	V	20
2798	14	162	P	V	F	I	K	Q	L	P	F	C	R	S	N	I	L	20
2799	15	199	V	Y	G	L	I	V	I	I	S	A	I	G	L	D	S	20
2800	16	224	L	K	T	V	L	G	L	T	R	E	A	Q	A	K	A	20
2801	17	256	F	I	G	L	S	M	V	H	R	F	S	K	R	R	D	20
2802	18	290	P	I	V	Y	G	V	K	T	K	E	I	R	Q	R	I	20

SEQ
ID
NO:

HLA-DRB1*1101 15-mers

		<u>Pos</u>		<u>score</u>
			1 2 3 4 5 6 7 8 9 0 1 2 3 4 5	
2803	19	301	R Q R I L R L F H V A T H A S	20
2804	20	65	L C M L S G I D I L I S T S S	19
2805	21	100	L L Q I F A I H S L S G M E S	19
2806	22	196	V N V V Y G L I V I I S A I G	19
2807	23	218	F S Y L L I L K T V L G L T R	19
2808	24	247	C A V F I F Y V P F I G L S M	19
2809	25	274	P V I L A N I Y L L V P P V L	19
2810	26	45	L T I I Y I V R T E H S L H E	18
2811	27	68	L S G I D I L I S T S S M P K	18
2812	28	80	M P K M L A I F W F N S T T I	18
2813	29	97	D A C L L Q I F A I H S L S G	18
2814	30	103	I F A I H S L S G M E S T V L	18
2815	31	208	A I G L D S L L I S F S Y L L	18
2816	32	249	V F I F Y V P F I G L S M V H	18
2817	33	61	M Y I F L C M L S G I D I L I	17
2818	34	215	L I S F S Y L L I L K T V L G	17
2819	35	259	L S M V H R F S K R R D S P L	17
2820	36	278	A N I Y L L V P P V L N P I V	17
2821	37	288	L N P I V Y G V K T K E I R Q	17
2822	38	11	A T Y F I L I G L P G L E E A	16
2823	39	24	E A Q F W L A F P L C S L Y L	16
2824	40	42	L G N L T I I Y I V R T E H S	16
2825	41	253	Y V P F I G L S M V H R F S K	16
2826	42	47	I I Y I V R T E H S L H E P M	15
2827	43	99	C L L Q I F A I H S L S G M E	15
2828	44	116	V L L A M A F D R Y V A I C H	15
2829	45	143	V T K I G V A A V V R G A A L	15
2830	46	179	S Y C L H Q D V M K L A C D D	15
2831	47	227	V L G L T R E A Q A K A F G T	15
2832	48	260	S M V H R F S K R R D S P L P	15
2833	49	261	M V H R F S K R R D S P L P V	15
2834	50	277	L A N I Y L L V P P V L N P I	15
2835	51	285	P P V L N P I V Y G V K T K E	15
2836	52	114	S T V L L A M A F D R Y V A I	14
2837	53	125	Y V A I C H P L R H A T V L T	14
2838	54	126	V A I C H P L R H A T V L T L	14
2839	55	140	L P R V T K I G V A A V V R G	14
2840	56	170	F C R S N I L S H S Y C L H Q	14
2841	57	180	Y C L H Q D V M K L A C D D I	14
2842	58	193	D I R V N V V Y G L I V I I S	14
2843	59	229	G L T R E A Q A K A F G T C V	14
2844	60	270	D S P L P V I L A N I Y L L V	14
2845	61	298	K E I R Q R I L R L F H V A T	14

Table XXIX. Nucleotide sequence in the 5' region close to 101P3A11 gene. (SEQ ID NO: 2846)

	1	TGCGCTCCAC	CAAGCCTGGC	TAACCTTTTGC	ATTTTAAATA	GAGGCAGGGT	TTCACCATGT
	61	TGGCCTGGCT	GGTCTCGAAC	CCCTGACCTT	GCGATCTGCC	CACCTCGGCC	TCCCAAAGTG
5	121	CTGGGATTAC	AGGCGTGAGC	CACGTGACCT	GGCGGGGCTT	ATTGTTTTTT	AAAAAGATTT
	181	CCAAAACCTT	GCCCTGGCAA	TTCTGATTTT	CTGGGCCTGG	AGCAGGACCT	GGAGGGATGG
	241	TGTTGTCAAT	TACTTTAGAT	GTTTCTATCA	GGAAAGTTTG	AGAAATGGTA	TTCAGGCCTA
	301	AACACAAACC	TCTCTTGAAG	TCTCATCCCA	GACTGAGCCC	CTGCTCCCTA	TCTTAAATTA
	361	GATTATAGTA	GGTCTTAAAG	TCAGCTGTAG	ACTGAGCCTC	TAAATCTGAA	CCCAGACCCA
10	421	CCCTAACCCC	AGGATACATC	AGAAGAGCTG	GTCAATGTGG	ACCATTCTGA	GCAATCCTGC
	481	AAGTCTACTC	TGATGGGAAA	AGGCTAAGAG	CAGTGCCCTG	GGCAGCAACA	TCAGCTCTGA
	541	AGATGCAGGA	CTGTGTTACA	TGTTTTATGA	GTGGGTCTTC	ACACACTGAG	ATTTCATGGGA
	601	CAGTAATAGA	ATCTGCTTGT	GCAGCACTGG	GGCCTTGGAG	GGTCAGGGTA	AGGCTCAAGA
	661	TGTCCAGGAA	GTTGTATATA	AGGAGAATCA	GAGCAGAGAG	AGACTAGGGT	TCAGAATTAC
15	721	CAGGATGACT	TAGTCTGTGT	TGTTACTGTC	ACCACTCCAA	TGCCTTTTCC	TCATTAGTCC
	781	TTTCTCTCCT	CTGAGCCACA	ACTAAATGAT	GTTTCTACTT	TTCCCTTTCT	ACTTTCCTAG
	841	ACCCTGGATT	TTGTATGCAG	AAGCCCCAGC	TCTTGGTCCC	TATCATAGCC	ACTTCAAATG
	901	GAAATCTGGT	CCACGCAGCA	TACTTCCTTT	TGGTGGGTAT	CCCTGGCCTG	GGGCCTACCA
	961	TACACTTTTG	GCTGGCTTTC	CCACTGTGTT	TTATGTATGC	CTTGGCCACC	CTGGGTAACC
20	1021	TGACCATTGT	CCTCATCATT	CGTGTGGAGA	GGCGACTGCA	TGAGCCCATG	TACCTCTTCC
	1081	TGGCCATGCT	TTCCACTATT	GACCTAGTCC	TCTCCTCTAT	CACCATGCCC	AAGATGGCCA
	1141	GTCTTTTCTC	GATGGGCATC	CAGGAGATCG	AGTTCAACAT	TTGCCTGGCC	CAGATGTTCC
	1201	TTATCCATGC	TCTGTCAGCC	GTGGAGTCAG	CTGTCTGTCT	GGCCATGGCT	TTTGACCGCT
	1261	TTGTGGCCAT	TTGCCACCCA	TTGCGCCATG	CTTCTGTGCT	GACAGGGTGT	ACTGTGGCCA
25	1321	AGATTGGACT	ATCTGCCCTG	ACCAGGGGGT	TTGTATTCTT	CTTCCCACTG	CCCTTCATCC
	1381	TCAAGTGGTT	GTCCTACTGC	CAAACACATA	CTGTACACAC	CTCCTTCTGT	CTGCACCAAG
	1441	ATATTATGAA	GCTGTCCTGT	ACTGACACCA	GGGTCAATGT	GGTTTATGGA	CTCTTCATCA
	1501	TCCTCTCAGT	CATGGGTGTG	GACTCTCTCT	TCATTGGCTT	CTCATATATC	CTCATCCTGT
	1561	GGGCTGTTTT	GGAGCTGTCC	TCTCGGAGGG	CAGCACTCAA	GGCTTTCAAC	ACCTGCATCT
30	1621	CCCACCTCTG	TGCTGTTCTG	GTCTTCTATG	TACCCCTCAT	TGGGCTCTCG	GTGGTGCATA
	1681	GGCTGGGTGG	TCCCACCTCC	CTCCTCCATG	TGGTTATGGC	TAATACCTAC	TTGCTGCTAC
	1741	CACCTGTAGT	CAACCCCTTT	GTCTATGGAG	CCAAGACCAA	AGAGATCTGT	TCAAGGGTCC
	1801	TCTGTATGTT	CTCACAAGGT	GGCAAGTGAG	ACACCTTAGT	GTCTCGCTTC	TACTACTACT
	1861	ACAGAAGATG	GGAATATTAG	GATCCTATTG	AATGCCTTGG	TGATTAAAGT	ATCAAACCTA
35	1921	TTGTGCTGTC	TTCTTCCAGC	AATTTAAGTA	GATCATGTAT	TCTGTCTCCA	GGAATGTGTC
	1981	AGTACTGAAC	TTATGACCCT	GTCTGGACAT	CCTGGAGAAT	GACTGCACTA	GTCCCTCTGC
	2041	TATGGTGGTC	TTGCCTTCTC	CTTCTCTCTC	AGCTAGAAAA	TACATCTAGT	TTTGACATGG
	2101	GGAGGCTGTA	AAGATCACAC	CTCATGGTTC	ATTCCAGTTT	TGAAGTATGA	TTTTAATGTT
	2161	CTTGCCCCCA	TGTGCCCATG	TTGGTGAATT	TGCATGGACT	ATAAACGTTA	TTGCAAATAC
40	2221	CCTAAAGTGG	TTACCCAGCC	ATAATCAGGG	GTTAATGAAG	GTATTTGGGG	AATAGTAACT
	2281	GGAGAGACAG	CAACAAGACA	AGAGGCAGCT	CACATGCAAT	GTTGAAGTTT	CTGTATGCAA
	2341	GAGGGTGTGT	TGGCAGATTT	GTGAAATCTG	CCCATTTGCA	TCTGTATGGC	TCTATATGAC
	2401	TATTTGTCCA	TAAGGGTGCC	ATGTATTCTG	GTTGTGGGTG	TGAATGTGTG	GGTGTGTTTA
	2461	TGTGGACACT	TGCTTTTTCAG	TGTGCGTATA	TGTGAGAGAG	AGGGTGCACA	CATGGAATAC
45	2521	GTACTGGTTG	TGTCCTGGTG	AGTGTGGTAG	CTATGTCCTG	GCACATGTAT	GTTTCATGAG
	2581	ACGTGTCTCT	GATTGCGCAT	TTGTATTTCT	GTGGTATCTG	TTAGTTGGTA	TATGATATGT
	2641	GTCTACGTGA	GAATGCTGGT	GTCTGTATCT	GCATGGTGGG	CAGTACCTTT	ATGTGTATCT
	2701	GGTAAGAATG	CTGCCTCTAC	CTTTTCTTCC	TATTTGTACT	ATGTGAATGT	GGTGCATGAA
	2761	TGTGTGGAAT	GTGTGGAATG	TGTAGTATTG	GGATGCCTGT	ATCTTTCAGC	GTGTTTGGGT
50	2821	GTATGTCCAC	TGTGCATAAT	ATTTGAGATG	TAAAACCAAT	TTGTGCGGTA	TATGTGTTAT
	2881	TAGTTGTAAG	TCGGTGAAAT	GTACATCTGA	ATTCTGTGTG	CATATTGTTG	GTAATGATGC
	2941	TATTTTTCGTG	CATATGTCTA	GTGTATATGT	TTTAAGGCAA	ACTTTCTTTG	TGTGTTGGGT
	3001	GTGTATGTGA	CACGAATGGG	GACAGCATCT	GTATTTCTGA	GCATGGATTG	ATGTGTGGTG
	3061	TCTGTATGTA	TCTTGGAATG	GAGGAGGGAG	ATTGAAGAAG	TCTGGCTGTG	AGCAGCAGAA
55	3121	ATAATTTCCA	AAGTTGAGTG	ACATGACTCT	AAGATGCCCA	GTTTCTCGGC	CTGGGGTCAG
	3181	CCTGGGTGAT	AGCTCAGTCT	GTCAGAATGA	AAGGAAACAC	GGTGCTTCCT	TGCTCCACCT
	3241	TTTCACAGGC	CAGACCACAC	CTTCTTCATC	CTGAACACAA	GGATTTCAAG	GGCTTTTGTT
	3301	ACCTCTTCCT	ACGTTTCCTG	CCTCTGCTAT	CCGAGGCACT	GGCCTCCCTA	AACCTTGCCC

3361 TCCTGCCTCA ATAGCAAGTC ATGGTATCCT CACCTCTCCC TTCCCTTTTT GGCTTATCTG
 3421 CCAAACATGT ATAAAAGTCC TTGGTTCCCC ATCTCTACTA AAAATACAAC AATTAGCCGG
 3481 GTGTGATGGC GCGTGCCTGT AGTCCCAGCT AGTTGGGAGG CTGAGGCAGG AGAAACGCTT
 3541 GAGCCCGCAA GGTGGAGGTT GCAGTGAGCC GAGATCATGC CACTGCACTC CAGCCTGGTG
 5 3601 ACAGAGCAAG ACTCTGTGTC AAAAAAAAAA AAAAAAAAAA AGCCTTGGTT GTAGGGAGTT
 3661 TCTCCTAATC CCTCTGGGAA AGCAAGGGTG GAGGGGAAGC CAGTCAATCT CCCTTCTGTT
 3721 GCCGCATGGA AACTCCCTTA AGGCAGGAAG CTGAAAAAAC TGTAGCATTG ACCTCATTAT
 3781 TCACCTTGTC TCATGTCTCA CTGTCCTTCC ACATGTCTCA TTGTTACTCC ATATTGGATG
 3841 GAAGTAGAAG TCCCTTTGGT ATTTTTTAAA GTCTTTGCCA TGTCTAAGTT AATGAGGTTA
 10 3901 ATGGAGGCAG CAGAGATGGC TCCAGGGTTC TGATAGCAAG TGTGAGGCTG CGTGCTCTGT
 3961 AGGCACCAGA AACTGTTGTC ACCAGTAATT TTGATGTGGT CTGAGTTAGA ATGGTCTGAT
 4021 TTGCCATGAT CTATTTAACA TAGCTTGATT TAGCGTGTCC TGTGTTCTGA ATTTAAACT
 4081 CACAGTTGTG AAACTGATCA GTAAAAAATA AGGGGAGACC AACTAAAAAC CATGTTGTTC
 4141 TATTTATAGA TGTAGTTTTT ACTTATTTCA AAATACGAGG TATTTAGTTT TACATTCAAA
 15 4201 TTGTTCTCTA ACTCTCTAAA ATGTTCTCTG ACTATTTTTG CCCTTAAGGG AGAAACCAGA
 4261 TGTCATTGGT CTTACGTGGC TGGTGTGGG GGTGGGGAGG GTTAAAGAAA CCACGTTCTC
 4321 TGTCCTCAGC CAGAAGTTCA GTAATCCAAG GCCAGAGAGT GGACGGCAGA GGCAGTGTCC
 4381 CTGGGGACCT TGGTTATAAG TTATCCAGAC ACAGGGACCA GAGCCTGGGA GACAAAAAAA
 4441 GATGTAGCCC TAGGGCTTTG GGAAAAGGAG GATGGACCCA GTGAATTCCA CGCTTAGCAA
 20 4501 GGACCTAAAC AGTGTCCCC AAATGAGAGA AGGGAGGACA GAAAGAACAC TTCAGGATGG
 4561 AAATGGGCTG AACTTAACC GTGGAGTGTC TCTGCAAACT TCCTTTGCCA TTCTCCTGTT
 4621 TGAGTTTGAT AAACCTGAGA AGAGACTTGG ATAAAGACCG TCACGAAGAC TACACTAATG
 4681 AGTTTCTTCT AGCTTTTTTC TACTCACTTT CCCTATCTAT CCTTCACATT GGGAGTTGGC
 4741 ATGAGGATCC CAGCAGCCCA TCAGGGGAGG ACTCTAGAGA TCCCTTTCCC CATTGCCTCT
 25 4801 CCTCCCCATA CCCCAGGCA TATCCTCCCA GGGCACGGAA GCTGAGAAGC AGTCCAGAAC
 4861 CACAGTGGGC TAGTGAGGGG TACCTGCTGA TGTACCCTTT GGACAGCATT CTGCCCCACC
 4921 CTGCAGGAAG AAGCAGAAGG AGGGAGAGGG TGAGGCAGAG AATAAATAAC CCTGACCAGG
 4981 GAGGTCCAAG GGAGTAGGCG GAGAcagaga ggctgtattt cagtgcagcc tgccagacct

30 Note: The three high score predictions of promoters were bold and underlined.
 The lower case sequence indicates the beginning part of the transcript of
 101P3A11 gene.

35 **Table XXX: Promoters and their positions predicted by Neural Network Promoter
 Prediction computer program.**

		SEQ		ID_NO	Promoter Sequence
Start	End	Score			
40	25	75	-0.91	<u>-2847</u>	TTTTGCATTTTTAATAGAGGCAGGGTTTCACCATGTTGGCCTGGCTGGTC
	665	715	-0.95	<u>-2848</u>	CAGGAAGTTGTATATAAGGAGAATCAGAGCAGAGAGAGACTAGGGTTCAG
	2477	2527	-0.91	<u>-2849</u>	TCAGTGTGCGTATATGTGAGAGAGAGGGTGCACACATGGAATACGTACTG
	3139	3189	-0.82	<u>-2850</u>	TGACATGACTCTAAGATGCCAGTTTCTCGGCCTGGGGTCAGCCTGGGTG
	3420	3470	-0.96	<u>-2851</u>	GCCAAACATGTATAAAAAGTCCTTGGTTCCCATCTCTACTAAAAATACAA
45	4092	4142	-0.99	<u>-2852</u>	AACTGATCAGTAAAAAATAAGGGGAGACCAACTAAAAACCATGTTGTTCT
	4953	5003	-0.97	<u>-2853</u>	AGGCAGAGAATAAATAACCCTGACCAGGGAGGTCCAAGGGAGTAGGCGGA

Table XXXI: Alignment of five homologous 5' upstream genomic regulatory regions of the human 101P3A11 and PSA genes.

1. QUERY (SEQ ID NO: 2854) AND SUBJECT (SEQ ID NO: 2855)

2. QUERY (SEQ ID NO: 2856) AND SUBJECT (SEQ ID NO: 2857)

```

30      Query: 4730 aggttgcaatgagccgagattgcgccactgcactccagcctgggtgacagagtgagactc 4789
      ||||||| ||||||||| ||||||||||||||||| ||||||||| |||||||
      Sbjct: 3556 aggttgcaatgagccgagatcatgccactgcactccagcct-ggtgacagagcaagactc 3614

35      Query: 4790 tgtctcaaaaaaaaaaaaaa 4807
      ||| |||||||||||||||||
      Sbjct: 3615 tgtctcaaaaaaaaaaaaaa 3632

```

40 3. QUERY (SEO ID NO: 2858) AND SUBJECT (SEO ID NO: 2859)

50

NF-1

Query: 262 tacaggcaccgc**gcc**accacgcctggctaannnnnnngtatttttagtagagatgggg 318
 ||||| ||||| || || ||||| |||||

Sbjct: 3501 tacaggcacgc**gcc**atcacaccgcgctaa--ttgtgtatttttagtagagatgggg 3447

